PTO/SB/05 (07-06)

Approved for use through 01/31/2007. OMB 0651-0032

Under the Paperwork Reduction Act of 1995, no persons are required to res	U.S. Patent and Tra spond to a collection of infor	ademark Office. U.S. DEPARTMENT OF COMMERCE rmation unless it displays a valid OMB control number.
UTILITY	Attorney Docket No.	10012-710.401
PATENT APPLICATION	First Inventor	Amr SALAHIEH et al.
TRANSMITTAL	Title	Everting Heart Valve
(Only for new nonprovisional applications under 37 CFR 1.53(b))	Express Mail Label No	5. FILED VIA EFS
APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application contents.	ADDRESS TO:	Commissioner for Patents P.O. Box 1450 Alexandria VA 22313-1450
1 Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original and a duplicate for fee processing)	АССОМРА	NYING APPLICATION PARTS
2. Applicant claims small entity status. See 37 CFR 1.27.	9. 🔲 Assignment	t Papers (cover sheet & document(s))
3. Specification [<i>Total Pages</i>] Both the claims and abstract must start on a new page	Name of A	ssignee
(For information on the preferred arrangement, see MPEP 608.01(a)) 4. Tawing(s) (35 U.S.C. 113) [Total Sheets]		······································
5. Oath or Declaration [Total Sheets 4] a. Newly executed (original or copy) b. A copy from a prior application (37 CFR 1.63(d))		(b) Statement Power of e is an assignee) Attorney
(for continuation/divisional with Box 18 completed) i. DELETION OF INVENTOR(S)	11. English Tra	nslation Document (if applicable)
Signed statement attached deleting inventor(s) name in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).		Disclosure Statement (PTO/SB/08 or PTO-1449) ies of citations attached
6. Application Data Sheet. See 37 CFR 1.76	13. Preliminary	Amendment
7. CD-ROM or CD-R in duplicate, large table or Computer Program (<i>Appendix</i>) Landscape Table on CD		eipt Postcard (MPEP 503) e specifically itemized)
8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, items a. – c. are required)		ppy of Priority Document(s) priority is claimed)
a. Computer Readable Form (CRF) b. Specification Sequence Listing on:		tion Request under 35 U.S.C. 122(b)(2)(B)(i). nust attach form PTO/SB/35 or equivalent.
i. CD-ROM or CD-R (2 copies); or ii. Paper		nunication re Order of Inventors
c. Statements verifying identity of above copies		
18. If a CONTINUING APPLICATION, check appropriate box, and sup specification following the title, or in an Application Data Sheet under 3		tion below and in the first sentence of the
Continuation Divisional Continua	ation-in-part (CIP) o	f prior application No.: 12/269,213
Prior application information: Examiner Ann M. SCHILLINGE	ER An	t Unit: <u>3774</u>
19. CORRESPON	DENCE ADDRESS	
The address associated with Customer Number:	354	OR Correspondence address below
Name		
Address		
City State		Zip Code
Country Telephone		Email
Signature Shomas 3		Date JUNE 26, 2009
Name (Print/Type) THOMAS M. ZLOGAR		Registration No. (Attorney/Agent) 55,760

This collection of information is required by 37 CFR 1.53(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

FILED VIA EFS ON JUNE 26, 2009

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Confirmation No.:

Appl. No.	:	
Applicant	•	Amr SALAHIEH et al.
Filing Date	:	June 26, 2009 (herewith)
Title	:	Everting Heart Valve
Group Art Unit	:	
Examiner	:	
Docket No.	:	10012-710.401
Customer No.	•	66854

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313 Sir:

COMMUNICATION RE ORDER OF INVENTORS

This communication accompanies a new application, which is a divisional of U.S. Application No. 12/269,213, which in turn is a continuation of US Application No. 10/870,340. In that application, a petition was filed and granted, changing the order of inventors as follows:

Amr SALAHIEH, Ulrich R. HAUG, Hans. F. VALENCIA, Robert A. GESHLIDER, Tom SAUL, Dwight P. MOREJOHN and Kenneth J. MICHLITSCH.

Copies of the granted petition and the corrected filing receipt are attached. It is requested that the subject divisional application herein retain the same order of inventors.

By:

Respectfully submitted,

home Hoga

Date: June 26, 2009

Thomas Zlogar, Reg. No. 55,760

SHAY GLENN LLP 2755 Campus Drive, Suite 210 San Mateo, CA 94403 Telephone: 650.212.1700 Facsimile: 650.212.7562

Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 2 of 442

11000

Commissioner for Patents United States Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450

UNITED STATES PATENT AND TRADEMARK OFFICE

FEB 2 4 2006

WILSON, SONDINI, GOODRICH & ROSATI

> WILSON SONSINI GOODRICH & DOCKETED COPY MAILED 650 PAGE MILL ROAD PALO ALTO CA 94304-1050 FEB 1 6 2006

> > **OFFICE OF PETITIONS**

In re Application of Arm Salahieh et al Application No. 10/870,340 Filed: June 16, 2004 Attorney Docket No. 30207-710.201

ON PETITION

This is a decision on the petition under 37 CFR 1.182, filed September 29, 2005, to change the order of the names of the inventors.

The petition is Granted.

A corrected Filing Receipt with the desired order of the names of the inventors accompanies this decision on petition.

Telephone inquiries regarding the above matter should be directed to the undersigned at (571)272-3208.

This matter is being referred to Technology Center AU 3738.

Un

Karen Creasy Petitions Examiner Office of Petitions Office of the Deputy Commissioner for Patent Examination Policy

ATTACHMENT: CORRECTED FILING RECEIPT

P) R. Michael as a consideration on a spectral of a second sec

1997 - Mendelen de Franke, Kañserren ver Der Dernelsen de Flanke en sour- 2005. F

se che majeratignes al (212)schossel Le che majeratignes al (212)schossel

Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 3 of 442

17 A. 17 F

2 4 2006

CEIVER

	H & ROSAT			United S Addrew: CC PC Al	D STATES DEPARTM States Patent and Th OMMISSIONER FOR P 0. Box 1450 lexandria, Virginia 22313-14: www.spico.gov	rademark Of ATENTS	
APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY.DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/870,340	06/16/2004	3738	971	30207-710.201	63	67	5

021971 WILSON SONSINI GOODRICH & ROSATI 650 PAGE MILL ROAD PALO ALTO, CA 94304-1050

CONFIRMATION NO. 7111 CORRECTED FILING RECEIPT *OC00000018061255* *OC00000018061255*

"OC00000016061255"

Date Mailed: 02/15/2006

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Amr Salahieh, Saratoga, CA; Ulrich R. Haug, Campbell, CA; Hans F. Valencia, Berkeley, CA; Robert A. Geshlider, San Francisco, CA; Tom Saul, El Granada, CA; Dwight P. Morejohn, Davis, CA; Kenneth J. Michlitsch, Livermore, CA;

Power of Attorney: The patent practitioners associated with Customer Number 021971.

Domestic Priority data as claimed by applicant

Foreign Applications

If Required, Foreign Filing License Granted: 08/03/2004

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is US10/870,340

Projected Publication Date: Not Applicable

Non-Publication Request: No

Early Publication Request: No

Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 4 of 442

** SMALL ENTITY **

Title

Everting heart valve

Preliminary Class

623

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted

under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

Attorney Docket No. 10012-710.401

UNITED STATES PATENT APPLICATION

EVERTING HEART VALVE

Inventor(s):

SALAHIEH, Amr,
HAUG, Ulrich R.,
VALENCIA, Hans F.,
GESHLIDER, Robert A.,
SAUL, Tom,
MOREJOHN, Dwight P.,
MICHLITSCH, Kenneth J.

ShayGlennup

2755 Campus Drive, Suite 210 San Mateo, CA 94403 (650) 212-1700 Main Phone (650) 212-7562 Facsimile

FILED VIA EFS ON JUNE 26, 2009

Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 7 of 442

EVERTING HEART VALVE

CROSS-REFERENCE TO RELATED APPLICATION

[0001] This application is a divisional of pending U.S. Application No. 12/269,213, filed November 12, 2008; which application is a continuation of pending U.S. Application No. 10/870,340, filed June 16, 2004, entitled "Everting Heart Valve", the disclosures of which are incorporated by reference in their entirety.

BACKGROUND OF THE INVENTION

[0002] The present invention relates to methods and apparatus for endovascularly replacing a heart valve. More particularly, the present invention relates to methods and apparatus for endovascularly replacing a heart valve with a replacement valve and an expandable and retrievable anchor. The replacement valve preferably is not connected to the expandable anchor and may be wrapped about an end of the anchor, for example, by everting during endovascular deployment.

[0003] Heart valve surgery is used to repair or replace diseased heart valves. Valve surgery is an openheart procedure conducted under general anesthesia. An incision is made through the patient's sternum (sternotomy), and the patient's heart is stopped while blood flow is rerouted through a heart-lung bypass machine.

[0004] Valve replacement may be indicated when there is a narrowing of the native heart valve, commonly referred to as stenosis, or when the native valve leaks or regurgitates. When replacing the valve, the native valve is excised and replaced with either a biologic or a mechanical valve. Mechanical valves require lifelong anticoagulant medication to prevent blood clot formation, and clicking of the valve often may be heard through the chest. Biologic tissue valves typically do not require such medication. Tissue valves may be obtained from cadavers or may be porcine or bovine, and are commonly attached to synthetic rings that are secured to the patient's heart.

[0005] Valve replacement surgery is a highly invasive operation with significant concomitant risk. Risks include bleeding, infection, stroke, heart attack, arrhythmia, renal failure, adverse reactions to the anesthesia medications, as well as sudden death. 2-5% of patients die during surgery.

[0006] Post-surgery, patients temporarily may be confused due to emboli and other factors associated with the heart-lung machine. The first 2-3 days following surgery are spent in an intensive care unit where heart functions can be closely monitored. The average hospital stay is between 1 to 2 weeks, with several more weeks to months required for complete recovery.

[0007] In recent years, advancements in minimally invasive surgery and interventional cardiology have encouraged some investigators to pursue percutaneous replacement of the aortic heart valve. See, e.g.,

- 2 of 29 -

FILED VIA EFS

Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 8 of 442

U.S. Patent No. 6,168,614. In many of these procedures, the replacement valve is deployed across the native diseased valve to permanently hold the valve open, thereby alleviating a need to excise the native valve and to position the replacement valve in place of the native valve.

[0008] In the endovascular aortic valve replacement procedure, accurate placement of aortic valves relative to coronary ostia and the mitral valve is critical. Standard self-expanding systems have very poor accuracy in deployment, however. Often the proximal end of the stent is not released from the delivery system until accurate placement is verified by fluoroscopy, and the stent typically jumps once released. It is therefore often impossible to know where the ends of the stent will be with respect to the native valve, the coronary ostia and the mitral valve.

[0009] Also, visualization of the way the new valve is functioning prior to final deployment is very desirable. Visualization prior to final and irreversible deployment cannot be done with standard self-expanding systems, however, and the replacement valve is often not fully functional before final deployment.

[0010] Another drawback of prior art self-expanding replacement heart valve systems is their lack of radial strength. In order for self-expanding systems to be easily delivered through a delivery sheath, the metal needs to flex and bend inside the delivery catheter without being plastically deformed. In arterial stents, this is not a challenge, and there are many commercial arterial stent systems that apply adequate radial force against the vessel wall and yet can collapse to a small enough of a diameter to fit inside a delivery catheter without plastic deformation. However when the stent has a valve fastened inside it, as is the case in a ortic valve replacement, the anchoring of the stent to vessel walls is significantly challenged during diastole. The force to hold back arterial pressure and prevent blood from going back inside the ventricle during diastole will be directly transferred to the stent/vessel wall interface. Therefore, the amount of radial force required to keep the self-expanding stent/valve in contact with the vessel wall and not sliding will be much higher than in stents that do not have valves inside of them. Moreover, a selfexpanding stent without sufficient radial force will end up dilating and contracting with each heartbeat, thereby distorting the valve, affecting its function and possibly migrating and dislodging completely. Simply increasing strut thickness of the self-expanding stent is not a practical solution as it runs the risk of larger profile and/or plastic deformation of the self-expanding stent.

[0011] In view of drawbacks associated with previously known techniques for endovascularly replacing a heart valve, it would be desirable to provide methods and apparatus that overcome those drawbacks.

- 3 of 29 -

FILED VIA EFS

Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 9 of 442

SUMMARY OF THE INVENTION

[0012] One aspect of the present invention provides apparatus for endovascularly replacing a patient's heart valve, the apparatus including: a replacement valve; and an expandable anchor, wherein the replacement valve and expandable anchor are configured for endovascular delivery to the vicinity of the heart valve, and wherein at least a portion of the replacement valve is configured to evert about the anchor during endovascular deployment.

[0013] Another aspect of the invention provides a method for endovascularly replacing a patient's heart valve. In some embodiments the method includes the steps of: endovascularly delivering a replacement valve and an expandable anchor to a vicinity of the heart valve; everting at least a portion of the replacement valve about the anchor; and expanding the anchor to a deployed configuration.

[0014] Yet another aspect of the invention provides apparatus for endovascularly replacing a patient's heart valve including: an anchor comprising a lip region and a skirt region; and a replacement valve, wherein at least a portion of the replacement valve is configured to evert about the anchor during endovascular deployment, and wherein the lip region and skirt region are configured for percutaneous expansion to engage the patient's heart valve.

[0015] Still another aspect of the present invention provides a method for endovascularly replacing a patient's heart valve, the method including: endovascularly delivering a replacement valve and an expandable anchor to a vicinity of the heart valve, endovascularly wrapping at least a portion of the replacement valve about the anchor, and expanding the anchor to a deployed configuration.

[0016] Another aspect of the present invention provides apparatus for endovascularly replacing a patient's heart valve, the apparatus including: a replacement valve, and an expandable anchor, wherein the replacement valve and the anchor are configured for endovascular delivery to a vicinity of the patient's heart valve, and wherein at least a portion of the replacement valve is wrapped about an end of the anchor in a deployed configuration.

INCORPORATION BY REFERENCE

[0017] All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

BRIEF DESCRIPTION OF THE DRAWINGS

[0018] The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:

- 4 of 29 -

FILED VIA EFS

Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 10 of 442

[0019] Figures 1A-B are elevational views of a replacement heart value and anchor according to one embodiment of the invention.

[0020] Figures 2A-B are sectional views of the anchor and valve of Figures 1.

[0021] Figures 3A-B show delivery and deployment of a replacement heart valve and anchor, such as the anchor and valve of Figures 1 and 2.

[0022] Figures 4A-F also show delivery and deployment of a replacement heart valve and anchor, such as the anchor and valve of Figures 1 and 2.

[0023] Figures 5A-F show the use of a replacement heart valve and anchor to replace an aortic valve.

[0024] Figures 6A-F show the use of a replacement heart valve and anchor with a positive registration feature to replace an aortic valve.

[0025] Figure 7 shows the use of a replacement heart valve and anchor with an alternative positive registration feature to replace an aortic valve.

[0026] Figures 8A-C show another embodiment of a replacement heart valve and anchor according to the invention.

[0027] Figures 9A-H show delivery and deployment of the replacement heart valve and anchor of Figures 8.

[0028] Figure 10 is a cross-sectional drawing of the delivery system used with the method and apparatus of Figures 8 and 9.

[0029] Figures 11A-C show alternative locks for use with replacement heart valves and anchors of this invention.

[0030] Figures 12A-C show a vessel wall engaging lock for use with replacement heart valves and anchors of this invention.

[0031] Figure 13 demonstrates paravalvular leaking around a replacement heart valve and anchor.

[0032] Figure 14 shows a seal for use with a replacement heart valve and anchor of this invention.

[0033] Figures 15A-E show alternative arrangements of seals on a replacement heart valve and anchor.

[0034] Figures 16A-C show alternative seal designs for use with replacement heart valves and anchors.

[0035] Figures 17 show an alternative anchor lock embodiment in an unlocked configuration.

[0036] Figures 18A-B show the anchor lock of Figure 17 in a locked configuration.

[0037] Figure 19 shows an alternative anchor deployment tool attachment and release mechanism for use with the invention.

[0038] Figure 20 shows the attachment and release mechanism of Figure 19 in the process of being released.

[0039] Figure 21 shows the attachment and release mechanism of Figures 19 and 20 in a released condition.

- 5 of 29 -

FILED VIA EFS

Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 11 of 442

[0040] Figure 22 shows an alternative embodiment of a replacement heart valve and anchor and a deployment tool according to the invention in an undeployed configuration.

[0041] Figure 23 shows the replacement heart valve and anchor of Figure 22 in a partially deployed configuration.

[0042] Figure 24 shows the replacement heart valve and anchor of Figures 22 and 23 in a more fully deployed configuration but with the deployment tool still attached.

[0043] Figure 25 shows yet another embodiment of the delivery and deployment apparatus of the invention in use with a replacement heart valve and anchor.

[0044] Figure 26 shows the delivery and deployment apparatus of Figure 25 in the process of deploying a replacement heart valve and anchor.

[0045] Figure 27 shows an embodiment of the invention employing seals at the interface of the replacement heart valve and anchor and the patient's tissue.

[0046] Figure 28 is a longitudinal cross-sectional view of the seal shown in Figure 27 in compressed form.

[0047] Figure 29 is a transverse cross-sectional view of the seal shown in Figure 28.

[0048] Figure 30 is a longitudinal cross-sectional view of the seal shown in Figure 27 in expanded form.

[0049] Figure 31 is a transverse cross-sectional view of the seal shown in Figure 30.

[0050] Figure 32 shows yet another embodiment of the replacement heart valve and anchor of this invention in an undeployed configuration.

[0051] Figure 33 shows the replacement heart valve and anchor of Figure 32 in a deployed configuration.

[0052] Figure 34 shows the replacement heart valve and anchor of Figures 32 and 33 deployed in a patient's heart valve.

[0053] Figures 35A-H show yet another embodiment of a replacement heart valve, anchor and deployment system according to this invention.

[0054] Figures 36A-E show more detail of the anchor of the embodiment shown in Figures 35A-H.

[0055] Figures 37A-B show other embodiments of the replacement heart value and anchor of the invention.

[0056] Figures 38A-C illustrate a method for endovascularly replacing a patient's diseased heart valve.
[0057] Figures 39A-G are side views, partially in section, as well as an isometric view, illustrating a method for endovascularly replacing a patient's diseased heart valve with an embodiment of the present invention comprising a replacement valve that is not connected to the expandable anchor, the replacement valve wrapped about the anchor, illustratively by everting during deployment.

- 6 of 29 -

FILED VIA EFS

Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 12 of 442

[0058] Figures 40A-D are side views, partially in section, illustrating a method for endovascularly replacing a patient's diseased heart valve with another everting embodiment of the present invention.

[0059] Figures 41A-E are side views, partially in section, illustrating a method for endovascularly replacing a patient's diseased heart valve with yet another everting embodiment of the present invention, wherein the replacement valve and the anchor are telescoped relative to one another during endovascular delivery.

[0060] Figures 42A-B are side-sectional views of alternative everting apparatus comprising everting valve leaflets.

[0061] Figures 43A-B, are side-sectional views of further alternative everting apparatus comprising a locking mechanism coupled to the everting segment.

[0062] Figures 44A-B are side-sectional views of telescoping embodiments of the present invention comprising U-shaped valve frames.

DETAILED DESCRIPTION OF THE INVENTION

[0063] While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. For example, for the two-part locking mechanisms described hereinafter, it will be apparent that the locations of the male and female elements may be reversed. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby. [0064] With reference now to Figures 1-4, a first embodiment of replacement heart valve apparatus in accordance with the present invention is described, including a method of actively foreshortening and expanding the apparatus from a delivery configuration and to a deployed configuration. Apparatus 10 comprises replacement valve 20 disposed within and coupled to anchor 30. Figures 1 schematically illustrate individual cells of anchor 30 of apparatus 10, and should be viewed as if the cylindrical anchor has been cut open and laid flat. Figures 2 schematically illustrate a detail portion of apparatus 10 in sidesection.

[0065] Anchor 30 has a lip region 32, a skirt region 34 and a body region 36. First, second and third posts 38a, 38b and 38c, respectively, are coupled to skirt region 34 and extend within lumen 31 of anchor 30. Posts 38 preferably are spaced 120° apart from one another about the circumference of anchor 30.
[0066] Anchor 30 preferably is fabricated by using self-expanding patterns (laser cut or chemically milled), braids and materials, such as a stainless steel, nickel-titanium ("Nitinol") or cobalt chromium, but

- 7 of 29 - FILED VIA EFS

Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 13 of 442

alternatively may be fabricated using balloon-expandable patterns where the anchor is designed to plastically deform to its final shape by means of balloon expansion. Replacement valve 20 is preferably made from biologic tissues, e.g. porcine valve leaflets or bovine or equine pericardium tissues or human cadaver tissue. Alternatively, it can be made from tissue engineered materials (such as extracellular matrix material from Small Intestinal Submucosa (SIS)) or may be prosthetic and made from an elastomeric polymer or silicone, Nitinol or stainless steel mesh or pattern (sputtered, chemically milled or laser cut). The leaflet may also be made of a composite of the elastomeric or silicone materials and metal alloys or other fibers such Kevlar or carbon. Annular base 22 of replacement valve 20 preferably is coupled to skirt region 34 of anchor 30, while commissures 24 of replacement valve leaflets 26 are coupled to and supported by posts 38.

[0067] Anchor 30 may be actuated using external non-hydraulic or non-pneumatic force to actively foreshorten in order to increase its radial strength. As shown below, the proximal and distal end regions of anchor 30 may be actuated independently. The anchor and valve may be placed and expanded in order to visualize their location with respect to the native valve and other anatomical features and to visualize operation of the valve. The anchor and valve may thereafter be repositioned and even retrieved into the delivery sheath or catheter. The apparatus may be delivered to the vicinity of the patient's aortic valve in a retrograde approach in a catheter having a diameter no more than 23 french, preferably no more than 21 french, more preferably no more than 19 french, or more preferably no more than 17 french. Upon deployment the anchor and replacement valve capture the native valve leaflets and positively lock to maintain configuration and position.

[0068] A deployment tool is used to actuate, reposition, lock and/or retrieve anchor 30. In order to avoid delivery of anchor 30 on a balloon for balloon expansion, a non-hydraulic or non-pneumatic anchor actuator is used. In this embodiment, the actuator is a deployment tool that includes distal region control wires 50, control rods or tubes 60 and proximal region control wires 62. Locks 40 include posts or arms 38 preferably with male interlocking elements 44 extending from skirt region 34 and mating female interlocking elements 42 in lip region 32. Male interlocking elements 44 have eyelets 45. Control wires 50 pass from a delivery system for apparatus 10 through female interlocking elements 42, through eyelets 45 of male interlocking elements 44, and back through female interlocking elements 42, such that a double strand of wire 50 passes through each female interlocking element 42 for manipulation by a medical practitioner external to the patient to actuate and control the anchor by changing the anchor's shape. Control wires 50 may comprise, for example, strands of suture.

[0069] Tubes 60 are reversibly coupled to apparatus 10 and may be used in conjunction with wires 50 to actuate anchor 30, e.g., to foreshorten and lock apparatus 10 in the fully deployed configuration. Tubes 60 also facilitate repositioning and retrieval of apparatus 10, as described hereinafter. For example,

- 8 of 29 -

FILED VIA EFS

Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 14 of 442

anchor 30 may be foreshortened and radially expanded by applying a distally directed force on tubes 60 while proximally retracting wires 50. As seen in Figures 3, control wires 62 pass through interior lumens 61 of tubes 60. This ensures that tubes 60 are aligned properly with apparatus 10 during deployment and foreshortening. Control wires 62 can also actuate anchor 60; proximally directed forces on control wires 62 contacts the proximal lip region 32 of anchor 30. Wires 62 also act to couple and decouple tubes 60 from apparatus 10. Wires 62 may comprise, for example, strands of suture.

[0070] Figures 1A and 2A illustrate anchor 30 in a delivery configuration or in a partially deployed configuration (e.g., after dynamic self-expansion from a constrained delivery configuration within a delivery sheath). Anchor 30 has a relatively long length and a relatively small width in the delivery or partially deployed configuration, as compared to the foreshortened and fully deployed configuration of Figures 1B and 2B.

[0071] In Figures 1A and 2A, replacement valve 20 is collapsed within lumen 31 of anchor 30. Retraction of wires 50 relative to tubes 60 foreshortens anchor 30, which increases the anchor's width while decreasing its length. Such foreshortening also properly seats replacement valve 20 within lumen 31 of anchor 30. Imposed foreshortening will enhance radial force applied by apparatus 10 to surrounding tissue over at least a portion of anchor 30. In some embodiments, the anchor is capable of exerting an outward radial force on surrounding tissue to engage the tissue in such way to prevent migration of anchor. This outward radial force is preferably greater than 2 psi, more preferably greater than 4 psi, more preferably greater than 6 psi, more preferably greater than 8 psi, more preferably greater than 10 psi, more preferably greater than 20 psi, or more preferably greater than 30 psi. Enhanced radial force of the anchor is also important for enhanced crush resistance of the anchor against the surrounding tissue due to the healing response (fibrosis and contraction of annulus over a longer period of time) or to dynamic changes of pressure and flow at each heart beat. In an alternative embodiment, the anchor pattern or braid is designed to have gaps or areas where the native tissue is allowed to protrude through the anchor slightly (not shown) and, as the foreshortening is applied, the tissue and anchor become intertwined and immobilized. This feature would provide additional means to prevent anchor migration and enhance long-term stability of the device.

[0072] Deployment of apparatus 10 is fully reversible until lock 40 has been locked via mating of male interlocking elements 44 with female interlocking elements 42. Deployment is then completed by decoupling tubes 60 from lip section 32 of anchor 30 by retracting one end of each wire 62 relative to the other end of the wire, and by retracting one end of each wire 50 relative to the other end of the wire until each wire has been removed from eyelet 45 of its corresponding male interlocking element 44.

- 9 of 29 -

FILED VIA EFS

Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 15 of 442

[0073] As best seen in Figure 2B, body region 36 of anchor 30 optionally may comprise barb elements 37 that protrude from anchor 30 in the fully deployed configuration, for example, for engagement of a patient's native valve leaflets and to preclude migration of the apparatus.

[0074] With reference now to Figures 3, a delivery and deployment system for a self-expanding embodiment of apparatus 10 including a sheath 110 having a lumen 112. Self-expanding anchor 30 is collapsible to a delivery configuration within lumen 112 of sheath 110, such that apparatus 10 may be delivered via delivery system 100. As seen in Figure 3A, apparatus 10 may be deployed from lumen 112 by retracting sheath 110 relative to apparatus 10, control wires 50 and tubes 60, which causes anchor 30 to dynamically self-expand to a partially deployed configuration. Control wires 50 then are retracted relative to apparatus 10 and tubes 60 to impose foreshortening upon anchor 30, as seen in Figure 3B. [0075] During foreshortening, tubes 60 push against lip region 32 of anchor 30, while wires 50 pull on posts 38 of the anchor. Wires 62 may be retracted along with wires 50 to enhance the distally directed pushing force applied by tubes 60 to lip region 32. Continued retraction of wires 50 relative to tubes 60 would lock locks 40 and fully deploy apparatus 10 with replacement valve 20 properly seated within anchor 30, as in Figures 1B and 2B. Apparatus 10 comprises enhanced radial strength in the fully deployed configuration as compared to the partially deployed configuration of Figure 3A. Once apparatus 10 has been fully deployed, wires 50 and 62 may be removed from apparatus 10, thereby separating delivery system 100 and tubes 60 from the apparatus.

[0076] Deployment of apparatus 10 is fully reversible until locks 40 have been actuated. For example, just prior to locking the position of the anchor and valve and the operation of the valve may be observed under fluoroscopy. If the position needs to be changed, by alternately relaxing and reapplying the proximally directed forces exerted by control wires 50 and/or control wires 62 and the distally directed forces exerted by tubes 60, expansion and contraction of the lip and skirt regions of anchor 30 may be independently controlled so that the anchor and valve can be moved to, e.g., avoid blocking the coronary ostia or impinging on the mitral valve. Apparatus 10 may also be completely retrieved within lumen 112 of sheath 110 by simultaneously proximally retracting wires 50 and tubes 60/wires 62 relative to sheath 110. Apparatus 10 then may be removed from the patient or repositioned for subsequent redeployment. [0077] Referring now to Figures 4, step-by-step deployment of apparatus 10 via delivery system 100 is described. In Figure 4A, sheath 110 is retracted relative to apparatus 10, wires 50 and tubes 60, thereby causing self-expandable anchor 30 to dynamically self-expand apparatus 10 from the collapsed delivery configuration within lumen 112 of sheath 110 to the partially deployed configuration. Apparatus 10 may then be dynamically repositioned via tubes 60 to properly orient the apparatus, e.g. relative to a patient's native valve leaflets.

- 10 of 29 -

FILED VIA EFS

[0078] In Figure 4B, control wires 50 are retracted while tubes 60 are advanced, thereby urging lip region 32 of anchor 30 in a distal direction while urging posts 38 of the anchor in a proximal direction. This foreshortens apparatus 10, as seen in Figure 4C. Deployment of apparatus 10 is fully reversible even after foreshortening has been initiated and has advanced to the point illustrated in Figure 4C.

[0079] In Figure 4D, continued foreshortening causes male interlocking elements 44 of locks 40 to engage female interlocking elements 42. The male elements mate with the female elements, thereby locking apparatus 10 in the foreshortened configuration, as seen in Figure 4E. Wires 50 are then pulled through eyelets 45 of male elements 44 to remove the wires from apparatus 10, and wires 62 are pulled through the proximal end of anchor 30 to uncouple tubes 60 from the apparatus, thereby separating delivery system 100 from apparatus 10. Fully deployed apparatus 10 is shown in Figure 4F.

[0080] Referring to Figures 5, a method of endovascularly replacing a patient's diseased aortic valve with apparatus 10 and delivery system 100 is described. As seen in Figure 5A, sheath 110 of delivery system 100, having apparatus 10 disposed therein, is endovascularly advanced over guide wire G, preferably in a retrograde fashion (although an antegrade or hybrid approach alternatively may be used), through a patient's aorta A to the patient's diseased aortic valve AV. A nosecone 102 precedes sheath 110 in a known manner. In Figure 5B, sheath 110 is positioned such that its distal region is disposed within left ventricle LV of the patient's heart H.

[0081] Apparatus 10 is deployed from lumen 112 of sheath 110, for example, under fluoroscopic guidance, such that anchor 30 of apparatus 10 dynamically self-expands to a partially deployed configuration, as in Figure 5C. Advantageously, apparatus 10 may be retracted within lumen 112 of sheath 110 via wires 50 - even after anchor 30 has dynamically expanded to the partially deployed configuration, for example, to abort the procedure or to reposition apparatus 10 or delivery system 100. As yet another advantage, apparatus 10 may be dynamically repositioned, e.g. via sheath 110 and/or tubes 60, in order to properly align the apparatus relative to anatomical landmarks, such as the patient's coronary ostia or the patient's native valve leaflets **L**. When properly aligned, skirt region 34 of anchor 30 preferably is disposed distal of the leaflets, while body region 36 is disposed across the leaflets and lip region 32 is disposed proximal of the leaflets.

[0082] Once properly aligned, wires 50 are retracted relative to tubes 60 to impose foreshortening upon anchor 30 and expand apparatus 10 to the fully deployed configuration, as in Figure 5D. Foreshortening increases the radial strength of anchor 30 to ensure prolonged patency of valve annulus **An**, as well as to provide a better seal for apparatus 10 that reduces paravalvular regurgitation. As seen in Figure 5E, locks 40 maintain imposed foreshortening. Replacement valve 20 is properly seated within anchor 30, and normal blood flow between left ventricle **LV** and aorta **A** is thereafter regulated by

- 11 of 29 -

FILED VIA EFS

Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 17 of 442

apparatus 10. Deployment of apparatus 10 advantageously is fully reversible until locks 40 have been actuated.

[0083] As seen in Figure 5F, wires 50 are pulled from eyelets 45 of male elements 44 of locks 40, tubes 60 are decoupled from anchor 30, e.g. via wires 62, and delivery system 100 is removed from the patient, thereby completing deployment of apparatus 10. Optional barb elements 37 engage the patient's native valve leaflets, e.g. to preclude migration of the apparatus and/or reduce paravalvular regurgitation. **[0084]** With reference now to Figures 6, a method of endovascularly replacing a patient's diseased aortic valve with apparatus 10 is provided, wherein proper positioning of the apparatus is ensured via positive registration of a modified delivery system to the patient's native valve leaflets. In Figure 6A, modified delivery system 100' delivers apparatus 10 to diseased aortic valve **AV** within sheath 110. As seen in Figures 6B and 6C, apparatus 10 is deployed from lumen 112 of sheath 110, for example, under fluoroscopic guidance, such that anchor 30 of apparatus 10 dynamically self-expands to a partially deployed configuration. As when deployed via delivery system 100, deployment of apparatus 10 via delivery system 100' is fully reversible until locks 40 have been actuated.

[0085] Delivery system 100' comprises leaflet engagement element 120, which preferably selfexpands along with anchor 30. Engagement element 120 is disposed between tubes 60 of delivery system 100' and lip region 32 of anchor 30. Element 120 releasably engages the anchor. As seen in Figure 6C, the element is initially deployed proximal of the patient's native valve leaflets L. Apparatus 10 and element 120 then may be advanced/dynamically repositioned until the engagement element positively registers against the leaflets, thereby ensuring proper positioning of apparatus 10. Also, delivery system 100' includes filter structure 61A (e.g., filter membrane or braid) as part of push tubes 60 to act as an embolic protection element. Emboli can be generated during manipulation and placement of anchor, from either diseased native leaflet or surrounding aortic tissue, and can cause blockage. Arrows 61B in Figure 6E show blood flow through filter structure 61A where blood is allowed to flow but emboli is trapped in the delivery system and removed with it at the end of the procedure.

[0086] Alternatively, foreshortening may be imposed upon anchor 30 while element 120 is disposed proximal of the leaflets, as in Figure 6D. Upon positive registration of element 120 against leaflets L, element 120 precludes further distal migration of apparatus 10 during additional foreshortening, thereby reducing a risk of improperly positioning the apparatus. Figure 6E details engagement of element 120 against the native leaflets. As seen in Figure 6F, once apparatus 10 is fully deployed, element 120, wires 50 and tubes 60 are decoupled from the apparatus, and delivery system 100' is removed from the patient, thereby completing the procedure.

[0087] With reference to Figure 7, an alternative embodiment of the apparatus of Figures 6 is described, wherein leaflet engagement element 120 is coupled to anchor 30 of apparatus 10', rather than

- 12 of 29 - FILED VIA EFS

Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 18 of 442

to delivery system 100. Engagement element 120 remains implanted in the patient post-deployment of apparatus 10'. Leaflets L are sandwiched between lip region 32 of anchor 30 and element 120 in the fully deployed configuration. In this manner, element 120 positively registers apparatus 10' relative to the leaflets and precludes distal migration of the apparatus over time.

[0088] Referring now to Figures 8, an alternative delivery system adapted for use with a balloon expandable embodiment of the present invention is described. In Figure 8A, apparatus 10" comprises anchor 30' that may be fabricated from balloon-expandable materials. Delivery system 100" comprises inflatable member 130 disposed in a deflated configuration within lumen 31 of anchor 30'. In Figure 8B, optional outer sheath 110 is retracted, and inflatable member 130 is inflated to expand anchor 30' to the fully deployed configuration. As inflatable member 130 is being deflated, as in earlier embodiments, wires 50 and 62 and tubes 60 may be used to assist deployment of anchor 30' and actuation of locks 40, as well as to provide reversibility and retrievability of apparatus 10" prior to actuation of locks 40. Next, wires 50 and 62 and tubes 60 are removed from apparatus 10", and delivery system 100" is removed, as seen in Figure 8C.

[0089] As an alternative delivery method, anchor 30' may be partially deployed via partial expansion of inflatable member 130. The inflatable member would then be advanced within replacement valve 20 prior to inflation of inflatable member 130 and full deployment of apparatus 10". Inflation pressures used will range from about 3 to 6 atm, or more preferably from about 4 to 5 atm, though higher and lower atm pressures may also be used (e.g., greater than 3 atm, more preferably greater than 4 atm, more preferably greater than 5 atm, or more preferably greater than 6 atm). Advantageously, separation of inflatable member 130 from replacement valve 20, until partial deployment of apparatus 10" at a treatment site, is expected to reduce a delivery profile of the apparatus, as compared to previously known apparatus. This profile reduction may facilitate retrograde delivery and deployment of apparatus 10", even when anchor 30' is balloon-expandable.

[0090] Although anchor 30' has illustratively been described as fabricated from balloon-expandable materials, it should be understood that anchor 30' alternatively may be fabricated from self-expanding materials whose expansion optionally may be balloon-assisted. In such a configuration, anchor 30' would expand to a partially deployed configuration upon removal of outer sheath 110. If required, inflatable member 130 then would be advanced within replacement valve 20 prior to inflation. Inflatable member 130 would assist full deployment of apparatus 10'', for example, when the radial force required to overcome resistance from impinging tissue were too great to be overcome simply by manipulation of wires 50 and tubes 60. Advantageously, optional placement of inflatable member 130 within replacement valve 20, only after dynamic self-expansion of apparatus 10'' to the partially deployed configuration at a

- 13 of 29 -

FILED VIA EFS

Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 19 of 442

treatment site, is expected to reduce a delivery profile of the apparatus, as compared to previously known apparatus. This reduction may facilitate retrograde delivery and deployment of apparatus 10".

[0091] With reference to Figures 9 and 10, methods and apparatus for a balloon-assisted embodiment of the present invention are described in greater detail. Figures 9 and 10 illustratively show apparatus 10' of Figures 7 used in combination with delivery system 100'' of Figures 8. Figure 10 illustrates a sectional view of delivery system 100''. Inner shaft 132 of inflatable member 130 preferably is about 4 Fr in diameter, and comprises lumen 133 configured for passage of guidewire **G**, having a diameter of about 0.035'', therethrough. Push tubes 60 and pull wires 50 pass through guidetube 140, which preferably has a diameter of about 15 Fr or smaller. Guide tube 140 is disposed within lumen 112 of outer sheath 110, which preferably has a diameter of about 17 Fr or smaller.

[0092] In Figure 9A, apparatus 10' is delivered to diseased aortic valve **AV** within lumen 112 of sheath 110. In Figure 9B, sheath 110 is retracted relative to apparatus 10' to dynamically self-expand the apparatus to the partially deployed configuration. Also retracted and removed is nosecone 102, which is attached to a pre-slit lumen (not shown) that facilitates its removal prior to loading and advancing of a regular angioplasty balloon catheter over guidewire and inside delivery system 110.

[0093] In Figure 9C, pull wires 50 and push tubes 60 are manipulated from external to the patient to foreshorten anchor 30 and sufficiently expand lumen 31 of the anchor to facilitate advancement of inflatable member 130 within replacement valve 20. Also shown is the tip of an angioplasty catheter 130 being advanced through delivery system 110.

[0094] The angioplasty balloon catheter or inflatable member 130 then is advanced within the replacement valve, as in Figure 9D, and additional foreshortening is imposed upon anchor 30 to actuate locks 40, as in Figure 9E. The inflatable member is inflated to further displace the patient's native valve leaflets L and ensure adequate blood flow through, and long-term patency of, replacement valve 20, as in Figure 9F. Inflatable member 130 then is deflated and removed from the patient, as in Figure 9G. A different size angioplasty balloon catheter could be used repeat the same step if deemed necessary by the user. Push tubes 60 optionally may be used to further set leaflet engagement element 120, or optional barbs B along posts 38, more deeply within leaflets L, as in Figure 9H. Then, delivery system 100'' is removed from the patient, thereby completing percutaneous heart valve replacement.

[0095] As will be apparent to those of skill in the art, the order of imposed foreshortening and balloon expansion described in Figures 9 and 10 is only provided for the sake of illustration. The actual order may vary according to the needs of a given patient and/or the preferences of a given medical practitioner. Furthermore, balloon-assist may not be required in all instances, and the inflatable member may act merely as a safety precaution employed selectively in challenging clinical cases.

- 14 of 29 -

FILED VIA EFS

Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 20 of 442

[0096] Referring now to Figures 11, alternative locks for use with apparatus of the present invention are described. In Figure 11A, lock 40' comprises male interlocking element 44 as described previously. However, female interlocking element 42' illustratively comprises a triangular shape, as compared to the round shape of interlocking element 42 described previously. The triangular shape of female interlocking element 42' may facilitate mating of male interlocking element 44 with the female interlocking element without necessitating deformation of the male interlocking element.

[0097] In Figure 11B, lock 40'' comprises alternative male interlocking element 44' having multiple in-line arrowheads 46 along posts 38. Each arrowhead comprises resiliently deformable appendages 48 to facilitate passage through female interlocking element 42. Appendages 48 optionally comprise eyelets 49, such that control wire 50 or a secondary wire may pass therethrough to constrain the appendages in the deformed configuration. To actuate lock 40'', one or more arrowheads 46 of male interlocking element 42' are drawn through female interlocking element 42, and the wire is removed from eyelets 49, thereby causing appendages 48 to resiliently expand and actuate lock 40''.

[0098] Advantageously, providing multiple arrowheads 46 along posts 38 yields a ratchet that facilitates *in-vivo* determination of a degree of foreshortening imposed upon apparatus of the present invention. Furthermore, optionally constraining appendages 48 of arrowheads 46 via eyelets 49 prevents actuation of lock 40'' (and thus deployment of apparatus of the present invention) even after male element 44' has been advanced through female element 42. Only after a medical practitioner has removed the wire constraining appendages 48 is lock 40'' fully engaged and deployment no longer reversible.

[0099] Lock 40" of Figure 11C is similar to lock 40" of Figure 11B, except that optional eyelets 49 on appendages 48 have been replaced by optional overtube 47. Overtube 47 serves a similar function to eyelets 49 by constraining appendages 48 to prevent locking until a medical practitioner has determined that apparatus of the present invention has been foreshortened and positioned adequately at a treatment site. Overtube 47 is then removed, which causes the appendages to resiliently expand, thereby fully actuating lock 40".

[00100] With reference to Figures 12, an alternative locking mechanism is described that is configured to engage the patient's aorta. Male interlocking elements 44'' of locks 40'''' comprise arrowheads 46' having sharpened appendages 48'. Upon expansion from the delivery configuration of Figure 12A to the foreshortened configuration of Figure 12B, apparatus 10 positions sharpened appendages 48' adjacent the patient's aorta **A**. Appendages 48' engage the aortic wall and reduce a risk of device migration over time. [00101] With reference now to Figure 13, a risk of paravalvular leakage or regurgitation around apparatus of the present invention is described. In Figure 13, apparatus 10 has been implanted at the site of diseased aortic valve **AV**, for example, using techniques described hereinabove. The surface of native

- 15 of 29 -

FILED VIA EFS

Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 21 of 442

valve leaflets L is irregular, and interface I between leaflets L and anchor 30 may comprise gaps where blood B may seep through. Such leakage poses a risk of blood clot formation or insufficient blood flow. [00102] Referring to Figure 14, optional elements for reducing regurgitation or leakage are described. Compliant sacs 200 may be disposed about the exterior of anchor 30 to provide a more efficient seal along irregular interface I. Sacs 200 may be filled with an appropriate material, for example, water, blood, foam or a hydrogel. Alternative fill materials will be apparent.

[00103] With reference to Figures 15, illustrative arrangements for sacs 200 are provided. In Figure 15A, sacs 200 are provided as discrete sacs at different positions along the height of anchor 30. In Figure 15B, the sacs are provided as continuous cylinders at various heights. In Figure 15C, a single sac is provided with a cylindrical shape that spans multiple heights. The sacs of Figure 15D are discrete, smaller and provided in larger quantities. Figure 15E provides a spiral sac. Alternative sac configurations will be apparent to those of skill in the art.

[00104] With reference to Figures 16, exemplary techniques for fabricating sacs 200 are provided. In Figure 16A, sacs 200 comprise 'fish-scale' slots 202 that may be back-filled, for example, with ambient blood passing through replacement valve 20. In Figure 16B, the sacs comprise pores 204 that may be used to fill the sacs. In Figure 16C, the sacs open to lumen 31 of anchor 30 and are filled by blood washing past the sacs as the blood moves through apparatus 10.

[00105] Figures 17 and 18 show yet another alternative embodiment of the anchor lock. Anchor 300 has a plurality of male interlocking elements 302 having eyelets 304 formed therein. Male interlocking elements are connected to braided structure 300 by inter-weaving elements 302 (and 308) or alternatively suturing, soldering, welding, or connecting with adhesive. Valve commissures 24 are connected to male interlocking elements 302 along their length. Replacement valve 20 annular base 22 is connected to the distal end 34 of anchor 300 (or 30) as is illustrated in figures 1A and 1B. Male interlocking elements 302 also include holes 306 that mate with tabs 310 extending into holes 312 in female interlocking elements 308. To lock, control wires 314 passing through eyelets 304 and holes 312 are pulled proximally with respect to the proximal end of braided anchor 300 to draw the male interlocking elements through holes 312 so that tabs 310 engage holes 306 in male interlocking element 302. Also shown is release wires 314B that pass through eyelet 304B in female interlocking element 308. If needed, during the procedure, the user may pull on release wires 314B, thereby reversing orientation of tabs 310, releasing the anchor and allowing for repositioning of the device or its removal from the patient. Only when finally positioned as desired by the operating physician, would release wire 314B and control wire 314 be cut and removed from the patient with the delivery system.

[00106] Figures 19-21 show an alternative way of releasing the connection between the anchor and its actuating tubes and control wires. Control wires 62 extend through tubes 60 from outside the patient,

- 16 of 29 -

FILED VIA EFS

Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 22 of 442

loop through the proximal region of anchor 30 and extend partially back into tube 60. The doubled up portion of control wire 62 creates a force fit within tube 60 that maintains the control wire's position with respect to tube 60 when all control wires 62 are pulled proximally to place a proximally directed force on anchor 30. When a single control wire 62 is pulled proximally, however, the frictional fit between that control wire and the tube in which it is disposed is overcome, enabling the end 63 of control wire 62 to pull free of the tube, as shown in Figure 21, thereby releasing anchor 30.

[00107] Figures 22-24 show an alternative embodiment of the anchor. Anchor 350 is made of a metal braid, such as Nitinol or stainless steel. A replacement valve 354 is disposed within anchor 350 and supported by a replacement valve support, such as the posts described in earlier embodiments. Anchor 350 preferably is fabricated from a single strand of metal wire wound into the braid. It is expected that fabricating anchor 350 from a single strand of wire will facilitate deployment of the anchor, as well as retrieval of the anchor, by more evenly distributing forces applied to the anchor. Fabrication from a single strand is also expected to facilitate coupling of replacement valve 354 to the anchor, as well as coupling and decoupling of control wires (not shown) and tubes 352 thereto. Anchor 350 is actuated in substantially the same way as anchor 30 of Figures 1-4 through the application of proximally and distally directed forces from control wires and tubes 352 and may be locked in its expanded deployed configuration, as described above. The employed configuration of anchor 354 may have the shape and anchoring characteristics described with respect to other embodiments as well.

[00108] The braid forming anchor 350 (as well as that forming previously described anchor 30) optionally may be locally increased in diameter, e.g. via dipping in silicone or a hydrogel, in order to provide a better or complete seal against the patient's anatomy. An improved seal is expected to reduce paravalvular leakage, as well as migration of the anchor over time. The local increase in diameter of the braid may, for example, be provided over a full radial segment of anchor 350.

[00109] Figures 25 and 26 show yet another embodiment of the delivery and deployment apparatus of the invention. As an alternative to the balloon expansion method described with respect to Figures 8, in this embodiment the nosecone (e.g., element 102 of Figures 5) is replaced by an angioplasty balloon catheter 360. Thus, angioplasty balloon catheter 360 precedes sheath 110 on guidewire G. When anchor 30 and valve 20 are expanded through the operation of tubes 60 and the control wires (not shown) as described above, balloon catheter 360 is retracted proximally within the expanded anchor and valve and expanded further as described above with respect to Figures 8.

[00110] As an alternative, or in addition, to further expansion of balloon catheter 360 within valve 20 and expanded anchor 30 to further expand the anchor, the balloon may be deflated prior to proximal retraction within and past the valve and anchor. In this manner, balloon catheter 360 may act as an atraumatic nosecone during delivery of valve 20 and anchor 30, but then may be deflated to provide a

- 17 of 29 -

FILED VIA EFS

Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 23 of 442

reduced profile, as compared to a standard nosecone, during retrieval of the balloon catheter through the deployed valve. It is expected that a smaller balloon catheter 360 may be provided when the catheter is utilized merely in place of a nosecone than when the catheter is also utilized to complete expansion of anchor 30.

[00111] Figures 27-31 show seals 370 that expand over time to seal the interface between the anchor and valve and the patient's tissue. Seals 370 are preferably formed from Nitinol wire surrounded by an expandable foam. As shown in cross-section in Figures 28 and 29, at the time of deployment, the foam 372 is compressed about the wire 374 and held in the compressed form by a time-released coating 376. After deployment, coating 376 dissolves in vivo to allow foam 372 to expand, as shown in Figures 30 and 31.

[00112] Figures 32-34 show another way to seal the replacement valve against leakage. A fabric seal 380 extends from the distal end of valve 20 and back proximally over anchor 30 during delivery. When deployed, as shown in Figures 33 and 34, fabric seal 380 bunches up to create fabric flaps and pockets that extend into spaces formed by the native valve leaflets 382, particularly when the pockets are filled with blood in response to backflow blood pressure. This arrangement creates a seal around the replacement valve.

[00113] Figures 35A-H show another embodiment of a replacement heart valve apparatus in accordance with the present invention. Apparatus 450 comprises replacement valve 460 (see Figures 37B and 38C) disposed within and coupled to anchor 470. Replacement valve 460 is preferably biologic, e.g. porcine, but alternatively may be synthetic. Anchor 470 preferably is fabricated from self-expanding materials, such as a stainless steel wire mesh or a nickel-titanium alloy ("Nitinol"), and comprises lip region 472, skirt region 474, and body regions 476a, 476b and 476c. Replacement valve 460 preferably is coupled to skirt region 474, but alternatively may be coupled to other regions of the anchor. As described hereinbelow, lip region 472 and skirt region 474 are configured to expand and engage/capture a patient's native valve leaflets, thereby providing positive registration, reducing paravalvular regurgitation, reducing device migration, etc.

[00114] As seen in Figure 35A, apparatus 450 is collapsible to a delivery configuration, wherein the apparatus may be delivered via delivery system 410. Delivery system 410 comprises sheath 420 having lumen 422, as well as wires 424a and 424b seen in Figures 35D-35G. Wires 424a are configured to expand skirt region 474 of anchor 470, as well as replacement valve 460 coupled thereto, while wires 424b are configured to expand lip region 472.

[00115] As seen in Figure 35B, apparatus 450 may be delivered and deployed from lumen 422 of catheter 420 while the apparatus is disposed in the collapsed delivery configuration. As seen in Figures 35B-35D, catheter 420 is retracted relative to apparatus 450, which causes anchor 470 to dynamically

- 18 of 29 -

FILED VIA EFS

Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 24 of 442

self-expand to a partially deployed configuration. Wires 424a are then retracted to expand skirt region 474, as seen in Figures 35E and 35F. Preferably, such expansion may be maintained via locking features described hereinafter.

[00116] In Figure 35G, wires 424b are retracted to expand lip region 472 and fully deploy apparatus 450. As with skirt region 474, expansion of lip region 472 preferably may be maintained via locking features. After both lip region 472 and skirt region 474 have been expanded, wires 424 may be removed from apparatus 450, thereby separating delivery system 410 from the apparatus. Delivery system 410 then may be removed, as seen in Figure 35H.

[00117] As will be apparent to those of skill in the art, lip region 472 optionally may be expanded prior to expansion of skirt region 474. As yet another alternative, lip region 472 and skirt region 474 optionally may be expanded simultaneously, in parallel, in a step-wise fashion or sequentially. Advantageously, delivery of apparatus 450 is fully reversible until lip region 472 or skirt region 474 has been locked in the expanded configuration.

[00118] With reference now to Figures 36A-E, individual cells of anchor 470 of apparatus 450 are described to detail deployment and expansion of the apparatus. In Figure 36A, individual cells of lip region 472, skirt region 474 and body regions 476a, 476b and 476c are shown in the collapsed delivery configuration, as they would appear while disposed within lumen 422 of sheath 420 of delivery system 410 of Figures 35. A portion of the cells forming body regions 476, for example, every 'nth' row of cells, comprises locking features.

[00119] Body region 476a comprises male interlocking element 482 of lip lock 480, while body region 476b comprises female interlocking element 484 of lip lock 480. Male element 482 comprises eyelet 483. Wire 424b passes from female interlocking element 484 through eyelet 483 and back through female interlocking element 484, such that there is a double strand of wire 424b that passes through lumen 422 of catheter 420 for manipulation by a medical practitioner external to the patient. Body region 476b further comprises male interlocking element 492 of skirt lock 490, while body region 476c comprises female interlocking element 492 of skirt lock 490, while body region 476c comprises female interlocking element 494 of the skirt lock. Wire 424a passes from female interlocking element 494 through eyelet 493 of male interlocking element 492, and back through female interlocking element 494. Lip lock 480 is configured to maintain expansion of lip region 472, while skirt lock 490 is configured to maintain expansion of lip region 472, while skirt lock 490 is configured to maintain expansion of lip region 472.

[00120] In Figure 36B, anchor 470 is shown in the partially deployed configuration, e.g., after deployment from lumen 422 of sheath 420. Body regions 476, as well as lip region 472 and skirt region 474, self-expand to the partially deployed configuration. Full deployment is then achieved by retracting wires 424 relative to anchor 470, and expanding lip region 472 and skirt region 474 outward, as seen in Figures 36C and 36D. As seen in Figure 36E, expansion continues until the male elements engage the

- 19 of 29 -

FILED VIA EFS

Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 25 of 442

female interlocking elements of lip lock 480 and skirt lock 490, thereby maintaining such expansion (lip lock 480 shown in Figure 36E). Advantageously, deployment of apparatus 450 is fully reversible until lip lock 480 and/or skirt lock 490 has been actuated.

[00121] With reference to Figures 37A-B, isometric views, partially in section, further illustrate apparatus 450 in the fully deployed and expanded configuration. Figure 37A illustrates the wireframe structure of anchor 470, while Figure 37B illustrates an embodiment of anchor 470 covered in a biocompatible material **B**. Placement of replacement valve 460 within apparatus 450 may be seen in Figure 37B. The patient's native valve is captured between lip region 472 and skirt region 474 of anchor 470 in the fully deployed configuration (see Figure 38B).

[00122] Referring to Figures 38A-C, in conjunction with Figures 35 and 36, a method for endovascularly replacing a patient's diseased aortic valve with apparatus 450 is described. Delivery system 410, having apparatus 450 disposed therein, is endovascularly advanced, preferably in a retrograde fashion, through a patient's aorta **A** to the patient's diseased aortic valve **AV**. Sheath 420 is positioned such that its distal end is disposed within left ventricle **LV** of the patient's heart **H**. As described with respect to Figures 35, apparatus 450 is deployed from lumen 422 of sheath 420, for example, under fluoroscopic guidance, such that skirt section 474 is disposed within left ventricle **LV**, body section 476b is disposed across the patient's native valve leaflets **L**, and lip section 472 is disposed within the patient's aorta **A**. Advantageously, apparatus 450 may be dynamically repositioned to obtain proper alignment with the anatomical landmarks. Furthermore, apparatus 450 may be retracted within lumen 422 of sheath 420 via wires 424, even after anchor 470 has dynamically expanded to the partially deployed configuration, for example, to abort the procedure or to reposition sheath 420.

[00123] Once properly positioned, wires 424a are retracted to expand skirt region 474 of anchor 470 within left ventricle **LV**. Skirt region 474 is locked in the expanded configuration via skirt lock 490, as previously described with respect to Figures 36. In Figure 38A, skirt region 474 is maneuvered such that it engages the patient's valve annulus **An** and/or native valve leaflets **L**, thereby providing positive registration of apparatus 450 relative to the anatomical landmarks.

[00124] Wires 424b are then actuated external to the patient in order to expand lip region 472, as previously described in Figures 35. Lip region 472 is locked in the expanded configuration via lip lock 480. Advantageously, deployment of apparatus 450 is fully reversible until lip lock 480 and/or skirt lock 490 has been actuated. Wires 424 are pulled from eyelets 483 and 493, and delivery system 410 is removed from the patient. As will be apparent, the order of expansion of lip region 472 and skirt region 474 may be reversed, concurrent, etc.

[00125] As seen in Figure 38B, lip region 472 engages the patient's native valve leaflets L, thereby providing additional positive registration and reducing a risk of lip region 472 blocking the patient's

- 20 of 29 -

FILED VIA EFS

Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 26 of 442

coronary ostia **O**. Figure 38C illustrates the same in cross-sectional view, while also showing the position of replacement valve 460. The patient's native leaflets are engaged and/or captured between lip region 472 and skirt region 474. Advantageously, lip region 472 precludes distal migration of apparatus 450, while skirt region 474 precludes proximal migration. It is expected that lip region 472 and skirt region 474 also will reduce paravalvular regurgitation.

[00126] Referring now to Figures 39, an embodiment of apparatus in accordance with the present invention is described, wherein the replacement valve is not connected to the expandable portion of the anchor. Rather, the replacement valve is wrapped about an end of the anchor. Such wrapping may be achieved, for example, by everting the valve during endovascular deployment.

[00127] In Figures 39, apparatus 500 comprises expandable anchor 30' and everting replacement valve 520, as well as delivery system 100' for endoluminally delivering and deploying the expandable anchor and everting valve. Expandable anchor 30' illustratively is described as substantially the same as previously described anchor 30 of Figures 1-4; however, it should be understood that anchor 30' alternatively may be substantially the same as anchor 300 of Figures 17 and 18, anchor 350 of Figures 24-26, or anchor 470 of Figures 35. As with anchor 30, anchor 30' comprises posts 38 and locks (comprised of elements 523 and 532). Alternative locks may be provided, such as locks 40', 40'', 40''' or 40''' of Figures 11 and 12, or the reversible lock of anchor 300 described with respect to Figures 17 and 18. **[00128]** Everting value 520 is similar to previously described value 20, in that commissures 524 of replacement valve leaflets 526 are coupled to and supported by posts 38 of anchor 30'. However, annular base 522 of replacement valve 520 is not coupled to anchor 30'. Rather, annular base 522 is coupled to everting segment 528 of everting replacement valve 520. Everting segment 528 is disposed distal of anchor 30' in the delivery configuration and is configured to wrap about the distal end of the anchor during deployment, such as by everting, thereby holding (such as by friction locking) replacement valve 520 between the anchor and the patient's tissue, thereby creating a seal between the anchor and the patient's tissue. In this manner, replacement valve 520 is entirely disconnected from the expandable/collapsible portion of anchor 30', and a delivery profile of apparatus 500 is reduced, as compared to previously described apparatus 10.

[00129] Everting segment 528 of valve 520 may be fabricated from the same material as valve leaflets 526, e.g., a biologic tissue or a polymeric material. Alternatively, the segment may comprise a fabric, such as a permeable or impermeable fabric, a fabric that promotes or retards tissue ingrowth, a sealing foam, etc. Additional materials will be apparent.

[00130] Delivery system 100' for use with anchor 30' and replacement valve 520, is similar to previously described delivery system 100. The delivery system comprises sheath 110' having lumen 112', in which anchor 30' may be collapsed for delivery. Control wires 50, tubes 60 and control wires 62

- 21 of 29 -

Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 27 of 442

FILED VIA EFS

have been provided to deploy, foreshorten, retrieve, etc., anchor 30', as discussed previously, and optional balloon catheter 360 has been provided as a collapsible nosecone (see Figure 25). In delivery system 100', the posts are connected to the distal end of the anchor and the everting valve is connected to the posts. Delivery system 100' differs from system 100 in that it further comprises eversion control wires 550, which may, for example, be fabricated from suture.

[00131] Control wires 550 are coupled to a distal region of everting segment 528 of valve 520, and then pass proximally out of the patient external to anchor 30' for manipulation by a medical practitioner. Control wires 550 preferably are kept taut to keep everting segment 528 in tension. Upon retraction of sheath 110' relative to anchor 30' and valve 520 (or advancement of the anchor and valve relative to the sheath), the tension applied to segment 528 by wires 550 causes the segment to evert and wrap about the distal end of anchor 30'. Anchor 30' then may be expanded and deployed as described previously, thereby friction locking everting segment 528 between the anchor and the patient's anatomy.

[00132] Figures 39 illustrate a device and method for endovascularly replacing a patient's diseased aortic valve utilizing apparatus 500. In Figure 39A, sheath 110' of delivery system 100', having expandable anchor 30' and everting valve 520 disposed therein within lumen 112', is endovascularly advanced over guide wire G, preferably in a retrograde fashion (although an antegrade or hybrid approach alternatively may be used), through a patient's aorta A to the patient's diseased aortic valve AV. Balloon catheter nosecone 360 precedes sheath 110'. Sheath 110' is positioned such that its distal region is disposed within left ventricle LV of the patient's heart H. In Figure 39A, wires 550 pass from segment 528 and lumen 112' to the exterior of sheath 110' via through-holes 111a', and then more proximally pass back into the interior of sheath 110' via through-holes 111b', which are disposed proximal of anchor 30'.

[00134] Figure 39C illustrates the beginning of the everting process wherein everting segment 528 is being pulled proximally over the exterior of anchor 30'. As seen in Figure 39C, which provides and isometric view of the device, the inflatable element of balloon catheter 360 is deflated and further distally advanced within left ventricle LV along guide wire G relative to sheath 110'. Anchor 30' and replacement valve 520 then are advanced relative to the sheath via tubes 60 and control wires 62, thereby deploying everting segment 528 of valve 520, as well as a distal region of anchor 30', from the distal end of lumen 112'. Tension applied to everting segment 528 via control wires 550 connected through eyelets 529 causes the segment to wrap about the distal region of anchor 30' by everting.

[00135] In Figure 39C, wires 550 may pass distally from everting segment 528 out the distal end of lumen 112' of sheath 110', then proximally along the interior surface of the sheath all the way out of the patient. Optional through-holes 111b' allow wires 550 to be disposed within lumen 112' along a majority of their length. Wires 550 may also pass back into multi-lumen sheath 180.

- 22 of 29 -

FILED VIA EFS

Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 28 of 442

[00136] Figure 39D provides a cross sectional view of apparatus 500 after replacement valve 520 has everted about anchor 30'. This and other cross sectional figures portray a 120° view of the apparatus herein. Sheath 110' is then retracted relative to anchor 30' and valve 520, which deploys a remainder of the anchor and the replacement valve from lumen 112' of the sheath. Such deployment may be conducted, for example, under fluoroscopic guidance. Anchor 30' dynamically self-expands to a partially deployed configuration.

[00137] Advantageously, anchor 30' and replacement valve 520 may be retrieved and retracted within the lumen of sheath 110' via retraction of multi-lumen catheter 180 to which tubes 60 are attached and release of wires 50. Such retrieval of apparatus 500 may be achieved even after segment 528 has been wrapped about anchor 30', and even after anchor 30' has dynamically expanded to the partially deployed configuration. Retrieval of apparatus 500 may be utilized, for example, to abort the procedure or to reposition the apparatus. As yet another advantage, anchor 30' and valve 520 may be dynamically repositioned, e.g. via proximal retraction of multi-lumen catheter 180 and/or release of wires 50, in order to properly align the apparatus relative to anatomical landmarks, such as the patient's coronary ostia **O** or the patient's native valve leaflets **L**.

[00138] Once properly aligned sheath 110', tubes 60 and wires 62 are advanced relative to wires 50 and 550 to impose foreshortening upon anchor 30', thereby expanding the anchor to the fully deployed configuration, as in Figure 39G. Foreshortening friction locks everting segment 528 of valve 520 between anchor 30' and annulus **An**/leaflets **L** of the patient's diseased valve, thus properly seating the valve within the anchor while providing an improved seal between the replacement and native valves that is expected to reduce paravalvular regurgitation. Foreshortening also increases a radial strength of anchor 30', which is expected to prolong patency of valve annulus **An**. Furthermore, foreshortening actuates the anchor's locks, which maintain such imposed foreshortening.

[00139] Deployment of anchor 30' and replacement valve 520 advantageously is fully reversible until the anchor locks have been actuated. Furthermore, if the anchor's locks are reversible locks or buckles, such as those described in conjunction with anchor 300 of Figures 17 and 18, deployment of the anchor and valve may be fully reversible even after actuation of the locks/buckles, right up until delivery system 100' is decoupled from the replacement apparatus.

[00140] As seen in Figure 39G, in order to complete deployment of anchor 30' and replacement valve 520, wires 50 of delivery system 100' are decoupled from posts 38 of anchor 30', tubes 60 are decoupled from anchor 30', e.g. via wires 62, and wires 550 are decoupled from friction-locked everting segment 528 of replacement valve 520. Figure 39E illustrates how wires 50 are associated with posts 38. In one example, wires 50 are decoupled from posts 38 by pulling on one of the wires. Decoupling of the wires and tubes may also be achieved, for example, via eyelets (see Figures 4E, 19-21 and 39E) or via cutting of

- 23 of 29 -

FILED VIA EFS

Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 29 of 442

the wires. Delivery system 100' then is removed from the patient, as are deflated balloon catheter 360 and guide wire **G**, both of which are retracted proximally across the replacement valve and anchor. Normal blood flow between left ventricle **LV** and aorta **A** thereafter is regulated by replacement valve 520. Figure 39F is a blow up illustration of replacement valves 526 which are connected to everting segment 528, wherein everting segment 528 has been everted around anchor 30'.

[00141] Referring now to Figures 40, an alternative embodiment of everting apparatus in accordance with the present invention is described, wherein the posts are connected and the everting valve is disposed within the anchor to the proximal end of the anchor in the delivery configuration. In Figures 40, apparatus 600 comprises everting replacement valve 620 and anchor 630, as well as previously described delivery system 100'. Replacement valve 620 and anchor 630 are substantially the same as valve 520 and anchor 30' of Figures 39, except that valve 620 is initially seated more proximally within anchor 630, such that everting segment 628 of valve 620 is initially disposed within the anchor. Locking mechanisms as described previously may be implemented at the distal end of the post and anchor or proximal end of everted segment and anchor.

[00142] As with replacement value 520, everting segment 628 of value 620 is configured to wrap about the distal end of anchor 630 by everting during deployment, thereby friction locking the replacement value between the anchor and the patient's anatomy. Furthermore, replacement value 620 is entirely disconnected from the expandable/collapsible portion of anchor 630. In the delivery configuration, since only a single circumferential layer of value 620 is present along any cross section of apparatus 600, a delivery profile of the apparatus is reduced, as compared to previously described apparatus 10. With apparatus 10, two circumferential layers of value 20 are present in the cross section where annular base 22 of the value is coupled to the expandable anchor 30.

[00143] Figures 40 illustrate a method of endovascularly replacing a patient's diseased aortic valve utilizing apparatus 600. In Figure 40A, apparatus 600 is endovascularly advanced into position with valve 620 and anchor 630 disposed within lumen 112' of sheath 110' of delivery system 100'. As seen in Figure 40B, the valve and anchor are advanced relative to the sheath and/or the sheath is retracted relative to the valve and anchor, which deploys everting segment 628 of the valve, as well as a distal region of the anchor. Tension applied to the everting segment via control wires 550 causes the segment to evert and wrap about the distal region of anchor 630. Control wires 550 may enter the multi-lumen catheter at the distal end of the catheter or more proximally as is illustrated in 40C. Further retraction of sheath 110' deploys a remainder of replacement valve 620 and anchor 630 from lumen 112' of the sheath. Such deployment may be conducted, for example, under fluoroscopic guidance. Anchor 630 dynamically self-expands to a partially deployed configuration.

- 24 of 29 -

FILED VIA EFS

Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 30 of 442

[00144] Once the anchor and valve have been properly aligned in relation to anatomical landmarks, foreshortening is imposed upon anchor 630 to expand the anchor to the fully deployed configuration, as in Figure 40C. At this point, Locks may be actuated as previously described. Foreshortening friction locks everting segment 628 of valve 620 between anchor 630 and annulus **An**/leaflets **L** of the patient's diseased valve, thus properly seating the valve within the anchor while providing an improved seal between the replacement and native valves. Foreshortening also increases a radial strength of anchor 630, which is expected to prolong patency of valve annulus **An**. Deployed valve 620 and anchor 630 then are decoupled from delivery system 100', as in Figure 40D, thereby completing deployment of apparatus 600. Thereafter, normal blood flow between left ventricle **LV** and aorta **A** is regulated by replacement valve 620.

[00145] As with apparatus 500, apparatus 600 may be dynamically repositioned during deployment, for example, in order to properly align the apparatus relative to anatomical landmarks. Furthermore, apparatus 600 advantageously may be retrieved at any point at least up until actuation of optimal locks maintaining foreshortening. When the optional locks are reversible, retrieval may be achieved until valve 620 and anchor 630 are separated from delivery system 100'.

[00146] Figures 41 illustrate an alternative embodiment of the present invention wherein the everting valve is distal to the anchor and the posts are not connected to the braid in the delivery configuration. As is illustrated in Figure 41A, apparatus 700 comprises everting valve 720 and expandable anchor 730, as well as delivery system 750. Delivery system 750 includes multi-lumen catheter 180. Anchor 730 is fabricated from an expandable braid and comprises female/male element 732 of a locking mechanism, which is preferably reversible. Everting valve 720 comprises valve leaflets 726 and everting segment 728. Everting valve 720 further comprises posts 722 to which valve leaflets 726 are attached to provide commissure support. Posts 722, which are non-expandable and non-collapsible, comprise opposite male/female elements 723 of locking mechanism comprising eyelets. In the delivery configuration of Figure 41A, anchor 730 may extend distally far enough to just overlap the proximal-most section of valve 720.

[00147] Delivery system 750 is similar to previously described delivery system 100' and includes multilumen catheter 180. As with previous embodiments, delivery system 750 facilitates dynamic repositioning and/or retrieval of apparatus 700 after partial or full deployment of the apparatus, e.g., right up until the apparatus is separated from the delivery system.

[00148] As seen in Figure 41A, wires 50 pass from the multi-lumen catheter 180 through the female/male locking mechanism 732, which is associated with anchor 730. Wires 50 then further pass through female/male locking mechanism 723, which is at the proximal end of posts 722. Preferably, a double strand of each wire 50 is provided to facilitate decoupling of wires 50 from valve 720 and anchor

- 25 of 29 -

FILED VIA EFS

Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 31 of 442

730 in the manner described previously. When wires 50 are pulled proximally into the multi lumen catheter 180, posts 722 move proximally within anchor 730, and the female/male element 723 interacts with female/male element 732 of anchor 730. In this embodiment, when element 723 is male, then element 732 is female, and vice versa.

[00149] Thus, valve 720 and anchor 730 are entirely decoupled from one another in the delivery configuration. Wires 50 are configured to approximate the telescoped valve and anchor, as well as to actuate locking mechanism 740 and contribute to foreshortening of anchor 730. By separating valve 720 and anchor 730 within lumen 112' of sheath 110', a delivery profile of apparatus 700 may be reduced. [00150] In Figure 41A, apparatus 700 is endovascularly advanced into position with valve 720 and anchor 730 spaced from one another within lumen 112' of sheath 110' of delivery system 750. Substantially all of valve 720 and its supporting posts 722 are disposed distal to the anchor during delivery. As seen in Figure 41B, to evert valve 720, sheath 110' is pulled proximally around anchor 730 is pushed distally to the base of posts 722 using tubes 60 maintained in association with anchor 730 by wire 62. Anchor 730 will engage with the distal end of posts 722 - an anchor engagement feature 729. In some embodiments, as illustrated in Figure 41C, wires 550 re-enter sheath 110' proximal to the distal end of the multi-lumen catheter 180.

[00152] In Figure 41D, the multi-lumen catheter 180 is held steady, while wires 50 are pulled proximally. This allows the foreshortening of anchor 730 and the engagement of the male and female elements of locking mechanism of 740. Foreshortening friction locks segment 728 of valve 720 against valve annulus **An**/leaflets **L**, thereby properly seating the valve within anchor 730. Foreshortening also completes expansion of anchor 730 and actuates locking mechanism 740, which maintains such expansion of the anchor. Delivery system 750 then may be decoupled from valve 720 and anchor 730, thereby completing deployment of apparatus 700. Normal blood flow between left ventricle **LV** and aorta **A** thereafter is regulated by replacement valve 720.

[00153] With reference now to Figures 42, yet another alternative embodiment of everting apparatus in accordance with the present invention is described, wherein the replacement valve leaflets evert and wrap about the distal region of the anchor. Apparatus 800 comprises everting replacement valve 820 and expandable anchor 830. Valve 820 comprises posts 822, to which valve leaflets 826 are attached. The valve further comprises everting segment 828. Proximal regions 823 of posts 822 are rotatably coupled to a distal region of anchor 830, while distal regions 824 of the posts are coupled to control wires 50. [00154] In the delivery configuration of Figure 42A, posts 822 (and, thus, valve leaflets 826) and everting segment 828 of replacement valve 820 are disposed distal of anchor 830. Figure 42B illustrates deployment of apparatus 800, whereby tubes 60/wires 62 (see, e.g., Figures 41) are actuated in

- 26 of 29 -

FILED VIA EFS

Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 32 of 442

conjunction with control wires 50 to actively foreshorten anchor 830 and rotate posts 822 into position within the lumen of anchor 830, thereby everting valve leaflets 826 into position within the anchor. Furthermore, eversion wires 550 are actuated to evert segment 828 and wrap the segment about the exterior of anchor 830. Locks 840 maintain expansion and foreshortening of anchor 830. **[00155]** Referring to Figures 43, an everting embodiment of the present invention is described wherein a portion of the locking mechanism configured to maintain expansion of the anchor is coupled to the everting segment of the replacement valve instead of, or in addition to, the anchor posts and anchor posts P are only loosely associated with the anchor 930. Apparatus 900 comprises replacement valve 920 and anchor 930. Everting segment 928 of the replacement valve comprises male elements 942 of locks 940, while anchor 930 comprises female elements 944 of locks 940. Upon deployment of apparatus 900 from the delivery configuration of Figure 43A to the deployed configuration of Figure 43B, segment 928 of replacement valve 920 everts to wrap about the exterior of anchor 930, which is actively foreshortened during expansion. Locks 940 maintain anchor expansion.

[00156] With reference to Figures 44, another telescoping embodiment of the present invention is described wherein the replacement valve comprises a U-shaped frame configured to receive the anchor. Optionally, the valve may comprise an everting segment that everts about the frame and/or the anchor during deployment. Apparatus 1000 comprises replacement valve 1020 and expandable anchor 1030. Replacement valve 1020 comprises frame 1022, leaflets 1026 and optional everting segment 1028.
[00157] Valve 1020 and anchor 1030 are configured for relative movement, such that the valve and anchor may be telescoped and spaced apart during delivery, thereby reducing a delivery profile of apparatus 1000, but may be approximated during deployment. Everting segment 1028 of valve 1020 optionally may be disposed distal of valve frame 1022 during delivery, thereby further reducing a delivery profile of apparatus 1000, then everted during deployment.

[00158] As seen in Figure 44A, the U-shape of valve frame 1022 preferably tilts leaflets 1026 of replacement valve 1020 slightly inward relative to blood flow through apparatus 1000. As seen in Figure 44B, valve frame 1022 optionally may comprise a symmetric U-shape, which captures anchor 1030 on both sides in the deployed configuration. Frame 1022 may comprise lock 1040 that closes the frame's U-shape into an elliptical shape in the deployed configuration, thereby maintaining expansion of anchor 1030.

[00159] Prior to implantation of one of the replacement valves described above, it may be desirable to perform a valvuloplasty on the diseased valve by inserting a balloon into the valve and expanding it using saline mixed with a contrast agent. In addition to preparing the valve site for implant, fluoroscopic viewing of the valvuloplasty will help determine the appropriate size of replacement valve implant to use.

- 27 of 29 -

FILED VIA EFS

Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 33 of 442

WHAT IS CLAIMED IS:

1. A system for replacing a heart valve, comprising:

an expandable anchor having a collapsed delivery configuration and an expanded configuration; a replacement valve commissure support element attached to the expandable anchor; a commissure portion of a replacement valve leaflet attached to the commissure support element;

and

a seal at least partially disposed around an exterior portion of the expandable anchor when the anchor is in the expanded configuration, wherein the seal is adapted to prevent blood from flowing between the seal and heart tissue,

wherein a distal end of the replacement valve leaflet is attached to the seal.

2. The system of claim 1 wherein the expandable anchor is not attached to the replacement valve leaflet.

3. The system of claim 1 wherein the distal end of the replacement valve leaflet is attached to a distal end of the seal when the expandable anchor is in the expanded configuration.

4. The system of claim 1 wherein the commissure support element is configured to interface with an anchor actuator.

5. The system of claim 4 wherein the anchor actuator is adapted to apply a proximally directed force on the commissure support element to foreshorten the expandable anchor.

6. The system of claim 1 further comprising a lock comprising a first lock element and a second lock element, wherein the first and second lock elements are attached to the expandable anchor and adapted to engage with one another to lock the expandable anchor in the expanded configuration, and wherein the commissure support element includes the first lock element.

7. The system of claim 6 wherein the second lock element is attached to the expandable anchor and is disposed proximal to the first lock element when the expandable anchor is in the collapsed configuration within a delivery catheter.

- 28 of 29 -

FILED VIA EFS

Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 34 of 442

EVERTING HEART VALVE

ABSTRACT OF THE DISCLOSURE

The present invention provides methods and apparatus for endovascularly replacing a patient's heart valve. The apparatus includes a replacement valve and an expandable anchor configured for endovascular delivery to a vicinity of the patient's heart valve. In some embodiments, the replacement valve is adapted to wrap about the anchor, for example, by everting during endovascular deployment. In some embodiments, the replacement valve is not connected to expandable portions of the anchor. In some embodiments, the anchor is configured for active foreshortening during endovascular deployment. In some embodiments, the anchor includes expandable lip and skirt regions for engaging the patient's heart valve during deployment. In some embodiments, the anchor includes expandable lip and skirt regions for engaging the patient's heart valve during deployment. In some embodiments, the apparatus includes a lock configured to maintain anchor expansion. The invention also includes methods for endovascularly replacing a patient's heart valve. In some embodiments, the method includes the steps of endovascularly delivering a replacement valve and an expandable anchor to a vicinity of the heart valve, wrapping at least a portion of the replacement valve about the anchor, and expanding the anchor to a deployed configuration.

- 29 of 29 -

FILED VIA EFS

Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 35 of 442

Please type a plus sign (+) inside this box

PTO/SB/01 (12-97)

Under the Paperwork Reduction Act of 1995, no persons are OMB control number.	Patent and Trademark Office:	or use through 9/30/00.OMB 0651-0032 U.S. DEPARTMENT OF COMMERCE of information unless it contains a valid
DECLARATION FOR UTILITY OR	Attorney Docket Number	30207-710.201
DESIGN	First Named Inventor	Ulrich R. Haug
PATENT APPLICATION	COMPLE	TE IF KNOWN

	R 1.63)	Application Number	10/870,340
Submitted	Declaration Submitted after Initial	Filing Date	June 16, 2004
with Initial OR Filing	Filing (surcharge (37 CFR 1.16(e))	Group Art Unit	3738
Filling	required)	Examiner Name	Unassigned
As a below named inventor,	I hereby declare that:		
My residence, post office ad	Idress, and citizenship are as	stated below next to my name	
I believe I am the original, f names are listed below) of t	irst and sole inventor (if only he subject matter which is clai	one name is listed below) or a imed and for which a patent is	an original, first and joint inventor (if plural sought on the invention entitled:
	EVEDT	ING HEART VALVE	
	EVENI	ING HEART VALVE	
	(T	itle of the Invention)	
the specification of which is attached hereto			
OR Manual filed on (MM/D)	D/YYYY) 06/16/2004		
was filed on (MM/D		-	ates Application Number or PCT International
Application Number 10/870,3	and was amended on (M	M/DD/YYYY) [] (if applical	ble).
I hereby state that I have r			
i noroby state that I have I	eviewed and understand the	contents of the above iden	tified specification, including the claims, as
amended by any amendment	specifically referred to above.	•	
amended by any amendment	eviewed and understand the specifically referred to above close information which is mat	•	
amended by any amendment I acknowledge the duty to dis	specifically referred to above. close information which is mat	terial to patentability as define	d in 37 CFR 1.56.
amended by any amendment I acknowledge the duty to dis I hereby claim foreign priorit certificate, or 365(a) of any	specifically referred to above. close information which is mar y benefits under 35 U.S.C. 1 PCT international applicatior	terial to patentability as define 19(a)-(d) or []3(65(b) of any f n which designated at least o	d in 37 CFR 1.56. foreign application(s) for patent or inventor's one country other than the United States of
amended by any amendment I acknowledge the duty to dis I hereby claim foreign priorit certificate, or 365(a) of any America, listed below and ha	specifically referred to above. close information which is mar y benefits under 35 U.S.C. 1 PCT international applicatior	terial to patentability as define 119(a)-(d) or []365(b) of any f n which designated at least of hecking the box, any foreign	d in 37 CFR 1.56. foreign application(s) for patent or inventor's one country other than the United States of application for patent or inventor's certificate.
amended by any amendment I acknowledge the duty to dis I hereby claim foreign priorit certificate, or 365(a) of any America, listed below and ha or of any PCT international a	specifically referred to above, close information which is main by benefits under 35 U.S.C. 1 PCT international application ave also identified below, by c pplication having a filing date	terial to patentability as define 19(a)-(d) or []3(65(b) of any f which designated at least of hecking the box, any foreign before that of the application of	d in 37 CFR 1.56. foreign application(s) for patent or inventor's one country other than the United States of application for patent or inventor's certificate, on which priority is claimed.
amended by any amendment I acknowledge the duty to dis I hereby claim foreign priorit certificate, or 365(a) of any America, listed below and ha	specifically referred to above. close information which is mar- by benefits under 35 U.S.C. 1 PCT international application ave also identified below, by c pplication having a filing date in Foreign F	terial to patentability as define 119(a)-(d) or []365(b) of any f n which designated at least of hecking the box, any foreign	d in 37 CFR 1.56. foreign application(s) for patent or inventor's one country other than the United States of application for patent or inventor's certificate, on which priority is claimed.
amended by any amendment I acknowledge the duty to dis I hereby claim foreign priorit certificate, or 365(a) of any America, listed below and ha or of any PCT international a Prior Foreign Application	specifically referred to above. close information which is mar- by benefits under 35 U.S.C. 1 PCT international application ave also identified below, by c pplication having a filing date in Foreign F	terial to patentability as define 119(a)-(d) or [1365(b) of any f which designated at least of hecking the box, any foreign before that of the application of filing Date Priority	d in 37 CFR 1.56. foreign application(s) for patent or inventor's one country other than the United States of application for patent or inventor's certificate, on which priority is claimed.
amended by any amendment I acknowledge the duty to dis I hereby claim foreign priorit certificate, or 365(a) of any America, listed below and ha or of any PCT international a Prior Foreign Application	specifically referred to above. close information which is mar- by benefits under 35 U.S.C. 1 PCT international application ave also identified below, by c pplication having a filing date in Foreign F	terial to patentability as define 119(a)-(d) or []365(b) of any f n which designated at least of thecking the box, any foreign before that of the application of illing Date Priority Not Claim	d in 37 CFR 1.56. foreign application(s) for patent or inventor's one country other than the United States of application for patent or inventor's certificate, on which priority is claimed. Certified Copy Attached? YES NO
amended by any amendment I acknowledge the duty to dis I hereby claim foreign priorit certificate, or 365(a) of any America, listed below and ha or of any PCT international a Prior Foreign Application	specifically referred to above. close information which is mark by benefits under 35 U.S.C. 1 PCT international application ave also identified below, by c pplication having a filing date in Foreign F	terial to patentability as define 119(a)-(d) or []365(b) of any f which designated at least of thecking the box, any foreign before that of the application of illing Date Priority Not Claim	d in 37 CFR 1.56. foreign application(s) for patent or inventor's one country other than the United States of application for patent or inventor's certificate, on which priority is claimed. Certified Copy Attached? YES NO
amended by any amendment I acknowledge the duty to dis I hereby claim foreign priorit certificate, or 365(a) of any America, listed below and ha or of any PCT international a Prior Foreign Application	specifically referred to above. close information which is mark by benefits under 35 U.S.C. 1 PCT international application ave also identified below, by c pplication having a filing date in Foreign F	terial to patentability as define 119(a)-(d) or []365(b) of any f which designated at least of thecking the box, any foreign before that of the application of illing Date Priority Not Claim	d in 37 CFR 1.56. foreign application(s) for patent or inventor's one country other than the United States of application for patent or inventor's certificate, on which priority is claimed. Certified Copy Attached? YES NO
amended by any amendment I acknowledge the duty to dis I hereby claim foreign priorit certificate, or 365(a) of any America, listed below and ha or of any PCT international a Prior Foreign Application Number(s) Additional foreign applica	specifically referred to above. close information which is mar- ty benefits under 35 U.S.C. 1 PCT international application ave also identified below, by c pplication having a filing date in Country Foreign F (MM/DE) ation numbers are listed on a s	terial to patentability as define 119(a)-(d) or []365(b) of any f in which designated at least of the chiral the box, any foreign before that of the application of illing Date Priority Not Claim DYYYY) Not Claim	d in 37 CFR 1.56. foreign application(s) for patent or inventor's one country other than the United States of application for patent or inventor's certificate, on which priority is claimed. <u>Certified Copy Attached?</u> <u>YES NO</u> <u>Certified Copy Attached?</u> <u>YES NO</u> <u>Certified Copy Attached?</u> <u>YES NO</u> <u>Certified Copy Attached?</u> <u>Certified Copy Attached?</u>
amended by any amendment I acknowledge the duty to dis I hereby claim foreign priorit certificate, or 365(a) of any America, listed below and ha or of any PCT international a Prior Foreign Application Number(s) Additional foreign applica I hereby claim the benefit un	specifically referred to above. close information which is mar- ty benefits under 35 U.S.C. 1 PCT international application ave also identified below, by c pplication having a filing date in Country Foreign F (MM/DE ation numbers are listed on a s der 35 U.S.C. 119(h) of any U	terial to patentability as define 119(a)-(d) or []365(b) of any f in which designated at least of the checking the box, any foreign before that of the application of illing Date Priority Not Claim C	d in 37 CFR 1.56. foreign application(s) for patent or inventor's one country other than the United States of application for patent or inventor's certificate, on which priority is claimed. <u>Certified Copy Attached?</u> <u>YES NO</u> <u>Certified Copy Attached?</u> <u>YES NO</u> <u>Certified Copy Attached?</u> <u>YES NO</u> <u>Certified Copy Attached?</u> <u>Certified Copy Attached?</u>
amended by any amendment I acknowledge the duty to dis I hereby claim foreign priorit certificate, or 365(a) of any America, listed below and ha or of any PCT international a Prior Foreign Application Number(s) Additional foreign applica	specifically referred to above. close information which is mar- ty benefits under 35 U.S.C. 1 PCT international application ave also identified below, by c pplication having a filing date in Country Foreign F (MM/DE ation numbers are listed on a s der 35 U.S.C. 119(h) of any U	terial to patentability as define 119(a)-(d) or []365(b) of any f in which designated at least of the chiral the box, any foreign before that of the application of illing Date Priority Not Claim DYYYY) Not Claim	d in 37 CFR 1.56. foreign application(s) for patent or inventor's one country other than the United States of application for patent or inventor's certificate, on which priority is claimed. Certified Copy Attached? YES NO Certified Copy Attached? YES NO Certified Copy Attached? Ted YES NO
amended by any amendment I acknowledge the duty to dis I hereby claim foreign priorit certificate, or 365(a) of any America, listed below and ha or of any PCT international a Prior Foreign Application Number(s) Additional foreign applica I hereby claim the benefit un	specifically referred to above. close information which is mar- ty benefits under 35 U.S.C. 1 PCT international application ave also identified below, by c pplication having a filing date in Country Foreign F (MM/DE ation numbers are listed on a s der 35 U.S.C. 119(h) of any U	terial to patentability as define 119(a)-(d) or []365(b) of any f in which designated at least of the checking the box, any foreign before that of the application of illing Date Priority Not Claim C	d in 37 CFR 1.56. foreign application(s) for patent or inventor's one country other than the United States of application for patent or inventor's certificate, on which priority is claimed.
amended by any amendment I acknowledge the duty to dis I hereby claim foreign priorit certificate, or 365(a) of any America, listed below and ha or of any PCT international a Prior Foreign Application Number(s) Additional foreign applica I hereby claim the benefit un	specifically referred to above. close information which is mar- ty benefits under 35 U.S.C. 1 PCT international application ave also identified below, by c pplication having a filing date in Country Foreign F (MM/DE ation numbers are listed on a s der 35 U.S.C. 119(h) of any U	terial to patentability as define 119(a)-(d) or []365(b) of any f in which designated at least of the checking the box, any foreign before that of the application of illing Date Priority Not Claim C	d in 37 CFR 1.56. foreign application(s) for patent or inventor's one country other than the United States of application for patent or inventor's certificate, on which priority is claimed. Certified Copy Attached? YES NO Certified Copy Attached? YES NO Certified Copy Attached? Description Certified Copy Attached? Description Ce
amended by any amendment I acknowledge the duty to dis I hereby claim foreign priorit certificate, or 365(a) of any America, listed below and ha or of any PCT international a Prior Foreign Application Number(s) Additional foreign applica I hereby claim the benefit un	specifically referred to above. close information which is mar- ty benefits under 35 U.S.C. 1 PCT international application ave also identified below, by c pplication having a filing date in Country Foreign F (MM/DE ation numbers are listed on a s der 35 U.S.C. 119(h) of any U	terial to patentability as define 119(a)-(d) or []365(b) of any f in which designated at least of the checking the box, any foreign before that of the application of illing Date Priority Not Claim C	ad in 37 CFR 1.56. foreign application(s) for patent or inventor's one country other than the United States of application for patent or inventor's certificate, on which priority is claimed. // Certified Copy Attached? // YES // Certified Copy Attached? // YES // Or and the state of application for patent or inventor's certificate, on which priority is claimed. // Certified Copy Attached? // YES // Implication // Implication // Certified Copy Attached? // YES // Implication // Implication // Implication // Implication // Additional provisional application numbers are listed on a

(Page 1 of 2)

Burden Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

C:\NrPortbl\PALIB1\DH1\2520926_1.DOC (8499)

Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 36 of 442

Please Type a plus sign (+) inside this box

PTO/SB/01 (12-97)

Approved for use through 9/30/00.OMB 0651-0032

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

÷

DECLARATION — Utility or Design Patent Application I hereby claim the benefit under 35 U.S.C. 120 of any United States application(s), or 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of the application is not designated in the prior United States or PCT international application in the manner provided by the first paragraph of 31 U.S.C. 112. I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application. **Parent Filing Date Parent Patent Number U.S. Parent Application or PCT Parent Number** (MM/DD/YYYY) (if applicable) Additional U.S. or PCT international application numbers are listed on a supplemental priority data sheet PTO/SB/028 attached hereto. As a named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith: X Customer Number 021971 Place Custome OR Code Label here Registered practitioner(s) name/registration number listed below Registration Registration Name Number Name Number Additional registered practitioner(s) named on supplemental Registered Practitioner Information sheet PTO/SB/02C attached hereto. Direct all correspondence to: Customer Number OR 🛛 Correspondence address below or Bar Code Label Maya Skubatch Name Wilson Sonsini Goodrich & Rosati Address 650 Page Mill Road Address State ZIP 94304 City Paio Alto CA 650-493-9300 U.S. Telephone Fax 650-493-6811 Country I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon. Name of Sole or First Inventor: A petition has been filed for this unsigned inventor Given Name (first and middle (if any) Family Name or Surname Ulrich R. Haug 06 04 19 **Inventor's Signature** Date USA **Residence: City** Campbell State CA Country Citizenship Germany Post Office Address 2479 Twyla Court, Campbell, CA 95008 **Post Office Address** Campbell State CA ZIP 95008 City Country USA

Additional inventors are being named on the 2 supplemental Additional Inventor(s) sheet(s) PTO/SB/02A attached hereto:

C:\NrPortbl\PALIB1\DH1\2520926_1.DOC (8499)

Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 37 of 442

Please Type a plus sign (+) inside this box

PTO/SB/02A (3-97)

Approved for use through 9/30/98,OMB 0651-0032 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

+

DECLARATION				ADDITIONAL INVENTOR(S) Supplemental Sheet Page <u>1</u> of <u>2</u>							
Name of Additional Joint Inventor, if any:				A petition has been filed for this unsigned inventor							
Given Name (first and middle (if any)				Family Name or Surname							
Hans F. / /				Valencia							
Inventor's Signature	Malaca			Date	10/08/04						
City	Berkeley	State	C/		Country	USA	Citizenship Peru		I		
Post Office Address	1609 La Vereda R	load, Berkel	ley, Ca	a 94709							
Post Office Address											
City	Berkeley	State	CA		ZIP	94709	Country			USA	
Name of Additional	f Additional Joint Inventor, if any:										
Given Name (first and middle (if any)				Family Name or Surname							
	Robert A.		Geshlider								
Inventor's Signature	Tohot	\sim		Date 10/8/04							
Residence: City	San Francisco	State	C,	CA Country USA			Citizenship USA				
Post Office Address	233 27 th Street, San Francisco, CA 94131										
Post Office Address											
City	San Francisco	State	с	CA ZIP 94131 Country		Country			USA		
Name of Additional Joint Inventor, if any:										tor	
Given Name (first and middle (if any)				Family Name or Surname							
Tom				Saul							
Inventor's Signature	for	Som	l	1			Date	14	2	04	
City	El Granada	State		A Country		USA	Citizenship USA		A		
Post Office Address 151 Madrid Avenue, El Granada, CA 94018											
Post Office Address	-						-				
City	El Granada	State	C	CA ZIP 94018		Country	Country		USA		

Burden Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

C:\NrPortbl\PALIB1\DH1\2520926_1.DOC (8499)

Please Type a plus sign (+) inside this box

PTO/SB/02A (3-97) Approved for use through 9/30/98,OMB 0651-0032

+ Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION

ADDITIONAL INVENTOR(S) **Supplemental Sheet** Page 2 of 2

Name of Additional Joint Inventor, if any:			A petition has been filed for this unsigned inventor								
Given Name (first and middle (if any)				Family Name or Surname							
Amr				Salahieh							
Inventor's Signature	The Date 10/8/0						0/8/04				
City	Saratoga	State	CA		Country	USA	Citizenship	USA			
Post Office Address	18729 Metler Court, Saratoga, CA 95070										
Post Office Address	e Address										
City	Saratoga	State	CA	CA ZIP 95070 Coun		Country	USA				
Name of Additional Joint Inventor, if any:											
Given Name (first and middle (if any) Family Name or					or Surname						
	Dwight P. Morejo					ohn					
Inventor's Signature	Devryk	AP?	Morcio Date 10:				0-20-04				
Residence: City	Davis	State	CA		Country	USA	Citizenshi	USA			
Post Office Address 731 N. Campus Way, Davis, CA 95616											
Post Office Address											
City	San Francisco	State	CA		ZIP	95616	Country	USA			
Name of Additional Joint Inventor, if any:											
Given Name	Given Name (first and middle (if any) Family Name or Surname						}				
	Kenneth J.			Michlitsch							
Inventor's Signature	Ka	\sim		Date			14/11/04				
City	Livermore	State	c	<u>A</u>	Country	USA	Citizenshi	p USA			
Post Office Address	Post Office Address 822 South M Street, Livermore, CA 94550										
Post Office Address											
City	Livermore	State	c	A	ZIP	94550	Country	USA			

Burden Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

C:\NrPortbl\PALIB1\DH1\2520926_1.DOC (8499)

FILED VIA EFS "Everting Heart Valve" Inventors: Amr SALAHIEH et al. Attorney Docket No. 10012-710.401 Sheet 1 of 63




FIG. 2A

FILED VIA EFS "Everting Heart Valve" Inventors: Amr SALAHIEH et al. Attorney Docket No. 10012-710.401 Sheet 2 of 63 ł

ł

ł

ł

ł


ł

ł


ł

ł

ł



FILED VIA EFS "Everting Heart Valve" Inventors: Amr SALAHIEH et al. Attorney Docket No. 10012-710.401 Sheet 3 of 63



FILED VIA EFS "Everting Heart Valve" Inventors: Amr SALAHIEH et al. Attorney Docket No. 10012-710.401 Sheet 4 of 63




FIG. 3B

FILED VIA EFS "Everting Heart Valve" Inventors: Amr SALAHIEH et al. Attorney Docket No. 10012-710.401 Sheet 5 of 63







FIG. 4A








FILED VIA EFS "Everting Heart Valve" Inventors: Amr SALAHIEH et al. Attorney Docket No. 10012-710.401 Sheet 6 of 63










FIG. 4F


FILED VIA EFS "Everting Heart Valve" Inventors: Amr SALAHIEH et al. Attorney Docket No. 10012-710.401 Sheet 7 of 63




FILED VIA EFS "Everting Heart Valve" Inventors: Amr SALAHIEH et al. Attorney Docket No. 10012-710.401 Sheet 8 of 63



FILED VIA EFS "Everting Heart Valve" Inventors: Amr SALAHIEH et al. Attorney Docket No. 10012-710.401 Sheet 9 of 63




FILED VIA EFS "Everting Heart Valve" Inventors: Amr SALAHIEH et al. Attorney Docket No. 10012-710.401 Sheet 10 of 63



Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 49 of 442

FILED VIA EFS "Everting Heart Valve" Inventors: Amr SALAHIEH et al. Attorney Docket No. 10012-710.401 Sheet 11 of 63



FILED VIA EFS "Everting Heart Valve" Inventors: Amr SALAHIEH et al. Attorney Docket No. 10012-710.401 Sheet 12 of 63




FIG. 5F

FILED VIA EFS "Everting Heart Valve" Inventors: Amr SALAHIEH et al. Attorney Docket No. 10012-710.401 Sheet 13 of 63




FIG. 6A

FILED VIA EFS "Everting Heart Valve" Inventors: Amr SALAHIEH et al. Attorney Docket No. 10012-710.401 Sheet 14 of 63




FIG. 6B

FILED VIA EFS "Everting Heart Valve" Inventors: Amr SALAHIEH et al. Attorney Docket No. 10012-710.401 Sheet 15 of 63






FIG. 6C

FILED VIA EFS "Everting Heart Valve" Inventors: Amr SALAHIEH et al. Attorney Docket No. 10012-710.401 Sheet 16 of 63



FILED VIA EFS "Everting Heart Valve" Inventors: Amr SALAHIEH et al. Attorney Docket No. 10012-710.401 Sheet 17 of 63



FILED VIA EFS "Everting Heart Valve" Inventors: Amr SALAHIEH et al. Attorney Docket No. 10012-710.401 Sheet 18 of 63




FIG. 6F

FILED VIA EFS "Everting Heart Valve" Inventors: Amr SALAHIEH et al. Attorney Docket No. 10012-710.401 Sheet 19 of 63





FIG. 7

FILED VIA EFS "Everting Heart Valve" Inventors: Amr SALAHIEH et al. Attorney Docket No. 10012-710.401 Sheet 20 of 63



Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 59 of 442

FILED VIA EFS "Everting Heart Valve" Inventors: Amr SALAHIEH et al. Attorney Docket No. 10012-710.401 Sheet 21 of 63






FIG. 8C

FILED VIA EFS "Everting Heart Valve" Inventors: Amr SALAHIEH et al. Attorney Docket No. 10012-710.401 Sheet 22 of 63







Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 61 of 442

FILED VIA EFS "Everting Heart Valve" Inventors: Amr SALAHIEH et al. Attorney Docket No. 10012-710.401 Sheet 23 of 63





FIG 9C









FIG. 9D





Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 62 of 442

FILED VIA EFS "Everting Heart Valve" Inventors: Amr SALAHIEH et al. Attorney Docket No. 10012-710.401 Sheet 24 of 63








FIG. IIA


FIG. IIB





FILED VIA EFS "Everting Heart Valve" Inventors: Amr SALAHIEH et al. Attorney Docket No. 10012-710.401 Sheet 25 of 63



FILED VIA EFS "Everting Heart Valve" Inventors: Amr SALAHIEH et al. Attorney Docket No. 10012-710.401 Sheet 26 of 63









Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 65 of 442

FILED VIA EFS "Everting Heart Valve" Inventors: Amr SALAHIEH et al. Attorney Docket No. 10012-710.401 Sheet 27 of 63













FIG. 16B



FILED VIA EFS "Everting Heart Valve" Inventors: Amr SALAHIEH et al. Attorney Docket No. 10012-710.401 Sheet 28 of 63





FILED VIA EFS "Everting Heart Valve" Inventors: Amr SALAHIEH et al. Attorney Docket No. 10012-710.401 Sheet 29 of 63







FIG. 17B

FILED VIA EFS "Everting Heart Valve" Inventors: Amr SALAHIEH et al. Attorney Docket No. 10012-710.401 Sheet 30 of 63



FILED VIA EFS "Everting Heart Valve" Inventors: Amr SALAHIEH et al. Attorney Docket No. 10012-710.401 Sheet 31 of 63








FIG. 21

FILED VIA EFS "Everting Heart Valve" Inventors: Amr SALAHIEH et al. Attorney Docket No. 10012-710.401 Sheet 32 of 63





FIG 22

Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 71 of 442

FILED VIA EFS "Everting Heart Valve" Inventors: Amr SALAHIEH et al. Attorney Docket No. 10012-710.401 Sheet 33 of 63



FILED VIA EFS "Everting Heart Valve" Inventors: Amr SALAHIEH et al. Attorney Docket No. 10012-710.401 Sheet 34 of 63






FIG. 24

FILED VIA EFS "Everting Heart Valve" Inventors: Amr SALAHIEH et al. Attorney Docket No. 10012-710.401 Sheet 35 of 63





FILED VIA EFS "Everting Heart Valve" Inventors: Amr SALAHIEH et al. Attorney Docket No. 10012-710.401 Sheet 36 of 63





F/G. 26

FILED VIA EFS "Everting Heart Valve" Inventors: Amr SALAHIEH et al. Attorney Docket No. 10012-710.401 Sheet 37 of 63









FILED VIA EFS "Everting Heart Valve" Inventors: Amr SALAHIEH et al. Attorney Docket No. 10012-710.401 Sheet 38 of 63






FIG. 32



Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 77 of 442

FILED VIA EFS "Everting Heart Valve" Inventors: Amr SALAHIEH et al. Attorney Docket No. 10012-710.401 Sheet 39 of 63



Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 78 of 442

FILED VIA EFS "Everting Heart Valve" Inventors: Amr SALAHIEH et al. Attorney Docket No. 10012-710.401 Sheet 40 of 63






FIG. 35C


FILED VIA EFS "Everting Heart Valve" Inventors: Amr SALAHIEH et al. Attorney Docket No. 10012-710.401 Sheet 41 of 63



FILED VIA EFS "Everting Heart Valve" Inventors: Amr SALAHIEH et al. Attorney Docket No. 10012-710.401 Sheet 42 of 63



FILED VIA EFS "Everting Heart Valve" Inventors: Amr SALAHIEH et al. Attorney Docket No. 10012-710.401 Sheet 43 of 63



Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 82 of 442

FILED VIA EFS "Everting Heart Valve" Inventors: Amr SALAHIEH et al. Attorney Docket No. 10012-710.401 Sheet 44 of 63






FIG. 36E

FILED VIA EFS "Everting Heart Valve" Inventors: Amr SALAHIEH et al. Attorney Docket No. 10012-710.401 Sheet 45 of 63



FILED VIA EFS "Everting Heart Valve" Inventors: Amr SALAHIEH et al. Attorney Docket No. 10012-710.401 Sheet 46 of 63



FILED VIA EFS "Everting Heart Valve" Inventors: Amr SALAHIEH et al. Attorney Docket No. 10012-710.401 Sheet 47 of 63





FIG. 38A

FILED VIA EFS "Everting Heart Valve" Inventors: Amr SALAHIEH et al. Attorney Docket No. 10012-710.401 Sheet 48 of 63



LV

FIG. 38B

FILED VIA EFS "Everting Heart Valve" Inventors: Amr SALAHIEH et al. Attorney Docket No. 10012-710.401 Sheet 49 of 63





FIG. 38C

FILED VIA EFS "Everting Heart Valve" Inventors: Amr SALAHIEH et al. Attorney Docket No. 10012-710.401 Sheet 50 of 63



FILED VIA EFS "Everting Heart Valve" Inventors: Amr SALAHIEH et al. Attorney Docket No. 10012-710.401 Sheet 51 of 63





FIG. 39C

Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 90 of 442

FILED VIA EFS "Everting Heart Valve" Inventors: Amr SALAHIEH et al. Attorney Docket No. 10012-710.401 Sheet 52 of 63



Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 91 of 442

FILED VIA EFS "Everting Heart Valve" Inventors: Amr SALAHIEH et al. Attorney Docket No. 10012-710.401 Sheet 53 of 63






FIG. 39G

FILED VIA EFS "Everting Heart Valve" Inventors: Amr SALAHIEH et al. Attorney Docket No. 10012-710.401 Sheet 54 of 63




FILED VIA EFS "Everting Heart Valve" Inventors: Amr SALAHIEH et al. Attorney Docket No. 10012-710.401 Sheet 55 of 63



FILED VIA EFS "Everting Heart Valve" Inventors: Amr SALAHIEH et al. Attorney Docket No. 10012-710.401 Sheet 56 of 63 ł

1 1

ł



FILED VIA EFS "Everting Heart Valve" Inventors: Amr SALAHIEH et al. Attorney Docket No. 10012-710.401 Sheet 57 of 63




FIG. 40D

FILED VIA EFS "Everting Heart Valve" Inventors: Amr SALAHIEH et al. Attorney Docket No. 10012-710.401 Sheet 58 of 63




FIG. 4IA

FILED VIA EFS "Everting Heart Valve" Inventors: Amr SALAHIEH et al. Attorney Docket No. 10012-710.401 Sheet 59 of 63




FIG. 418

FILED VIA EFS "Everting Heart Valve" Inventors: Amr SALAHIEH et al. Attorney Docket No. 10012-710.401 Sheet 60 of 63




FIG. 41C

FILED VIA EFS "Everting Heart Valve" Inventors: Amr SALAHIEH et al. Attorney Docket No. 10012-710.401 Sheet 61 of 63






FIG. 4/E

FILED VIA EFS "Everting Heart Valve" Inventors: Amr SALAHIEH et al. Attorney Docket No. 10012-710.401 Sheet 62 of 63



Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 101 of 442

FILED VIA EFS "Everting Heart Valve" Inventors: Amr SALAHIEH et al. Attorney Docket No. 10012-710.401 Sheet 63 of 63







FIG. 43B



Electronic Patent Application Fee Transmittal					
Application Number:					
Filing Date:					
Title of Invention:	Eve	rting Heart Valve			
First Named Inventor/Applicant Name:	Am	r Salahieh			
Filer:	Tho	mas M. Zlogar/Sue	Bromaghim		
Attorney Docket Number:	100	12-710.401			
Filed as Small Entity					
Utility under 35 USC 111(a) Filing Fees					
Description		Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Basic Filing:					
Utility filing Fee (Electronic filing)		4011	1	82	82
Utility Search Fee		2111	1	270	270
Utility Examination Fee		2311	1	110	110
Pages:					
Claims:					
Miscellaneous-Filing:					
Petition:					
Patent-Appeals-and-Interference:					
Edwards Lifescienc	es C	orporation, et	t al. Exhibit	1102, Page 10	03 of 442

Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Post-Allowance-and-Post-Issuance:				
Extension-of-Time:				
Miscellaneous:				
	Tot	al in USD	(\$)	462

Electronic Acknowledgement Receipt		
EFS ID:	5595509	
Application Number:	12492512	
International Application Number:		
Confirmation Number:	7439	
Title of Invention:	Everting Heart Valve	
First Named Inventor/Applicant Name:	Amr Salahieh	
Customer Number:	66854	
Filer:	Thomas M. Zlogar/Sue Bromaghim	
Filer Authorized By:	Thomas M. Zlogar	
Attorney Docket Number:	10012-710.401	
Receipt Date:	26-JUN-2009	
Filing Date:		
Time Stamp:	14:22:04	
Application Type:	Utility under 35 USC 111(a)	

Payment information:

Submitted wi	th Payment	yes		
Payment Type [Deposit Account		
Payment was successfully received in RAM		\$462		
RAM confirma	ation Number	525		
Deposit Acco	unt	504050		
Authorized User				
File Listing:				
Document Number	Document Pescription Edwards Lifescien	File Size(Bytes)/ Multi Pages ces Corporation, et al. ExNeisiagel@igeBageFlaf5/02ipf42ifappl.)		

		Í	1 1		i	
1 10012-710-401-trans-co app-decl.pdf		10012-710-401-trans-comm-	6358328	yes	39	
	app-deci.pdi	62065256888eb2d7e45b655ef543c68eec9 b89c0	·			
	Multipart Description/PDF files in .zip description					
	Document De	scription	Start	E	nd	
	Transmittal of New Application		1		1	
	Miscellaneous Incoming Letter		2 6		6	
	Specification		7		33	
	Claims		34		34	
	Abstract		35		35	
	Oath or Declaration filed		36		39	
Warnings:						
Information:						
2	Drawings-only black and white line drawings	10012-710-401-drawings.pdf	1706989	no	63	
	diawings		8e650dc62ce1b6dc99fc64cc9ef341f527ab 1163			
Warnings:						
Information:			· · · · · · · · · · · · · · · · · · ·			
3	Fee Worksheet (PTO-875)	fee-info.pdf	32389 no		2	
			7fcff10f9649e0e60ba724140702891b3619 9fd4			
Warnings:						
Information:						
		Total Files Size (in bytes)	80	97706		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application. Filing Date: 06/26/09

AMEND

Independent

(37 CFR 1.16(h))

Application Size Fee (37 CFR 1.16(s))

Approved for use through 7/31/2006. OMB 0651-0032 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Application or Docket Number PATENT APPLICATION FEE DETERMINATION RECORD 12/492.512 OTHER THAN SMALL ENTITY OR SMALL ENTITY

OR

OR

OR

OR

OR

OR

TOTAL

ADD'T FEE

FEE (\$)

82

270

110

APPLICATION AS FILED – PART I (Column 1) (Column 2)						
	FOR	·	NUN	IBER FILED	NUMBER EXTRA	
	IC FEE CFR 1.16(a), (b), o	r (c))		N/A	N/A ·	
SEA	RCH FEE CFR 1.16(k), (i), or			N/A	N/A	
EXA	MINATION FEE CFR 1.16(o), (p), o			N/A	N/A	
TOT	AL CLAIMS CFR 1.16(i))		7	minus 20 =		
	EPENDENT CLAIN CFR 1.16(h))	IS	1	minus 3 =	*	e.
FEE	LICATION SIZE		If the specification and drawings exceed 100 sheets of paper, the application size fee due is \$260 (\$130 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR			
MUI	LTIPLE DEPEN	DENT CLAIM PI	RESENT	(37 CFR 1.16	(j))	
* If the difference in column 1 is less than zero, enter "0" in column 2. APPLICATION AS AMENDED – PART II (Column 1) (Column 2) (Column 3)						
VT A		CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	
DMENT	Total (37 CFR 1.16(i))	*	Minus	**	=	

Substitute for Form PTO-875

TOTAL 462 SMALL ENTITY ADDI-RATE (\$) TIONAL FEE (\$) = X = х N/A TOTAL ADD'T FEE

RATE (\$)

N/A

N/A

N/A

x\$26

x\$110

195

• -	
390	
TOTAL	
	R THAN ENTITY
RATE (\$)	ADDI- TIONAL FEE (\$)
RATE (\$)	TIONAL
	TIONAL
x =	TIONAL

RATE (\$)

N/A

N/A

N/A

x\$52

x\$220

	•	(Column 1)	. 	(Column 2)	(Column 3)
NT B		CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA
AMENDMENT	Total (37 CFR 1.16(i))	*	Minus	**	= .
MEN	Independent (37 CFR 1.16(h))	*	Minus	***	=
A	Application Size Fee (37 CFR 1.16(s))				
	FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))				

Minus

FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))

=

		OR
RATE (\$)	ADDI- TIONAL FEE (\$)	
x =		OR
x =		OR
N/A		OR
TOTAL ADD'T FEE		OR

`		
	RATE (\$)	ADDI- TIONAL FEE (\$)
२	x =	
२	x =	
२	N/A	
र	TOTAL ADD'T FEE	

* If the entry in column 1 is less than the entry in column 2, write "0" in column 3.

If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20".

If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3".

The "Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1

This collection of information is required by 37 CFR 1.16. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

> If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2. Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 108 of 442

PTO/SB/06 (12-04)

FEE (\$)

	United State	<u>s Patent</u>	and Tradema	UNITED ST United Stat Address COMM P.O. Bo	dria, Virginia 22313-1450
APPLICATION NUMBER	FILING or 371(c) DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	TOT CLAIMS IND CLAIMS
12/492,512	06/26/2009	3738	462	10012-710.401	7 1
					CONFIRMATION NO. 7439
66854				FILING	RECEIPT
SHAY GLENN	LLP				
2755 CAMPUS	S DRIVE				*OC00000036815329*
SUITE 210	<u></u>				000000036815329
SAN MATEO,	CA 94403				

Date Mailed: 07/14/2009

Receipt is acknowledged of this non-provisional patent application. The application will be taken up for examination in due course. Applicant will be notified as to the results of the examination. Any correspondence concerning the application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please submit a written request for a Filing Receipt Correction. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections

Applicant(s)

Ulrich R. Haug, Campbell, CA; Hans F. Valencia, Berkeley, CA; Robert A. Geshlider, San Francisco, CA; Tom Saul, El Granada, CA; Amr Salahieh, Saratoga, CA; Dwight P. Morejohn, Davis, CA; Kenneth J. Michlitsch, Livermore, CA;

Power of Attorney: The patent practitioners associated with Customer Number 021971

Domestic Priority data as claimed by applicant

This application is a DIV of 12/269,213 11/12/2008 which is a CON of 10/870,340 06/16/2004

Foreign Applications

If Required, Foreign Filing License Granted: 07/07/2009

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US 12/492,512**

Projected Publication Date: 10/22/2009

Non-Publication Request: No

Early Publication Request: No ** SMALL ENTITY **

page 1 of 3

Title

Everting Heart Valve

Preliminary Class

623

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

LICENSE FOR FOREIGN FILING UNDER

Title 35, United States Code, Section 184

Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as

page 2 of 3

set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign AssetsControl, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

FILED VIA EFS ON JULY 22, 2009

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.	:	12/492,512
Applicant	:	Amr SALAHIEH et al
Filing Date	:	June 26, 2009
Title	:	Everting Heart Valve
Group Art Unit	:	3738
Examiner	:	unassigned
Docket No.	:	10012-710.401
Customer No.	•	66854

Mail Stop Missing Parts Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313 Sir:

REQUEST FOR CORRECTED FILING RECEIPT

Please change the order of inventors as shown on the attached receipt, and as shown on the COMMUNICATION RE ORDER OF INVENTORS filed with this application. This Communication accompanied a granted petition in the parent application, as well as a corrected filing receipt.

It is again requested that this granted order of inventors be maintained in this application and that a corrected filing receipt reflecting such order be issued for the instant application.

Please charge any fees for the issuance of this corrected filing receipt to Deposit Account No. 50-4050.

Respectfully submitted,

Date: July 22, 2009

By:

Thomas M. Zlogar, Reg. No. 55,760

Confirmation No.:

7439

SHAY GLENN LLP 2755 Campus Drive, Suite 210 San Mateo, CA 94403 Telephone: 650.212.1700 Facsimile 650.212.7562

						RECEIVED
	United State	s Patent	and Tradema	ark Office		JUL 17 2009
					UNITED STATES I United States Pate Address: COMMISSION P.O. Box 1450	EPARTMENT OF COMMERCE It and SHAPTCHEENN LLP ER FOR PATENTS
Charlin Car Contain					P.O. Box 1450 Alexandria, Virgini www.uspto.gov	a 22313-1450
APPLICATION NUMBER	FILING or 371(c) DATE	GRP ART UNIT	FIL FEE REC'D		ATTY.DOCKET.NO	TOT CLAIMS IND CLAIMS
12/492,512	06/26/2009	3738	462		10012-710.401	7 1
66854 SHAY GLENN	ILLP	C/M#	SHAY GLENN LI DOCKET 6013-710.4		CO FILING REC	NFIRMATION NO. 7439 EIPT
2755 CAMPUS SUITE 210 SAN MATEO,		Attorney: Action: Due Date	TIMZ Past C-FI	<u>5</u>		00000036815329*
- 		Final: Docketed	: 7/17/01	By: ell		Date Mailed: 07/14/2009

Receipt is acknowledged of this non-provisional patent application. The application will be taken up for examination in due course. Applicant will be notified as to the results of the examination. Any correspondence concerning the application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please submit a written request for a Filing Receipt Correction. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections

Applicant(s)

Ulrich R. Haug, Campbell, CA; Hans F. Valencia, Berkeley, CA;

----Robert A. Geshlider, San Francisco, CA;

J-Tom Saul, El Granada, CA;

- Amr Salahieh, Saratoga, CA; -

6. - Dwight P. Morejohn, Davis, CA;

7 - Kenneth J. Michlitsch, Livermore, CA;

Power of Attorney: The patent practitioners associated with Customer Number 021971

Domestic Priority data as claimed by applicant

This application is a DIV of 12/269,213 11/12/2008 which is a CON of 10/870,340 06/16/2004

Foreign Applications

If Required, Foreign Filing License Granted: 07/07/2009

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is US 12/492,512

Projected Publication Date: 10/22/2009

Non-Publication Request: No

Early Publication Request: No ** SMALL ENTITY **

page 1 of 3

4

11 / 17 10

Everting Heart Valve

Preliminary Class

623

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

LICENSE FOR FOREIGN FILING UNDER

Title 35, United States Code, Section 184

Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as

page 2 of 3

Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 114 of 442

Title

set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign AssetsControl, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

page 3 of 3

Electronic Ac	knowledgement Receipt
EFS ID:	5749129
Application Number:	12492512
International Application Number:	
Confirmation Number:	7439
Title of Invention:	Everting Heart Valve
First Named Inventor/Applicant Name:	Ulrich R. Haug
Customer Number:	66854
Filer:	James R. Shay/Sue Bromaghim (TZ)
Filer Authorized By:	James R. Shay
Attorney Docket Number:	10012-710.401
Receipt Date:	22-JUL-2009
Filing Date:	26-JUN-2009
Time Stamp:	15:16:37
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted wit	h Payment	no	no					
File Listing	j :							
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)			
1	Request for Corrected Filing Receipt	10012-710-401-	517857 no		4			
	Request for confected ming Receipt	Req_Corrected_FR.pdf	4090addb3425c7ba2ecb3435d98386e3b1 109e7e	110	4			
Warnings:	·		· · · ·					
Information:	Edwards Lifesci	ences Corporation, et	al. Exhibit 1102. Pag	e 116 of 4	42			

Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 116 of 442

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

	United State	<u>s Patent</u>	and Tradema	UNITED STAT United States Address: COMMIS P.O. Box I	, Virginia 22313-1450
APPLICATION NUMBER	FILING or 371(c) DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	TOT CLAIMS IND CLAIMS
12/492,512	06/26/2009	3774	462	10012-710.401	7 1
					CONFIRMATION NO. 7439
66854				CORREC	TED FILING RECEIPT
SHAY GLENN	LLP				
2755 CAMPUS	S DRIVE				
SUITE 210	04.04400				000000037062270*
SAN MATEO,	CA 94403				

Date Mailed: 07/27/2009

Receipt is acknowledged of this non-provisional patent application. The application will be taken up for examination in due course. Applicant will be notified as to the results of the examination. Any correspondence concerning the application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please submit a written request for a Filing Receipt Correction. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections

Applicant(s)

Amr Salahieh, Saratoga, CA; Ulrich R. Haug, Campbell, CA; Hans F. Valencia, Berkeley, CA; Robert A. Geshlider, San Francisco, CA; Tom Saul, El Granada, CA; Dwight P. Morejohn, Davis, CA; Kenneth J. Michlitsch, Livermore, CA;

Power of Attorney: The patent practitioners associated with Customer Number 021971

Domestic Priority data as claimed by applicant

This application is a DIV of 12/269,213 11/12/2008 which is a CON of 10/870,340 06/16/2004

Foreign Applications

If Required, Foreign Filing License Granted: 07/07/2009

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US 12/492,512**

Projected Publication Date: 10/22/2009

Non-Publication Request: No

Early Publication Request: No ** SMALL ENTITY **

page 1 of 3

Title

Everting Heart Valve

Preliminary Class

623

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

LICENSE FOR FOREIGN FILING UNDER

Title 35, United States Code, Section 184

Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as

page 2 of 3

set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign AssetsControl, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

Approved for use through 07/31/2009. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

Substitute for form 1449/PTO

Sheet 1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of 23

Coi	mplete if Known
Application Number	12/492,512
Filing Date	June 26, 2009
First Named Inventor	Amr Salahieh
Art Unit	3774
Examiner Name	Unassigned
Attorney Docket Number	10012-710.401

			U. S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (if known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	106	^{US-} 3,334,629	8/8/1967	Cohn	
	107	^{US-} 3,540,431	11/17/1970	Mobin-Uddin	
	108	^{US-} 3,628,535	12/21/1971	Ostrowsky et al.	
	109	^{US-} 3,642,004	2/15/1972	Osthagen et al.	
	110	^{US-} 3,657,744	4/25/1972	Ersek	
-	111	^{US-} 3,671,979	6/27/1972	Moulopoulos	
	112	^{US-} 3,795,246	3/5/1974	Sturgeon	
	113	^{US-} 3,839,741	10/8/1974	Haller	
	114	^{US-} 3,868,956	3/4/1975	Alfidi et al.	
	115	^{US-} 3,874,388	4/1/1975	King et al.	
	116	^{US-} 4,056,854	11/8/1977	Boretos et al.	
	117	^{US-} 4,106,129	8/15/1978	Carpentier et al.	
	118	^{US-} 4,233,690	11/18/1980	Akins	
	119	^{US-} 4,291,420	9/29/1981	Reul	
	422	^{US-} 4,326,306	4/27/1982	Poler	
	423	^{US-} 4,423,809	1/3/1984	Mazzocco	
	120	^{US-} 4,425,908	1/17/1984	Simon	
	121	^{US-} 4,501,030	2/26/1985	Lane	
	122	^{US-} 4,580,568	4/8/1986	Gianturco	· .

		FORE	IGN PATENT DOCL	JMENTS		
Examiner Initials*		Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
c	Country Code ³ "Number ⁴ "Kind Code ⁵ (<i>if known</i>)	MM-DD-YYYY	·	Or Relevant Figures Appear	⊤ ⁶	
	440	CN1338951A (Eng Abs)	3/6/2002	Impella Cardiotechnik AG		
	307	EP 0409929 B1	4/23/1997	Boston Scientific Corp.		
	308	EP 0819013	6/23/2004	Heartport, Inc.		
	309	EP 0937439B1	9/17/2003	Heartport, Inc.		
	310	EP 1000590 A1	5/17/2000	Cordis Corporation		
	311	EP 1042045 B1	5/19/2004	Domnick Hunter Ltd.		

Examiner Signature

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at <u>www.uspto.gov</u> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Date Considered

Approved for use through 07/31/2009. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

12

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of 23

Coi	nplete if Known	
Application Number	12/492,512	
Filing Date	June 26, 2009	
First Named Inventor	Amr Salahieh	
Art Unit	3774	
Examiner Name	Unassigned	
Attorney Docket Number	10012-710.401	

Examiner	Cite	Document Number	Publication Date	DOCUMENTS Name of Patentee or	Pages, Columns, Lines, Where
Initials*	No. ¹	Number-Kind Code ^{2 (if known)}	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
	438	^{US-} 4,602,911	7/29/1986	Ahmadi et al.	
	123	^{US-} 4,610,688	9/9/1986	Silvestrini et al.	
	124	^{US-} 4,647,283	3/3/1987	Carpentier et al.	
	125	^{US-} 4,648,881	3/10/1987	Carpentier et al.	
	126	^{US-} 4,655,771	4/7/1987	Wallsten	
	127	^{US-} 4,662,885	5/5/1987	DiPisa, Jr.	
	128	^{US-} 4,665,906	5/19/1987	Jervis	
·····	129	^{US-} 4,710,192	12/1/1987	Liotta et al.	
	130	^{US-} 4,733,665	3/29/1988	Palmaz	
	131	^{US-} 4,796,629	1/10/1989	Grayzel	
	132	^{US-} 4,819,751	4/11/1989	Shimada et al.	
	133	^{US-} 4,834,755	5/30/1989	Silvestrini et al.	
	134	^{US-} 4,856,516	8/15/1989	Hillstead	
	135	^{US-} 4,872,874	10/10/1989	Taheri	
	136	^{US-} 4,909,252	3/20/1990	Goldberger	
	137	^{US-} 4,917,102	4/17/1990	Miller et al.	
	138	^{US-} 4,954,126	9/4/1990	Wallsten	
	139	^{US-} 4,986,830	1/22/1991	Owens et al.	
	140	^{US-} 4,994,077	2/19/1991	Dobben	

Initials* No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear		
	Country Code ³ "Number ⁴ "Kind Code ⁵ (<i>if known</i>)	MM-DD-YYYY			T ⁶	
	312	EP 1057459	12/6/2000	Numed, Inc.		
	313	EP 1057460	12/6/2000	Numed, Inc.		
	314	EP 1059894 B1	7/20/2005	Boston Scientific Limited		
	315	EP 1078610 B1	8/10/2005	Cordis Corp.		
	316	EP 1156757 B1	12/7/2005	Board of Regents, The Univer		
	317	EP 1229864 B1	4/27/2005	Boston Scientific Limited		

Examiner Signature

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at <u>www.uspto.gov</u> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 07/31/2009. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet 3

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of 23

Cor	nplete if Known
Application Number	12/492,512
Filing Date	June 26, 2009
First Named Inventor	Amr Salahieh
Art Unit	3774
Examiner Name	Unassigned
 Attorney Docket Number	10012-710.401

				DOCUMENTS	
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (if known)}		Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	141	US- 5,002,559	3/26/1991	Tower	
	142	^{US-} 5,064,435	11/12/1991	Porter	
	143	^{US-} 5,161,547	11/10/1992	Tower	
	144	^{US-} 5,163,953	11/17/1992	Vince	
	145	^{US-} 5,209,741	5/11/1993	Spaeth	
·····	146	^{US-} 5,217,483	7/8/1993	Tower	
	147	^{US-} 5,258,042	11/2/1993	Mehta	
	148	^{US-} 5,332,402	7/26/1994	Teitelbaum	
******	149	^{US-} 5,350,398	9/27/1994	Pavcnik et al.	
	150	^{US-} 5,370,685	12/6/1994	Stevens	
	151	^{US-} 5,389,106	2/14/1995	Tower	
	152	^{US-} 5,397,351	3/14/1995	Pavcnik et al.	
	153	^{US-} 5,411,552	5/2/1995	Andersen et al.	
	154	^{US-} 5,425,762	6/20/1995	Muller	
	155	^{US-} 5,431,676	7/11/1995	Dubrul et al.	,
· · ·	156	^{US-} 5,443,495	8/22/1995	Buscemi et al.	
	394	^{US-} 5,443,499	8/22/1995	Schmitt, Peter	
	406	^{US-} 5,476,506	12/19/1995	Lunn	
	437	^{US-} 5,476,510	12/19/1995	Eberhardt et al.	

		FOREIGN	PATENT DOCU	IMENTS		
Examiner Initials*	Cite No. ¹		Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ "Number ⁴ "Kind Code ⁵ (<i>if known</i>)	MM-DD-YYYY		Or Relevant Figures Appear	− T ⁶
	318	EP 1340473 A2	9/3/2003	3F Therapeutics, Inc.		
	319	EP 1356793	10/29/2003	Numed, Inc.		
	320	EP 1430853 A2	6/8/2005	M. I. Tech Co., Ltd.		
	321	EP 1469797(German w/ Eng. Claims	11/2/2005	Figulla, Hans-Reiner		
	322	EP 1576937 A2	9/21/2005	Board of Regents, The Univer		
	323	EP 1582178 A2	10/5/2005	Board of Regents, The Univer		
	323	EP 1582178 A2	10/5/2005			

Examiner Signature

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at <u>www.uspto.gov</u> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Date

Approved for use through 07/31/2009. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

Sheet 4

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of 23

Coi	mplete if Known	
Application Number	12/492,512	
Filing Date	June 26, 2009	
First Named Inventor	Amr Salahieh	
Art Unit	3774	
Examiner Name	Unassigned	
Attorney Docket Number	10012-710.401	

			U. S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (# known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	157	^{US-} 5,507,767	4/16/1996	Maeda et al.	
	158	^{US-} 5,545,133	8/13/1996	Burns et al.	
	159	^{US-} 5,545,211	8/13/1996	An et al.	
	160	^{US-} 5,554,185	9/10/1996	Block et al.	
	161	^{US-} 5,575,818	11/19/1996	Pinchuk	
	162	^{US-} 5,645,559	7/8/1997	Hachtman et al.	
	407	^{US-} 5,662,671	9/2/1997	Barbut et al.	
	163	^{US-} 5,667,523	9/16/1997	Bynon et al.	
	164	^{US-} 5,674,277	10/7/1997	Freitag	
	165	^{US-} 5,695,498	12/9/1997	Tower	
	166	^{US-} 5,713,953	2/3/1998	Vallana et al.	
	380	^{US-} 5,720,391	2/24/1998	Dohm et al.	
	443	^{US-} 5,735,842	4/7/1998	Krueger et al.	
	167	^{US-} 5,800,456	9/1/1998	Maeda et al.	
	168	^{US-} 5,817,126	10/6/1998	Imran	
	375	^{US-} 5,824,041	10/20/1998	Lenker et al.	
	169	^{US-} 5,824,043	10/20/1998	Cottone Jr.	
	170	^{US-} 5,824,053	10/20/1999	Khosravi et al.	
	395	^{US-} 5,824,055	10/20/1998	Spiridigliozzi et al.	

Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	JMENTS Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	
			MM-DD-YYYY			
	324	EP 1582179 A2	10/5/2005	Board of Regents, The Univer		
	325	EP 1600121A1	11/30/2005	William Cook Europe ApS		
	326	EP 1616531	1/18/2006	Boston Scientific Limited		
	354	WO 93/15693	8/19/1993	Vince Medical Company Limit		
	355	WO 95/04556	2/16/1995	Active Control Experts, Inc.		
	356	WO 95/29640 (AB TRN)	11/9/1995	Aesculap AG		

Examiner Signature

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at <u>www.uspto.gov</u> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 124 of 442

Date

Approved for use through 07/31/2009. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet 5

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of 23

	Cor	mplete if Known
	Application Number	12/492,512
	Filing Date	June 26, 2009
	First Named Inventor	Amr Salahieh
	Art Unit	3774
	Examiner Name	Unassigned
	Attorney Docket Number	10012-710.401

				DOCUMENTS	
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (if known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	171	^{US-} 5,824,056	10/20/2000	Rosenberg	
	172	^{US-} 5,824,064	10/20/2001	Taheri	
	173	^{US-} 5,840,081	11/24/1998	Andersen et al.	
	174	^{US-} 5,843,158	12/1/1998	Lenker et al.	
	175	^{US-} 5,855,597	1/5/1999	Jayaraman	
	176	^{US-} 5,855,601	1/5/1999	Bessler et al.	
	177	^{US-} 5,860,996	1/19/1999	Tower	
	178	^{US-} 5,861,028	1/19/1999	Angell	
	179	^{US-} 5,868,783	2/9/1999	Tower	
	180	^{US-} 5,876,448	3/2/1999	Thompson et al.	
	181	^{US-} 5,888,201	3/30/1999	Stinson et al.	
	182	^{US-} 5,891,191	4/6/1999	Stinson	
	408	^{US-} 5,895,399	4/20/1999	Barbut et al.	
	183	^{US-} 5,907,893	6/1/1999	Zadno-Azizi et al.	
	184	^{US-} 5,910,154	6/8/1999	Tsugita et al.	
	185	^{US-} 5,911,734	6/15/1999	Tsugita et al.	·
	186	^{US-} 5,925,063	7/20/1999	Khosravi	
	187	^{US-} 5,944,738	8/31/1999	Amplatz et al.	
	188	^{US-} 5,954,766	9/21/1999	Zadno-Azizi et al.	

Examiner Initials*	Cite No. ¹		PATENT DOCU Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ "Number ⁴ "Kind Code ⁵ (<i>if known</i>)	MM-DD-YYYY		Or Relevant Figures Appear	T
	357	WO 96/14032	5/17/1996	Duran, Carlos		
	358	WO 96/24306 A1(French W/ Eng ab)	8/15/1996	De Fays, Robert		
	359	WO 98/36790	8/27/1998	Conado Medical Devices Cor		
	360	WO 98/50103 A1	11/12/1998	Embol-X, Inc.		
	361	WO 98/57599 A2	12/23/1998	Camilli, Sante		
	362	WO 99/44542 A2	9/10/1999	Scimed Life Systems, Inc.		

Examiner Signature

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at <u>www.uspto.gov</u> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Date

Approved for use through 07/31/2009. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

Sheet 6

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of 23

Coi	mplete if Known	
Application Number	12/492,512	
Filing Date	June 26, 2009	
First Named Inventor	Amr Salahieh	
Art Unit	3774	
Examiner Name	Unassigned	
Attorney Docket Number	10012-710.401	

Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
Initials*	No.1	Number-Kind Code ^{2 (if known)}	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
	189	^{US-} 5,957,949	9/28/1999	Leonhardt et al.	· · ·
	190	^{US-} 5,968,070	10/19/1999	Bley et al.	
	191	^{US-} 5,984,957	11/16/1999	Laptewicz, Jr. et al.	
	439	^{US-} 5,984,959	11/16/1999	Robertson et al.	
	409	^{US-} 5,993,469	11/30/1999	McKenzie et al.	
	410	^{US-} 5,997,557	12/7/1999	Barbut et al.	
	411	^{US-} 6,010,522	1/4/2000	Barbut et al.	· · · · ·
	192	^{US-} 6,022,370	2/8/2000	Tower	
	193	^{US-} 6,027,520	2/22/2000	Tsugita et al.	
	194	^{US-} 6,027,525	2/22/2000	Suh et al.	
	195	^{US-} 6,042,598	3/28/2000	Tsugita et al.	
	196	^{US-} 6,042,607	3/28/2000	Williamson, IV et al.	
	197	^{US-} 6,123,723	9/26/2000	Konya et al.	
	198	^{US-} 6,162,245	12/19/2000	Jayaraman	
	199	^{US-} 6,165,200	12/26/2000	Tsugita et al.	
	200	^{US-} 6,168,579	1/2/2001	Tsugita	·
	201	^{US-} 6,168,614	1/2/2001	Andersen et al.	
	202	^{US-} 6,171,327	1/9/2001	Daniel et al.	· · · · · · · · · · · · · · · · · · ·
-	203	^{US-} 6,179,859	1/30/2001	Bates	· · · · · · · · · · · · · · · · · · ·

Examiner Initials*	Cite No. ¹	Foreign Patent Document	EIGN PATENT DOCU Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ "Number ⁴ "Kind Code ⁵ (<i>if known</i>)	MM-DD-YYYY		Or Relevant Figures Appear	T ⁶
	327	WO 00/09059	2/24/2000	Prodesco, Inc.		1.
	328	WO 00/44308	8/3/2000	Board of Regents, The Univer		
	329	WO 00/44313	8/3/2000	Viacor, Inc.		Γ
	330	WO 00/49970 A1	8/31/2000	Scimed Life Systems, Inc.		
_	331	WO 00/67661	11/16/2000	Ortiz, Mark		
	332	WO 01/05331	1/25/2001	Biocompatibles Ltd.		
Examiner				Date		

Examiner Signature

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at <u>www.uspto.gov</u> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 07/31/2009. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

Sheet 7

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of 23

Coi	mplete if Known
Application Number	12/492,512
Filing Date	June 26, 2009
First Named Inventor	Amr Salahieh
Art Unit	3774
Examiner Name	Unassigned
Attorney Docket Number	10012-710.401

				DOCUMENTS	
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (if known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	370		02/06/2001		
		^{US-} 6,197,053	03/06/2001	Cosgrove et al.	
	204	^{US-} 6,200,336	03/13/2001	Pavcnik et al.	
	205	^{US-} 6,221,006	04/24/2001	Dubrul et al.	
	206	^{US-} 6,221,091	04/24/2001	Khosravi	
	401	^{US-} 6,221,096	04/24/2001	Aiba et al.	
	412	^{US-} 6,231,544	5/15/2001	Tsugita et al.	
	413	^{US-} 6,231,551	5/15/2001	Barbut	
	207	^{US-} 6,241,757	06/05/2001	An et al.	
	208	^{US-} 6,245,102	06/12/2001	Jayaraman	
	209	^{US-} 6,258,114	07/10/2001	Konya et al.	
	210	^{US-} 6,258,115	07/10/2001	Dubrul	
	211	^{US-} 6,258,120	07/10/2001	McKenzie et al.	
	212	^{US-} 6,270,513	08/07/2001	Tsugita et al.	
	213	^{US-} 6,277,555	08/21/2001	Duran et al.	
	214	^{US-} 6,309,417	10/30/2001	Spence et al.	
	215	^{US-} 6,319,281	11/20/2001	Patel	
	216	^{US-} 6,327,772	12/11/2001	Zadno-Azizi et al.	
	217	^{US-} 6,336,934	01/08/2002	Gilson et al.	
	218	^{US-} 6,338,735	01/15/2002	Stevens	

	FOREIGN	I PATENT DOCU	JMENTS		
Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
	Country Code ³ "Number ⁴ "Kind Code ⁵ (<i>if known</i>)	MM-DD-YYYY		Or Relevant Figures Appear	T ⁶
333	WO 01/08596 A1	02/08/2001	Scimed Life Systems, Inc.		
334	WO 01/10320 A1	02/15/2001	Scimed Life Systems, Inc.		
335	WO 01/10343 A1	02/15/2001	Scimed Life Systems, Inc.		
336	WO 01/35870(French w/ Eng. Ab)	05/25/2001	Seguin		
337	WO 01/64137(German w/ Eng. Ab)	09/07/2001	Fraunhofer-Gesellschaft Zur f		
339	WO 02/36048(French W/Eng. Ab)	05/10/2002	Seguin		
	No. ¹ 333 334 335 336 337	Cite No.1 Foreign Patent Document Country Code ³ "Number ⁴ -Kind Code ⁵ (if known) 333 WO 01/08596 A1 334 WO 01/10320 A1 335 WO 01/10343 A1 336 WO 01/35870(French w/ Eng. Ab) 337 WO 01/64137(German w/ Eng. Ab)	Cite No. ¹ Foreign Patent Document Publication Date MM-DD-YYYY 333 WO 01/08596 A1 02/08/2001 334 WO 01/10320 A1 02/15/2001 335 WO 01/10343 A1 02/15/2001 336 WO 01/35870(French w/ Eng. Ab) 05/25/2001 337 WO 01/64137(German w/ Eng. Ab) 09/07/2001	No.1 Date MM-DD-YYYY Applicant of Cited Document 333 WO 01/08596 A1 02/08/2001 Scimed Life Systems, Inc. 334 WO 01/10320 A1 02/15/2001 Scimed Life Systems, Inc. 335 WO 01/10343 A1 02/15/2001 Scimed Life Systems, Inc. 336 WO 01/35870(French w/ Eng. Ab) 05/25/2001 Seguin 337 WO 01/64137(German w/ Eng. Ab) 09/07/2001 Fraunhofer-Gesellschaft Zur F	Cite No. ¹ Foreign Patent Document Publication Date MM-DD-YYYY Name of Patentee or Applicant of Cited Document Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear 333 WO 01/08596 A1 02/08/2001 Scimed Life Systems, Inc. Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear 334 WO 01/0320 A1 02/15/2001 Scimed Life Systems, Inc. Image: Columns, Lines, Where Relevant Passages Or Relevant Figures Appear 335 WO 01/10320 A1 02/15/2001 Scimed Life Systems, Inc. Image: Columns, Lines, Where Relevant Passages Or Relevant Figures Appear 336 WO 01/10343 A1 02/15/2001 Seguin Image: Columns, Lines, Where Relevant Passages Or Relevant Figures Appear 337 WO 01/64137(German w/ Eng. Ab) 09/07/2001 Fraunhofer-Gesellschaft Zur f

Examiner Signature		Date Considered	
*EXAMINER	initial if reference considered, whether or not citation is in conformance with MPEP 609. Dra	w line through	citation if no

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at <u>www.uspto.gov</u> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Approved for use through 07/31/2009. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control nur

Substitute for form 1449/PTO

Sheet 8

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of 23

Cor	nplete if Known
Application Number	12/492,512
Filing Date	June 26, 2009
First Named Inventor	Amr Salahieh
Art Unit	3774
Examiner Name	Unassigned
Attorney Docket Number	10012-710.401

				DOCUMENTS	
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (# known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	219	^{US-} 6,348,063	2/19/2002	Yassour et al.	
	220	^{US-} 6,352,708	3/5/2002	Duran et al.	
	363	^{US-} 6,361,545	3/26/2002	Macoviak et al.	
	431	^{US-} 6,336,937	1/8/2002	Vonesh et al.	
	221	^{US-} 6,371,970	4/16/2002	Khosravi et al.	
	222	^{US-} 6,371,983	4/16/2002	Lane	
	223	^{US-} 6,379,383	4/30/2002	Palmaz et al.	
	224	^{US-} 6,398,807	6/4/2002	Chouinard et al.	
	225	^{US-} 6,409,750	6/25/2002	Hyodoh et al.	· · · · · · · · · · · · · · · · · · ·
	226	^{US-} 6,425,916	7/30/2002	Garrison et al.	
	227	^{US-} 6,440,164	8/27/2002	DiMatteo et al.	
	228	^{US-} 6,458,153	10/1/2002	Bailey et al.	
	229	^{US-} 6,468,303	10/22/2002	Amplatz et al.	
	230	^{US-} 6,475,239	11/5/2002	Campbell et al.	
	231	^{US-} 6,482,228	11/19/2002	Norred	
	232	^{US-} 6,485,502	11/26/2002	Don Michael et al.	
	233	^{US-} 6,494,909	12/17/2002	Greenhalgh	
	234	^{US-} 6,503,272	1/7/2003	Duerig et al.	
	235	^{US-} 6,508,833	1/21/2003	Pavcnik et al.	

		FOREIGN	PATENT DOCU	IMENTS		
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ "Number ⁴ "Kind Code ⁵ (<i>if known</i>)	MM-DD-YYYY		Or Relevant Figures Appear	Т
	385	WO 02/41789 A2	5/30/2002	Rex Medical, L. P.	а.	
	338	WO 02/100297	12/19/2002	Rex Medical, L. P.		
	340	WO 03/003943	1/16/2003	Advanced Bio Prosthetic Surf		
	341	WO 03/003949(French W/ Eng Ab)	1/16/2003	Seguin		
	342	WO 03/011195(AB TRN)	2/13/2003	Seguin, Jacques		
	343	WO 03/015851	11/27/2003	Scimed Life Systems, Inc.		

Examiner Signature

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at <u>www.uspto.gov</u> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Date

Approved for use through 07/31/2009. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet 9

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of 23

Complete if Known					
Application Number	12/492,512				
Filing Date	June 26, 2009				
First Named Inventor	Amr Salahieh				
Art Unit	3774				
Examiner Name	Unassigned				
Attorney Docket Number	10012-710.401				

	-			DOCUMENTS	
Examiner Initials*	Cite No. ¹		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	000	Number-Kind Code ^{2 (if known)}	2/4/2002	McQuelin la stal	
	236	^{US-} 6,527,800	3/4/2003	McGuckin, Jr. et al.	
	237	^{US-} 6,530,949	3/11/2003	Konya et al.	
	238	^{US-} 6,537,297	3/25/2003	Tsugita et al.	
	239	^{US-} 6,540,768	4/1/2003	Diaz et al.	
	240	^{US-} 6,562,058	5/13/2003	Seguin et al.	
	241	^{US-} 6,592,546	7/15/2003	Barbut et al.	
	242	^{US-} 6,592,614	7/15/2003	Lenker et al.	
	368	^{US-} 6,610,077	8/26/2003	Hancock et al.	
	414	^{US-} 6,616,682	9/9/2003	Joergensen et al.	
	243	^{US-} 6,622,604	9/23/2003	Chouinard et al.	
	244	^{US-} 6,632,243	10/14/2003	Zadno-Azizi et al.	
	245	^{US-} 6,635,068	10/21/2003	Dubrul et al.	
	246	^{US-} 6,652,571	11/25/2003	White et al.	
	247	^{US-} 6,652,578	11/25/2003	Bailey et al.	
	248	^{US-} 6,663,663	12/16/2003	Kim et al.	· ·
	249	^{US-} 6,669,724	12/30/2003	Park et al.	
	250	^{US-} 6,673,089	1/6/2004	Yassour et al.	
	251	^{US-} 6,673,109	1/6/2004	Сох	
	252	^{US-} 6,676,698	1/13/2004	McGuckin, Jr. et al.	

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ "Number ⁴ "Kind Code ⁵ (<i>if known</i>)	MM-DD-YYYY		Or Relevant Figures Appear	T
	344	WO 2004/014256 A1	2/19/2004	Abbott Laboratories Vascular		
	345	WO 2004/019811	3/11/2004	Heart Leaflet Technologies		
	346	WO 2004/023980	3/25/2004	3F Therapeutics, Inc.		
	347	WO 2004/026117 A2	4/1/2004	3F Therapeutics, Inc.		
	348	WO 2004/041126	5/21/2004	Seguin, Jacques		
	349	WO 2004/047681 A1(AB TRN)	6/10/2004	Boudjemline		

Examiner		Date	
Signature		Considered	
*EXAMINER:	Initial if reference considered, whether or not citation is in conformance with MPEP 609. Dra	w line through	citation if not in conformance and not

considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at <u>www.uspto.gov</u> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2009, OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number,

Substitute for form 1449/PTO

Sheet 10

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of 23

	Cor	mplete if Known
	Application Number	12/492,512
	Filing Date	June 26, 2009
	First Named Inventor	Amr Salahieh
	Art Unit	3774
	Examiner Name	Unassigned
-	Attorney Docket Number	10012-710.401

Examiner	Cite	Document Number	Publication Date	DOCUMENTS Name of Patentee or	Pages, Columns, Lines, Where
Initials*	No. ¹	Number-Kind Code ^{2 (if known)}	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
	415	^{US-} 6,682,543	1/27/2004	Barbut et al.	
	253	^{US-} 6,682,558	1/27/2004	Tu et al.	
	254	^{US-} 6,682,559	1/27/2004	Myers et al.	
	255	^{US-} 6,685,739	2/3/2004	DiMatteo et al.	
	256	^{US-} 6,689,144	2/10/2004	Gerberding	
	257	^{US-} 6,689,164	2/10/2004	Seguin	
	258	^{US-} 6,692,512	2/17/2004	Jang	
	259	^{US-} 6,695,864	2/24/2004	Macoviak et al.	
	260	^{US-} 6,695,865	2/24/2004	Boyle et al.	
	261	^{US-} 6,702,851	3/9/2004	Chinn et al.	
	377	^{US-} 6,712,842	3/30/2004	Gifford et al.	· ·
	262	^{US-} 6,712,843	3/30/2004	Elliott	· · · · · · · · · · · · · · · · · · ·
	402	^{US-} 6,714,842	3/30/2004	Ito, Hiroshi	
	263	^{US-} 6,719,789	4/13/2004	Cox	· · · · · · · · · · · · · · · · · · ·
	264	^{US-} 6,730,118	5/4/2004	Spenser et al.	
	265	^{US-} 6,730,377	5/4/2004	Wang	
	266	^{US-} 6,733,525	5/11/2004	Yang et al.	
	267	^{US-} 6,736,846	5/18/2004	Сох	
	268	^{US-} 6,752,828	6/22/2004	Thornton	

Examiner Initials*	Cite No.1		IGN PATENT DOCU Publication Date	Name of Patentee or Pages, Columns, Lines, Applicant of Cited Document Where Relevant Passage	
•		Country Code ³ Number ⁴ Kind Code ⁵ (<i>if known</i>)	MM-DD-YYYY	Or Relevant Figures App	ar T ^e
	350	WO 2004/066876 A1	8/12/2004	Ave Connaught	
	351	WO 2004/082536 A1	9/30/2004	Aortech International PLC	
	352	WO 2005/084595 A1	9/15/2005	Cardiacmd, Inc.	
	353	WO 2005/087140 A1	9/22/2005	Percutaneous Cardiovascular	
Examiner Signature	1	I		Date	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at <u>www.uspto.gov</u> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2009. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet 11

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of 23

Complete if Known					
Application Number	12/492,512				
Filing Date	June 26, 2009				
First Named Inventor	Amr Salahieh				
Art Unit	3774				
Examiner Name	Unassigned				
Attorney Docket Number	10012-710.401				

			U. S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (# known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	269	^{US-} 6,758,855	7/6/2004	Fulton, III et al.	
	270	^{US-} 6,764,509	7/20/2004	Chinn et al.	
	416	^{US-} 6,767,345	7/27/2004	St. Germain et al.	
	271	^{US-} 6,773,454	8/10/2004	Wholey et al.	
	369	^{US-} 6,790,229	9/14/2004	Berreklouw, Eric	
	272	^{US-} 6,790,230	9/14/2004	Beyersdorf et al.	
	433	^{US-} 6,790,237	9/14/2004	Stinson	
	273	^{US-} 6,792,979	9/21/2004	Konya et al.	
	398	^{US-} 6,821,297	11/23/2004	Snyders	
	274	^{US-} 6,840,957	1/11/2005	DiMatteo et al.	
	275	^{US-} 6,849,085	2/1/2005	Marton	
	376	^{US-} 6,863,668	3/8/2005	Gillespie et al.	
	276	^{US-} 6,872,226	3/29/2005	Cali et al.	
	277	^{US-} 6,875,231	4/5/2005	Anduiza et al.	
	278	^{US-} 6,887,266	5/3/2005	Williams et al.	
	279	^{US-} 6,890,340	5/10/2005	Duane	
	396	^{US-} 6,893,459	5/17/2005	Macoviak, John	
	280	^{US-} 6,893,460	5/17/2005	Spenser et al.	
	281	^{US-} 6,905,743	6/14/2005	Chen et al.	· · · · · · · · · · · · · · · · · · ·

		FOREIC	GN PATENT DOCU	MENTS		
Examiner	Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines,	
Initials*	No.'	Country Code ³ "Number ⁴ "Kind Code ⁵ (<i>if known</i>)	Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages Or Relevant Figures Appear	T6
Examiner Signature				Date Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at <u>www.uspto.gov</u> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2009. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

Sheet 12

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of 23

	Cor	mplete if Known
	Application Number	12/492,512
	Filing Date	June 26, 2009
	First Named Inventor	Amr Salahieh
	Art Unit	3774
	Examiner Name	Unassigned
-	Attorney Docket Number	10012-710.401

			U. S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (if known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	282	^{US-} 6,908,481	6/21/2005	Cribier	
		^{US-} 6,911,036		· · · · · · · · · · · · · · · · · · ·	
	283		6/28/2005	Douk et al.	······································
	284	^{US-} 6,911,043	6/28/2005	Myers et al.	
	285	^{US-} 6,936,067	8/30/2005	Buchanan	
	286	^{US-} 6,953,332	10/11/2005	Kurk et al.	
	287	^{US-} 6,964,673	11/15/2005	Tsugita et al.	
	288	^{US-} 6,974,464	12/13/2005	Quijano et al.	
	289	^{US-} 6,974,474	12/13/2005	Pavcnik et al.	
	290	^{US-} 6,974,476	12/23/2005	McGuckin, Jr. et al.	
	291	^{US-} 6,979,350	12/27/2005	Moll et al.	
	292	^{US-} 6,984,242	1/10/2006	Campbell et al.	
	400	^{US-} 7,011,681	3/14/2006	Veseley, ivan	
	384	^{US-} 7,018,406	3/28/2006	Seguin et al.	
	417	^{US-} 7,166,097	1/23/2007	Barbut	
	371	^{US-} 7,189,258	3/13/2007	Johnson et al.	
	447	^{US-} 7,191,018	3/13/2007	Gielen et al.	
	418	^{US-} 7,374,560	5/20/2008	Ressemann et al.	· ·
	1	^{US-} 2001/0039450	11/8/2001	Pavcnik et al.	
	2	^{US-} 2001/0041928	11/15/2001	Pavcnik et al.	

		FORE'	IGN PATENT DOCU	MENTS		· ·	
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of F	Patentee or Dited Document	Pages, Columns, Lines, Where Relevant Passages	
	110.	Country Code ³ "Number ⁴ "Kind Code ⁵ (if known)	MM-DD-YYYY			Or Relevant Figures Appear	Т6
Examiner					Date		
Signature					Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at <u>www.uspto.gov</u> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Traisculor is altorized. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO:** Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2009. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet 13

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of 23

Complete if Known				
Application Number	12/492,512			
Filing Date	June 26, 2009			
First Named Inventor	Amr Salahieh			
Art Unit	3774			
Examiner Name	Unassigned			
Attorney Docket Number	10012-710.401			

			U. S. PATENI	DOCUMENTS	
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ^{2 (if known)}			
	3	^{US-} 2001/0044634	11/22/2001	Don Michael et al.	
	381	^{US-} 2001/0044656 A1	11/22/2001	Williamson et al.	
	4	^{US-} 2002/0010489 A1	1/24/2002	Grayzel et al.	
	5	^{US-} 2002/0058995	5/16/2002	Stevens	
	6	^{US-} 2002/0077696	6/20/2002	Zadno-Azizi et al.	
	7	^{US-} 2002/0095173	7/18/2002	Mazzocchi et al.	
	8	^{US-} 2002/0095209	7/18/2002	Zadno-Azizi et al.	
	9	^{US-} 2002/0111674	8/15/2002	Chouinard et al.	
	10	^{US-} 2002/0151970	10/17/2002	Garrison et al.	
	11	^{US-} 2002/0161392	10/31/2002	Dubrul	
	12	^{US-} 2002/0161394	10/31/2002	Macoviak et al.	
	13	^{US-} 2003/0023303	1/30/2003	Palmaz et al.	
	14	^{US-} 2003/0036791	2/20/2003	Philipp et al.	
	15	^{US-} 2003/0040771	2/27/2003	Hyodoh et al.	
	16	^{US-} 2003/0040772	2/27/2003	Hyodoh et al.	
	17	^{US-} 2003/0055495	3/20/2003	Pease et al.	
	18	^{US-} 2003/0060844	3/27/2003	Borillo et al.	
	19	^{US-} 2003/0109924	6/12/2003	Cribier	
	20	^{US-} 2003/0125795	7/3/2003	Pavcnik et al.	

			GN PATENT DOCU	MENTS		
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ Number ⁴ Kind Code ⁵ (<i>if known</i>)	MM-DD-YYYY		Or Relevant Figures Appear	T ⁶
		·				
Examiner Signature				Date Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at <u>www.uspto.gov</u> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2009. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet 14

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of 23

Complete if Known				
Application Number	12/492,512			
Filing Date	June 26, 2009			
First Named Inventor	Amr Salahieh			
Art Unit	3774			
Examiner Name	Unassigned			
Attorney Docket Number	10012-710.401			

			U. S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ^{2 (if known)}			Figures Appear
	21	^{US-} 2003/0130729	7/10/2003	Paniagua et al.	
	22	^{US-} 2003/0149476	8/7/2003	Damm et al.	
	23	^{US-} 2003/0149478	8/7/2003	Figulla et al.	
	24	^{US-} 2003/0176884	9/18/2003	Berrada et al.	
	25	^{US-} 2003/0181850	9/25/2003	Diamond et al.	
	26	^{US-} 2003/0187495	10/2/2003	Cully et al.	
	27	^{US-} 2003/0199913	10/23/2003	Dubrul et al.	
	28	^{US-} 2003/0199971	10/23/2003	Tower et al.	· ·
	29	^{US-} 2003/0199972	10/23/2003	Zadno-Azizi et al.	
	30	^{US-} 2003/0208224	11/6/2003	Broome	
	31	^{US-} 2003/0212452	11/13/2003	Zadno-Azizi et al.	
	32	^{US-} 2003/0212454	11/13/2003	Scott et al.	
	33	^{US-} 2003/0216774	11/20/2003	Larson	
	397	^{US-} 2003/0229390 A1	12/11/2003	Ashton et al.	
	366	^{US-} 2003/0233117 A1	12/18/2003	Adams et al.	
	34	^{US-} 2004/0034411	2/19/2004	Quijano et al.	
	35	^{US-} 2004/0039436	2/26/2004	Spenser et al.	······
	36	^{US-} 2004/0049224	3/11/2004	Buehlmann et al.	
	37	^{US-} 2004/0049262	3/11/2004	Obermiller et al.	

		FOREI	GN PATENT DOCU	MENTS		
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ₆
Examiner Signature				Date		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at <u>www.uspto.gov</u> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2009. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet 15

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of 23

Complete if Known				
Application Number	12/492,512			
Filing Date	June 26, 2009			
First Named Inventor	Amr Salahieh			
Art Unit	3774			
Examiner Name	Unassigned			
Attorney Docket Number	10012-710.401			

			U. S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (# known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	38	^{US-} 2004/0073198	4/15/2004	Gilson et al.	
	39	^{US-} 2004/0082904	4/29/2004	Houde et al.	· · ·
	40	^{US-} 2004/0082967	4/29/2004	Broome et al.	
	365	^{US-} 2004/0087982 A1	5/6/2004	Eskuri et al.	
	41	^{US-} 2004/0088045	5/6/2004	Cox	
	42	^{US-} 2004/0093016	5/13/2004	Root et al.	
	43	^{US-} 2004/0111096	6/10/2004	Tu et al.	
	44	^{US-} 2004/0116951	6/17/2004	Rosengart	
	45	^{US-} 2004/0117004	6/17/2004	Osborne et al.	
	46	^{US-} 2004/0122468	6/24/2004	Yodfat et al.	
	47	^{US-} 2004/0127979	7/1/2004	Wilson et al.	
	48	^{US-} 2004/0138694	7/15/2004	Tran et al.	
	49	^{US-} 2004/0138742	7/15/2004	Myers et al.	
	364	^{US-} 2004/0153094 A1	8/5/2004	Dunfee et al.	· · · · · · · · · · · · · · · · · · ·
	50	^{US-} 2004/0158277	8/12/2004	Lowe et al.	
	51	^{US-} 2004/0167565	8/26/2004	Beulke et al.	
	52	^{US-} 2004/0186563	9/23/2004	Lobbi	
· ·	53	^{US-} 2004/0204755 A1	10/14/2004	Robin	
	378	^{US-} 2004/0215331	10/28/2004	Chew et al.	······

		FOREIC	GN PATENT DOCU	MENTS		
Examiner	Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines,	
Initials*	No. ¹		Date	Applicant of Cited Document	Where Relevant Passages	- -6
 	'	Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	
i			·			
		·				
Examiner	<u> </u>			Date		
Signature				Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at <u>www.uspto.gov</u> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2009. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet 16

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of 23

Cor	Complete if Known				
Application Number	12/492,512				
Filing Date	June 26, 2009				
First Named Inventor	Amr Salahieh				
Art Unit	3774				
Examiner Name	Unassigned				
Attorney Docket Number	10012-710.401				

			U. S. PATEN	DOCUMENTS	
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (# known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	54	^{US-} 2004/0215339	10/28/2004	Drasler et al.	· · · · · · · · · · · · · · · · · · ·
	55	^{US-} 2004/0225321	11/11/2004	Krolik et al.	
	56	^{US-} 2004/0254636 A1	12/16/2004	Flagle et al.	
	57	^{US-} 2005/0075662 A1	4/7/2005	Pedersen et al.	
	58	^{US-} 2005/0085841	4/21/2005	Eversull et al.	
	59	^{US-} 2005/0085842	4/21/2005	Eversull et al.	
	60	^{US-} 2005/0085843	4/21/2005	Opolski et al.	· · · · · · · · · · · · · · · · · · ·
	61	^{US-} 2005/0085890	4/21/2005	Rasmussen et al.	
	62	^{US-} 2005/0090846 A1	4/28/2005	Pedersen et al.	
	63	^{US-} 2005/0096692	5/5/2005	Linder et al.	
	64	^{US-} 2005/0096734	5/5/2005	Majercak et al.	
	65	^{US-} 2005/0096735	5/5/2005	Hojeibane et al.	
	66	^{US-} 2005/0096736 A1	5/5/2005	Osse et al.	······································
_	67	^{US-} 2005/0096738	5/5/2005	Cali et al.	
	68	^{US-} 2005/0100580	5/12/2005	Osborne et al.	
	367	^{US-} 2005/0107822 A1	5/19/2005	WasDyke, Joel	
	69	^{US-} 2005/0113910 A1	5/26/2005	Paniagua et al.	··· · · · · · · · · · · · · · · · · ·
	70	^{US-} 2005/0137686	6/23/2005	Salahieh et al.	
	71	^{US-} 2005/0137687	6/23/2005	Salahieh et al.	

		FOREIG	SN PATENT DOCU	MENTS		
Examiner	Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines,	
Initials*	No.1		Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages Or Relevant Figures Appear	7 6
		Country Code ³ Number ⁴ Kind Code ⁵ (<i>if known</i>)			Of Relevant Figures Appear	'
				· · · · · · · · · · · · · · · · · · ·		
				······································		
	• • • • • • • • • • • • • • • • • • • •				· · · · · · · · · · · · · · · · · · ·	
Examiner				Date		

Signature

Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at <u>www.uspto.gov</u> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2009, OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet 17

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of 23

Complete if Known				
Application Number	12/492,512			
Filing Date	June 26, 2009			
First Named Inventor	Amr Salahieh			
Art Unit	3774			
Examiner Name	Unassigned			
Attorney Docket Number	10012-710.401			

			U. S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (# known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	72	^{US-} 2005/0137688	6/23/2005	Salahieh et al.	
	73	^{US-} 2005/0137689	6/23/2005	Salahieh et al.	
	74	^{US-} 2005/0137690	6/23/2005	Salahieh et al.	
	75	^{US-} 2005/0137691	6/23/2005	Salahieh et al.	
	76	^{US-} 2005/0137692	6/23/2005	Haug et al.	
	77	^{US-} 2005/0137693	6/23/2005	Haug et al.	
	78	^{US-} 2005/0137694	6/23/2005	Haug et al.	
	304	^{US-} 2005/0137695 A1	6/23/2005	Salahieh et al.	
	79	^{US-} 2005/0137696	6/23/2005	Salahieh et al.	
	80	^{US-} 2005/0137697	6/23/2005	Salahieh et al.	
	81	^{US-} 2005/0137698	6/23/2005	Salahieh et al.	
	82	^{US-} 2005/0137699	6/23/2005	Salahieh et al.	
	83	^{US-} 2005/0137701	6/23/2005	Salahieh et al.	
	84	^{US-} 2005/0137702	6/23/2005	Haug et al.	
	85	^{US-} 2005/0143809	6/30/2005	Salahieh et al.	
	86	^{US-} 2005/0165352 A1	7/28/2005	Henry, et al.	
	87	^{US-} 2005/0165477 A1	7/28/2005	Anduiza et al.	
	88	^{US-} 2005/0197695 A1	9/8/2005	Stacchino et al.	
	89	^{US-} 2005/0203614 A1	9/15/2005	Forster	

		FORE	IGN PATENT DOCU	MENTS		
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documer		т ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (<i>if known</i>)			Or Relevant Figures Appear	
				N		11
Examiner				Date		
Signature				Considered		

Signature

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at <u>www.uspto.gov</u> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2009. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet 18

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of 23

	Complete if Known					
	Application Number	12/492,512				
	Filing Date	June 26, 2009				
	First Named Inventor	Amr Salahieh				
I	Art Unit	3774				
I	Examiner Name	Unassigned				
1	Attorney Docket Number	10012-710.401				

			U. S. PATENT	DOCUMENTS	······································
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant
		Number-Kind Code ^{2 (if known)}			Figures Appear
	90	^{US-} 2005/0203615 A1	9/15/2005	Forster	
	91	^{US-} 2005/0203616 A1	9/15/2005	Cribier	
	92	^{US-} 2005/0203617 A1	9/15/2005	Forster, et al.	
	93	^{US-} 2005/0209580 A1	9/22/2005	Freyman	
	94	^{US-} 2005/0228472 A1	10/13/2005	Case et al.	
	95	^{US-} 2005/0251250	11/10/2005	Verhoeven et al.	
	96	^{US-} 2005/0251251	11/10/2005	Cribier	
	97	^{US-} 2005/0261759 A1	11/24/2005	Lambrecht et al.	
	98	^{US-} 2005/0267560 A1	12/1/2005	Bates	
	99	^{US-} 2005/0283231	12/22/2005	Haug et al.	· · · · · · · · · · · · · · · · · · ·
	100	^{US-} 2005/0283962	12/29/2005	Boudjemline	
	298	^{US-} 2006/0058872	3/16/2006	Salahieh et al.	
	302	^{US-} 2006/0173524	8/3/2006	Salahieh et al.	
	297	^{US-} 2006/0253191	11/9/2006	Salahieh et al.	
	296	^{US-} 2006/0287668	12/21/2006	Fawzi et al.	
	305	^{US-} 2007/0010876	1/11/2007	Salahieh et al.	
	306	^{US-} 2007/0010877	1/11/2007	Salahieh et al.	
	303	^{US-} 2007/0061008	3/15/2007	Salahieh et al.	
	299	^{US-} 2007/0112355	5/17/2007	Salahieh et al.	····

		FOREIG	SN PATENT DOCU	MENTS		
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ "Number ⁴ "Kind Code ⁵ (<i>if known</i>)	MM-DD-YYYY		Or Relevant Figures Appear	T ⁶
					·	
Examiner Signature				Date		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at <u>www.uspto.gov</u> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2009. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet 19

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of 23

Complete if Known			
Application Number	12/492,512		
Filing Date	June 26, 2009		
First Named Inventor	Amr Salahieh		
Art Unit	3774		
Examiner Name	Unassigned		
Attorney Docket Number	10012-710.401		

			U. S. PATEN	DOCUMENTS	, , ,
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (# known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	301	^{US-} 2007/0118214	5/24/2007	Salahieh et al.	
	374	^{US-} 2007/0162107	7/12/2007	Haug et al.	
	372	^{US-} 2007/0203503	8/30/2007	Salahieh et al.	
	373	^{US-} 2007/0244552	10/18/2007	Salahieh et al.	
	429	^{US-} 2001/0041930	11/15/2001	Globerman et al.	
	424	^{US-} 2002/0029981	3/14/2002	Nigam	
	382	^{US-} 2002/0032481	3/14/2002	Gabbay, Shlomo	
	428	^{US-} 2002/0055769	5/9/2002	Wang	
	425	^{US-} 2002/0082609	6/27/2002	Green	
	379	^{US-} 2002/0120328	8/29/2002	Pathak et al.	
	432	^{US-} 2002/0188341	12/12/2002	Elliott	
	434	^{US-} 2003/0050694	3/13/2003	Yang et al.	
	426	^{US-} 2003/0070944	4/17/2003	Nigam	
	444	^{US-} 2003/0109930	6/12/2003	Bluni et al.	
	445	^{US-} 2003/0144732	7/31/2003	Cosgrove et al.	· · · · · · · · · · · · · · · · · · ·
	419	^{US-} 2003/0212429	11/13/2003	Keegan et al.	
	420	^{US-} 2004/0049226	3/11/2004	Keegan et al.	
	421	^{US-} 2004/0098022	5/20/2004	Barone	
	427	^{US-} 2004/0098099	5/20/2004	McCullagh et al.	

		FOREIC	GN PATENT DOCU	IMENTS		
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document		\Box
		Country Code ³ "Number ⁴ "Kind Code ⁵ (<i>if known</i>)	MM-DD-YYYY		Or Relevant Figures Appear	T ⁶
Examiner		· · · · · · · · · · · · · · · · · · ·		Date	1	
Signature				Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at <u>www.uspto.gov</u> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2009. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet 20

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of 23

Complete if Known				
Application Number	12/492,512			
Filing Date	June 26, 2009			
First Named Inventor	Amr Salahieh			
Art Unit	3774			
Examiner Name	Unassigned			
Attorney Docket Number	10012-710.401			

			U. S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (# known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	446	^{US-} 2004/0133274	7/8/2004	Webler et al.	
·	404	^{US-} 2005/0033402	2/10/2005	Cully et al.	·····
	448	^{US-} 2005/0043711	2/24/2005	Corcoran et al.	
	383	^{US-} 2006/0259134	11/16/2006	Schwammenthal et al.	
	399	^{US-} 2008/0125859	5/29/2008	Salahieh et al.	· · ·
	403	^{US-} 2008/0234814	9/25/2008	Salahieh et al.	
	449	^{US-} 2008/0288054	11/20/2008	Pulnev et al.	
	435	^{US-} 2009/0054969	2/26/2009	Salahieh et al.	
	436	^{US-} 2009/0076598	3/19/2009	Salahieh et al.	
	451	^{US-} 5,769,812	06/23/1998	Sevens et al.	
	452	^{US-} 2002/0002396-A	01/03/2002	Fulkerson	
	453	^{US-} 6,454,799	09/24/2002	Schreck	
		US-			· · · · · · · · · · · · · · · · · · ·
		US-			
		US-			
		US-		·	

		FOREIG	N PATENT DOCU	MENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ "Number ⁴ "Kind Code ⁵ (<i>if known</i>)	MM-DD-YYYY		Or Relevant Figures Appear	T ⁶
Examiner	-			Date		
Signature				Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at <u>www.uspto.gov</u> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2009. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOS STATEMENT BY APPLIC		Complete if Known			
Cuboun				Application Number	12/492,512
INF	ORMATION	DIS	CLOSURE	Filing Date	June 26, 2009
STA	ATEMENT E	BY A	PPLICANT	First Named Inventor	Amr Salahieh
	(Use as many she	ofe ac n	acassary)	Art Unit	3774
	(Ose as many she	ets as 11	ecessary)	Examiner Name	Unassigned
Sheet	21	of	23	Attorney Docket Number	10012-710.401

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	263	ANDERSEN, H.R. et al. "Transluminal implantation of artificial heart valves. Description of a new expandable aortic valve and initial results with implantation by catheter technique in closed chest pigs." Euro. Heart J. 1992; 13:704-708.	
	264	ATWOOD, A. et al. "Insertion of Heart Valves by Catheterization." Project Supervised by Prof. S. Muftu of Northeaster University 2001-2002: 36-40.	
	265	BODNAR, E. et al. Replacement Cardiac Valves R Chapter 13: Extinct cardiac valve prostheses. Pergamon Publishing Corporation. New York, 1991: 307-322.	
	266	BOUDJEMLINE, Y. et al. "Percutaneous implantation of a biological valve in the aorta to treat aortic valve insufficiency - a sheep study.f Med Sci. Monit. 2002; Vol. 8, No. 4: BR113-116	
	267	BOUDJEMLINE, Y. et al. "Percutaneous implantation of a valve in the descending aorta in lambs." Euro. Heart J. 2002; 23: 1045-1049.	
	268	BOUDJEMLINE, Y. et al. "Percutaneous pulmonary valve replacement in a large right ventricular outflow tract: an experimental study." Journal of the Americal College of Cardiology. 2004; Vol. 43(6): 1082-1087.	
	269	BOUDJEMLINE, Y. et al. "Percutaneous valve insertion: A new approach?" J. of Thoracic and Cardio. Surg. 2003; 125(3): 741-743.	
	270	BOUDJEMLINE, Y. et al. "Steps Toward Percutaneous Aortic Valve Replacement." Circulation. 2002; 105: 775-778.	
	271	CRIBIER, A. et al. "Early Experience with Percutaneous Transcatheter Implantation of Heart Valve Prosthesis for the Treatment of End-Stage Inoperable Patients with Calcific Aortic Stenosis." J. of Am. Coll. of Cardio. 2004; 43(4): 698-703.	
	272	CRIBIER, A., et al. "Percutaneous Transcatheter Implantation of an Aortic Valve Prosthesis for Calcific Aortic Stenosis: First Human Case Description." Circulation. 2002; 106: 3006-3008.	

Examiner Signature

Considered *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Date

Approved for use through 07/31/2009. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO	Complete if Known		
	Application Number	12/492,512	
INFORMATION DISCLOSURE	Filing Date	June 26, 2009	
STATEMENT BY APPLICANT	First Named Inventor	Amr Salahieh	
(Use as many sheets as necessary)	Art Unit	3774	
	Examiner Name	Unassigned	
Sheet 22 of 23	Attorney Docket Number	10012-710.401	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	273	CRIBIER, A., et al. "Percutaneous Transcatheter Implantation of an Aortic Valve Prosthesis for Calcific Aortic Stenosis: First Human Case." Percutaneous Valve Technologies, Inc. 2002: 16 pages.	
	274	FERRARI, M. et al. "Percutaneous transvascular aortic valve replacement with self expanding stent-valve device." Poster from the presentation given at SMIT 2000, 12th International Conference. September 5, 2000.	
	275	HIJAZI, Z.M. "Transcatheter Valve Replacement: A New Era of Percutaneous Cardiac Intervention Begins." J. of Am. College of Cardio. 2004; 43(6): 1088-1089.	
	276	HUBER, C.H. et al. "Do valved stents compromise coronary flow?" European Journal of Cardio-thoracic Surgery. 2004; Vol. 25: 754-759.	
	277	KNUDSEN, L. L. et al. "Catheter-implanted prosthetic heart valves." Int'l J. of Art. Organs. 1993; 16(5): 253-262.	
	278	KORT, S. et al. "Minimally invasive aortic valve replacement: Echocardiographic and clinical results." Am. Heart J. 2001; 142(3): 476-481.	
	279	LOVE, C. et al. fThe Autogenous Tissue Heart Valve: Current Stat.f Journal of Cardiac Surgery. 1991; 6(4): 499-507.	
	280	LUTTER, G. et al. "Percutaneous aortic valve replacement: An experimental study. I. Studies on implantation." J. of Thoracic and Cardio. Surg. 2002; 123(4): 768-776.	
	281	MOULOPOULOS, S. D. et al. "Catheter-Mounted Aortic Valves." Annals of Thoracic Surg. 1971; 11(5): 423-430.	
	282	PANIAGUA, D. et al. "Percutaneous heart valve in the chronic in vitro testing model." Circulation. 2002; 106: e51-e52.	

Signature		Considered	
*EXAMINER: Ini	tial if reference considered, whether or not citation is in conformance with MPEP 60	9. Draw line through c	itation if not in conformance and not
considered. Inclu	ude copy of this form with next communication to applicant.		

Examiner

1 Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 142 of 442

Date

Approved for use through 07/31/2009. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known			
Cubolitu				Application Number	12/492,512
INF	ORMATION	DIS	SCLOSURE	Filing Date	June 26, 2009
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	Amr Salahieh
(Use as many sheets as necessary)				Art Unit	3774
(Use as many sneets as necessary)			iecessary)	Examiner Name	Unassigned
Sheet	23	of	23	Attorney Docket Number	10012-710.401

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title o the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
	283	PANIAGUA, D. et al. Heart Watch (2004). Texas Heart Institute. Spring, 2004 Edition: 8 pages.	
	284	PAVCNIK, D. et al. "Percutaneous bioprosthetic veno valve: A long-term study in sheep." J. of Vascular Surg. 2002; 35(3): 598-603.	
	285	PHILLIPS, S. J. et al. "A Temporary Catheter-Tip Aortic Valve: Hemodynamic Effects on Experimental Acute Aortic Insufficiency." Annals of Thoracic Surg. 1976; 21(2): 134-136.	
	286	SOCHMAN, J. et al. "Percutaneous Transcatheter Aortic Disc Valve Prosthesis Implantation: A Feasibility Study." Cardiovasc. Intervent. Radiol. 2000; 23: 384-388.	
	287	STUART, M. "In Heart Valves, A Brave, New Non-Surgical World." Start-Up. 2004: 9-17.	
	288	VAHANIAN, A. et al. "Percutaneous Approaches to Valvular Disease." Circulation. 2004; 109: 1572-1579.	
	289	VAN HERWERDEN, L. A. et al., "Percutaneous valve implantation: back to the future?" Euro. Heart J. 2002; 23(18): 1415-1416.	
	290	ZHOU, J. Q. et al. "Self-expandable valved stent of large size: off-bypass implantation in pulmonary position." Eur. J. Cardiothorac. 2003; 24: 212-216	
		· · · · · · · · · · · · · · · · · · ·	

Examiner Signature Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Electronic Acknowledgement Receipt			
EFS ID:	5865160		
Application Number:	12492512		
International Application Number:			
Confirmation Number:	7439		
Title of Invention:	Everting Heart Valve		
First Named Inventor/Applicant Name:	Amr Salahieh		
Customer Number:	66854		
Filer:	Thomas M. Zlogar/Angelica Zuniga		
Filer Authorized By:	Thomas M. Zlogar		
Attorney Docket Number:	10012-710.401		
Receipt Date:	11-AUG-2009		
Filing Date:	26-JUN-2009		
Time Stamp:	13:29:52		
Application Type:	Utility under 35 USC 111(a)		

Payment information:

Submitted wi	th Payment	no	no				
File Listing:							
Document Number	Document Description	Description File Name File Size(Bytes Message Diges		Multi Part /.zip	Pages (if appl.)		
1		10012-710401.pdf	5740042 e8729d15e7d76ef1e30918ca04537820155 8ec13	yes	26		

	Multipart Description/PDF files in .zip description					
	Document D	escription	Start	E	nd	
	Transmitta	al Letter	1		3	
	Information Disclosure Stat	ement (IDS) Filed (SB/08)	4		26	
Warnings:						
Information:					-	
2	Foreign Reference	CN1338951A.pdf	1270365	no	14	
	-		b45810bc911e30a0fbf53e0c5be3bc52cc93 959d			
Warnings:						
Information:						
3	Foreign Reference	EP0409929B1.pdf	1066970	no	15	
			25d9f7d5223f79516b367205337ebfa33a9f 98d5			
Warnings:						
Information:						
4	Foreign Reference	EP0819013B1.pdf	259097	no	23	
	l'oreign nererence	Li consonspripar	3fc506bbbd267eb4c73b04cd4f073321ede 2438e	110		
Warnings:						
Information:					-	
5	Foreign Reference	EP0937439.pdf	138738	no	12	
	, ereigin kerenee		1940e7de2081be5244f5754426623d3dada 9ebb8			
Warnings:						
Information:						
6	Foreign Reference	EP1000590A1.pdf	210298	no	18	
			d464aa033c0bf07d9dce0774a59334a4f032 c2e3			
Warnings:						
Information:		- T				
7	Foreign Reference	EP1042045B1.pdf	144308	no	18	
,	l'oreign nerenere		7c3542ff4f9792bde4d6d8eff49251cb4fe87 1d9	110		
Warnings:		·	· · ·		-	
Information:						
8	Foreign Reference	EP1057459A1.pdf	213371	no	12	
o	r oreign kererence		c77da489c6fdcffd977e35281947a1807534 7968	no		
Warnings:		1	·		•	
Information:						

Integrate Section Integrate Section Integrate Section Integrate Section Warnings: Integrate Section	9	Foreign Reference	EP1057460A1.pdf	140238	no	10	
Information: 10 Foreign Reference EP105989481.pdf 1099816 no 14 Warnings: UNXERPORT OF CONSTRUCTION OF CONSTRUCT OF CONSTRUCTION OF CONSTRUCTION OF CONSTRUCT OF CONSTRUCTION OF CONSTRUCTION OF CONSTRUCTION OF CONSTRUCT OF CONSTRUCTION OF CONSTRUCT OF CONSTRUT	,	roleiginkelerenee	El 1037400/(1.pdf				
10 Foreign Reference EP105989481.pdf 1098816 (mathemations/mathemathemations/mathemathemathemathemations/mathemathemations/mathema	Warnings:						
10Foreign ReferenceEP1059894B1.pdf	Information:			1			
Marings:Warnings:Information:11Proreign Reference324773 Proreign Reference324773 Proreign ReferenceProveProve12Proreign Reference1757666 Proreign ReferenceProveProve12Proreign Reference1757666 	10	Foreign Reference	EP1059894B1.pdf	1098816	no	14	
Information: Image: state							
11 Foreign Reference EP1078610B1.pdf 324773 Automationality and and an an and an an an and an and an and an							
11 Foreign Reference EP107861081.pdf no 10 Warnings: Information: Information: Information: Information: 12 Foreign Reference EP115675781.pdf 757666 no 85 Warnings: Information:	Information:			1			
Image: bis statement of the statement of	11	Foreign Reference	EP1078610B1.pdf	324773	no	10	
Information:12Foreign ReferenceEP115675781.pdf $\frac{73766}{40.047040000000000000000000000000000000$		5					
12 Foreign Reference EP115675781.pdf 737666 (abd/def victor interaction booked and antication interaction booked and antication interaction (abd/def victor interaction (abd/def vic	Warnings:						
12 Foreign Reference EP115675781.pdf	Information:			1		1	
Information Image: Description of the state and the stat	12	Foreign Reference	FP1156757B1.pdf	757666	no	85	
Information: Image: Proteign Reference Protei	12	roleigintererere	21 1 1 3 07 57 5 1. par		110		
13 Foreign Reference EP1229864B1.pdf 703875 before 2000 August	Warnings:						
13 Foreign Reference EP1229864B1.pdf	Information:						
InformationDevicement of the series of the seri	13	Foreign Reference	EP1229864B1 pdf	703875	no	45	
Information:14Foreign ReferenceEP1340473A2.pdf239114 (dea2234786080407749808044573908045739080445739080749079000000000000000000000000000000		roleginkelerenee	Li 122300-01.pdi		10		
14 Foreign Reference EP1340473A2.pdf 239114 (dec/2.bs/7/88068645/553200 8000 no 27 Warnings: Information: 15 Foreign Reference EP1356793.pdf 97560 (def/s2268630017472552000048802500 diffe no 7 Warnings: Information: Information: <td>Warnings:</td> <td></td> <td></td> <td></td> <td></td> <td></td>	Warnings:						
14 Foreign Reference EP1340473A2.pdf Image: Participation Participati Partecomposite Partinano Participati Participation Pa	Information:						
Marnings: deac2:347(80)200207,318000804533200 deac2:347(80)200207,318000804533200 deac2:347(80)200207,318008084533200 deac2:347(80)200207,31800808454533200 deac2:347(80)200207,31800808454533200 deac2:347(80)200207,31800808454533200 deac2:347(80)200207,31800808454533200 deac2:347(80)200207,31800808454533200 deac2:347(80)200207,31800808454533200 deac2:347(80)200207,31800808454533200 deac2:347(80)200207,3180080845453300 deac2:347(80)200207,3180080864545380700 deac2:347(80)200207,3180080864545380700 deac2:347(80)200207,3180080864545880700 deac2:347(80)200207,3180080864545880700 deac2:347(80)200207,3180080864545880700 deac2:347(80)200207,3180080864545880700 deac2:347(80)200207,3180080864545880700 deac2:347(80)200207,3180080864545880700 deac2:347(80)200207,3180080664545880700 deac2:347(80)200207,31800806645880700 deac2:347(80)200207,318008066458800700 deac	14	Foreign Reference	EP134047342 ndf	239114	no	77	
Information:15Foreign ReferenceEP1356793.pdf97560 080582856603001747-35.e200686892999 d146no7Warnings:16Foreign ReferenceEP1430853A2.pdf160868 d2e52043drfcd08969693227233becents s017no20Warnings:Information: <td colspa<="" td=""><td></td><td>l'oreign hererenee</td><td></td><td></td><td>110</td><td></td></td>	<td></td> <td>l'oreign hererenee</td> <td></td> <td></td> <td>110</td> <td></td>		l'oreign hererenee			110	
15 Poreign Reference EP1356793.pdf 97560 Poreign Reference	Warnings:			·			
15 Foreign Reference EP1356793.pdf Image: P1356793.pdf Poor P135	Information:						
Information: 084c582c5f643/bb1747c75c30c6e48829a9 0 Warnings: Information: Information: </td <td>15</td> <td>Foreign Reference</td> <td>FP1356793 ndf</td> <td>97560</td> <td></td> <td>7</td>	15	Foreign Reference	FP1356793 ndf	97560		7	
Information: Information:<	- 5	roleginkelerenee	Er 1990/99.pdf		10	,	
16 Foreign Reference EP1430853A2.pdf 160868 no 20 Warnings: Image: Constraint of the second	Warnings:						
16 Foreign Reference EP1430853A2.pdf Ino 20 dzies203dfdd0b99993227a3fbe645 5017 20 Warnings: Information: 17 Foreign Reference Proeign Reference EP1576937A2.pdf 17 Foreign Reference Warnings: 100 Warnings: 100	Information:						
d2fee520d3dfcdc9b89693227a23fbe645 5017dWarnings:Information:17Foreign ReferenceForeign ReferencePEP1576937A2.pdf17Reference <td< td=""><td>16</td><td>Foreign Reference</td><td>EP143085342 ndf</td><td>160868</td><td>no</td><td>20</td></td<>	16	Foreign Reference	EP143085342 ndf	160868	no	20	
Information: 876870 No 888 17 Foreign Reference EP1576937A2.pdf 3876870 No 888 Warnings:	10	roreiginkelerenee	El 1430033/(2.pdf		10	20	
17 Foreign Reference EP1576937A2.pdf 8876870 no 888 Warnings:	Warnings:						
17 Foreign Reference EP1576937A2.pdf no 88 d783264c2a2a0986dc66dea0558b77a8f94 c4017 c4017 No 88	Information:						
Warnings:	17	Foreign Reference	EP1576937A2.pdf	d783264c2a2a0986dc66dea0558b77a8f94	no	88	
	Warnings:			(4017			
		Edwards Lifesc	iences Corporation, et a	l. Exhibit 1102, Pag	ge 146 of 4	42	

18	Foreign Reference	EP1582178A2.pdf	878756	no	88
	roreiginkerence	Li 1902 17 0A2.pui	898312ebafdec2df4eb62824fec36804ff48b fbc	10	
Warnings:					- -
Information:			-		
19	Foreign Reference	EP1582179A2.pdf	860201	no	88
			9b6998635e69307693af1801ee77d0f5f302 faec		
Warnings:					
Information:					i
20	Foreign Reference	EP1600121A1.pdf	270300	no	16
			9112f57a2422199476cf5ca614d10722ad12 906e		
Warnings:					
Information:					
21	Foreign Reference	EP1616531A2.pdf	240618	no	11
21	roreiginkerence	El lolossi Az.pui	71ab3b15592a528d551d554b76346bdea7 bd1dd7	10	
Warnings:					
Information:					
22	Foreign Reference	WO9315693.pdf	566299	no	14
22	Foreign Reference	TReference wossisoss.put		10	14
Warnings:			-		1
Information:				-	
23		WOOFOAFEG	961002		19
23	Foreign Reference	WO9504556.pdf	a4ce223b1c4bcdc0559629c3576c7e2a68c 62be4	no	19
Warnings:		I	1		I
Information:					
			625476		20
24	Foreign Reference	WO9529640.pdf		no	20
Warnings:		I	1		1
Information:					
25			1520313		42
25	Foreign Reference	WO9614032.pdf		no	43
Warnings:			1		1
Information:					
26			1127443		
26	Foreign Reference	WO9624306.pdf	a00405dbf5afc9d4bab3cb3dd1497751d96 82fc8	no	34
Warnings:		1	1		1
Information:	Edwards Lifesc	iences Corporation, et a	d. Exhibit 1102, Pag	ge 147 of 4	42

27	Foreign Reference	WO9836790.pdf	5115738	no	157
	5		701b901fba9c888b4d481363052e2843946 69ab1		
Warnings:					
Information:			1		1
28	Foreign Reference	WO9850103.pdf	2588154	no	63
			6a48e834224f9c6ebdaa4eb1f7fa58f639b2 0fd9		
Warnings:					
Information:					i
29	Foreign Reference	WO9857599_Camilli.pdf	885352	no	24
25	Toreign telefence	woooy ooy_camiii.pai	aed1b2a727b80cf7eaabb1289fda936f3bce 7d21	110	24
Warnings:					
Information:					
30	Foreign Reference	WO9944542.pdf	1545805	no	43
50	i oreign nerefence	W03944542.pul	3a5dcbed97541756604b837c594522757c3 b78d6	no	45
Warnings:					
Information:					
31	Foreign Reference	WO0009059.pdf	3376107	no	80
10	Foreign Reference	W00009039.pui	30d315dd3d3618119d310d11dc811dcb59 b470d7	no	
Warnings:					•
Information:					
22	Foreign Deference	WO0044308.pdf	6479060		160
32	Foreign Reference	W00044308.pdf	80353cefccb305b26d4d3649bdd27a76f45 5824e	no	169
Warnings:			•		1
Information:					
22	Foreign Deferonce		2818777		70
33	Foreign Reference	WO00044313.pdf	449f46f40d899972f204981910f63cf94ebfd b0e	no	72
Warnings:			•		•
Information:					
34	Foreign Deference	W000040070 - 46	1403232		47
54	Foreign Reference	WO00049970.pdf	ca72e798bbec53c77e6a7f3438415d59a2df 2329	no 11	47
Warnings:					
Information:					
35	Equation Defense		1752994		58
55	Foreign Reference	WO00067661.pdf	9567c2f2f34805064a1350160eee0bbddb5 89b05	no	58
Warnings:			1		1
Information:	Edwards Lifesc	iences Corporation, et al	l. Exhibit 1102, Pag	ge 148 of 4	42

36	36 Foreign Reference WO01005331.p	916848 WO01005331.pdf		no	23
50	Toreign Neierence	weeroosssn.pu	118c67df2871c8734b4f057425012d0a48f7 259c	110	
Warnings:					
Information:					
37	Foreign Reference	WO01008596.pdf	1003619	no	36
			729b9a1d722775f1f047f87098dbc248176a 68fa	110	
Warnings:					
Information:			-		
38	Foreign Reference	WO01010320.pdf	986620	no	34
30	Toreign telefence	11001010520.pu	- 26c15cdfb6aa3e328243cbfb5bb3784d281 08d74	110	
Warnings:					
Information:					
39	Foreign Reference	WO01010343.pdf	1055437	20	34
29	Foreign Reference	W001010343.pu	0784c66ec2c0ba566eb31cb1fcd27abd9e8 37ae3	no	54
Warnings:					
Information:					
40	Earaign Pafaranca	W001025870 pdf	1097292	no	28
40	40 Foreign Reference WO01035870.pdf	f2cadbaa43cc4f29451a759ef34e68ecbc95c a18	10	20	
Warnings:			•		1
Information:					
41			707456		21
41	Foreign Reference	WO01064137.pdf	7a562a2f4956804bcefb5768824bb5b77f76 5c5d	no	21
Warnings:			1		I
Information:					
			1251564		
42	Foreign Reference	WO02036048.pdf		no	32
Warnings:			1		I
Information:					
			1567495		
43	Foreign Reference	WO0241789A2.pdf	d4960bf261be5048c9408a68ec8a028cd0a d4a62	no ª	38
Warnings:			1		I
Information:					
			2608941		
44	Foreign Reference	WO02100297.pdf	4bbee1d0fb88d3a69d7dc8ed742ff7d193e 9690f	no	69
Warnings:		1	1		1
Information:	Edwards Lifesc	iences Corporation, et a	al. Exhibit 1102, Pag	ge 149 of 4	42

45	Foreign Reference	WO03003943.pdf	2440160	no	41
	i oreign Kererence	weessess43.pu	a9cdbaba622a6664c0b7ff6c5df0022ae1f7a 710	10	
Warnings:					
Information:			-		
46	Foreign Reference	WO03003949.pdf	1160861	no	24
	l'oreign neicheren ee	110050055 15.pdi	ea3e7d479c771a547ebda108d1841ef4592 0c603	110	2.
Warnings:					
Information:					
47	Foreign Reference	WO03011195.pdf	1135645	no	28
	roleighneichlice	W005011155.pdf	4d0d82cc68bc2547e358340a8f51777f6cce 49f6	110	20
Warnings:			·		
Information:					
48	Foreign Reference	WO03015851.pdf	674069	50	18
40	Foleigh Reference	woosorsest.pu	7f6faa83a39e98c054ba90faf5fdadbb38379 45c	no	18
Warnings:			·		•
Information:					
49	Foreign Reference	WO04014256.pdf	1168909	no	32
49	49 Foreign Reference W004014236.pdf	W004014230.pu	baffcb77fdcf6f967e565c26916a737f2cfc1e 0b	10	52
Warnings:			•		1
Information:					
50	Foreign Reference	W004010811 - df	2351774		56
50	Foreign Reference	WO04019811.pdf	c5147eca697f2c786bbc0ff1e95c703ba240 49b3	no	00
Warnings:			1		1
Information:					
51	Couciers Deferrence		1414882		34
51	Foreign Reference	WO04023980.pdf	6fdd164a876c75a0eac35893b2ae0cc9be3 491b7	no	54
Warnings:			I		1
Information:					
52	Foreign Reference	WO04026117.pdf	3758688	20	67
52	Foleigh Reference	W004020117.pui	0e7eae6d87817e5452798005db6f7f0c38f5 79d2	no	0/
Warnings:					
Information:					
			1037237		
53	Foreign Reference	WO04041126.pdf		no	22
Warnings:		1	1		1
Information:	Edwards Lifesci	iences Corporation, et a	al. Exhibit 1102, Pag	ge 150 of 4	42

		Total Files Size (in byte	837	97002	
Information:					
Warnings:			2130		
59	Foreign Reference	EP1469797B1.pdf	455488 034e8fa9377e646cb619acc12d1a39fa5798 2136	no	29
Information:			1 1	i	
Warnings:					
58	Foreign Reference	WO05087140.pdf	15c46aa51fcb27966cc33c7baebf7df8598d 3e00	no	42
			1830921		
Information:					
Warnings:			ef9a0		
57	Foreign Reference	WO05084595.pdf	2dd9bc4e4a9f4be322817c6da83c1fb8ab6	no	76
			3771691		
Information:					
Warnings:			9d9		
56	Foreign Reference	WO04082536.pdf	afdc399c03fa9aca3d48ea84f2c52c3fab561	no	95
		3043970			1
Information:					
Warnings:			d0ee6		
55	Foreign Reference	WO04066876.pdf	691831 5b7de050a548f04d360c381bc16a03c9e9b	no	19
Information:			1		
Warnings:					
			eebde9ad20a74395d87ccd7547a758d360e b02ca		
54	Foreign Reference	WO04047681.pdf	1207008	no	25

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

VIA EFS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.:	12/492,512	Confirmation No.: 7439
Applicant(s):	Amr Salahieh	
Filed:	June 26, 2009	
Art Unit:	3774	
Examiner:	Unassigned	
Title:	EVERTING HEART VALVE	3
Customer No.:	66854	

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

<u>INFORMATION DISCLOSURE STATEMENT UNDER</u> <u>37 CFR § 1.97 & § 1.98</u>

Sir:

In accordance with 37 CFR § 1.97-1.98, applicants hereby submit an Information Disclosure Statement, including attached forms(s) PTO/SB/08. A copy of each reference is being submitted herewith, along with a concise explanation in English for those publications in a foreign language.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. Applicants further request that the Examiner initial and return a copy of the attached form(s) PTO/SB/08 in accordance with MPEP §609.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and /or to prove that this information may not be enabling for the teachings purportedly offered.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, prior art or material to patentability as defined in 37 CFR §1.56.

FILING OF INFORMATION DISCLOSURE STATEMENT

37 CFR §1.97(b)

This statement is being submitted under 37 CFR §1.97(b) because the IDS is being filed: 1). Within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d), or

2). Within 3 months of entry of a national stage as set forth in § 1.491, or

3). Before the mail date of a first Office Action on the merits, or

4). Before the mailing of a first Office Action after filing a request for continued examination under § 1.114.

37 CFR § 1.97(c)

This statement is being filed after the latest of:

1). Three months beyond the filing date of a national application, or

2). Three months beyond the date of entry of the national stage as set forth in § 1.491 in an international application, or

3). The mailing date of a first Office Action on the merits, but before the mailing date of the earlier of a final Office Action under § 1.113 or a Notice of Allowance under § 1.311, and then either:

 \square A). A fee of \$180.00 as set forth in § 1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement. or \square B). A certification as specified in § 1.97(e) is provided below; thus no fee is required.

37 CFR § 1.97(d)

This statement is being filed after the mailing date of a Final Office action, a Notice of Allowance under § 1.311, or an action that otherwise closes prosecution, but on or before payment of the issue fee, and then:

A). A fee of 180.00 as set forth in 1.17(p) is authorized below, enclosed, or payment is included with other papers filed together with this statement

--AND---

B). A certification as specified in § 1.97(e) is included below.

CONTENT OF INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.98

37 CFR §1.98 (a)(2)(ii), U.S. patents or patent application publication(s) cited

1). Since not requested by the Office, U.S. patents and U.S. patent application publications are not included.

2). At the request of the Office, a copy of the following U.S. patent or patent application publication is attached:

37 CFR §1.98 (a)(2)(iii) and (d), Pending unpublished U.S. applications cited

1). A copy of each application specification including the claim(s)s, and any drawing, or that portion of the application that caused it to be listed, is attached.

2). A copy of each application specification is not submitted because the specification was previously submitted in the IDS of the following, earlier filed application relied on for an earlier effective filing date:

3). A copy of each application specification is not submitted because the application is stored in the IFW.

37 CFR §1.98 (a)(2)(iii) and (d), English language publication (other than U.S. patents, patent applications, or pending unpublished applications) cited

1). A legible copy of each publication or that portion which caused it to be listed is attached.

2). A copy of each publication or that portion which caused it to be listed is not submitted because the publication was previously submitted in the IDS of the following, earlier filed application relied on for an earlier effective filing date:

Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 154 of 442

37 CFR §1.98 (a)(2)(i) and (d), Foreign patent(s) in English cited

1). A legible copy of each foreign patent or that portion which caused it to be listed is attached.

2). A copy of each foreign patent is not submitted because the publication was previously submitted in the IDS of the following, earlier filed application relied on for an earlier effective filing date:

37 CFR §1.98 (a)(2)(i), (a)(3)(i-ii) and MPEP 609(B), Foreign patent(s) or other foreign documents not in English cited. Either:

1). A legible copy of each foreign patent, each publication or that portion which caused it to be listed, is attached --AND---

2a). A concise explanation of the relevance, as it is presently understood by the individual designated in § 1.56 (c) most knowledgeable about the content of the information, of each patent, publication, or other information listed that is not in the English language is provided herewith:

--OR---

2b). A copy of a written, English-language translation or portion thereof is readily available and attached,

--OR---

2c). An English language copy of a foreign search report is submitted.

---OR---

3). A copy of each foreign patent is not submitted because the publication was previously submitted in the IDS of the following, earlier filed application relied on for an earlier effective filing date:

STATEMENT UNDER 37 CFR § 1.97(e)

Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.

No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.

FEE AUTHORIZATION

The Commissioner is hereby authorized to charge the above-referenced fees of 0.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 0.4050.

Dated:

Shay Glenn LLP 2755 Campus Drive, Suite 210 San Mateo, CA 94403 (650) 212-1700 Customer No. 66854

Respectfully Submitted,

Bv:

Thomas Zlogar Reg. # 55760

UNITED STA	tes Patent and Tradema	UNITED STA United State: Address: COMMI P.O. Box	ia, Virginia 22313-1450
APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
12/492,512	06/26/2009	Amr Salahieh	10012-710.401
66854 SHAY GLENN LLP 2755 CAMPUS DRIVE SUITE 210 SAN MATEO, CA 94403			CONFIRMATION NO. 7439 TION NOTICE

Title:Everting Heart Valve

Publication No.US-2009-0264997-A1 Publication Date:10/22/2009

NOTICE OF PUBLICATION OF APPLICATION

The above-identified application will be electronically published as a patent application publication pursuant to 37 CFR 1.211, et seq. The patent application publication number and publication date are set forth above.

The publication may be accessed through the USPTO's publically available Searchable Databases via the Internet at www.uspto.gov. The direct link to access the publication is currently http://www.uspto.gov/patft/.

The publication process established by the Office does not provide for mailing a copy of the publication to applicant. A copy of the publication may be obtained from the Office upon payment of the appropriate fee set forth in 37 CFR 1.19(a)(1). Orders for copies of patent application publications are handled by the USPTO's Office of Public Records. The Office of Public Records can be reached by telephone at (703) 308-9726 or (800) 972-6382, by facsimile at (703) 305-8759, by mail addressed to the United States Patent and Trademark Office, Office of Public Records, Alexandria, VA 22313-1450 or via the Internet.

In addition, information on the status of the application, including the mailing date of Office actions and the dates of receipt of correspondence filed in the Office, may also be accessed via the Internet through the Patent Electronic Business Center at www.uspto.gov using the public side of the Patent Application Information and Retrieval (PAIR) system. The direct link to access this status information is currently http://pair.uspto.gov/. Prior to publication, such status information is confidential and may only be obtained by applicant using the private side of PAIR.

Further assistance in electronically accessing the publication, or about PAIR, is available by calling the Patent Electronic Business Center at 1-866-217-9197.

Office of Data Managment, Application Assistance Unit (571) 272-4000, or (571) 272-4200, or 1-888-786-0101

page 1 of 1

PTO/SB/08a (07-09) Approved for use through 07/31/2012. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet 1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of 1

Complete if Known					
Application Number	12/492,512				
Filing Date	June 26, 2009				
First Named Inventor	Amr Salahieh				
Art Unit	3774				
Examiner Name	Unassigned				
Attorney Docket Number	10012-710.401	/			

			U. S. PATENT	DOCUMENTS	· · · · · · · · · · · · · · · · · · ·
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (# known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	460	^{US-} 3,409,013	11/5/1968	Berry	
	461	^{US-} 4,655,218	4/7/1987	Kulik et al.	
	462	^{US-} 4,755,181	7/5/1988	Igoe	
	463	^{US-} 4,865,600	9/12/1989	Carpentier et al.	
	456	^{US-} 5,549,665	8/27/1996	Vesely et al.	
	465	^{US-} 5,885,228	3/23/1999	Rosenman et al.	
	466	^{US-} 6,623,518	9/23/2003	Thompson et al.	
	467	^{US-} 6,635,079	10/21/2003	Unsworth et al.	·
	468	^{US-} 6,776,791	8/17/2004	Stallings et al.	
	469	^{US-} 7,025,791	4/11/2006	Levine et al.	
	470	^{US-} 7,037,331	5/2/2006	Mitelberg et al.	
	471	^{US-} 7,175,653	2/13/2007	Gaber	
	472	^{US-} 7,175,654	2/13/2007	Bonsignore et al.	
	473	^{US-} 7,235,093	6/26/2007	Gregorich	
	474	^{US-} 7,258,696	8/21/2007	Rabkin et al.	
	455	^{US-} 2002/0188344	12/12/2002	Bolea et al.	
	458	^{US-} 2006/0155312	7/13/2006	Levine et al.	
	457	^{US-} 2005/0197694	9/8/2005	Pai et al.	
	1	US-			

	FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY		Patentee or ited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶		
		Country Code ³ "Number ⁴ "Kind Code ⁵ (if known)				Of Relevant Figures Appear	<u> </u>		
Examiner Signature					Date Considered				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at <u>www.uspto.gov</u> or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Electronic Acl	Electronic Acknowledgement Receipt				
EFS ID:	6557481				
Application Number:	12492512				
International Application Number:					
Confirmation Number:	7439				
Title of Invention:	Everting Heart Valve				
First Named Inventor/Applicant Name:	Amr Salahieh				
Customer Number:	66854				
Filer:	Thomas M. Zlogar/Angelica Zuniga				
Filer Authorized By:	Thomas M. Zlogar				
Attorney Docket Number:	10012-710.401				
Receipt Date:	02-DEC-2009				
Filing Date:	26-JUN-2009				
Time Stamp:	15:12:31				
Application Type:	Utility under 35 USC 111(a)				

Payment information:

Submitted wi	th Payment	no			
File Listin	g:				
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		10012-710401_IDS.pdf	251589 b78f0cd07395484400394748c56b6735cd3 08863	yes	4

Document Description Transmittal Letter ation Disclosure Statement (IDS) Filed (SB/08) Total Files Size (in bytes): ot evidences receipt on the noted date by the USPTermination	Start 1 1 4 251	End 3 4
ation Disclosure Statement (IDS) Filed (SB/08) Total Files Size (in bytes):	4	4
Total Files Size (in bytes):		
· · · · ·	251	
· · · · ·	251	
· · · · ·	251	
		589
led and the application includes the necessary com iling Receipt (37 CFR 1.54) will be issued in due cou		
the national stage of an international application i e requirements a Form PCT/DO/EO/903 indicating a	acceptance of the a	pplication as a
	Filing Receipt (37 CFR 1.54) will be issued in due cou ill establish the filing date of the application. ional Application under 35 U.S.C. 371 r the national stage of an international application i le requirements a Form PCT/DO/EO/903 indicating a	iled and the application includes the necessary components for a filing Filing Receipt (37 CFR 1.54) will be issued in due course and the date sh ill establish the filing date of the application.

an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

VIA EFS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.:	12/492,512	Confirmation No.: 7439
Applicant(s):	Amr Salahieh	
Filed:	June 26, 2009	
Art Unit:	3774	
Examiner:	Unassigned	
Title:	EVERTING HEART VALVE	3
Customer No.:	66854	

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

<u>INFORMATION DISCLOSURE STATEMENT UNDER</u> <u>37 CFR § 1.97 & § 1.98</u>

Sir:

In accordance with 37 CFR § 1.97-1.98, applicants hereby submit an Information Disclosure Statement, including attached forms(s) PTO/SB/08. A copy of each reference is being submitted herewith, along with a concise explanation in English for those publications in a foreign language.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. Applicants further request that the Examiner initial and return a copy of the attached form(s) PTO/SB/08 in accordance with MPEP §609.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and /or to prove that this information may not be enabling for the teachings purportedly offered.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, prior art or material to patentability as defined in 37 CFR §1.56.

FILING OF INFORMATION DISCLOSURE STATEMENT

37 CFR §1.97(b)

This statement is being submitted under 37 CFR §1.97(b) because the IDS is being filed:

1). Within 3 months of the application filing date and is other than a continued prosecution application under \S 1.53(d), or

2). Within 3 months of entry of a national stage as set forth in § 1.491, or

3). Before the mail date of a first Office Action on the merits, or

4). Before the mailing of a first Office Action after filing a request for continued examination under § 1.114.

37 CFR § 1.97(c)

This statement is being filed after the latest of:

1). Three months beyond the filing date of a national application, or

2). Three months beyond the date of entry of the national stage as set forth in § 1.491 in an international application, or

3). The mailing date of a first Office Action on the merits, but before the mailing date of the earlier of a final Office Action under § 1.113 or a Notice of Allowance under § 1.311, and then either:

 \square A). A fee of \$180.00 as set forth in § 1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement. or \square B). A certification as specified in § 1.97(e) is provided below; thus no fee is required.

37 CFR § 1.97(d)

This statement is being filed after the mailing date of a Final Office action, a Notice of Allowance under § 1.311, or an action that otherwise closes prosecution, but on or before payment of the issue fee, and then:

A). A fee of \$180.00 as set forth in § 1.17(p) is authorized below, enclosed, or payment is included with other papers filed together with this statement

--AND---

B). A certification as specified in § 1.97(e) is included below.

<u>CONTENT OF INFORMATION DISCLOSURE STATEMENT UNDER</u> <u>37 CFR § 1.98</u>

37 CFR §1.98 (a)(2)(ii), U.S. patents or patent application publication(s) cited

1). Since not requested by the Office, U.S. patents and U.S. patent application publications are not included.

2). At the request of the Office, a copy of the following U.S. patent or patent application publication is attached:

3). Items identified by a double asterisk (**) on the SB08A are *commonly-owned U.S. patents and U.S. patent application publications.

37 CFR §1.98 (a)(2)(iii) and (d), *Commonly-owned, unpublished U.S. applications cited
1). A copy of each application specification including the claim(s), and any drawing, or that portion of the application that caused it to be listed, is attached.

2). A copy of each application specification is not submitted because the specification was previously submitted in the IDS of the following, earlier filed application relied on for an earlier effective filing date:

3). A copy of each application specification is not submitted because the application is stored in the IFW.

*Applicant(s) assume the Examiner has access to the file histories of these items. However, if the Examiner would like to receive copies of Office Actions in any of the commonly-owned applications, publications and/or patents identified on the attached SB08, please inform the undersigned and copies will be provided.

37 CFR §1.98 (a)(2)(iii) and (d), English language publication (other than U.S. patents, patent applications, or pending unpublished applications) cited

1). A legible copy of each publication or that portion which caused it to be listed is attached.
 2). A copy of each publication or that portion which caused it to be listed is not submitted because the publication was previously submitted in the IDS of the following, earlier filed application relied on for an earlier effective filing date:

Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 161 of 442

37 CFR §1.98 (a)(2)(i) and (d), Foreign patent(s) in English cited

1). A legible copy of each foreign patent or that portion which caused it to be listed is attached.

2). A copy of each foreign patent is not submitted because the publication was previously submitted in the IDS of the following, earlier filed application relied on for an earlier effective filing date:

37 CFR §1.98 (a)(2)(i), (a)(3)(i-ii) and MPEP 609(B), Foreign patent(s) or other foreign documents not in English cited. Either:

1). A legible copy of each foreign patent, each publication or that portion which caused it to be listed, is attached --AND---

2a). A concise explanation of the relevance, as it is presently understood by the individual designated in § 1.56 (c) most knowledgeable about the content of the information, of each patent, publication, or other information listed that is not in the English language is provided herewith:

--OR--

--OR---

2b). A copy of a written, English-language translation or portion thereof is readily available and attached,

2c). An English language copy of a foreign search report is submitted.

--OR--3). A copy of each foreign patent is not submitted because the publication was previously submitted in the IDS of the following, earlier filed application relied on for an earlier effective filing date:

STATEMENT UNDER 37 CFR § 1.97(e)

Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.

No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.

FEE AUTHORIZATION

The Commissioner is hereby authorized to charge the above-referenced fees of \$0.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 50-4050.

Dated: 12/2/09

Shay Glenn LLP 2755 Campus Drive, Suite 210 San Mateo, CA 94403 (650) 212-1700 Customer No. 66854

Respectfully Submitted,

Shomes By:

Thomas Zlogar Reg. # 55760

POWER OF ATTORNEY BY ASSIGNEE TO EXCLUSION OF INVENTOR UNDER 37 C.F.R. § 3.71 WITH REVOCATION OF PRIOR POWERS

The undersigned ASSIGNEE of the entire interest in:

	U.S. Patent No
\boxtimes	U.S. Application

U.S. Application No. 12/492,512, filed on June 26, 2009

hereby appoints all Shay Glenn LLP attorneys registered to practice before the United States Patent and Trademark Office, as associated with:

CUSTOMER NO. 66854

to prosecute this application and transact all business in the United States Patent and Trademark Office in connection therewith and hereby revokes all prior powers of attorney; said appointment to be to the exclusion of the inventors and the inventors' attorneys in accordance with the provisions of 37 C.F.R. § 3.71.

STATEMENT PURSUANT TO 37 C.F.R. § 3.73(b)

The following evidentiary documents establish a chain of title from the original owner to the Assignee:

(complete one of the following)

- a copy of an Assignment attached hereto, which Assignment has been (or is herewith) forwarded to the Patent and Trademark Office for recording; or
- the Assignment recorded on <u>11/20/2009</u> at reel/frame 023551/0485 pursuant to 37 C.F.R. § 3.11.

Pursuant to 37 C.F.R. § 3.73(b) the undersigned Assignee hereby states that evidentiary documents have been reviewed and hereby certifies that, to the best of ASSIGNEE's knowledge and belief, the entire right, title and interest is in the identified ASSIGNEE.

Direct all correspondence and telephone calls to:

Name	James R. Sha	у				
Address	Shay Glenn L	LP				
Address	2755 Campus	Drive, Suite 2	10			
City	San Mateo	State	CA	Zip	94403	Customer No.: 66854
Country	USA	Telephone	650.212.1700	Fax	650.212.7562	

The undersigned is authorized and empowered to act on behalf of said Assignee.

ASSIGNEE:	VIAL
Name: <u>Ken Martin</u>	Signature: Character
Title: President and CEO	Date: 3/16/2010

Electronic Ac	Electronic Acknowledgement Receipt				
EFS ID:	7221564				
Application Number:	12492512				
International Application Number:					
Confirmation Number:	7439				
Title of Invention:	Everting Heart Valve				
First Named Inventor/Applicant Name:	Amr Salahieh				
Customer Number:	66854				
Filer:	Thomas M. Zlogar/Sue Bromaghim				
Filer Authorized By:	Thomas M. Zlogar				
Attorney Docket Number:	10012-710.401				
Receipt Date:	16-MAR-2010				
Filing Date:	26-JUN-2009				
Time Stamp:	17:00:36				
Application Type:	Utility under 35 USC 111(a)				

Payment information:

Submitted with Payment no						
File Listing:						
Document Number	Document Description		File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Power of Attorney	10012-710-401-POA.pdf	50789	no	1	
	1 Power of Attorney 10012-710-401-POA.pdf		586c7be0d23555914cf6ead43197695f7834 32f1	110	I	
Warnings:		•		· · ·		
Information:	Edwards Lifesc	ienc	es Corporation, et a	l. Exhibit 1102. Pag	e 164 of 4	42

_____Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 164 of 442______

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

UNITED STA	ates Patent and Trademai	UNITED STA' United States Address: COMMI PO. Box I	a, Virginia 22313-1450
APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
12/492,512	06/26/2009	Amr Salahieh	10012-710.401
66854 SHAY GLENN LLP 2755 CAMPUS DRIVE			CONFIRMATION NO. 7439 EPTANCE LETTER
SUITE 210 SAN MATEO, CA 94403			JC00000040740142"

Date Mailed: 03/22/2010

NOTICE OF ACCEPTANCE OF POWER OF ATTORNEY

This is in response to the Power of Attorney filed 03/16/2010.

The Power of Attorney in this application is accepted. Correspondence in this application will be mailed to the above address as provided by 37 CFR 1.33.

/tnnguyen/

Office of Data Management, Application Assistance Unit (571) 272-4000, or (571) 272-4200, or 1-888-786-0101

UNITED ST	ates Patent and Trademar	UNITED STA' United States Address: COMMIS P.O. Box 1	, Virginia 22313-1450
APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
12/492,512	06/26/2009	Amr Salahieh	10012-710.401
66854 SHAY GLENN LLP 2755 CAMPUS DRIVE SUITE 210 SAN MATEO, CA 94403			CONFIRMATION NO. 7439 F ATTORNEY NOTICE

Date Mailed: 03/22/2010

NOTICE REGARDING CHANGE OF POWER OF ATTORNEY

This is in response to the Power of Attorney filed 03/16/2010.

• The Power of Attorney to you in this application has been revoked by the assignee who has intervened as provided by 37 CFR 3.71. Future correspondence will be mailed to the new address of record(37 CFR 1.33).

/tnnguyen/

Office of Data Management, Application Assistance Unit (571) 272-4000, or (571) 272-4200, or 1-888-786-0101

PTO/SB/08a (07-09) Approved for use through 07/31/2012. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO Application Number 12/492,512 Filing Date June 26, 2009 INFORMATION DISCLOSURE First Named Inventor Amr Salahieh STATEMENT BY APPLICANT Art Unit 3774 (Use as many sheets as necessary) Examiner Name Unassigned Attorney Docket Number 10012-710.401 Sheet 1 of 3

Examiner	Cito	Decument Number			
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (# known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevan Figures Appear
	497	^{US-} 4,617,932	10/21/1986	Kornberg	
	498	^{US-} 5,002,556	3/26/1991	Ishida et al.	
	499	^{US-} 5,336,258	8/9/1994	Quintero et al.	
	500	^{US-} 5,480,423	1/2/1996	Ravenscroft et al.	
	501	^{US-} 5,693,083	12/2/1997	Baker et al.	
	494	^{US-} 5,716,370	2/10/1998	Williamson, IV et al.	
	502	^{US-} 5,733,325	3/31/1998	Robinson et al.	······································
	476	^{US-} 5,807,405	9/15/1998	Vanney et al.	
	477	^{US-} 5,861,024	1/19/1999	Rashidi	
	503	^{US-} 6,165,209	12/26/2000	Patterson et al.	
	504	^{US-} 6,187,016	2/13/2001	Hedges et al.	
	505	^{US-} 6,214,036	4/10/2001	Letendre et al.	
	506	^{US-} 6,267,783	7/31/2001	Letendre et al.	
	478	^{US-} 6,416,510	7/9/2002	Altman et al.	
	480	^{US-} 6,663,588	12/16/2003	DuBois et al.	
	507	^{US-} 6,676,692	1/13/2004	Rabkin et al.	
	508	^{US-} 6,814,746	11/9/2004	Thompson et al.	······································
	509	^{US-} 6,837,901	1/4/2005	Rabkin et al.	
	510	^{US-} 6,843,802	1/18/2005	Villalobos et al.	

			N PATENT DOCU	MENTS			
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of P Applicant of Cit		Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ "Number ⁴ "Kind Code ⁵ (<i>if known</i>)	MM-DD-YYYY			Or Relevant Figures Appear	T ⁶
					Ŷ		
					Dete	······································	
Examiner Signature					Date Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at <u>www.uspto.gov</u> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO:** Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08a (07-09) Approved for use through 07/31/2012. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sub	stitute for form 1449/PTO		Complete if Known		
			Application Number	12/492,512	
IN	FORMATION D		Filing Date	June 26, 2009	
			First Named Inventor	Amr Salahieh	
S	TATEMENT BY		Art Unit	3774	
(Use as many sheets as necessary)		Examiner Name	Unassigned		
Sheet	2 of	3	Attorney Docket Number	10012-710.401	

		• • • • • • • • • • • • • • • • • • •		DOCUMENTS	
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (If Known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	511	^{US-} 6,881,220	4/19/2005	Edwin et al.	
	512	^{US-} 6,936,058	8/30/2005	Forde et al.	
	513	^{US-} 7,632,298	12/15/2009	Hijlkema et al.	
	482	^{US-} 2002/0177766	11/28/2002	Mogul	
	485	^{US-} 2004/0181140	9/16/2004	Falwell et al.	
	514	^{US-} 2005/0182486	8/18/2005	Gabbay	
	516	^{US-} 2007/0016286	1/18/2007	Herrmann et al.	
	487	^{US-} 2008/0188928**	8/7/2008	Salahieh et al.	
		US-			
	[US-			
		US-			

		FOREIC	GN PATENT DOCU	MENTS		
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
				· .		
	<u> </u>					
	<u> </u>					
Examiner Signature	T			Date Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at <u>www.uspto.gov</u> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND** TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08b (07-09)

Approved for use through 07/31/2012. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known
	Application Number	12/492,512
INFORMATION DISCLOSURE	Filing Date	June 26, 2009
STATEMENT BY APPLICANT	First Named Inventor	Amr Salahieh
(Use as many sheets as necessary)	Art Unit	3774
(Use as many sheets as necessary)	Examiner Name	Unassigned
Sheet 3 of 3	Attorney Docket Number	10012-710.401

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in ĆAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	495	PAUL et al.; U.S. Pat. App. # 12/578,463 entitled "Medical Devices and Delivery Systems for Delivering Medical Devices," filed 10/13/2009	
	496	PAUL et al.; U.S. Pat. App. # 12/578,447 entitled "Medical Devices and Delivery Systems for Delivering Medical Devices," filed 10/13/2009	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner

Signature

Considered. Include copy or this form with next communication to applicant.
1 Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 170 of 442

Date

Considered

Electronic Acl	knowledgement Receipt
EFS ID:	7294161
Application Number:	12492512
International Application Number:	
Confirmation Number:	7439
Title of Invention:	Everting Heart Valve
First Named Inventor/Applicant Name:	Amr Salahieh
Customer Number:	66854
Filer:	Thomas M. Zlogar/Angelica Zuniga
Filer Authorized By:	Thomas M. Zlogar
Attorney Docket Number:	10012-710.401
Receipt Date:	26-MAR-2010
Filing Date:	26-JUN-2009
Time Stamp:	14:11:31
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted wi	th Payment	no			
File Listin	g:				
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		10012-710401_IDS.pdf	904734 55f762e0b2230427e32435f613ea776906d 05af0	yes	6

	Multipart Description/PDF files in .zip description					
	Document Description	Start	End			
	Transmittal Letter	1	3			
	Information Disclosure Statement (IDS) Filed (SB/08)	4	6			
Warnings:						
Information:						
	Total Files Size (in bytes):	904	734			
characterized	edgement Receipt evidences receipt on the noted date by the USPT by the applicant, and including page counts, where applicable. It s described in MPEP 503.					
characterized Post Card, as <u>New Applicat</u> If a new appli 1.53(b)-(d) an	by the applicant, and including page counts, where applicable. It s	erves as evidence o ponents for a filing	of receipt similar to date (see 37 CFR			
characterized Post Card, as <u>New Applicat</u> If a new appli 1.53(b)-(d) an Acknowledge <u>National Stag</u> If a timely suk U.S.C. 371 and	by the applicant, and including page counts, where applicable. It s described in MPEP 503. <u>ions Under 35 U.S.C. 111</u> cation is being filed and the application includes the necessary com d MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due cou	erves as evidence o ponents for a filing rse and the date sh s compliant with th acceptance of the a	of receipt similar to date (see 37 CFR own on this ne conditions of 35 pplication as a			

national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of

the application.

VIA EFS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.:	12/492,512	Confirmation No.: 7439
Applicant(s):	Amr Salahieh	
Filed:	June 26, 2009	
Art Unit:	3774	
Examiner:	Unassigned	
Title:	EVERTING HEART VALVE	
Customer No.:	66854	

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

<u>INFORMATION DISCLOSURE STATEMENT UNDER</u> <u>37 CFR § 1.97 & § 1.98</u>

Sir:

In accordance with 37 CFR § 1.97-1.98, applicants hereby submit an Information Disclosure Statement, including attached forms(s) PTO/SB/08. A copy of each reference is being submitted herewith, along with a concise explanation in English for those publications in a foreign language.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. Applicants further request that the Examiner initial and return a copy of the attached form(s) PTO/SB/08 in accordance with MPEP §609.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and /or to prove that this information may not be enabling for the teachings purportedly offered.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, prior art or material to patentability as defined in 37 CFR §1.56.

FILING OF INFORMATION DISCLOSURE STATEMENT

37 CFR §1.97(b)

This statement is being submitted under 37 CFR §1.97(b) because the IDS is being filed:

1). Within 3 months of the application filing date and is other than a continued prosecution application under 1.53(d), or

2). Within 3 months of entry of a national stage as set forth in § 1.491, or

3). Before the mail date of a first Office Action on the merits, or

4). Before the mailing of a first Office Action after filing a request for continued examination under \S 1.114.

37 CFR § 1.97(c)

This statement is being filed after the latest of:

1). Three months beyond the filing date of a national application, or

2). Three months beyond the date of entry of the national stage as set forth in § 1.491 in an international application, or

3). The mailing date of a first Office Action on the merits, but before the mailing date of the earlier of a final Office Action under § 1.113 or a Notice of Allowance under § 1.311, and then either:

 \square A). A fee of \$180.00 as set forth in § 1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement. or \square B). A certification as specified in § 1.97(e) is provided below; thus no fee is required.

37 CFR § 1.97(d)

This statement is being filed after the mailing date of a Final Office action, a Notice of Allowance under § 1.311, or an action that otherwise closes prosecution, but on or before payment of the issue fee, and then:

A). A fee of 180.00 as set forth in 1.17(p) is authorized below, enclosed, or payment is included with other papers filed together with this statement

---AND---

B). A certification as specified in § 1.97(e) is included below.

CONTENT OF INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.98

37 CFR §1.98 (a)(2)(ii), U.S. patents or patent application publication(s) cited

1). Since not requested by the Office, U.S. patents and U.S. patent application publications are not included.

2). At the request of the Office, a copy of the following U.S. patent or patent application publication is attached:

3). Items identified by a double asterisk (**) on the SB08A are *commonly-owned U.S. patents and U.S. patent application publications.

37 CFR §1.98 (a)(2)(iii) and (d), *Commonly-owned, unpublished U.S. applications cited

1). A copy of each application specification including the claim(s), and any drawing, or that portion of the application that caused it to be listed, is attached.

2). A copy of each application specification is not submitted because the specification was previously submitted in the IDS of the following, earlier filed application relied on for an earlier effective filing date:

3). A copy of each application specification is not submitted because the application is stored in the IFW.

*Applicant(s) assume the Examiner has access to the file histories of these items. However, if the Examiner would like to receive copies of Office Actions in any of the commonly-owned applications, publications and/or patents identified on the attached SB08, please inform the undersigned and copies will be provided.

37 CFR §1.98 (a)(2)(iii) and (d), English language publication (other than U.S. patents, patent applications, or pending unpublished applications) cited

A legible copy of each publication or that portion which caused it to be listed is attached.
 A copy of each publication or that portion which caused it to be listed is not submitted because the publication was previously submitted in the IDS of the following, earlier filed application relied on for an earlier effective filing date:

37 CFR §1.98 (a)(2)(i) and (d), Foreign patent(s) in English cited

1). A legible copy of each foreign patent or that portion which caused it to be listed is attached.

2). A copy of each foreign patent is not submitted because the publication was previously submitted in the IDS of the following, earlier filed application relied on for an earlier effective filing date:

37 CFR §1.98 (a)(2)(i), (a)(3)(i-ii) and MPEP 609(B), Foreign patent(s) or other foreign documents not in English cited. Either:

1). A legible copy of each foreign patent, each publication or that portion which caused it to be listed, is attached --AND---

2a). A concise explanation of the relevance, as it is presently understood by the individual designated in § 1.56 (c) most knowledgeable about the content of the information, of each patent, publication, or other information listed that is not in the English language is provided herewith:

--OR--

2b). A copy of a written, English-language translation or portion thereof is readily available and attached,

--OR---

2c). An English language copy of a foreign search report is submitted.

--OR---

3). A copy of each foreign patent is not submitted because the publication was previously submitted in the IDS of the following, earlier filed application relied on for an earlier effective filing date:

STATEMENT UNDER 37 CFR § 1.97(e)

Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.

No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in \S 1.56(c) more than three months prior to the filing of the information disclosure statement.

FEE AUTHORIZATION

 \boxtimes The Commissioner is hereby authorized to charge the above-referenced fees of \$0.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 50-4050.

Dated: 3/25/10

Shav Glenn LLP 2755 Campus Drive, Suite 210 San Mateo, CA 94403 (650) 212-1700 Customer No. 66854

Respectfully Submitted By:

Thomas Zlogar Reg. # 55760

VIA EFS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.:	12/492,512	Confirmation No.: 7439
Applicant(s):	Amr Salahieh	
Filed:	June 26, 2009	
Art Unit:	3774	
Examiner:	Unassigned	
Title:	EVERTING HEART VALVE	
Customer No.:	66854	

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

DISCLOSURE TRANSMITTAL LETTER: **COMMONLY-OWNED APPLICATION(S) / PATENT(S)**

Sir:

The following page contains a list of commonly-owned patent applications, publications and/or patents, along with their corresponding cite numbers. The items identified on the list have been included in Information Disclosure Statements submitted previously in the above-identified application.

Applicant(s) assume the Examiner has access to the file histories of these items. However, if the Examiner would like to receive copies of Office Actions issued in any of the commonly-owned applications, publications and/or patents identified on the list, please inform the undersigned.

Respectfully Submitted,

Dated: 4/19/10

Shay Glenn LLP 2755 Campus Drive, Suite 210 San Mateo, CA 94403 (650) 212-1700 Customer No. 66854

Thomas Zlogar Reg. # 55760 By:

Cite No.	Application No.	Publication No.	Patent No.
77			7,329,279
74	,		7,381,219
84			7,445,631
70		2005/0137686	· · · · · · · · · · · · · · · · · · ·
71	and an and a second	2005/0137687	
72		2005/0137688	
73		2005/0137689	
75	1 12 4 2 7 4 4 7 4 4 4 4 4 4 4 4 4 4 4 4 4	2005/0137691	
76		2005/0137692	
78		2005/0137694	
304		2005/0137695	, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
79		2005/0137696	
80	an a sa an	2005/0137697	
81		2005/0137698	ution
82		2005/0137699	en 41
83		2005/0137701	
85		2005/0143809	
99		2005/0283231	
298	an an an an ann an an an an an an an an	2006/0058872	<u>, , , , , , , , , , , , , , , , , , , </u>
302		2006/0173524	
297		2006/0253191	,
296		2006/0287668	
305		2007/0010876	
306		2007/0010877	
303		2007/0061008	
299		2007/0112355	
301	, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	2007/0118214	
374		2007/0162107	
372	,	2007/0203503	
373		2007/0244552	
399	••••••••••••••••••••••••••••••••••••••	2008/0125859	, , and a second sec
403		2008/0234814	n an an Anna an
435		2009/0054969	
436		2009/0076598	·····

Electronic Acknowledgement Receipt				
EFS ID:	7443024			
Application Number:	12492512			
International Application Number:				
Confirmation Number:	7439			
Title of Invention:	Everting Heart Valve			
First Named Inventor/Applicant Name:	Amr Salahieh			
Customer Number:	66854			
Filer:	Thomas M. Zlogar/Angelica Zuniga			
Filer Authorized By:	Thomas M. Zlogar			
Attorney Docket Number:	10012-710.401			
Receipt Date:	19-APR-2010			
Filing Date:	26-JUN-2009			
Time Stamp:	17:23:22			
Application Type:	Utility under 35 USC 111(a)			

Payment information:

Submitted with Payment		no	no					
File Listing:								
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)			
1	Miscellaneous Incoming Letter	10012-710401.pdf	178898	no	2			
		10012 / 10401.pdf	d5c0e667c885b2fe91ae952b3b6daea67c4 28a48	110				
Warnings:			· ·					
Information:	Edwards Lifesci	ences Corporation, et	al. Exhibit 1102. Pag	e 178 of 4	42			

Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 178 of 442

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

PTO/SB/08a (07-09)

Approved for use through 07/31/21. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known			
		Application Number	12/492,512		
INFORMATION DISCLOSURE		Filing Date	June 26, 2009 Amr Salahieh		
		First Named Inventor			
STATEMENT BY APPLICANT	Art Unit	3774			
(Use as many sheets as necessary)		Examiner Name	SCHILLINGER, ANN M		
Sheet 1	of 2	Attorney Docket Number	10012-710.401	フ	

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (# known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	525	^{US-} 5,571,215	11/5/1996	Sterman et al.	
	528	^{US-} 6,142,987	11/7/2000	Tsugita	
	524	^{US-} 2001/0044652	11/22/2001	Moore	
	526	^{US-} 2002/0026233	2/28/2002	Shaknovich	· · · · · · · · · · · · · · · · · · ·
	531	^{US-} 2003/0040791	2/27/2003	Oktay	
	527	^{US-} 2004/0148021	7/29/2004	Cartledge et al.	
	533	^{US-} 5,860,966	01/19/1999	Tower	
		US-		· · · · · · · · · · · · · · · · · · ·	
		US-			
		US-			
		US-			· · · · · · · · · · · · · · · · · · ·
		US-			
		US-			
		US-			
		US-			·····
		US-			
		US-			
		US-	· ······		
		US-			

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ "Number ⁴ - Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of P	Patentee or Sited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ₆	
	<u> </u>			<u> </u>				
				<u> </u>				
	<u> </u>							
		I						
Examiner Signature	—	C			Date Considered		_	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at <u>www.uspto.gov</u> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08b (07-09)

Approved for use through 07/31/2012. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known
	Application Number	12/492,512
INFORMATION DISCLOSURE	Filing Date	June 26, 2009
STATEMENT BY APPLICANT	First Named Inventor	Amr Salahieh
(Use as many sheets as necessary)	Art Unit	3774
(Use as many sneeds as necessary)	Examiner Name	SCHILLINGER, ANN M
Sheet 2 of 2	Attorney Docket Number	10012-710.401

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	529	SALAHIEH et al.; U.S. Pat. App. # 12/777,161 entitled "Two-Part Package for Medical Implant," filed 5/10/2010	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner

Signature

1 Applicant's unique critation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Date

Considered

Electronic Ac	Electronic Acknowledgement Receipt			
EFS ID:	8034848			
Application Number:	12492512			
International Application Number:				
Confirmation Number:	7439			
Title of Invention:	Everting Heart Valve			
First Named Inventor/Applicant Name:	Amr Salahieh			
Customer Number:	66854			
Filer:	Thomas M. Zlogar/Angelica Zuniga			
Filer Authorized By:	Thomas M. Zlogar			
Attorney Docket Number:	10012-710.401			
Receipt Date:	16-JUL-2010			
Filing Date:	26-JUN-2009			
Time Stamp:	16:31:42			
Application Type:	Utility under 35 USC 111(a)			

Payment information:

Submitted wi	th Payment	no			
File Listin	g:				
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		10012-710401_IDS.pdf	686010 1018ff5a487a4aaf30c08eb922e9fce735c8f d1a	yes	5

	Multipart Description/PDF files in .zip description				
	Document Description	Start	End		
	Transmittal Letter	1	3		
	Information Disclosure Statement (IDS) Filed (SB/08)	4	5		
Warnings:					
Information:					
	Total Files Size (in bytes):	686	5010		
characterized	dgement Receipt evidences receipt on the noted date by the USPT by the applicant, and including page counts, where applicable. It s escribed in MPEP 503.		-		
characterized Post Card, as d <u>New Applicatic</u> If a new applic 1.53(b)-(d) and	by the applicant, and including page counts, where applicable. It s	erves as evidence of the serves as evidence of the serves as evidence of the serves as	of receipt similar to g date (see 37 CFR		
characterized Post Card, as d <u>New Applicatio</u> If a new applic 1.53(b)-(d) and Acknowledger <u>National Stage</u>	by the applicant, and including page counts, where applicable. It s escribed in MPEP 503. ons Under 35 U.S.C. 111 ation is being filed and the application includes the necessary com I MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due cou nent Receipt will establish the filing date of the application.	erves as evidence of a filing ponents for a filing trace and the date sh	of receipt similar to g date (see 37 CFR nown on this		
characterized I Post Card, as d <u>New Application</u> If a new applic 1.53(b)-(d) and Acknowledger <u>National Stage</u> If a timely subi U.S.C. 371 and	by the applicant, and including page counts, where applicable. It s escribed in MPEP 503. ons Under 35 U.S.C. 111 ation is being filed and the application includes the necessary com I MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due cou nent Receipt will establish the filing date of the application.	erves as evidence of ponents for a filing rse and the date sh is compliant with th acceptance of the a	of receipt similar to g date (see 37 CFR hown on this he conditions of 35 application as a		

an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

VIA EFS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.:	12/492,512	Confirmation No.:	7439
Applicant(s):	Amr Salahieh		
Filed:	June 26, 2009		
Art Unit:	3774		
Examiner:	SCHILLINGER, ANN M		
Title:	EVERTING HEART VALVE		
Customer No.:	66854		

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

<u>INFORMATION DISCLOSURE STATEMENT UNDER</u> <u>37 CFR § 1.97 & § 1.98</u>

Sir:

In accordance with 37 CFR § 1.97-1.98, applicants hereby submit an Information Disclosure Statement, including attached forms(s) PTO/SB/08. A copy of each reference is being submitted herewith, along with a concise explanation in English for those publications in a foreign language.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. Applicants further request that the Examiner initial and return a copy of the attached form(s) PTO/SB/08 in accordance with MPEP §609.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and /or to prove that this information may not be enabling for the teachings purportedly offered.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, prior art or material to patentability as defined in 37 CFR §1.56.

FILING OF INFORMATION DISCLOSURE STATEMENT

37 CFR §1.97(b)

This statement is being submitted under 37 CFR §1.97(b) because the IDS is being filed:

1). Within 3 months of the application filing date and is other than a continued prosecution application under 1.53(d), or

2). Within 3 months of entry of a national stage as set forth in § 1.491, or

3). Before the mail date of a first Office Action on the merits, or

4). Before the mailing of a first Office Action after filing a request for continued examination under \S 1.114.

Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 184 of 442

37 CFR § 1.97(c)

This statement is being filed after the latest of:

1). Three months beyond the filing date of a national application, or

 \square 2). Three months beyond the date of entry of the national stage as set forth in § 1.491 in an international application, or

3). The mailing date of a first Office Action on the merits, but before the mailing date of the earlier of a final Office Action under § 1.113 or a Notice of Allowance under § 1.311, and then either:

A). A fee of \$180.00 as set forth in § 1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement. or
 B). A certification as specified in § 1.97(e) is provided below; thus no fee is required.

37 CFR § 1.97(d)

This statement is being filed after the mailing date of a Final Office action, a Notice of Allowance under § 1.311, or an action that otherwise closes prosecution, but on or before payment of the issue fee, and then:

A). A fee of 180.00 as set forth in 1.17(p) is authorized below, enclosed, or payment is included with other papers filed together with this statement

---AND---

B). A certification as specified in § 1.97(e) is included below.

<u>CONTENT OF INFORMATION DISCLOSURE STATEMENT UNDER</u> <u>37 CFR § 1.98</u>

37 CFR §1.98 (a)(2)(ii), U.S. patents or patent application publication(s) cited

1). Since not requested by the Office, U.S. patents and U.S. patent application publications are not included.

2). At the request of the Office, a copy of the following U.S. patent or patent application publication is attached:

3). Items identified by a double asterisk (**) on the SB08A are *commonly-owned U.S. patents and U.S. patent application publications.

37 CFR §1.98 (a)(2)(iii) and (d), *Commonly-owned, unpublished U.S. applications cited

1). A copy of each application specification including the claim(s), and any drawing, or that portion of the application that caused it to be listed, is attached.

2). A copy of each application specification is not submitted because the specification was previously submitted in the IDS of the following, earlier filed application relied on for an earlier effective filing date:

3). A copy of each application specification is not submitted because the application is stored in the IFW.

*Applicant(s) assume the Examiner has access to the file histories of these items. However, if the Examiner would like to receive copies of Office Actions in any of the commonly-owned applications, publications and/or patents identified on the attached SB08, please inform the undersigned and copies will be provided.

37 CFR §1.98 (a)(2)(iii) and (d), English language publication (other than U.S. patents, patent applications, or pending unpublished applications) cited

1). A legible copy of each publication or that portion which caused it to be listed is attached.
 2). A copy of each publication or that portion which caused it to be listed is not submitted because the publication was previously submitted in the IDS of the following, earlier filed application relied on for an earlier effective filing date:

Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 185 of 442

37 CFR §1.98 (a)(2)(i) and (d), Foreign patent(s) in English cited

1). A legible copy of each foreign patent or that portion which caused it to be listed is attached.

2). A copy of each foreign patent is not submitted because the publication was previously submitted in the IDS of the following, earlier filed application relied on for an earlier effective filing date:

37 CFR §1.98 (a)(2)(i), (a)(3)(i-ii) and MPEP 609(B), Foreign patent(s) or other foreign documents not in English cited. Either:

1). A legible copy of each foreign patent, each publication or that portion which caused it to be listed, is attached --AND---

2a). A concise explanation of the relevance, as it is presently understood by the individual designated in § 1.56 (c) most knowledgeable about the content of the information, of each patent, publication, or other information listed that is not in the English language is provided herewith:

--OR--

2b). A copy of a written, English-language translation or portion thereof is readily available and attached,

--OR--

2c). An English language copy of a foreign search report is submitted.

--OR---

3). A copy of each foreign patent is not submitted because the publication was previously submitted in the IDS of the following, earlier filed application relied on for an earlier effective filing date:

STATEMENT UNDER 37 CFR § 1.97(e)

Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.

No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.

FEE AUTHORIZATION

The Commissioner is hereby authorized to charge the above-referenced fees of \$0.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 50-4050.

Dated: 7/16/10

Shay Glenn LLP 2755 Campus Drive, Suite 210 San Mateo, CA 94403 (650) 212-1700 Customer No. 66854

Respectfully Submitted,

By:

Thomas Zlogar Reg. # 55760

PTO/SB/08a (07-09)

Approved for use through 07/31/2012. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet 1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary) of

1

Complete if Known			
Application Number	12/492,512		
Filing Date	June 26, 2009		
First Named Inventor	Amr Salahieh		
Art Unit	3774		
Examiner Name	SCHILLINGER, ANN M		
Attorney Docket Number	10012-710.401		

		······································	U. S. PATEN1	DOCUMENTS	
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant
		Number-Kind Code ^{2 (if known)}			Figures Appear
	538	^{US-} 5,534,007	7/9/1996	St. Germain et al.	
	539	^{US-} 6,093,203	7/25/2000	Uflacker	
	536	^{US-} 6,251,135	6/26/2001	Stinson et al.	
	540	^{US-} 6,676,668	1/13/2004	Mercereau et al.	
	541	^{US-} 6,764,503	7/20/2004	Ishimaru	
	537	^{US-} 7,201,772	4/10/2007	Schwammenthal et al.	
	543	^{US-} 2003/0114912	6/19/2003	Sequin et al.	
. P - 18	544	^{US-} 2003/0135257	7/17/2003	Taheri	······································
	545	^{US-} 2003/0225445	12/4/2003	Derus et al.	
·····	546	^{US-} 2004/0220655	11/4/2004	Swanson et al.	
·····		US-			
		US-		· · · · · · · · · · · · · · · · · · ·	······
		US-			······
		US-			·····
		US-		· · · · · · · · · · · · · · · · · · ·	
		US-			
		US-		<u> </u>	
		US-			
		US-			

		FOREI	GN PATENT DOCL	MENTS		
Examiner	Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines,	
Initials*	No. ¹		Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (<i>if known</i>)			- · · · · · · · · · · · · · · · · · · ·	
	534	WO03/030776 A2	4/17/2003	Gabbay, Shlomo		
	535	WO03/094797	11/20/2003	Cordis Corporation		
Examiner	- 1			Date		

Examiner Signature

Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at <u>www.uspto.gov</u> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language For Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Electronic Ac	Electronic Acknowledgement Receipt			
EFS ID:	8521849			
Application Number:	12492512			
International Application Number:				
Confirmation Number:	7439			
Title of Invention:	Everting Heart Valve			
First Named Inventor/Applicant Name:	Amr Salahieh			
Customer Number:	66854			
Filer:	Thomas M. Zlogar/Angelica Zuniga			
Filer Authorized By:	Thomas M. Zlogar			
Attorney Docket Number:	10012-710.401			
Receipt Date:	29-SEP-2010			
Filing Date:	26-JUN-2009			
Time Stamp:	11:57:43			
Application Type:	Utility under 35 USC 111(a)			

Payment information:

Submitted wi	th Payment	no			
File Listin	g:				
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		10012-710401_IDS.pdf	589855 2431d972a2ec80cc7c2bac2c7c0c6027f989 6ebb	yes	4

Warnings: 25350eaddc03d92bet1af1405274addbox and an		Multipart Description/PDF files in .zip description				
$\frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ $		Document De	scription	Start	E	nd
Warnings: Information: 2 Foreign Reference Woo3030776A2.pdf 2784905 33398886038438415414495214888602 2005 no 5 Warnings: 1 Information: 2870914 no 5 Marnings: 2870914 no 9 Warnings: 2870914 no 9 Warnings: 2870914 no 9 Warnings: 2870914 no 9 Warnings: 5 5 5 Information: 2870914 no 9 Warnings: 5 5 5 Information: 5 5 5 Warnings: 5 5 5 Information: 5 5 5		Transmittal	Letter	1	3	
Information: 2 Foreign Reference W003030776A2.pdf 2784905 23350exted00301001000000000000000000000000000000		Information Disclosure Stater	Information Disclosure Statement (IDS) Filed (SB/08)			4
2 Foreign Reference WO03030776A2.pdf 2784905 no 5 Warnings: Information: 3 Foreign Reference WO03094797A1.pdf 2870914 no 9 3 Foreign Reference WO03094797A1.pdf 2870914 no 9 WO03094797A1.pdf 2870914 no 9 WO03094797A1.pdf 2870914 no 9 Wondentee Size (in bytes) 6245674 Total Files Size (in bytes) 6245674 This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar Post Card, as described in MPEP 503. Mew Applications Under 35 U.S.C. 111 If a new application includes the necessary components for a filing date (see 37 CFI 1.53(b)-(d) and MPEP 506), a filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application. National Stage of an International Application under 35 U.S.C. 371 If a timely submission to enter the national stage of an international application.	Warnings:					
2 Foreign Reference WO03030776A2.pdf no 5 233500000000000000000000000000000000000	Information	:				
Warnings: 23300eaded0340 Land H2H9292 Medded047 Information: 2870914 3 Foreign Reference WO03094797A1.pdf 2870914 2007483c1887c151698022464c00451bb no 9 2007483c1887c151698022464c00451bb Warnings: 100 Total Files Size (in bytes): 6245674	2	Foreign Reference	WQ03030776A2.pdf	2784905	no	56
Information: 3 Foreign Reference WO03094797A1.pdf 2870914 no 9 3 Foreign Reference 2870914 no 9 WO03094797A1.pdf Warnings: Information: Total Files Size (in bytes): 6245674 This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar Post Card, as described in MPEP 503. New Applications Under 35 U.S.C. 111 If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFI 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application. National Stage of an International Application under 35 U.S.C. 371 If a timely submission to enter the national stage of an international application is compliant with the conditions of U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a	_					
3 Foreign Reference WO03094797A1.pdf 2870914 no 9 3 your and the second of	Warnings:					
3 Foreign Reference WO03094797A1.pdf no 9 3 Foreign Reference b974b3ca1847c151559032464cd04451b no 9 Warnings: Information: Total Files Size (in bytes): 6245674 This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar Post Card, as described in MPEP 503. New Applications Under 35 U.S.C. 111 If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFI 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application. National Stage of an International Application under 35 U.S.C. 371 If a timely submission to enter the national stage of an international application is compliant with the conditions of U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a	Information	:	1			
Warnings: Information: Total Files Size (in bytes): 6245674 This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar Post Card, as described in MPEP 503. New Applications Under 35 U.S.C. 111 If a new application is being filed and the application includes the necessary components for a filing date (see 37 CF 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application. National Stage of an International Application under 35 U.S.C. 371 If a timely submission to enter the national stage of an international application is compliant with the conditions of U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a	3	Foreign Reference	W003094797A1 pdf	2870914	no	92
Information: Total Files Size (in bytes): 6245674 This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar Post Card, as described in MPEP 503. New Applications Under 35 U.S.C. 111 If a new application is being filed and the application includes the necessary components for a filing date (see 37 CF 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application. National Stage of an International Application under 35 U.S.C. 371 If a timely submission to enter the national stage of an international application is compliant with the conditions of U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a	Ū.				110	
Total Files Size (in bytes):6245674This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar Post Card, as described in MPEP 503.New Applications Under 35 U.S.C. 111 If a new application is being filed and the application includes the necessary components for a filing date (see 37 CF 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.National Stage of an International Application under 35 U.S.C. 371 If a timely submission to enter the national stage of an international application is compliant with the conditions of U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a	Warnings:					
This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar Post Card, as described in MPEP 503. New Applications Under 35 U.S.C. 111 If a new application is being filed and the application includes the necessary components for a filing date (see 37 CF 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application. National Stage of an International Application under 35 U.S.C. 371 If a timely submission to enter the national stage of an international application is compliant with the conditions of U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a	Information	:				
characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar Post Card, as described in MPEP 503. <u>New Applications Under 35 U.S.C. 111</u> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CF 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application. <u>National Stage of an International Application under 35 U.S.C. 371</u> If a timely submission to enter the national stage of an international application is compliant with the conditions of U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a			Total Files Size (in bytes)	: 62	45674	
national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course. <u>New International Application Filed with the USPTO as a Receiving Office</u> If a new international application is being filed and the international application includes the necessary component an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Numb and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concern national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.	characterize Post Card, as <u>New Applica</u> If a new app 1.53(b)-(d) a Acknowledg <u>National Sta</u> If a timely su U.S.C. 371 an	ed by the applicant, and including pars s described in MPEP 503. <u>Initions Under 35 U.S.C. 111</u> lication is being filed and the applica nd MPEP 506), a Filing Receipt (37 CI gement Receipt will establish the filin uge of an International Application un ubmission to enter the national stage and other applicable requirements a F	ge counts, where applicable. ation includes the necessary of FR 1.54) will be issued in due ng date of the application. <u>nder 35 U.S.C. 371</u> e of an international applicat Form PCT/DO/EO/903 indicat	It serves as evidence components for a filin course and the date s ion is compliant with ing acceptance of the	of receipt s og date (see hown on th the conditio applicatior	similar to a 37 CFR is ons of 35

VIA EFS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.:	12/492,512	Confirmation No.: 7439	
Applicant(s):	Amr Salahieh		
Filed:	June 26, 2009		
Art Unit:	3774		
Examiner:	SCHILLINGER, ANN M		
Title:	EVERTING HEART VALVE		
Customer No.:	66854		

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

<u>INFORMATION DISCLOSURE STATEMENT UNDER</u> <u>37 CFR § 1.97 & § 1.98</u>

Sir:

In accordance with 37 CFR § 1.97-1.98, applicants hereby submit an Information Disclosure Statement, including attached forms(s) PTO/SB/08. A copy of each reference is being submitted herewith, along with a concise explanation in English for those publications in a foreign language.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. Applicants further request that the Examiner initial and return a copy of the attached form(s) PTO/SB/08 in accordance with MPEP §609.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and /or to prove that this information may not be enabling for the teachings purportedly offered.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, prior art or material to patentability as defined in 37 CFR §1.56.

FILING OF INFORMATION DISCLOSURE STATEMENT

37 CFR §1.97(b)

This statement is being submitted under 37 CFR §1.97(b) because the IDS is being filed:

1). Within 3 months of the application filing date and is other than a continued prosecution application under 1.53(d), or

2). Within 3 months of entry of a national stage as set forth in § 1.491, or

 \boxtimes 3). Before the mail date of a first Office Action on the merits, or

4). Before the mailing of a first Office Action after filing a request for continued examination under § 1.114.

37 CFR § 1.97(c)

This statement is being filed after the latest of:

1). Three months beyond the filing date of a national application, or

2). Three months beyond the date of entry of the national stage as set forth in § 1.491 in an international application, or

 \Box 3). The mailing date of a first Office Action on the merits, but before the mailing date of the earlier of a final Office Action under § 1.113 or a Notice of Allowance under § 1.311, and then either:

□ A). A fee of \$180.00 as set forth in § 1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement. or
 □ B). A certification as specified in § 1.97(e) is provided below; thus no fee is required.

37 CFR § 1.97(d)

This statement is being filed after the mailing date of a Final Office action, a Notice of Allowance under § 1.311, or an action that otherwise closes prosecution, but on or before payment of the issue fee, and then:

A). A fee of 180.00 as set forth in 1.17(p) is authorized below, enclosed, or payment is included with other papers filed together with this statement

--AND--

B). A certification as specified in § 1.97(e) is included below.

<u>CONTENT OF INFORMATION DISCLOSURE STATEMENT UNDER</u> <u>37 CFR § 1.98</u>

37 CFR §1.98 (a)(2)(ii), U.S. patents or patent application publication(s) cited

1). Since not requested by the Office, U.S. patents and U.S. patent application publications are not included.

2). At the request of the Office, a copy of the following U.S. patent or patent application publication is attached:

3). Items identified by a double asterisk (**) on the SB08A are *commonly-owned U.S. patents and U.S. patent application publications.

37 CFR §1.98 (a)(2)(iii) and (d), *Commonly-owned, unpublished U.S. applications cited
 1). A copy of each application specification including the claim(s), and any drawing, or that

portion of the application that caused it to be listed, is attached.

2). A copy of each application specification is not submitted because the specification was previously submitted in the IDS of the following, earlier filed application relied on for an earlier effective filing date:

3). A copy of each application specification is not submitted because the application is stored in the IFW.

*Applicant(s) assume the Examiner has access to the file histories of these items. However, if the Examiner would like to receive copies of Office Actions in any of the commonly-owned applications, publications and/or patents identified on the attached SB08, please inform the undersigned and copies will be provided.

37 CFR §1.98 (a)(2)(iii) and (d), English language publication (other than U.S. patents, patent applications, or pending unpublished applications) cited

A legible copy of each publication or that portion which caused it to be listed is attached.
 A copy of each publication or that portion which caused it to be listed is not submitted because the publication was previously submitted in the IDS of the following, earlier filed application relied on for an earlier effective filing date:

37 CFR §1.98 (a)(2)(i) and (d), Foreign patent(s) in English cited

 \square 1). A legible copy of each foreign patent or that portion which caused it to be listed is attached.

2). A copy of each foreign patent is not submitted because the publication was previously submitted in the IDS of the following, earlier filed application relied on for an earlier effective filing date:

37 CFR §1.98 (a)(2)(i), (a)(3)(i-ii) and MPEP 609(B), Foreign patent(s) or other foreign documents not in English cited. Either:

1). A legible copy of each foreign patent, each publication or that portion which caused it to be listed, is attached --AND---

2a). A concise explanation of the relevance, as it is presently understood by the individual designated in § 1.56 (c) most knowledgeable about the content of the information, of each patent, publication, or other information listed that is not in the English language is provided herewith:

--OR---

---OR---

2b). A copy of a written, English-language translation or portion thereof is readily available and attached,

2c). An English language copy of a foreign search report is submitted.

--OR---

3). A copy of each foreign patent is not submitted because the publication was previously submitted in the IDS of the following, earlier filed application relied on for an earlier effective filing date:

STATEMENT UNDER 37 CFR § 1.97(e)

Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.

No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.

FEE AUTHORIZATION

The Commissioner is hereby authorized to charge the above-referenced fees of \$0.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 50-4050.

Respectfully Submitted,

Shomo Hog By:_

Thomas Zlogar Reg. # 55760

Dated: 92810

Shay Glenn LLP 2755 Campus Drive, Suite 210 San Mateo, CA 94403 (650) 212-1700 Customer No. 66854

Unit	ed States Patent	AND TRADEMARK OFFICE	UNITED STATES DEPAR United States Patent and Address: COMMISSIONER F P.O. Box 1450 Alexandria, Virginia 22: www.uspto.gov	FOR PATENTS
APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
12/492,512	06/26/2009	Amr Salahieh	10012-710.401	7439
SHAY GLENN 2755 CAMPUS			EXAM	
SUITE 210 SAN MATEO,	CA 94403		ART UNIT	PAPER NUMBER
······································			3774	
			MAIL DATE	DELIVERY MODE
			12/17/2010	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

		Application No.	Applicant(s)
	o <i>m</i>	12/492,512	SALAHIEH ET AL.
	Office Action Summary	Examiner	Art Unit
		ANN SCHILLINGER	3774
Period fo	The MAILING DATE of this communication ap or Reply	pears on the cover sheet with the	e correspondence address
WHIC - Exte after - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR REPL CHEVER IS LONGER, FROM THE MAILING D nsions of time may be available under the provisions of 37 CFR 1. SIX (6) MONTHS from the mailing date of this communication. D period for reply is specified above, the maximum statutory period ire to reply within the set or extended period for reply will, by statute reply received by the Office later than three months after the mailin ed patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNICATIN 136(a). In no event, however, may a reply be will apply and will expire SIX (6) MONTHS fr e, cause the application to become ABANDO	ON. e timely filed om the mailing date of this communication. NED (35 U.S.C. § 133).
Status			
1)	Responsive to communication(s) filed on 26 J	lune 2009.	
·		s action is non-final.	
3)	Since this application is in condition for allowa	unce except for formal matters, p	prosecution as to the merits is
	closed in accordance with the practice under	<i>Ex parte Quayle</i> , 1935 C.D. 11,	453 O.G. 213.
Disposit	ion of Claims		
4)	Claim(s) <u>1-6</u> is/are pending in the application.		
	4a) Of the above claim(s) is/are withdra	wn from consideration.	
5)	Claim(s) is/are allowed.		
· ·	Claim(s) <u>1-6</u> is/are rejected.		
	Claim(s) is/are objected to.		
	Claim(s) are subject to restriction and/o	or election requirement.	
Applicat	ion Papers		
	-	or	
· · · · · · · · · · · · · · · · · · ·	The specification is objected to by the Examine The drawing(s) filed on is/are: a) \Box acc		o Examinar
	Applicant may not request that any objection to the		
	Replacement drawing sheet(s) including the correct		
	The oath or declaration is objected to by the E		-
'—			
Priority (under 35 U.S.C. § 119		
12)	Acknowledgment is made of a claim for foreigr	n priority under 35 U.S.C. § 119	(a)-(d) or (f).
a)	□ All b)□ Some * c)□ None of:		
	1. Certified copies of the priority documen		
	2. Certified copies of the priority documen		
	3. Copies of the certified copies of the pric	•	ived in this National Stage
	application from the International Burea		
*	See the attached detailed Office action for a list	t of the certified copies not recei	ived.
Attachmer			
	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948)	4) 🔟 Interview Summa Paper No(s)/Mail	
	mation Disclosure Statement(s) (PTO/SB/08)	5) D Notice of Informa	
Pape	er No(s)/Mail Date <u>8/11/09,12/2/09,3/26/10,7/16/10,9/29/10</u>	2. 6) Other:	
U.S. Patent and 1 PTOL-326 (F		ction Summary	Part of Paper No./Mail Date 20101215

Office Action Summary Part of Paper No./Mail Date 20101215 Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 194 of 442

DETAILED ACTION

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-7 are rejected under 35 U.S.C. 102(b) as being anticipated by Bailey et al. (US

Pub. No. 2001/0021872). Bailey et al. discloses the following regarding claim 1: a system for replacing a heart valve, comprising: an expandable anchor (12) having a collapsed delivery configuration and an expanded configuration (para. 0021); a replacement valve commissure support element (24) attached to the expandable anchor; a commissure portion of a replacement valve leaflet (26) attached to the commissure support element (Fig. 2); and a seal at least partially disposed around an exterior portion of the expandable anchor when the anchor is in the expanded configuration, wherein the seal is adapted to prevent blood from flowing between the seal and heart tissue, wherein a distal end of the replacement valve leaflet is attached to the seal (Fig. 4; paras. 0021-0022, 0049).

Bailey et al. discloses the following regarding claim 2: the system of claim 1 wherein the expandable anchor is not attached to the replacement valve leaflet (Fig. 2).

Bailey et al. discloses the following regarding claim 3: the system of claim 1 wherein the distal end of the replacement valve leaflet is attached to a distal end of the seal when the expandable anchor is in the expanded configuration (Figs. 1, 13).

Application/Control Number: 12/492,512 Art Unit: 3774

Bailey et al. discloses the following regarding claim 4: the system of claim 1 wherein the commissure support element is configured to interface with an anchor actuator (13).

Bailey et al. discloses the following regarding claim 5: the system of claim 4 wherein the anchor actuator is adapted to apply a proximally directed force on the commissure support element to foreshorten the expandable anchor (paras. 0050, 0051).

Please note that language such as "configured to/for" and "adapted to/for" is functional language. The functional language of the claims has been considered to the extent that it further defines the structure of the claimed device.

Bailey et al. discloses the following regarding claim 6: the system of claim 1 further comprising a lock comprising a first lock element and a second lock element (anchoring flanges, shown in element 22), wherein the first and second lock elements are attached to the expandable anchor and adapted to engage with one another to lock the expandable anchor in the expanded configuration, and wherein the commissure support element includes the first lock element.

Bailey et al. discloses the following regarding claim 7: the system of claim 6 wherein the second lock element is attached to the expandable anchor and is disposed proximal to the first lock element when the expandable anchor is in the collapsed configuration within a delivery catheter (Figs. 1-2; para. 0022).

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to ANN SCHILLINGER whose telephone number is (571)272-6652. The examiner can normally be reached on Mon. thru Fri. 9 a.m. to 4 p.m..

Application/Control Number: 12/492,512 Art Unit: 3774

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, David Isabella can be reached on (571) 272-4749. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/A. S./ Examiner, Art Unit 3774

/DAVID ISABELLA/ Supervisory Patent Examiner, Art Unit 3774

	Application/Control No.	Applicant(s)/Patent Under Reexamination
Search Notes	12492512	SALAHIEH ET AL.
*1249251	Examiner	Art Unit
	ANN SCHILLINGER	3774
2*		

SEARCHED				
Class		Subclass	Date	Examiner
623	1.11-1.54		12/15/2010	AS

SEARCH NOTES		
Search Notes	Date	Examiner

Г

	INTERFERENCE SEARCH		
Class	Subclass	Date	Examiner

A. S./ Examiner.Art Unit 3774	

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:	Ulrich R. Haug, Hans F. Valencia, Robert A. Geshlider, Tom	
	Saul, Amr Salahieh, Dwight P. Morejohn, Kenneth J. Michlitse	
Application No.:	12/492512	
Filed:	June 26, 2009	
For:	Everting Heart Valve	
Examiner:	Ann M. Schillinger	
Group Art Unit:	3774	

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Docket No: S63.2Q-15141-US03

REVOCATION OF POWER OF ATTORNEY AND APPOINTMENT OF NEW ATTORNEY

I hereby revoke all previous powers of attorney given in the above identified application.

I hereby appoint all practitioners associated with Customer Number 00490 as my/our attorney(s) or (agent(s) to prosecute the above identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please address all future correspondence to James M. Urzedowski at Customer Number 00490.

I am the:

Date: 2/a/11

- □ Applicant/Inventor
- Assignee of record of the entire interest. (See 37 CFR 3.71) Statement under 37 CFR 3.73(b) or copy of previously filed 3.73(b) statement is enclosed.

Respectfully submitted,

SADRA MEDICAL, INC.

Bv:

Name: Ken Martin Title: President & CEO

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:	Ulrich R. Haug, Hans F. Valencia, Robert A. Geshlider, Tom
	Saul, Amr Salahieh, Dwight P. Morejohn, Kenneth J. Michlitsch
Application No.:	12/492512
Filed:	June 26, 2009
For:	Everting Heart Valve
Examiner: Ann M. Schillinger	
Group Art Unit:	3774

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Docket No: S63.2Q-15141-US03

NOTIFICATION OF CHANGE OF ENTITY STATUS

Applicant is no longer entitled to claim small entity status. Please update the record to reflect large entity status for this case.

Respectfully submitted,

VIDAS, ARRETT & STEINKRAUS

Date: February 11, 2011

By: /James M. Urzedowski/

James M. Urzedowski Registration No.: 48596

6640 Shady Oak Rd., Suite 400 Eden Prairie, MN 55344-7834 Telephone: (952) 563-3000 Facsimile: (952) 563-3001

Electronic Acknowledgement Receipt			
EFS ID:	9431059		
Application Number:	12492512		
International Application Number:			
Confirmation Number:	7439		
Title of Invention:	Everting Heart Valve		
First Named Inventor/Applicant Name:	Amr Salahieh		
Customer Number:	66854		
Filer:	James M. Urzedowski/Samantha Painschab		
Filer Authorized By:	James M. Urzedowski		
Attorney Docket Number:	10012-710.401		
Receipt Date:	11-FEB-2011		
Filing Date:	26-JUN-2009		
Time Stamp:	17:40:01		
Application Type:	Utility under 35 USC 111(a)		

Payment information:

Submitted with Payment		no				
File Listing:						
Document Number	Document Description		File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Transmittal Letter	15	141US03 tra 20110211.pdf	84873	no	1
			1410303_da_20110211.pdf	d46b345f1743818f62dca9b54bdc3d4e77b b3fdb	110	
Warnings:						
Information:	Edwards Lifes	scienc	es Corporation, et al	. Exhibit 1102, Pag	e 201 of 4	42

2	Assignee showing of ownership per 37 CFR 3.73(b).	15141US03_sta_20110207.pdf	70962 c2c6357a76a6e8530f57365f515f6140e9a1 ba35	no	1
Warnings:		I	I		I
Information					
3	Power of Attorney	15141US03_executedPOA.pdf	27429	no 1	
			997a238f86b0e213330d0609000c8fcfcf43e a4d		
Warnings:					
Information					1
4	Miscellaneous Incoming Letter	15141US03_entity_status_2011	66923	no 3	1
		0211.pdf	327c2060ca2114f6b29da8cffac4db38c91a 994e		
Warnings:					
Information	}		1		
		Total Files Size (in bytes)	2	50187	
characterize Post Card, as <u>New Applica</u>	vledgement Receipt evidences receip d by the applicant, and including pag s described in MPEP 503. <u>Itions Under 35 U.S.C. 111</u>	•			-
1.53(b)-(d) a Acknowledg <u>National Sta</u> If a timely su U.S.C. 371 ar	lication is being filed and the applica nd MPEP 506), a Filing Receipt (37 CF ement Receipt will establish the filin <u>ge of an International Application ur</u> Ibmission to enter the national stage nd other applicable requirements a F ge submission under 35 U.S.C. 371 wi	R 1.54) will be issued in due g date of the application. <u>ader 35 U.S.C. 371</u> of an international applicati orm PCT/DO/EO/903 indicati	course and the date s on is compliant with ng acceptance of the	hown on th the condition application	nis ons of 35

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:	Ulrich R. Haug, Hans F. Valencia, Robert A. Geshlider, Tom Saul, Amr
	Salahieh, Dwight P. Morejohn, Kenneth J. Michlitsch
Application No.:	12/492512
Filed:	June 26, 2009
For:	Everting Heart Valve
Examiner:	Ann M. Schillinger
Group Art Unit:	3774

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Docket No: S63.2Q-15141-US03

TRANSMITTAL LETTER

In regard to the above-identified application, in addition to this 1 page transmittal letter, we are submitting the attached:
 1 page Revocation of Power of Attorney and Appointment of New Attorney: 1 page Assignee's

1 page Revocation of Power of Attorney and Appointment of New Attorney; 1 page Assignee's Statement of Ownership and 1 page Notification of Change of Entity Status.

2. With respect to fees, applicant believes the fees required herein, if any, are being paid electronically.

3. CONDITIONAL PETITION FOR EXTENSION OF TIME

This conditional petition is being filed along with the papers identified in Item 1 above and provides for the possibility that Applicant has inadvertently overlooked the need for a petition and fee for extension of time or for a petition and fee for any other matter petitionable to the Commissioner as required. If any extension of time for the accompanying response is required or if a petition for any other matter is required, by petitioner, Applicant requests that this be considered a petition therefor.

- 4. Notwithstanding paragraph 2 above, if any additional fees associated with this communication are required and have not otherwise been paid, including any fee associated with the Conditional Petition for Extension of Time, or any request in the accompanying papers for action which requires a fee as a petition to the Commissioner, please charge the additional fees to Deposit Account No. 22-0350. Please charge any additional fees associated with this communication to the Deposit Account No. 22-0350.
- 5. **Certification:** I hereby certify that this Transmittal Letter and the paper(s) as described herein are being transmitted electronically to the USPTO on February 11, 2011.

Respectfully submitted,

VIDAS, ARRETT & STEINKRAUS

Date: February 11, 2011

By: /James M. Urzedowski/

James M. Urzedowski Registration No.: 48596

6640 Shady Oak Rd., Suite 400 Eden Prairie, MN 55344-7834 Telephone: (952) 563-3000 Facsimile: (952) 563-3001 f:\wpwork\jmu\15141us03_tra_20110211.doc

In Re Application of:	Ulrich R. Haug, Hans F. Valencia, Robert A. Geshlider, Tom	
	Saul, Amr Salahieh, Dwight P. Morejohn, Kenneth J. Michlitsch	
Application No.:	12/492512	
Filed:	June 26, 2009	
For:	Everting Heart Valve	
Examiner:	Ann M. Schillinger	
Group Art Unit:	3774	

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Docket No: S63.2Q-15141-US03

ASSIGNEE'S STATEMENT OF OWNERSHIP 37 CFR 3.73(B)

Sadra Medical, Inc., a corporation, is the assignee of the entire right, title and interest in the patent application identified above by virtue of a chain of title from the inventor(s), of the patent application identified above, to the current assignee as shown below:

 From : <u>Amr Salahieh, Ulrich R. Haug, Hans F. Valencia, Robert A.</u> <u>Geshlider, Tom Saul, Dwight P. Morejohn, Kenneth Michlitsch</u> To: <u>Sadra Medical, Inc.</u> The document was recorded in the Patent and Trademark Office at Reel <u>023551</u>, Frame <u>0485</u>, or for which a copy thereof is attached.

The undersigned is empowered to sign this statement of ownership certificate on behalf of the assignee.

Respectfully submitted,

VIDAS, ARRETT & STEINKRAUS

Date: February 11, 2011

By: /James M. Urzedowski/

James M. Urzedowski Registration No.: 48596

6640 Shady Oak Rd., Suite 400 Eden Prairie, MN 55344-7834 Telephone: (952) 563-3000 Facsimile: (952) 563-3001 f:\wpwork\jmu\15141us03_sta_20110207.doc

UNITED ST	ATES PATENT AND TRADEMARK OFFICE UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS PO. Box 1450 Alexandria, Virginia 22313-1450 www.usplogov			
APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE	
12/492,512	06/26/2009	Amr Salahieh	10012-710.401	
66854 SHAY GLENN LLP 2755 CAMPUS DRIVE SUITE 210 SAN MATEO, CA 94403			CONFIRMATION NO. 7439 F ATTORNEY NOTICE	

Date Mailed: 02/18/2011

NOTICE REGARDING CHANGE OF POWER OF ATTORNEY

This is in response to the Power of Attorney filed 02/11/2011.

• The Power of Attorney to you in this application has been revoked by the assignee who has intervened as provided by 37 CFR 3.71. Future correspondence will be mailed to the new address of record(37 CFR 1.33).

/erimando/

Office of Data Management, Application Assistance Unit (571) 272-4000, or (571) 272-4200, or 1-888-786-0101

page 1 of 1

United St	ates Patent and Trademai	UNITED STA' United States Address: COMMIS P.O. Box 1	, Virginia 22313-1450
APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
12/492,512	06/26/2009	Amr Salahieh	\$63.2Q-15141-U\$03
			CONFIRMATION NO. 7439
490		POA ACCI	EPTANCE LETTER
VIDAS, ARRETT & STEIN SUITE 400, 6640 SHADY EDEN PRAIRIE, MN 5534	OAK ROAD		C000000046060674*

Date Mailed: 02/18/2011

NOTICE OF ACCEPTANCE OF POWER OF ATTORNEY

This is in response to the Power of Attorney filed 02/11/2011.

The Power of Attorney in this application is accepted. Correspondence in this application will be mailed to the above address as provided by 37 CFR 1.33.

/erimando/

Office of Data Management, Application Assistance Unit (571) 272-4000, or (571) 272-4200, or 1-888-786-0101

UNITED STATES PATENT AND TRADEMARK OFFICE UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS PO. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov					
APPLICATION NUMBER	FILING or 371(c) DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	TOT CLAIMS IND CLAIMS
12/492,512	06/26/2009	3774	462	\$63.2Q-15141-U\$03	7 1
				CONF	FIRMATION NO. 7439
490				CORRECTED F	ILING RECEIPT
VIDAS, ARRE	TT & STEINKF	AUS, P.A.			
SUITE 400, 66		K ROAD			000046101872*
EDEN PRAIRI	E, MN 55344			*0C000	000046101872*

Date Mailed: 02/24/2011

Receipt is acknowledged of this non-provisional patent application. The application will be taken up for examination in due course. Applicant will be notified as to the results of the examination. Any correspondence concerning the application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please submit a written request for a Filing Receipt Correction. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections

Applicant(s)

Amr Salahieh, Saratoga, CA; Ulrich R. Haug, Campbell, CA; Hans F. Valencia, Berkeley, CA; Robert A. Geshlider, San Francisco, CA; Tom Saul, El Granada, CA; Dwight P. Morejohn, Davis, CA; Kenneth J. Michlitsch, Livermore, CA;

Power of Attorney: The patent practitioners associated with Customer Number 00490

Domestic Priority data as claimed by applicant

This application is a DIV of 12/269,213 11/12/2008 which is a CON of 10/870,340 06/16/2004 PAT 7,780,725

Foreign Applications (You may be eligible to benefit from the **Patent Prosecution Highway** program at the USPTO. Please see <u>http://www.uspto.gov</u> for more information.)

If Required, Foreign Filing License Granted: 07/07/2009

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US 12/492,512**

Projected Publication Date: Not Applicable

Non-Publication Request: No

Early Publication Request: No

page 1 of 3

Title

Everting Heart Valve

Preliminary Class

623

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

LICENSE FOR FOREIGN FILING UNDER

Title 35, United States Code, Section 184

Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as

page 2 of 3

set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign AssetsControl, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	Ulrich R. Haug, Hans F. Valencia, Robert A.
	Geshlider, Tom Saul, Amr Salahieh, Dwight P.
	Morejohn, Kenneth J. Michlitsch
Application No.:	12/492512
Filed:	June 26, 2009
For:	Everting Heart Valve
Examiner:	Ann M. Schillinger
Group Art Unit:	3774

Mail Stop <u>Amendment</u> Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Docket No.: S63.2Q-15141-US03

COMMUNICATION

This communication is in response to the Office Action dated December 17, 2010.

If an extension of time is required to make this response timely and no separate

petition is enclosed, Applicants hereby petition for an extension of time sufficient to make the

response timely. In the event that this response requires the payment of government fees and

payment is not enclosed, please charge Deposit Account No. 22-0350.

The Claims:

Claim 1. (Original) A system for replacing a heart valve, comprising:

an expandable anchor having a collapsed delivery configuration and an expanded configuration

a replacement valve commissure support element attached to the expandable anchor;

a commissure portion of a replacement valve leaflet attached to the commissure support element; and

a seal at least partially disposed around an exterior portion of the expandable anchor when the anchor is in the expanded configuration, wherein the seal is adapted to prevent blood from flowing between the seal and heart tissue,

wherein a distal end of the replacement valve leaflet is attached to the seal.

Claim 2. (Original) The system of claim 1 wherein the expandable anchor is not attached to the replacement valve leaflet.

Claim 3. (Original) The system of claim 1 wherein the distal end of the replacement valve leaflet is attached to a distal end of the seal when the expandable anchor is in the expanded configuration.

Claim 4. (Original) The system of claim 1 wherein the commissure support element is configured to interface with an anchor actuator.

Claim 5. (Original) The system of claim 4 wherein the anchor actuator is adapted to apply a proximally directed force on the commissure support element to foreshorten the expandable anchor.

Claim 6. (Original) The system of claim 1 further comprising a lock comprising a first lock element and a second lock element, wherein the first and second lock elements are attached to the expandable anchor and adapted to engage with one another to lock the expandable anchor in the expanded configuration, and

wherein the commissure support element includes the first lock element.

Claim 7. (Original) The system of claim 6 wherein the second lock element is attached to the expandable anchor and is disposed proximal to first lock element when the expandable anchor is in the collapsed configuration within a delivery catheter.

Remarks

This Communication is in response to the Office Action dated December 17, 2010.

Claims 1-7 are rejected under 35 U.S.C. 102(b) as being anticipated by Bailey et al. (US Pub. No. 2001/0021872, hereinafter Bailey). Applicants note that even though the text of the Office Action rejects claims 1-7, the Office Action Summary sheet only states claims 1-6 are pending and rejected. Applicants assume that the text of the Office Action is correct.

The rejections to claims 1-7 are traversed in this Communication. Reconsideration in view of the following remarks is respectfully requested.

35 U.S.C. 102 – Claim Rejections

Claims 1-7 are rejected under 35 U.S.C. 102(b) as being anticipated by Bailey. The rejections are traversed in this Communication.

"A claim is anticipated only if each and every element as set forth in the claim is found, either expressly or inherently described, in a single prior art reference." MPEP 2131, *Verdegaal Bros. v. Union Oil Co. of California*, 814 F.2d 628, 631, 2 USPQ2d 1051, 1053 (Fed. Cir. 1987).

Claim 1 is an independent claim. Claim 1 structurally requires an expandable anchor, a replacement valve commissure support element, and a commissure portion of a replacement valve leaflet. Claim 1 further requires "a seal at least partially disposed around an exterior portion of the expandable anchor when the anchor is in the expanded configuration, wherein the seal is adapted to prevent blood from flowing between the seal and heart tissue."

The Office Action apparently identifies the stent body member 12 in Bailey as being the expandable anchor of the instant claims. The valve arm 24 in Bailey is asserted to be the

Communication Attorney Docket No. S63.2Q-15141-US03

replacement valve commissure support member, and the valve body 26 in Bailey is asserted to correspond to the commissure portion of a replacement valve leaflet. (Figure 2, and paragraphs [0049] and [0050] of Bailey.) The Office Action also implies that Bailey discloses a seal at least partially disposed around an exterior portion to prevent blood from flowing between the seal and heart tissue. The Office Action however, fails to identify any structural component in Bailey corresponding to the seal or the requisite structural characteristics of the seal presented in the instant claims. The failure of Bailey to disclose all of the features of the instant claims, including the recited seal, is fatal to the Office's assertion that Bailey anticipates the instant claims.





Figure 2 of Bailey

It is clear from the figures and disclosure (Figures 15A-E, paragraphs [0102] and

[0103].) that the recited "seal" is a structurally distinguishable component.



Rather than provide a seal component, Bailey merely discloses that a valve prosthesis is deployed within the native valve annular space so that the intermediate annular stent section abuts and outwardly radially compresses the anatomic valve leaflets against the vascular wall. (Paragraph [0022] of Bailey.) Nowhere does Bailey teach or suggest the presence of a seal that is "disposed around an exterior portion of the expandable anchor" to prevent blood flow between the seal and heart tissue as claim 1 required. In light of at least this failure, Applicants respectfully request withdrawal of rejections under 35 U.S.C. 102(b).

Claims 2-7 are dependent over claim 1 directly or indirectly, and therefore patentable at least for the reasons cited for claim 1. Applicants respectfully request withdrawal of rejections under 35 U.S.C. 102(b).

Conclusion

Based on at least the foregoing remarks, Applicants respectfully submit this

application in condition for allowance. Favorable consideration and prompt allowance of claims

1-7 are earnestly solicited.

Should the Examiner believe that anything further would be desirable in order to

place this application in better condition for allowance; the Examiner is invited to contact

Applicants' undersigned representative at the telephone number listed below.

Respectfully submitted,

VIDAS, ARRETT & STEINKRAUS

Date: March 7, 2011

By: /James M. Urzedowski/ James M. Urzedowski Registration No.: 48596

6640 Shady Oak Rd., Suite 400 Eden Prairie, MN 55344-7834 Telephone: (952) 563-3000 Facsimile: (952) 563-3001 f:\wpwork\jmu\15141us03_amd_20110224.doc

Electronic Acknowledgement Receipt				
EFS ID:	9595176			
Application Number:	12492512			
International Application Number:				
Confirmation Number:	7439			
Title of Invention:	Everting Heart Valve			
First Named Inventor/Applicant Name:	Amr Salahieh			
Customer Number:	00490			
Filer:	James M. Urzedowski/Rebecca Leaf			
Filer Authorized By:	James M. Urzedowski			
Attorney Docket Number:	S63.2Q-15141-US03			
Receipt Date:	07-MAR-2011			
Filing Date:	26-JUN-2009			
Time Stamp:	10:00:45			
Application Type:	Utility under 35 USC 111(a)			

Payment information:

Submitted with Payment		no				
File Listing:						
Document Number	Document Description		File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Transmittal Letter	15	5141US03_tra_20110306.pdf	92122	no	1
'				3df990943fc452bc55fdd7995ddb5616c612 7ff6		
Warnings:						
Information:	Edwards Lifes	scienc	es Corporation, et al	. Exhibit 1102, Pag	e 216 of 4	42

2	15141US03	15141US03_amd_20110307. pdf	172838		-	
			4f2776da014d5bc3ef32ef8ea13cb52aee3d 6077	yes	6	
	Multipart Descript	tion/PDF files in	zip description	I		
	Document Description		Start	Eı	nd	
	Amendment/Req. Reconsideration-After Non-	Final Reject	1		1	
	Claims		2	:	2	
	Applicant Arguments/Remarks Made in an Ar	nendment	3	(5	
Warnings:			J			
-			1			
Information: This Acknowle characterized Post Card, as d <u>New Applicati</u> If a new applic	dgement Receipt evidences receipt on the note by the applicant, and including page counts, w lescribed in MPEP 503. ons Under 35 U.S.C. 111 ation is being filed and the application include	here applicable. s the necessary of	SPTO of the indicated It serves as evidence components for a filing	of receipt s g date (see	imilar to 37 CFR	
Information: This Acknowle characterized Post Card, as d New Application If a new application If a new application (1.53(b)-(d) and Acknowledgen National Stage U.S.C. 371 and national stage	dgement Receipt evidences receipt on the not by the applicant, and including page counts, w lescribed in MPEP 503. ons Under 35 U.S.C. 111	ed date by the U here applicable. s the necessary of be issued in due e application. <u>C. 371</u> ational applicat in addition to th	SPTO of the indicated It serves as evidence components for a filing course and the date sl ion is compliant with t	documents of receipt s g date (see hown on th he conditio application	imilar to 37 CFR is	

PATENT

In re Application of:	Ulrich R. Haug, Hans F. Valencia, Robert A. Geshlider, Tom Saul, Amr
	Salahieh, Dwight P. Morejohn, Kenneth J. Michlitsch
Application No.:	12/492512
Filed:	June 26, 2009
For:	Everting Heart Valve
Examiner:	Ann M. Schillinger
Group Art Unit:	3774

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Mail Stop <u>Amendment</u> Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Docket No.: S63.2Q-15141-US03

TRANSMITTAL LETTER

1. In regard to the above-identified application, in addition to this **1** page transmittal letter, we are submitting the attached:

6 page Communication.

2. With respect to fees, applicant believes the fees required herein, if any, are being paid electronically.

3. CONDITIONAL PETITION FOR EXTENSION OF TIME

This conditional petition is being filed along with the papers identified in Item 1 above and provides for the possibility that Applicant has inadvertently overlooked the need for a petition and fee for extension of time or for a petition and fee for any other matter petitionable to the Commissioner as required. If any extension of time for the accompanying response is required or if a petition for any other matter is required, by petitioner, Applicant requests that this be considered a petition therefor.

- 4. Notwithstanding paragraph 2 above, if any additional fees associated with this communication are required and have not otherwise been paid, including any fee associated with the Conditional Petition for Extension of Time, or any request in the accompanying papers for action which requires a fee as a petition to the Commissioner, please charge the additional fees to Deposit Account No. 22-0350. Please charge any additional fees associated with this communication to the Deposit Account No. 22-0350.
- 5. **Certification:** I hereby certify that this Transmittal Letter and the paper(s) as described herein are being transmitted electronically to the USPTO on March 7, 2011.

Respectfully submitted,

VIDAS, ARRETT & STEINKRAUS

Date: March 7, 2011

By: /James M. Urzedowski/

James M. Urzedowski Registration No.: 48596

6640 Shady Oak Rd., Suite 400 Eden Prairie, MN 55344-7834 Telephone: (952) 563-3000 Facsimile: (952) 563-3001 f:\wpwork\jmu\15141us03_tra_20110306.doc

PTO/SB/06 (07-06)

Approved for use through 1/31/2007. OMB 0651-0032

Under the Paperwork Reduction Act of 1995, no persons are required to respond PATENT APPLICATION FEE DETERMINATION RECORD Substitute for Form PTO-875				id to	a collection of pplication or l		ss it dis Fil		DMB control number.		
	AF	PLICATION	AS FILE (Column 1		Column 2)		SMALL		OR		HER THAN LL ENTITY
	FOR	N	UMBER FIL	.ED NUM	MBER EXTRA		RATE (\$)	FEE (\$)		RATE (\$)	FEE (\$)
	BASIC FEE (37 CFR 1.16(a), (b), (or (c))	N/A		N/A		N/A			N/A	
	SEARCH FEE (37 CFR 1.16(k), (i), c	or (m))	N/A		N/A		N/A			N/A	
	EXAMINATION FE (37 CFR 1.16(o), (p), (N/A		N/A		N/A			N/A	
(37 (TAL CLAIMS CFR 1.16(i))		min	us 20 = *			X \$ =		OR	X \$ =	
	EPENDENT CLAIM CFR 1.16(h))	S	mi	nus 3 = *			X \$ =			X \$ =	
APPLICATION SIZE FEE (37 CFR 1.16(s)) If the specification and drawings exceed 100 sheets of paper, the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).											
	MULTIPLE DEPEN						TOTAL			TOTAL	
)ED – PART II			TOTAL			IOTAL	
		(Column 1)		(Column 2)	(Column 3)		SMAL	L ENTITY	OR		ER THAN ILL ENTITY
AMENDMENT	03/07/2011	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA		RATE (\$)	ADDITIONAL FEE (\$)		RATE (\$)	ADDITIONAL FEE (\$)
ME	Total (37 CFR 1.16(i))	* 7	Minus	** 20	= 0		X \$ =		OR	X \$52=	0
L Z	Independent (37 CFR 1.16(h))	* 1	Minus	***3	= 0		X \$ =		OR	X \$220=	0
AME	Application Si	ze Fee (37 CFR 1	.16(s))								
1	FIRST PRESEN	ITATION OF MULTI	PLE DEPEN	DENT CLAIM (37 CFI	R 1.16(j))				OR		
							TOTAL ADD'L FEE		OR	TOTAL ADD'L FEE	0
		(Column 1)		(Column 2)	(Column 3)				-	•	
_		CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA		RATE (\$)	ADDITIONAL FEE (\$)		RATE (\$)	ADDITIONAL FEE (\$)
ENT	Total (37 CFR 1.16(i))	*	Minus	**	=		X \$ =		OR	X \$ =	
NΟ	Independent (37 CFR 1.16(h))	*	Minus	***	=		X \$ =		OR	X \$ =	
ЫN	Application Si	ze Fee (37 CFR 1	.16(s))								
AM			PLE DEPEN	DENT CLAIM (37 CFI	R 1.16(j))				OR		
						. 1	TOTAL ADD'L FEE		OR	TOTAL ADD'L FEE	
** If *** I The	 * If the entry in column 1 is less than the entry in column 2, write "0" in column 3. ** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20". *** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3". The "Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1. 										
	-	-			e highest number for n is required to obta			-		s to file (and b	v the USPTO to

process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

	<u>ed States Patent a</u>	and Trademark Office	UNITED STATES DEPAR United States Patent and Address: COMMISSIONER F P.O. Box 1450 Alexandria, Virginia 22: www.uspto.gov	FOR PATENTS
APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
12/492,512	06/26/2009	Amr Salahieh	\$63.2Q-15141-U\$03	7439
VIDAS, ARRE	490 7590 04/08/2011 VIDAS, ARRETT & STEINKRAUS, P.A. SUITE 400, 6640 SHADY OAK ROAD			IINER ER, ANN M
EDEN PRAIRI	ie, MN 55344		ART UNIT	PAPER NUMBER
			3774	
			MAIL DATE	DELIVERY MODE
			04/08/2011	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)			
	12/492,512	SALAHIEH ET AL.			
Office Action Summary	Examiner	Art Unit			
	ANN SCHILLINGER	3774			
The MAILING DATE of this communication ap Period for Reply	pears on the cover sheet wit	h the correspondence address			
 A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING D Extensions of time may be available under the provisions of 37 CFR 1. after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period Failure to reply within the set or extended period for reply will, by statut Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b). 	DATE OF THIS COMMUNIC 136(a). In no event, however, may a re will apply and will expire SIX (6) MONT e, cause the application to become ABA	ATION. ply be timely filed HS from the mailing date of this communication. NDONED (35 U.S.C. § 133).			
Status					
1) Responsive to communication(s) filed on <u>07 J</u>	lanuary 2011.				
2a) This action is FINAL . 2b) This	s action is non-final.				
3) Since this application is in condition for allowa	•	-			
closed in accordance with the practice under	<i>Ex parte Quayle</i> , 1935 C.D.	11, 453 O.G. 213.			
Disposition of Claims					
4) Claim(s) $1-7$ is/are pending in the application.					
4a) Of the above claim(s) is/are withdra	wn from consideration.				
5) Claim(s) is/are allowed.					
6) Claim(s) <u>1-7</u> is/are rejected.					
7) Claim(s) is/are objected to.					
8) Claim(s) are subject to restriction and/o	or election requirement.				
Application Papers					
9) The specification is objected to by the Examine	er.				
10) The drawing(s) filed on is/are: a) acc	cepted or b) displayed to b	y the Examiner.			
Applicant may not request that any objection to the					
Replacement drawing sheet(s) including the correct					
11) The oath or declaration is objected to by the E	xaminer. Note the attached	Office Action or form PTO-152.			
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreigr	n priority under 35 U.S.C. §	119(a)-(d) or (f).			
a) All b) Some * c) None of:					
1. Certified copies of the priority documen					
2. Certified copies of the priority documen	•	·			
3. Copies of the certified copies of the pric	•	eceived in this National Stage			
application from the International Burea * See the attached detailed Office action for a list		eceived			
Attachment(s)					
Attachment(s) 1) Notice of References Cited (PTO-892)	4) 🗍 Interview Si	ummary (PTO-413)			
2) D Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)	/Mail Date			
3) Information Disclosure Statement(s) (PTO/SB/08) 5) Notice of Informal Patent Application Paper No(s)/Mail Date 6) Other:					
U.S. Patent and Trademark Office					
	action Summary s Corporation, et al. Exl	Part of Paper No./Mail Date 20110329 nibit 1102, Page 221 of 442			

Office Action Summary	Part of Paper No./Mail L
Edwards Lifesciences Corporation, et al	. Exhibit 1102, Page 221

DETAILED ACTION

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-7 are rejected under 35 U.S.C. 102(b) as being anticipated by Bailey et al. (US

Pub. No. 2001/0021872). Bailey et al. discloses the following regarding claim 1: a system for replacing a heart valve, comprising: an expandable anchor (12) having a collapsed delivery configuration and an expanded configuration (para. 0021); a replacement valve commissure support element (24) attached to the expandable anchor; a commissure portion of a replacement valve leaflet (26) attached to the commissure support element (Fig. 2); and a seal at least partially disposed around an exterior portion of the expandable anchor when the anchor is in the expanded configuration, wherein the seal is adapted to prevent blood from flowing between the seal and heart tissue, wherein a distal end of the replacement valve leaflet is attached to the seal (Fig. 4; paras. 0021-0022, 0049).

Bailey et al. discloses the following regarding claim 2: the system of claim 1 wherein the expandable anchor is not attached to the replacement valve leaflet (Fig. 2).

Bailey et al. discloses the following regarding claim 3: the system of claim 1 wherein the distal end of the replacement valve leaflet is attached to a distal end of the seal when the expandable anchor is in the expanded configuration (Figs. 1, 13).

Application/Control Number: 12/492,512 Art Unit: 3774

Bailey et al. discloses the following regarding claim 4: the system of claim 1 wherein the commissure support element is configured to interface with an anchor actuator (13).

Bailey et al. discloses the following regarding claim 5: the system of claim 4 wherein the anchor actuator is adapted to apply a proximally directed force on the commissure support element to foreshorten the expandable anchor (paras. 0050, 0051).

Please note that language such as "configured to/for" and "adapted to/for" is functional language. The functional language of the claims has been considered to the extent that it further defines the structure of the claimed device.

Bailey et al. discloses the following regarding claim 6: the system of claim 1 further comprising a lock comprising a first lock element and a second lock element (anchoring flanges, shown in element 22), wherein the first and second lock elements are attached to the expandable anchor and adapted to engage with one another to lock the expandable anchor in the expanded configuration, and wherein the commissure support element includes the first lock element.

Bailey et al. discloses the following regarding claim 7: the system of claim 6 wherein the second lock element is attached to the expandable anchor and is disposed proximal to the first lock element when the expandable anchor is in the collapsed configuration within a delivery catheter (Figs. 1-2; para. 0022).

Response to Arguments

Applicant's arguments filed 3/7/2011 have been fully considered but they are not persuasive. The Applicant contends that Bailey et al. does not disclose a seal at least partially disclosed around the exterior of the anchor. The examiner respectfully disagrees. Bailey et al. describes in paragraph 0049 that the device may have an outer graft member that is disposed

Application/Control Number: 12/492,512 Art Unit: 3774

around an exterior portion of the anchor. Examiner maintains that the graft member may be broadly construed as providing a sealing function i.e. will act as a seal when the device is expanded to be flush against vessel walls (paragraphs 0021-0022). When the device is expanded it will force the blood to flow through the valve, and will not allow the blood to leak past the sides of the device between the outer graft member and the vessel walls.

Conclusion

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to ANN SCHILLINGER whose telephone number is (571)272-6652. The examiner can normally be reached on Mon. thru Fri. 9 a.m. to 4 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, David Isabella can be reached on (571) 272-4749. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 12/492,512 Art Unit: 3774

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

> /DAVID ISABELLA/ Supervisory Patent Examiner, Art Unit 3774

/A. S./ Examiner, Art Unit 3774

	Application/Control No.	Applicant(s)/Patent Under Reexamination
Search Notes	12492512	SALAHIEH ET AL.
	Examiner	Art Unit
	ANN SCHILLINGER	3774

	SEARCHED		
Class	Subclass	Date	Examiner

SEARCH NOTES	6	
Search Notes	Date	Examiner
Updated prior search	3/29/2011	AS

	INTERFERENCE SEARCH	1	
Class	Subclass	Date	Examiner

/A. S./ Examiner.Art Unit 3774	

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	Ulrich R. Haug, Hans F. Valencia, Robert A. Geshlider, Tom Saul, Amr Salahieh, Dwight P.
	Morejohn, Kenneth J. Michlitsch
Application No.:	12/492512
Filed:	June 26, 2009
For:	Everting Heart Valve
Examiner:	Ann M. Schillinger
Group Art Unit:	3774

Mail Stop <u>AF</u> Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Docket No.: S63.2Q-15141-US03

AMENDMENT AFTER FINAL AND REQUEST FOR RECONSIDERATION

In response to the Final Office Action dated **April 8, 2011**, the period of response for which runs through July 2011, please amend the application.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks begin on page 5 of this paper.

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of the Claims:

Claim 1 (Currently Amended): A system for replacing a heart valve, comprising:

an expandable anchor having a collapsed delivery configuration and an expanded configuration;

a replacement valve commissure support element attached to the expandable anchor;

a commissure portion of a replacement valve leaflet attached to the commissure support element; and

a seal at least partially disposed around an exterior portion of the expandable anchor when the anchor is in the expanded configuration, wherein the seal is adapted to prevent blood from flowing between the seal and heart tissue, <u>wherein the seal comprises an expandable foam</u> <u>disposed around a circumference of a wire, and</u>

wherein a distal end of the replacement valve leaflet is attached to the seal. Claim 2 (Original): The system of claim 1 wherein the expandable anchor is not attached to the replacement valve leaflet.

Claim 3 (Original): The system of claim 1 wherein the distal end of the replacement valve leaflet is attached to a distal end of the seal when the expandable anchor is in the expanded configuration.

Claim 4 (Original): The system of claim 1 wherein the commissure support element is configured to interface with an anchor actuator.

Claim 5 (Original): The system of claim 4 wherein the anchor actuator is adapted to apply a proximally directed force on the commissure support element to foreshorten the expandable anchor.

Claim 6 (Original): The system of claim 1 further comprising a lock comprising a first lock element and a second lock element, wherein the first and second lock elements are attached to the expandable anchor and adapted to engage with one another to lock the expandable anchor in the expanded configuration, and

wherein the commissure support element includes the first lock element.

Claim 7 (Original): The system of claim 6 wherein the second lock element is attached to the expandable anchor and is disposed proximal to first lock element when the expandable anchor is in the collapsed configuration within a delivery catheter.

Claim 8 (New): The system of claim 1, wherein the seal has a compressed state and a deployed state, and wherein in the compressed state, the seal further comprises a dissolvable coating disposed about the foam.

Claim 9 (New): A system for replacing a heart valve, comprising:

an expandable anchor having a collapsed delivery configuration and an expanded configuration;

a replacement valve commissure support element attached to the expandable anchor;

a commissure portion of a replacement valve leaflet attached to the commissure support element; and

a <u>fabric</u> seal at least partially disposed around an exterior portion of the expandable anchor when the anchor is in the expanded configuration, wherein the seal is adapted to prevent blood from flowing between the seal and heart tissue, <u>wherein the fabric seal has an undeployed state</u> <u>and a deployed state</u>, <u>wherein in the deployed state the fabric seal comprises flaps that extend into</u> <u>spaces formed by native valve leaflets, and</u>

wherein a distal end of the replacement valve leaflet is attached to the seal.

Claim 10 (New): A system for replacing a heart valve, comprising:

an expandable anchor having a collapsed delivery configuration and an expanded configuration;

a replacement valve commissure support element attached to the expandable anchor;

a commissure portion of a replacement valve leaflet attached to the commissure support element; and

a seal at least partially disposed around an exterior portion of the expandable anchor when the anchor is in the expanded configuration, wherein the seal is adapted to prevent blood from flowing between the seal and heart tissue, wherein the seal comprises at least one sac disposed about the exterior of the anchor, and

wherein a distal end of the replacement valve leaflet is attached to the seal.

Claim 11 (New): The system of claim 10, wherein the at least one sac is filled with a substance selected from the group consisting of water, blood, foam, and hydrogel.

Claim 12 (New): The system of claim 10, wherein the at least one sac comprises a first discrete sac and a second discrete sac, the first sac and the second sac being disposed at different positions along a height of the anchor.

Claim 13 (New): The system of claim 10, wherein the at least one sac comprises a first discrete cylindrical sac and a second discrete cylindrical sac, the first sac and the second sac being disposed at different positions along a height of the anchor.

Claim 14 (New): The system of claim 10, wherein the at least one sac comprises a single cylindrical sac that is disposed at different positions along a height of the anchor.

Claim 15 (New): The system of claim 10, wherein the at least one sac comprises a single sac that is disposed in a spiral along a height of the anchor.

REMARKS

This Amendment is responsive to the Final Office Action dated **April 8, 2011**. Applicant has amended claim 1 and added new claims 8-15. No new matter has been added. Claims 1-15 are pending upon entry of this Amendment.

Applicant respectfully requests that the Amendment be entered as it is believed to place the application in condition for allowance or better form for appeal.

Claim Rejections—35 U.S.C. § 102

In the Office Action, the Office rejected claims 1-7 under 35 U.S.C. § 102(b) as being anticipated by U.S. Patent Application Publication No. 2001/0021872 to Bailey et al. ("Bailey"). Applicant respectfully traverses the rejection to the extent such rejection is considered applicable to the amended claims.

In the Office Action, the Office indicated¹ that Bailey discloses a seal at least partially disposed around an exterior portion of the expandable anchor when the anchor is in the expanded configuration, wherein the seal is adapted to prevent blood from flowing between the seal and heart tissue, as required by claim 1 as presented previously. In the Response to Arguments section of the Office Action, the Office indicated² that the "graft member [of Bailey] may be broadly construed as providing a sealing function i.e. will act as a seal when the device is expanded to be flush against vessel walls (paragraphs 0021-0022)." Although Applicant disagrees with this assertion, Applicant has nevertheless amended claim 1 to further define claim 1 over Bailey. Amended claim 1 recites the following features:

A system for replacing a heart valve, comprising: an expandable anchor having a collapsed delivery configuration and an expanded configuration; a replacement valve commissure support element attached to the expandable anchor; a commissure portion of a replacement valve leaflet attached to the commissure support element; and a seal at least partially disposed around an exterior portion of the expandable anchor when the anchor is in the expanded configuration, wherein the seal is adapted to prevent blood from

¹ Office Action, dated April 8, 2011, page 2.

 $^{^{2}}$ Id. at page 4.

flowing between the seal and heart tissue, wherein the seal comprises an expandable foam disposed around a circumference of a wire, and

wherein a distal end of the replacement valve leaflet is attached to the seal.

Support for the amendment may be found throughout Applicant's disclosure, including, for example, Applicant's specification at paragraph [0111] and FIGS. 27-31.

Bailey fails to disclose or suggest a seal that comprises an expandable foam disposed around a circumference of a wire, particular in combination with the other features recited in amended claim 1. That is, even if the graft of Bailey is considered to be a seal,³ the graft does not comprise an expandable foam disposed around a circumference of a wire, as required by amended claim 1. Rather, Bailey discloses the following with respect to graft 11:

The graft member 11 is preferably made of biologically-derived membranes or biocompatible synthetic materials such as DACRON or expanded polytetrafluoroethylene.⁴

In accordance with one embodiment of the present invention, the graft member 11 consists of an outer or ablumenal graft member 11a and an inner or lumenal graft member 11b. The outer graft member 11a encloses at least a portion of the ablumenal surface of the intermediate annular section 20 of the stent body member, while the inner graft member 11b is coupled, on the lumenal surface of the intermediate annular section 20 of the stent body member 12, to the outer graft member 11a through the interstices 14 of the stent body member.⁵

Biocompatible synthetic materials such as DACRON or expanded polytetrafluoroethylene, however, are not examples of expandable foam, as required by amended claim 1. In addition, enclosing at least a portion of the ablumenal surface of intermediate annular section 20 of stent body member 12 and coupling inner graft member 11a and outer graft member 11b through the interstices 14 of the stent body member does not amount to a seal that comprises an expandable foam disposed around a circumference of a wire, as required by amended claim 1. As such, Bailey fails to disclose all the features of amended claim 1.

³ As asserted by the Office, and not agreed to be Applicant.

⁴ Bailey, paragraph [0048].

Application No. 12/492512 Page 7

Consequently, claim 1 is novel over Bailey. Claims 2-8 depend from independent claim 1. At least by virtue of their dependency, claims 2-8 are also novel over Bailey. Applicant respectfully requests that the rejection be withdrawn and that claims 1-8 be allowed.

New Claims:

Applicant has added new claims 8-15 to the pending application. No new matter has been added. The applied reference fails to disclose all the features recited in Applicant's new claims, and provide no apparent reason for modification to include such features.

Support for new claim 8 may be found at least at paragraph [0111] and FIGS. 27-31 of Applicant's disclosure. Support for new claim 9 may found at least at paragraph [0112] and FIGS. 32-34 of Applicant's disclosure. Support for new claims 10-15 may be found at least at paragraphs [0102]-[0104] and FIGS. 14-16C.

⁵ *Id.* at paragraph [0049].

CONCLUSION

In light of the amendments contained herein, Applicants submit that the application is in condition for allowance, for which early action is requested.

If an extension of time is required to make this response timely and no separate petition is enclosed, Applicants hereby petition for an extension of time sufficient to make the response timely. In the event that this response requires the payment of government fees and payment is not enclosed, please charge Deposit Account No. 22-0350.

Respectfully submitted,

VIDAS, ARRETT & STEINKRAUS

Date: May 2, 2011

By: /James L. Shands/ James L. Shands Registration No.: 54439

6640 Shady Oak Rd., Suite 400 Eden Prairie, MN 55344-7834 Telephone: (952) 563-3000 Facsimile: (952) 563-3001 f:\wpwork\jls\15141us03\15141us03_amd_20110502.doc

Electronic Ac	Electronic Acknowledgement Receipt						
EFS ID:	10000270						
Application Number:	12492512						
International Application Number:							
Confirmation Number:	7439						
Title of Invention:	Everting Heart Valve						
First Named Inventor/Applicant Name:	Amr Salahieh						
Customer Number:	00490						
Filer:	James Lee Shands/Samantha Painschab						
Filer Authorized By:	James Lee Shands						
Attorney Docket Number:	S63.2Q-15141-US03						
Receipt Date:	02-MAY-2011						
Filing Date:	26-JUN-2009						
Time Stamp:	16:19:47						
Application Type:	Utility under 35 USC 111(a)						

Payment information:

Submitted with F	Payment	no					
File Listing:							
Document Number	Document Description		File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)	
1	Transmittal Letter		141US03_tra_20110502.pdf	80141	no	1	
I			1410303_da_20110302.pdf	28e25b70347feddfa47ace0ca9e9c5636203 68bc	110		
Warnings:							
Information:	Edwards Lifes	cienc	es Corporation, et al	Exhibit 1102, Pag	e 235 of 4	42	

2		15141US03_amd_20110502.	113597	yes	8
		pdf	3ff7da43f9fe3061a7dd514ffd8ff858f08223 3e	yes	0
	Multip	oart Description/PDF files in a	zip description		
	Document De	Document Description			
	Amendment A	Amendment After Final			
	Claims	Claims			
	Amendment/Req. Reconsiderati	5	٤	3	
Warnings:			· · · · · ·		
Information:			1		
		Total Files Size (in bytes)	: 19	93738	
lf a new applic 1.53(b)-(d) and	ons Under 35 U.S.C. 111 cation is being filed and the applica d MPEP 506), a Filing Receipt (37 CF ment Receipt will establish the filin e of an International Application ur	R 1.54) will be issued in due			

In re Application of:	Ulrich R. Haug, Hans F. Valencia, Robert A. Geshlider, Tom Saul, Amr Salahieh, Dwight P. Morejohn, Kenneth J. Michlitsch
Application No.:	12/492512
Filed:	June 26, 2009
For:	Everting Heart Valve
Group Art Unit:	3774

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Docket No.: S63.2Q-15141-US03

TRANSMITTAL LETTER

1. In regard to the above-identified application, in addition to this **1** page transmittal letter, we are submitting the attached:

8 page Amendment After Final and Request for Reconsideration.

2. With respect to fees, applicant believes the fees required herein, if any, are being paid electronically.

3. CONDITIONAL PETITION FOR EXTENSION OF TIME

- This conditional petition is being filed along with the papers identified in Item 1 above and provides for the possibility that Applicant has inadvertently overlooked the need for a petition and fee for extension of time or for a petition and fee for any other matter petitionable to the Commissioner as required. If any extension of time for the accompanying response is required or if a petition for any other matter is required, by petitioner, Applicant requests that this be considered a petition therefor.
- 4. Notwithstanding paragraph 2 above, if any additional fees associated with this communication are required and have not otherwise been paid, including any fee associated with the Conditional Petition for Extension of Time, or any request in the accompanying papers for action which requires a fee as a petition to the Commissioner, please charge the additional fees to Deposit Account No. 22-0350. Please charge any additional fees associated with this communication to the Deposit Account No. 22-0350.
- 5. **Certification:** I hereby certify that this Transmittal Letter and the paper(s) as described herein are being transmitted electronically to the USPTO on May 2, 2011.

Respectfully submitted,

VIDAS, ARRETT & STEINKRAUS

Date: May 2, 2011

By: /James L. Shands/

James L. Shands Registration No.: 54439

6640 Shady Oak Rd., Suite 400 Eden Prairie, MN 55344-7834 Telephone: (952) 563-3000 Facsimile: (952) 563-3001 f:\wpwork\jls\15141us03_tra_20110502.doc

PTO/SB/06 (07-06)

Approved for use through 1/31/2007. OMB 0651-0032

P/	Under the Par		E DETI	ERMINATION		id to	a collection c pplication or I		ss it dis Fil		To be Mailed
	AF	PLICATION	AS FILE (Column 1		Column 2)		SMALL		OR		HER THAN LL ENTITY
	FOR	FOR NUMBER FILED NUMBER EXTRA			RATE (\$)	FEE (\$)		RATE (\$)	FEE (\$)		
	BASIC FEE (37 CFR 1.16(a), (b), (or (c))	N/A		N/A		N/A			N/A	
	SEARCH FEE (37 CFR 1.16(k), (i), c	or (m))	N/A N/A		N/A		N/A			N/A	
	EXAMINATION FE (37 CFR 1.16(o), (p), o		N/A		N/A		N/A			N/A	
(37 (AL CLAIMS CFR 1.16(i))		mir	nus 20 = *			X \$ =		OR	X \$ =	
	EPENDENT CLAIM CFR 1.16(h))	S	m	inus 3 = *			X \$ =			X \$ =	
(APPLICATION SIZE 37 CFR 1.16(s)) MULTIPLE DEPEN	FEE she add 35 l	ets of pap 250 (\$125 itional 50 s J.S.C. 41(ation and drawing er, the applicatio for small entity) sheets or fraction a)(1)(G) and 37	n size fee due for each n thereof. See						
_	he difference in colu						TOTAL			TOTAL	
				DED – PART II (Column 2)	(Column 3)			L ENTITY	OR	OTHE	ER THAN LL ENTITY
AMENDMENT	05/02/2011	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA		RATE (\$)	ADDITIONAL FEE (\$)		RATE (\$)	ADDITIONAL FEE (\$)
OME	Total (37 CFR 1.16(i))	* 15	Minus	** 20	= 0		X \$ =		OR	X \$52=	0
IN I	Independent (37 CFR 1.16(h))	* 3	Minus	***3	= 0		X \$ =		OR	X \$220=	0
AME	Application Si	ze Fee (37 CFR	1.16(s))								
1		ITATION OF MULT	IPLE DEPEN	DENT CLAIM (37 CFI	R 1.16(j))				OR		
						•	TOTAL ADD'L FEE		OR	TOTAL ADD'L FEE	0
		(Column 1)		(Column 2)	(Column 3)				-	-	
L		CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA		RATE (\$)	ADDITIONAL FEE (\$)		RATE (\$)	ADDITIONAL FEE (\$)
ENT	Total (37 CFR 1.16(i))	*	Minus	**	=		X \$ =		OR	X \$ =	
NO	Independent (37 CFR 1.16(h))	*	Minus	***	=		X \$ =		OR	X \$ =	
IEN	Application Si	ze Fee (37 CFR	1.16(s))								
AM		ITATION OF MULT	IPLE DEPEN	DENT CLAIM (37 CFI	R 1.16(j))				OR		
	he entry in column ⁻ the "Highest Numbe							nstrument Ex		TOTAL ADD'L FEE er:	
	the "Highest Numbe f the "Highest Numb					•	/NINA F	ATANAVON	G/		
The	"Highest Number P	reviously Paid F	or" (Total or	Independent) is th	e highest number f						
This c	ollection of informat	ion is required b	/ 37 CFR 1.	16. The informatio	n is required to obt	ain d	or retain a ber	efit by the public	which is	to file (and b	y the USPTO to

process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

	<u>ed States Patent a</u>	and Trademark Office	UNITED STATES DEPAR United States Patent and Address: COMMISSIONER F P.O. Box 1450 Alexandria, Virginia 223 www.uspto.gov	FOR PATENTS
APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
12/492,512	06/26/2009 Amr Salahieh		\$63.2Q-15141-U\$03	7439
VIDAS, ARRE	7590 05/19/2011 CTT & STEINKRAUS, P.A 40 SHADY OAK ROAD	EXAM		
EDEN PRAIRI			ART UNIT	PAPER NUMBER
			3774	
			MAIL DATE	DELIVERY MODE
			05/19/2011	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)					
Advisory, Astist							
Advisory Action	12/492,512	SALAHIEH ET AL.					
Before the Filing of an Appeal Brief	Examiner	Art Unit					
	ANN SCHILLINGER	3774					
The MAILING DATE of this communication appe	ears on the cover sheet with the o	correspondence add	ress				
 THE REPLY FILED <u>02 May 2011</u> FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. 1. ☐ The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time periods: a) ☐ The period for reply expiresmonths from the mailing date of the final rejection. b) ☑ The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS form the mailing date of the final rejection. Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final rejection, even if timely filed, may reduce any earned patent term adjustment. Sea 37 CFR 1.704(b). NOTICE OF APPEAL 2. ☐ The Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since a Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since a Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since a Notice of Appeal (37 CF							
 (b) They raise the issue of new matter (see NOTE belown (c) They are not deemed to place the application in be appeal; and/or (d) They present additional claims without canceling a NOTE: <u>See Continuation Sheet</u>. (See 37 CFR 1.1 	tter form for appeal by materially re corresponding number of finally rej		he issues for				
4. 🔲 The amendments are not in compliance with 37 CFR 1.1	21. See attached Notice of Non-Co	ompliant Amendment (PTOL-324).				
5. Applicant's reply has overcome the following rejection(s)							
 Newly proposed or amended claim(s) would be a non-allowable claim(s). 	llowable if submitted in a separate,	timely filed amendme	nt canceling the				
 non-allowable claim(s). 7. For purposes of appeal, the proposed amendment(s): a) will not be entered, or b) will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended. The status of the claim(s) is (or will be) as follows: Claim(s) allowed: Claim(s) objected to: Claim(s) withdrawn from consideration: 							
AFFIDAVIT OR OTHER EVIDENCE							
 The affidavit or other evidence filed after a final action, bubecause applicant failed to provide a showing of good an was not earlier presented. See 37 CFR 1.116(e). 	It before or on the date of filing a N d sufficient reasons why the affidav	otice of Appeal will <u>no</u> /it or other evidence is	<u>t</u> be entered necessary and				
 9. The affidavit or other evidence filed after the date of filing a Notice of Appeal, but prior to the date of filing a brief, will <u>not</u> be entered because the affidavit or other evidence failed to overcome <u>all</u> rejections under appeal and/or appellant fails to provide a showing a good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.33(d)(1). 10. The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached. <u>REQUEST FOR RECONSIDERATION/OTHER</u> 							
11. 🗌 The request for reconsideration has been considered but does NOT place the application in condition for allowance because:							
12. ☐ Note the attached Information <i>Disclosure Statement</i> (s). (PTO/SB/08) Paper No(s) 13. ☐ Other:							
/DAVID ISABELLA/ Supervisory Patent Examiner, Art Unit 3774	/A. S./ Examiner, Art Unit 3774						
U.S. Patent and Trademark Office							

Continuation of 3. NOTE: Amended independent claim 1 now requires a seal having an expandable foam disposed around a wire. New claim 9 requires a fabric seal wherein the fabric seal comprises flaps. These new limitations necessitate further search and consideration.

PATENT

DO NOT ENTER: /A.S./ 05/15/2011

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	Ulrich R. Haug, Hans F. Valencia, Robert A. Geshlider, Tom Saul, Amr Salahieh, Dwight P.
	Morejohn, Kenneth J. Michlitsch
Application No.:	12/492512
Filed:	June 26, 2009
For:	Everting Heart Valve
Examiner:	Ann M. Schillinger
Group Art Unit:	3774

Mail Stop <u>AF</u> Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Docket No.: S63.2Q-15141-US03

AMENDMENT AFTER FINAL AND REQUEST FOR RECONSIDERATION

In response to the Final Office Action dated **April 8, 2011**, the period of response for which runs through July 2011, please amend the application.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks begin on page 5 of this paper.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

REQUEST FOR CONTINUED EXAMINATION(RCE)TRANSMITTAL (Submitted Only via EFS-Web)									
Application Number	12492512	Filing Date	2009-06-26	Docket Number (if applicable)	S63.2-15141-US03	Art Unit	3774		
First Named Inventor	Ulrich R. Haug	·		Examiner Name	Ann M. Schillinger	·	•		
This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application. Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. The Instruction Sheet for this form is located at WWW.USPTO.GOV									
	SUBMISSION REQUIRED UNDER 37 CFR 1.114								
in which they	were filed unless	applicant ins		applicant does not wi	nents enclosed with the RCE w sh to have any previously filed				
EX Previously submission	y submitted. If a fi on even if this box	inal Office action is not check	ction is outstanding, a ked.	any amendments file	d after the final Office action n	ay be cor	isidered as a		
□ Co	nsider the argum	ents in the A	ppeal Brief or Reply	Brief previously filed	on				
🗌 Ott	ner								
Enclosed									
🗌 An	nendment/Reply								
🗌 Info	ormation Disclosu	ire Statemer	nt (IDS)						
🗌 Aff	idavit(s)/ Declarat	tion(s)							
🗌 Oti	her								
			MIS	CELLANEOUS					
			ntified application is a d 3 months; Fee und		CFR 1.103(c) for a period of n quired)	nonths _			
Other									
				FEES					
 The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed. The Director is hereby authorized to charge any underpayment of fees, or credit any overpayments, to Deposit Account No 220350 									
		SIGNATUR	RE OF APPLICAN	Γ, ATTORNEY, OF	AGENT REQUIRED				
	Practitioner Sign	ature							
Applica	ant Signature								

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Signature of Registered U.S. Patent Practitioner							
Signature	/James L. Shands/	Date (YYYY-MM-DD)	2011-06-10				
Name	James L. Shands	Registration Number	54439				

This collection of information is required by 37 CFR 1.114. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
- 2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- 3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- 5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- 6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
- 9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Electronic Patent Application Fee Transmittal						
Application Number:	12	492512				
Filing Date:	26	-Jun-2009				
Title of Invention:	Everting Heart Valve					
First Named Inventor/Applicant Name:	Amr Salahieh					
Filer:	Jar	nes Lee Shands/Sar	nantha Painscha	ab		
Attorney Docket Number:	S6.	3.2Q-15141-US03				
Filed as Large Entity						
Utility under 35 USC 111(a) Filing Fees						
Description		Fee Code	Quantity	Amount	Sub-Total in USD(\$)	
Basic Filing:						
Pages:						
Claims:						
Miscellaneous-Filing:						
Petition:						
Patent-Appeals-and-Interference:						
Post-Allowance-and-Post-Issuance:						
Extension-of-Time:	_					

Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Miscellaneous:				
Request for continued examination	1801	1	810	810
	Tot	810		

Electronic Acknowledgement Receipt					
EFS ID:	10278438				
Application Number:	12492512				
International Application Number:					
Confirmation Number:	7439				
Title of Invention:	Everting Heart Valve				
First Named Inventor/Applicant Name:	Amr Salahieh				
Customer Number:	00490				
Filer:	James Lee Shands/Samantha Painschab				
Filer Authorized By:	James Lee Shands				
Attorney Docket Number:	S63.2Q-15141-US03				
Receipt Date:	10-JUN-2011				
Filing Date:	26-JUN-2009				
Time Stamp:	14:12:38				
Application Type:	Utility under 35 USC 111(a)				

Payment information:

Submitted wi	th Payment	yes						
Payment Type	2	Credit Card						
Payment was	successfully received in RAM	\$810						
RAM confirmation Number		302	302					
Deposit Acco	unt							
Authorized Us	ser							
File Listing:								
Document Number	Document Description Edwards Lifescie	nces Corporation, et al. 1	File Size(Bytes)/ E Meibit glel DigePr ag	Multi çe P 2a18/02fip 1	Pages 4 2 if appl.)			

1	Transmittal Letter	15141US03_tra_20110610.pdf	79750	no	1
			1397b41c5562e1790e2b27eec0d87406f33 37d2c		
Warnings:					
Information					
2	Request for Continued Examination	15141US03_RCE_20110610.pdf	697848	no	3
	(RCE)		07bea7bee7d627ae7f222912d3ce2a8e8a7 cd36d		
Warnings:					
Information				_	
3	Fac Warkshart (SPOG)	foo info ndf	30098	20	2
5	Fee Worksheet (SB06)	fee-info.pdf	94fac370cca50d3764871e27de044811923 6b316	no	2
Warnings:					
Information	:		1		
		Total Files Size (in bytes)	8	07696	
characterize	ledgement Receipt evidences receip d by the applicant, and including pag described in MPEP 503.	•			
	tions Under 35 U.S.C. 111				
	lication is being filed and the applica nd MPEP 506), a Filing Receipt (37 CF				
	ement Receipt will establish the filin				
lf a timely su U.S.C. 371 ar	ge of an International Application ur Ibmission to enter the national stage nd other applicable requirements a F ge submission under 35 U.S.C. 371 wi	of an international applicati orm PCT/DO/EO/903 indicati	ng acceptance of the	application	
	tional Application Filed with the USP				_
an internatio and of the In	rnational application is being filed an onal filing date (see PCT Article 11 an ternational Filing Date (Form PCT/RG urity, and the date shown on this Ack ion.	d MPEP 1810), a Notification D/105) will be issued in due c	of the International ourse, subject to pres	Application scriptions c	Number oncerning
L					

In re Application of:	Ulrich R. Haug, Hans F. Valencia, Robert A. Geshlider, Tom Saul, Amr Salahieh, Dwight P. Morejohn, Kenneth J. Michlitsch
Application No.: Filed: For:	12/492512 June 26, 2009 Everting Heart Valve
Group Art Unit:	3774
Commissioner for Patents	Docket No.: S63.2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

P.O. Box 1450 Alexandria, VA 22313-1450)-15141-US03

TRANSMITTAL LETTER

1. In regard to the above-identified application, in addition to this 1 page transmittal letter, we are submitting the attached:

3 page Request for Continued Examination.

2. With respect to fees, applicant believes the fees required herein, if any, are being paid electronically.

3. **CONDITIONAL PETITION FOR EXTENSION OF TIME**

- This conditional petition is being filed along with the papers identified in Item 1 above and provides for the possibility that Applicant has inadvertently overlooked the need for a petition and fee for extension of time or for a petition and fee for any other matter petitionable to the Commissioner as required. If any extension of time for the accompanying response is required or if a petition for any other matter is required, by petitioner, Applicant requests that this be considered a petition therefor.
- Notwithstanding paragraph 2 above, if any additional fees associated with this communication are 4. required and have not otherwise been paid, including any fee associated with the Conditional Petition for Extension of Time, or any request in the accompanying papers for action which requires a fee as a petition to the Commissioner, please charge the additional fees to Deposit Account No. 22-0350. Please charge any additional fees associated with this communication to the Deposit Account No. 22-0350.
- 5. Certification: I hereby certify that this Transmittal Letter and the paper(s) as described herein are being transmitted electronically to the USPTO on June 10, 2011.

Respectfully submitted,

VIDAS, ARRETT & STEINKRAUS

Date: June 10, 2011

/James L. Shands/ By:____

James L. Shands Registration No.: 54439

6640 Shady Oak Rd., Suite 400 Eden Prairie, MN 55344-7834 Telephone: (952) 563-3000 Facsimile: (952) 563-3001 f:\wpwork\jls\15141us03 tra 20110610.doc

PTO/SB/06 (07-06)

Approved for use through 1/31/2007. OMB 0651-0032 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

P	Under the Par		E DET	RMINATION		d to	a collection c pplication or I		ss it dis Fili		DMB control number.
	AF	PLICATION	AS FILE (Column 1		Column 2)		SMALL		OR		HER THAN LL ENTITY
	FOR	N	UMBER FIL	.ED NUI	MBER EXTRA		RATE (\$)	FEE (\$)		RATE (\$)	FEE (\$)
	BASIC FEE (37 CFR 1.16(a), (b), (or (c))	N/A		N/A		N/A			N/A	
	SEARCH FEE (37 CFR 1.16(k), (i), c	or (m))	N/A		N/A		N/A			N/A	
	EXAMINATION FE (37 CFR 1.16(o), (p), (N/A		N/A		N/A			N/A	
(37 (AL CLAIMS CFR 1.16(i))		min	us 20 = *			X \$ =		OR	X \$ =	
	EPENDENT CLAIM CFR 1.16(h))	S	mi	nus 3 = *			X \$ =			X \$ =	
(APPLICATION SIZE 37 CFR 1.16(s))	FEE shee is \$2 addi 35 L	ts of pape 50 (\$125 tional 50 s .S.C. 41(a	ation and drawing er, the application for small entity) sheets or fraction a)(1)(G) and 37	n size fee due for each n thereof. See						
	MULTIPLE DEPEN						TOTAL			TOTAL	
^ IT L	he difference in colu						TOTAL			TOTAL	
	APPI	(Column 1)	AMEND	ED — PART II (Column 2)	(Column 3)		SMAL	L ENTITY	OR		ER THAN LL ENTITY
AMENDMENT	06/10/2011	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA		RATE (\$)	ADDITIONAL FEE (\$)		RATE (\$)	ADDITIONAL FEE (\$)
OME	Total (37 CFR 1.16(i))	* 15	Minus	** 20	= 0		X \$ =		OR	X \$52=	0
	Independent (37 CFR 1.16(h))	* 3	Minus	***3	= 0		X \$ =		OR	X \$220=	0
AMI	Application Si	ze Fee (37 CFR ·	.16(s))								
	FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))								OR		
							TOTAL ADD'L FEE		OR	TOTAL ADD'L FEE	0
		(Column 1)		(Column 2)	(Column 3)					•	
L		CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA		RATE (\$)	ADDITIONAL FEE (\$)		RATE (\$)	ADDITIONAL FEE (\$)
ENT	Total (37 CFR 1.16(i))	*	Minus	**	=		X \$ =		OR	X \$ =	
IMO	Independent (37 CFR 1.16(h))	*	Minus	***	=		X \$ =		OR	X \$ =	
ENDM	Application Si	ze Fee (37 CFR ·	.16(s))								
AM	FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))							OR			
				0			TOTAL ADD'L FEE		OR	TOTAL ADD'L FEE	
** lf	he entry in column ⁻ the "Highest Numbe ⁻ the "Highest Numb	er Previously Paid	For" IN TH	IIS SPACE is less	than 20, enter "20"			NSTRUMENT EX WASHINGTO		er:	
	"Highest Number P					ound	d in the appro	priate box in colu	mn 1.		
This c	ollection of informat	ion is required by	37 CFR 1.		n is required to obta		or retain a ber	nefit by the public	which is	s to file (and b	y the USPTO to

process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

	Application Number	12/492,512
	Filing Date	6/26/2009
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	Ulrich R. Haug
	Art Unit	3774
	Client Number	BostonScientificScimedInc.
Page 1 of 14	Matter Number	S63.2-15141-US03

U.S. PATENT DOCUMENTS						
Initials	Cite No.	Document Number	Issue/Publication Date	First Named Inventor	Т	
	1	0015192	6/24/1856	F. Peale		
	2	20010002445	5/31/2001	Vesely		
	3	20010007956	7/12/2001	Letac et al.		
	4	20010010017	7/26/2001	Letac et al		
	5	20010025196	9/27/2001	Chinn et al.		
	6	20010032013	10/18/2001	Marton		
	7	20020029014	3/7/2002	Jayaraman		
	8	20020032480	3/14/2002	Spence et al.		
	9	20020042651	4/11/2002	Liddicoat et al.		
	10	20020052651	5/2/2002	Myers et al.		
	11	20020055767	5/9/2002	Forde et al.		
	12	20020123802	9/5/2002	Snyders		
	13	20020138138	9/26/2002	Yang		
	14	20020165576	11/7/2002	Boyle et al.		
	15	20020183781	12/5/2002	Casey et al.		
	16	20020193871	12/19/2002	Beyersdorf et al.		
	17	20030014104	1/16/2003	Cribier		
	18	20030028247	2/6/2003	Cali		
	19	20030040736	2/27/2003	Stevens et al.		
	20	20030040792	2/27/2003	Gabbay		
	21	20030069492	4/10/2003	Abrams et al.		
	22	20030069646	4/10/2003	Stinson		
	23	20030100918	5/29/2003	Duane		
	24	20030114913	6/19/2003	Spenser et al.		
	25	20030149475	8/7/2003	Hyodoh et al.		
	26	20030153974	8/14/2003	Spenser et al.		
	27	20030191516	10/9/2003	Weldon et al.		
	28	20040049266	3/11/2004	Anduiza et al.		
	29	20040059409	3/25/2004	Stenzel		
	30	20040093060	5/13/2004	Seguin et al.		

 Examiner Signature
 Date Considered

 Examiner: Please initial if citation considered, whether or not citation is in conformance with MPEP Section

 609. Please draw a line through the citation if it is not in conformance and it is not considered. Please include a copy of this form with the next communication to the applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	12/492,512
	Filing Date	6/26/2009
	First Named Inventor	Ulrich R. Haug
	Art Unit	3774
	Client Number	BostonScientificScimedInc.
Page 2 of 14	Matter Number	S63.2-15141-US03

U.S. PATENT DOCUMENTS					
Initials	Cite No.	Document Number	Issue/Publication Date	First Named Inventor	Т
	31	20040097788	5/20/2004	Mourlas et al.	
	32	20040098098	5/20/2004	McGuckin, Jr et al.	
	33	20040098112	5/20/2004	DiMatteo et al.	
	34	20040107004	6/3/2004	Levine et al.	
	35	20040117009	6/17/2004	Cali et al.	
	36	20040122516	6/24/2004	Fogarty et al.	
	37	20040127936	7/1/2004	Salahieh et al.	
	38	20040138743	7/15/2004	Myers et al.	
	39	20040186558	9/23/2004	Pavcnik et al.	
	40	20040193261	9/30/2004	Berreklouw	
	41	20040210304	10/21/2004	Seguin et al.	
	42	20040210306	10/21/2004	Quijano et al.	
	43	20040210307	10/21/2004	Khairkhahan	
	44	20040215333	10/28/2004	Duran et al.	
	45	20040225353	11/11/2004	McGuckin, Jr. et al.	
	46	20040225354	11/11/2004	Allen et al.	
	47	20040225355	11/11/2004	Stevens	
	48	20040243221	12/2/2004	Fawzi et al.	
	49	20040260390	12/23/2004	Sarac et al.	
	50	20050010287	1/13/2005	Macoviak et al.	
	51	20050021136	1/27/2005	Xie et al.	
	52	20050033398	2/10/2005	Seguin	
	53	20050043757	2/24/2005	Arad et al.	
	54	20050043790	2/24/2005	Seguin	
	55	20050049692	3/3/2005	Numamoto et al.	
	56	20050049696	3/3/2005	Siess et al.	
	57	20050055088	3/10/2005	Liddicoat et al.	
	58	20050060029	3/17/2005	Le et al.	
	59	20050065594	3/24/2005	DiMatteo et al.	
	60	20050075584	4/7/2005	Cali	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	12/492,512
	Filing Date	6/26/2009
	First Named Inventor	Ulrich R. Haug
	Art Unit	3774
	Client Number	BostonScientificScimedInc.
Page 3 of 14	Matter Number	S63.2-15141-US03

		U.S. PATI	ENT DOCUMENTS		
Initials	Cite No.	Document Number	Issue/Publication Date	First Named Inventor	Т
	61	20050075712	4/7/2005	Biancucci et al.	
	62	20050075717	4/7/2005	Nguyen et al.	
	63	20050075719	4/7/2005	Bergheim	
	64	20050075724	4/7/2005	Svanidze et al.	
	65	20050075730	4/7/2005	Myers et al.	
	66	20050075731	4/7/2005	Artof et al.	
	67	20050131438	6/16/2005	Cohn	
	68	20050137683	6/23/2005	Hezi-Yamit et al.	
	69	20050143807	6/30/2005	Pavcnik et al.	
	70	20050165479	7/28/2005	Drews et al.	
	71	20050203549	9/15/2005	Realyvasquez	
	72	20050203618	9/15/2005	Sharkawy et al.	
	73	20050228495	10/13/2005	Macoviak	
	74	20050234546	10/20/2005	Nugent et al.	
	75	20050240200	10/27/2005	Bergheim	
	76	20050240262	10/27/2005	White	
	77	20060004439	1/5/2006	Spenser et al.	
	78	20060004442	1/5/2006	Spenser et al.	
	79	20060015168	1/19/2006	Gunderson	
	80	20060161249	7/20/2006	Realyvasquez et al.	
	81	20060195183	8/31/2006	Navia et al.	
	82	20060271166	11/30/2006	Thill et al.	
	83	20070055340	3/8/2007	Pryor	
	84	20070173918	7/26/2007	Dreher et al.	
	85	20070288089	12/13/2007	Gurskis et al.	
	86	20080009940	1/10/2008	Cribier	
	87	20080082165	4/3/2008	Wilson et al.	
	88	20080208328	8/28/2008	Antocci et al.	
	89	20080208332	8/28/2008	Lamphere et al.	
	90	20080221672	9/11/2008	Lamphere et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	12/492,512
	Filing Date	6/26/2009
	First Named Inventor	Ulrich R. Haug
	Art Unit	3774
	Client Number	BostonScientificScimedInc.
Page 4 of 14	Matter Number	S63.2-15141-US03

		U.S. PATE	ENT DOCUMENTS		
Initials	Cite No.	Document Number	Issue/Publication Date	First Named Inventor	Т
	91	20080269878	10/30/2008	lobbi	
	92	20090005863	1/1/2009	Goetz et al.	
	93	20090030512	1/29/2009	Thielen et al.	
	94	20090171456	7/2/2009	Kveen et al.	
	95	20090222076	9/3/2009	Figulla et al.	
	96	20090264759	10/22/2009	Byrd	
	97	20090264997	10/22/2009	Salahieh et al.	
	98	20090299462	12/3/2009	Fawzi et al.	
	99	20100049313	2/25/2010	Alon et al.	
	100	20100121434	5/13/2010	Paul et al.	
	101	20100219092	9/2/2010	Salahieh et al.	
	102	20100280495	11/4/2010	Paul et al.	
	103	2682057	6/29/1954	H. A. Lord	
	104	2701559	2/8/1955	W. A. Cooper	
	105	2832078	4/29/1958	D. T. Williams	
	106	3099016	7/30/1963	M. L. Edwards	
	107	3113586	12/10/1963	K. W. Edmark, Jr.	
	108	3130418	4/28/1964	L. R. Head et al.	
	109	3143742	8/11/1964	H. W. Cromie	
	110	3367364	2/6/1968	Cruz, Jr. et al.	
	111	3445916	5/27/1969	R. R. Schulte	
	112	3548417	12/22/1970	R. G. Kischer	
	113	3570014	3/16/1971	W. D. Hancock	
	114	3587115	6/28/1971	Shiley	
	115	3592184	7/13/1971	Watkins et al.	
	116	3714671	2/6/1973	Edwards et al.	
	117	3755823	9/4/1973	Hancock	
	118	3997923	12/21/1976	Possis	
	119	4035849	7/19/1977	Angell et al.	
	120	4222126	9/16/1980	Boretos et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	12/492,512
	Filing Date	6/26/2009
	First Named Inventor	Ulrich R. Haug
	Art Unit	3774
	Client Number	BostonScientificScimedInc.
Page 5 of 14	Matter Number	S63.2-15141-US03

	U.S. PATENT DOCUMENTS				
Initials	Cite No.	Document Number	Issue/Publication Date	First Named Inventor	Т
	121	4265694	5/5/1981	Boretos et al.	
	122	4297749	11/3/1981	Davis et al.	
	123	4323358	4/6/1982	Lentz et al.	
	124	4339831	7/20/1982	Johnson	
	125	4343048	8/10/1982	Ross et al.	
	126	4345340	8/24/1982	Rosen	
	127	4373216	2/15/1983	Klawitter	
	128	4406022	9/27/1983	Roy	
	129	4470157	9/11/1984	Love	
	130	4484579	11/27/1984	Meno et al.	
	131	4531943	7/30/1985	Van Tassel et al.	
	132	4535483	8/20/1985	Klawitter et al.	
	133	4574803	3/11/1986	Storz	
	134	4592340	6/3/1986	Boyles	
	135	4605407	8/12/1986	Black et al.	
	136	4612011	9/16/1986	Kautzky	
	137	4643732	2/17/1987	Pietsch et al.	
	138	4680031	7/14/1987	Alonso	
	139	4692164	9/8/1987	Dzemeshkevich et al.	
	140	4705516	11/10/1987	Barone et al.	
	141	4759758	7/26/1988	Gabbay	
	142	4777951	10/18/1988	Cribier et al.	
	143	4787899	11/29/1988	Lazarus	
	144	4787901	11/29/1988	Baykut	
	145	4829990	5/16/1989	Thuroff et al.	
	146	4851001	7/25/1989	Taheri	
	147	4873978	10/17/1989	Ginsburg	
	148	4878495	11/7/1989	Grayzel	
	149	4878906	11/7/1989	Lindemann et al.	
	150	4883458	11/28/1989	Shiber	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	12/492,512
	Filing Date	6/26/2009
	First Named Inventor	Ulrich R. Haug
	Art Unit	3774
	Client Number	BostonScientificScimedInc.
Page 6 of 14	Matter Number	S63.2-15141-US03

U.S. PATENT DOCUMENTS					
Initials	Cite No.	Document Number	Issue/Publication Date	First Named Inventor	Т
	151	4885005	12/5/1989	Nashef et al.	
	152	4922905	5/8/1990	Strecker	
	153	4927426	5/22/1990	Dretler	
	154	4966604	10/30/1990	Reiss	
	155	4969890	11/13/1990	Sugita et al.	
	156	4979939	12/25/1990	Shiber	
	157	5007896	4/16/1991	Shiber	
	158	5026366	6/25/1991	Leckrone	
	159	5032128	7/16/1991	Alonso	
	160	5037434	8/6/1991	Lane	
	161	5047041	9/10/1991	Samuels	
	162	5080668	1/14/1992	Bolz et al.	
	163	5085635	2/4/1992	Cragg	
	164	5089015	2/18/1992	Ross	
	165	5132473	7/21/1992	Furutaka et al.	
	166	5141494	8/25/1992	Danforth et al.	
	167	5152771	10/6/1992	Sabbaghian et al.	
	168	5159937	11/3/1992	Tremulis	
	169	5167628	12/1/1992	Boyles	
	170	5215541	6/1/1993	Nashef et al.	
	171	5282847	2/1/1994	Trescony et al.	
	172	5295958	3/22/1994	Shturman	
	173	5360444	11/1/1994	Kusuhara	
	174	5409019	4/25/1995	Wilk	
	175	5443446	8/22/1995	Shturman	
	176	5443449	8/22/1995	Buelna	
	177	5480424	1/2/1996	Сох	
	178	5500014	3/19/1996	Quijano et al.	
	179	5545209	8/13/1996	Roberts et al.	
	180	5545214	8/13/1996	Stevens	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	12/492,512
	Filing Date	6/26/2009
	First Named Inventor	Ulrich R. Haug
	Art Unit	3774
	Client Number	BostonScientificScimedInc.
Page 7 of 14	Matter Number	S63.2-15141-US03

	U.S. PATENT DOCUMENTS					
Initials	Cite No.	Document Number	Issue/Publication Date	First Named Inventor	Т	
	181	5571175	11/5/1996	Vanney et al.		
	182	5573520	11/12/1996	Schwartz et al.		
	183	5591185	1/7/1997	Kilmer et al.		
	184	5591195	1/7/1997	Taheri et al.		
	185	5607464	3/4/1997	Trescony et al.		
	186	5609626	3/11/1997	Quijano et al.		
	187	5693310	12/2/1997	Gries et al.		
	188	5709713	1/20/1998	Evans et al.		
	189	5713951	2/3/1998	Garrison et al.		
	190	5716417	2/10/1998	Girard et al.		
	191	5728068	3/17/1998	Leone et al.		
	192	5749890	5/12/1998	Shaknovich		
	193	5756476	5/26/1998	Epstein et al.		
	194	5800531	9/1/1998	Cosgrove et al.		
	195	5855602	1/5/1999	Angell		
	196	5906619	5/25/1999	Olson et al.		
	197	6051014	4/18/2000	Jang		
	198	6059827	5/9/2000	Fenton, Jr.		
	199	6074418	6/13/2000	Buchanan et al.		
	200	6096074	8/1/2000	Pedros		
	201	6132473	10/17/2000	Williams et al.		
	202	6146366	11/14/2000	Schachar		
	203	6168614	1/2/2001	Andersen et al.		
	204	6171335	1/9/2001	Wheatley et al.		
	205	6221100	4/24/2001	Strecker		
	206	6299637	10/9/2001	Shaolian et al.		
	207	6302906	10/16/2001	Goicoechea et al.		
	208	6461382	10/8/2002	Cao		
	209	6468660	10/22/2002	Ogle et al.		
	210	6485501	11/26/2002	Green		

	Application Number	12/492,512
	Filing Date	6/26/2009
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	Ulrich R. Haug
STATEWENT BY APPLICANT	Art Unit	3774
	Client Number	BostonScientificScimedInc.
Page 8 of 14	Matter Number	S63.2-15141-US03

	U.S. PATENT DOCUMENTS					
Initials	Cite No.	Document Number	Issue/Publication Date	First Named Inventor	Т	
	211	6488704	12/3/2002	Connelly et al.		
	212	6530952	3/11/2003	Vesely		
	213	6569196	5/27/2003	Vesely		
	214	6605112	8/12/2003	Moll et al.		
	215	6723116	4/20/2004	Taheri		
	216	6769434	8/3/2004	Liddicoat et al.		
	217	6786925	9/7/2004	Schoon et al.		
	218	6797002	9/28/2004	Spence et al.		
	219	6830585	12/14/2004	Artof et al.		
	220	6866650	3/15/2005	Stevens et al.		
	221	6872223	3/29/2005	Roberts et al.		
	222	6951571	10/4/2005	Srivastava		
	223	6969395	11/29/2005	Eskuri		
	224	6972025	12/6/2005	WasDyke		
	225	6989027	1/24/2006	Allen et al.		
	226	7041132	5/9/2006	Quijano et al.		
	227	7097658	8/29/2006	Oktay		
	228	7122020	10/17/2006	Mogul		
	229	7125418	10/24/2006	Duran et al.		
	230	7175656	2/13/2007	Khairkhahan		
	231	7267686	9/11/2007	DiMatteo et al.		
	232	7276078	10/2/2007	Spenser et al.		
	233	7322932	1/29/2008	Xie et al.		
	234	7329279	2/12/2008	Haug et al.		
	235	7381219	6/3/2008	Salahieh et al.		
	236	7381220	6/3/2008	Macoviak et al.		
	237	7399315	7/15/2008	lobbi		
	238	7445631	11/4/2008	Salahieh et al.		
	239	7470285	12/30/2008	Nugent et al.		
	240	7510574	3/31/2009	Le et al.		

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	12/492,512
	Filing Date	6/26/2009
	First Named Inventor	Ulrich R. Haug
STATEMENT DI AFFEICANT	Art Unit	3774
	Client Number	BostonScientificScimedInc.
Page 9 of 14	Matter Number	S63.2-15141-US03

	U.S. PATENT DOCUMENTS						
Initials	Cite No.	Document Number	Issue/Publication Date	First Named Inventor	Т		
	241	7524330	4/28/2009	Berreklouw			
	242	7530995	5/12/2009	Quijano et al.			
	243	7544206	6/9/2009	Cohn			
	244	7622276	11/24/2009	Cunanan et al.			
	245	7628803	12/8/2009	Pavcnik et al.			
	246	7712606	5/11/2010	Salahieh et al.			
	247	7722666	5/25/2010	Lafontaine			
	248	7748389	7/6/2010	Salahieh et al.			
	249	7780725	8/24/2010	Haug et al.			
	250	7803185	9/28/2010	Gabbay			
	251	7833262	11/16/2010	McGuckin, Jr. et al.			
	252	7846204	12/7/2010	Letac et al.			

	FOREIGN PATENT DOCUMENTS					
Initials	Cite No.	Document Number	Publication Date	Country	Т	
	253	0103546	5/4/1988	EP		
	254	0144167	11/8/1989	EP		
	255	0597967	12/1/1999	EP		
	256	0850607	7/1/1998	EP		
	257	10049812	4/18/2002	DE		
	258	10049813	4/18/2002	DE		
	259	10049814	4/18/2002	DE		
	260	10049815	4/25/2002	DE		
	261	1088529	4/4/2001	EP		
	262	1271508	11/23/1986	SU		
	263	1371700	2/7/1988	SU		
	264	1435879	7/14/2004	EP		
	265	1439800	7/28/2004	EP		
	266	1472996	11/3/2004	EP		
	267	1551274	7/13/2005	EP		

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	12/492,512
	Filing Date	6/26/2009
	First Named Inventor	Ulrich R. Haug
STATEWENT BY APPLICANT	Art Unit	3774
	Client Number	BostonScientificScimedInc.
Page 10 of 14	Matter Number	S63.2-15141-US03

FOREIGN PATENT DOCUMENTS					
Initials	Cite No.	Document Number	Publication Date	Country	Т
	268	1551336	7/13/2005	EP	
	269	1562515	8/17/2005	EP	
	270	1570809	9/7/2005	EP	
	271	1589902	11/2/2005	EP	
	272	1605871	7/23/2008	EP	
	273	19532846	3/13/1997	DE	
	274	19546692	6/19/1997	DE	
	275	19857887	7/6/2000	DE	
	276	19907646	8/24/2000	DE	
	277	1991017720	11/28/1991	WO	
	278	1992017118	10/15/1992	WO	
	279	1993001768	2/4/1993	WO	
	280	1998029057	7/9/1998	WO	
	281	1999033414	7/8/1999	WO	
	282	1999040964	8/19/1999	WO	
	283	1999047075	9/23/1999	WO	
	284	2000041652	7/20/2000	WO	
	285	2000044311	8/3/2000	WO	
	286	2000045874	8/10/2000	WO	
	287	2000047139	8/17/2000	WO	
	288	2001049213	7/12/2001	WO	
	289	2001054625	8/2/2001	WO	
	290	2001062189	8/30/2001	WO	
	291	2001097715	12/27/2001	WO	
	292	2002043620	6/6/2002	WO	
	293	2002047575	6/20/2002	WO	
	294	2003094793	11/20/2003	WO	
	295	2004058106	7/15/2004	WO	
	296	2004089250	10/21/2004	WO	
	297	2004089253	10/21/2004	WO	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	12/492,512
	Filing Date	6/26/2009
	First Named Inventor	Ulrich R. Haug
STATEWENT DT AFFLICANT	Art Unit	3774
	Client Number	BostonScientificScimedInc.
Page 11 of 14	Matter Number	S63.2-15141-US03

FOREIGN PATENT DOCUMENTS					
Initials	Cite No.	Document Number	Publication Date	Country	Т
	298	2004093728	11/4/2004	WO	
	299	2004105651	12/9/2004	WO	
	300	2005002466	1/13/2005	WO	
	301	2005004753	1/20/2005	WO	
	302	2005009285	2/3/2005	WO	
	303	2005011534	2/10/2005	WO	
	304	2005011535	2/10/2005	WO	
	305	2005023155	3/17/2005	WO	
	306	2005027790	3/31/2005	WO	
	307	2005046528	5/26/2005	WO	
	308	2005046529	5/26/2005	WO	
	309	2005048883	6/2/2005	WO	
	310	2005062980	7/14/2005	WO	
	311	2005065585	7/21/2005	WO	
	312	2005096993	10/20/2005	WO	
	313	2006009690	1/26/2006	WO	
	314	2006027499	3/16/2006	WO	
	315	2006138391	12/28/2006	WO	
	316	2007033093	3/22/2007	WO	
	317	2007035471	3/29/2007	WO	
	318	2007044285	4/19/2007	WO	
	319	2007053243	5/10/2007	WO	
	320	2007058847	5/24/2007	WO	
	321	2007092354	8/16/2007	WO	+
	322	2007097983	8/30/2007	WO	+
	323	2010042950	4/15/2010	WO	\neg
	324	2056023	3/11/1981	GB	
	325	2398245	8/18/2004	GB	
	326	2788217	7/13/2000	FR	\neg

	Application Number	12/492,512
	Filing Date	6/26/2009
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	Ulrich R. Haug
STATEMENT BT AFFEICANT	Art Unit	3774
	Client Number	BostonScientificScimedInc.
Page 12 of 14	Matter Number	S63.2-15141-US03

	OTHER DOCUMENTS				
Initials	Cite No.	Author, Title, Date, Pages, etc.	Т		
	327	A Matter of Size, Treiennial Review of the National Nanotechnology Initiative, 2006, v-13, The National Academies Press, Washington, DC http://www.nap.edu/catalog/11752.html			
	328	ATWOOD, A. et al., "Insertion of Heart Valves by Catheterization". The Capstone Design Course Report. MIME 1501-1502. Technical Design Report. Northeastern University. November 5, 2007, pp 1-93			
	329	August 19, 2011, Supplemental Search Report from EP Patent office, EP Application No. 04813777.2			
	330	August 19, 2011, Supplemental Search Report from EP Patent office, EP Application No. 04815634.3			
	331	CUNANAN, CRYSTAL, M., M.S., et al., Tissue Characterization and Calcification Potential of Commerical Bioprosthetic Heart Valves, Ann Thorac Surg, 2001, S417-21			
	332	CUNLIFFE, H.R. et al., Glutaraldehyde Inactivation of Exotic Animal Viruses in Swine Hearl Tissue, May 1979, 1044-1046, Vol. 37, No. 5., Applied and Environmental Microbiology, Greenport, New York			
	333	EP Search Report mailed August 10, 2011 for EP Application No.: 06824992.9			
	334	Heart Valve Materials - Bovine (cow), Equine & Porcine Pericardium, Maverick Biosciences PTY. LTD, 2009, http://www.maverickbio.com/biological-medical- device-materials.php?htm			
	335	HELMUS, M.N., Mechanical and bioprosthetic heart valves in biomaterials for artificial organs, 114-162, Woodhead Publishing Limited, 2011			
	336	HOURIHAN, MARIBETH, et al., Transcatheter Umbrella Closure of Valvular and Paravalvular Leaks, November 15, 1992, 1371-7, Vol. 20, No. 6, JACC, Boston Massachusetts			
	337	LABORDE, J.C. et al., Percutaneous implantation of the corevalve aortic valve prosthesis for patients presenting high risk for surgical valve replacement, 2006, 472-474, EuroIntervention			
	338	LEVY, CHARLES, M.D., Mycobacterium Chelonei Infection of Porcine Heart Valves, Sept. 22, 1977, Vol. 297, No. 12, The New England Journal of Medicine, Washington, D.C.			
	339	October 24, 2011, Supplemental Search Report from EP Patent office, EP Application No. 05758878.2			
	340	Pericardial Heart Valves, Edwards Lifesciences, Cardiovascular Surgery FAQ, 11/14/2010, http://www.edwards.com/products/cardiovascularsurgeryfaq.htm			
	341	Southern Lights Biomaterials Homepage, 1/7/2011, http://www.slv.co.nz/			

	Application Number	12/492,512
	Filing Date	6/26/2009
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	Ulrich R. Haug
STATEMENT DI AFFEICANT	Art Unit	3774
	Client Number	BostonScientificScimedInc.
Page 13 of 14	Matter Number	S63.2-15141-US03

		OTHER DOCUMENTS	
Initials	Cite No.	Author, Title, Date, Pages, etc.	Т
	342	STASSANO, PAOLO, Mid-term results of the valve-on-valve technique for bioprosthetic failure, 2000, 453-457, European Journal of Cardio-thoracic Surgery	
	343	TOPOL, ERIC J., M.D., Percutaneous Expandable Prosthetic Valves, Textbook of Interventional Cardiology, 1994, 1268-1276, Volume 2, W.B. Saunders Company, Philadelphia	

	Application Number	12/492,512
	Filing Date	6/26/2009
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	Ulrich R. Haug
STATEMENT DI AFFEIGANT	Art Unit	3774
	Client Number	BostonScientificScimedInc.
Page 14 of 14	Matter Number	S63.2-15141-US03

GENERAL

Pursuant to 37 C.F.R. 1.97 and 1.98 and to the duty of disclosure set forth in 37 C.F.R. 1.56, the Examiner in charge of the above-identified application is requested to consider and make of record the references listed herewith. A copy of each listed reference, other than U.S. patents/applications and references cited in a parent application, is enclosed.

Although the information submitted herewith may be "material" to the Examiner's consideration of the subject application, this submission is not intended to constitute an admission that such information is "prior art" as to the claimed invention.

In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

TIMING

In accordance with 37 CFR 1.97(b), this Information Disclosure Statement is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits; or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

CERTIFICATION STATEMENT

No certification statement is required. This Information Disclosure Statement is being filed in accordance with 37 CFR 1.97(b).

FEE

No fee is required. This Information Disclosure Statement is being filed in accordance with 37 CFR 1.97(b).

SI	GNATURE	
Signature /James M. Urzedowski/	Date	3/23/2012
Name James M. Urzedowski	Registration Number	48596

Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 265 of 442

Electronic Ac	Electronic Acknowledgement Receipt				
EFS ID:	12381090				
Application Number:	12492512				
International Application Number:					
Confirmation Number:	7439				
Title of Invention:	Everting Heart Valve				
First Named Inventor/Applicant Name:	Amr Salahieh				
Customer Number:	490				
Filer:	James M. Urzedowski/Samantha Painschab				
Filer Authorized By:	James M. Urzedowski				
Attorney Docket Number:	S63.2Q-15141-US03				
Receipt Date:	23-MAR-2012				
Filing Date:	26-JUN-2009				
Time Stamp:	15:13:01				
Application Type:	Utility under 35 USC 111(a)				

Payment information:

Submitted with F	Payment		no			
File Listing:						
Document Number	Document Description		File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Transmittal Letter	15	141US03_tra_20120323.pdf	80365	no	1
, , , , , , , , , , , , , , , , , , ,			1410303_da_20120323.pdf	bedb0038f1e914f51565144bd5b425743f5 aff8e		
Warnings:						
Information:	Edwards Lifes	cienc	es Corporation, et al	. Exhibit 1102. Pag	e 266 of 4	42

2	Information Disclosure Statement (IDS) Form (SB08)	15141US03_IDS_20120323_sig ned.pdf	104995	no	14
	Form (SB08)	nea.pai	baccc2c9a53742f0cb4adafb34f2f12577eab 7b2		
Warnings:					
Information:					
This is not an U	SPTO supplied IDS fillable form				
			1946584		
3	Non Patent Literature	A_Matter_of_Size_2006.pdf	de712d71df3b0b4903a17608e760dc8bb6c d23fe	no	30
Warnings:					-
Information:					
4	Non Patent Literature	Atwood_etal_Insertion_of_Hea rt_Valves_by_Catheterization_ 2007.pdf	4150302 efc5956c51b65dc8570823a1b6de244ed66 2a530	no	95
Warnings:			Lasso		
Information:					
			62074		
5	Non Patent Literature	August_19_2011_EP_Supp_Se arch_Report_04813777.pdf	50a826af9237daa13fda8884bdc2f1c3e921	no	2
			3633		
Warnings:					
Information:					[
6	Non Patent Literature	August_19_2011_EP_Supp_Se	63009	no	2
		arch_Report_04815634.pdf	476e39b62f1e1dc83fc7235b76c90a733099 8745		
Warnings:					-
Information:					
7	New Detect Literature	Cunanan_etal_Tissue_characte	573143		F
7	Non Patent Literature	rization_and_calcification_200 1.pdf	7c7d019028eb19c59c128b4398c574635af d76ab	no	5
Warnings:			U Vals		
- Information:					
		Cunliffe_etal_glut_inactivation	404632		
8	Non Patent Literature	_of_exotic_animal_viruses_197 9.pdf	f2fa7b69b11f39d74c99106e3b7f28343e09	no	3
\A/			94d1		
Warnings: Information:					
Information:					
9	Non Patent Literature	EP_Search_Report_05758878.	82776	no	3
		pdf	e504910c81a38884b9b15ef9aaf59d1b936 9090c		
Warnings:					
Information:					
		EP_Search_Report_August_10_	463447		
10	Non Patent Literature	2011_06824992.pdf	d47539377d36d0322d7a162c04695d2a76f	no	6
			dec46		

Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 267 of 442

Warnings:					
Information:					
11	Non Patent Literature	Heart_Valve_Materials_Maveric	161116	no	2
		kBiosciences_2009.pdf	db15985201cccbaedf3a83a9d836a1cfc684 366e		
Warnings:					
Information:					
12	Non Patent Literature	Helmus_etal_Mechanical_and_ bioprosthetic_heart_valves_20	6801546	no	54
		11.pdf	0af295eca7e9ab239c08847b20e78008642 dd2ea		
Warnings:					
Information:			· · ·		
13	Non Patent Literature	Hourihan_etal_Transcatheter_ Umbrella_Closure_1992.pdf	2514297	no	7
		offibrena_closure_1992.pdf	a0345b8bdcebb7f5446d53b9dee10ffecc55 f494		
Warnings:					
Information:					
14	Non Patent Literature	Laborde_etal_Percutaneous_i mplantation_of_the_corevalve	1311847	no	3
		_2006.pdf	de79731a4555fbba52237c469716fc0e75d 86773		
Warnings:					
Information:					
15	Non Patent Literature	Levy_etal_Mycobacterium_Che lonei_Infection_of_Porcine_He	424052	no	2
		art_Valves_1977.pdf	668924d1e8ea4fc0bfb3105cc287bf2508a0 48ce		
Warnings:					
Information:					
16	Non Patent Literature	Pericardial_Heart_Valves_Cardi ovascular_Surgery_FAQ_2010.	54313	no	1
		pdf	571a73d2f0afe0c5b4d8f1223821a9600980 f8e7		
Warnings:					
Information:					
17	Non Patent Literature	Southern_Lights_Biomaterials.	135803	no	1
		pdf	4d8bbf37794a3fa100b97b48bce9ee62527 2d2d5		
Warnings:			·		
Information:					
		Stassano_etal_Midterm_results	2135630		
18	Non Patent Literature	_of_the_valveonvalve_techniq ue_2000.pdf	90ca94cdd04a6484e8dfe9dfac2faa9889d0 196a	no	7
Warnings:			·	I	
Information:					
19	Non Patent Literature	Topol_etal_Percutaneous_Expa ndable_Prosthetic_Valves_199		no	11
-		esciences Corporation, et al.			

Warnings:					
Information:					
20	Foreign Reference	DE10049812.pdf	590259	no	7
			bdc41209e20e28b6ae205990c19b270297a 68d24		
Warnings:					
Information					
21	Foreign Reference	DE10049813.pdf	663798	no	7
			bf65fb493af5dc1c96e7ed00ddbe4543cbfd e9dc		
Warnings:					
Information:		1			
22	Foreign Reference	DE10049814.pdf	707692	no	9
			14fb9e10eb10d4621e0908eae94789b35bb 3e611		
Warnings:					-
Information:					
23	Foreign Reference	DE10049815.pdf	682738	no	8
25	roleign keleinee	DE10049815.pui	93856a6e11429e19dd69b74e76518c79acd 688c2	no	
Warnings:					
Information:					
24	Foreign Reference	DE19532846.pdf	799337	no	9
	-		7cb10486ce2941ce776d817fcf32528a33aa ceff		
Warnings:					
Information:					
25	Foreign Reference	DE19546692.pdf	444905	no	7
			bcc622c19b7fb649b97425706292f82c174c b338		
Warnings:					
Information:					
26	Foreign Reference	DE19857887.pdf	659840	no	7
	5		5577bf3bf8a08433f80f8d5af3b28547619ac 7e3		
Warnings:					
Information:					
27	Foreign Reference	DE19907646.pdf	852483	no	9
			820da2488b3668a07c69375624e2439b4c4 d07e3		
Warnings:					
Information:					
28	Foreign Reference	FR2788217.pdf	1488965	no	23
		ciences Corporation, et a			

Information bedd90der901(1987)07003906808 Image: Note of the second sec	Warnings:					
29 Foreign Reference GB2056023.pdf	Information:					
Warnings:30Foreign ReferenceGB2398245.pdf843128 4803020000000000000000000000000000000000	29	Foreign Reference	GB2056023.pdf	296276	no	8
Information: 30 Foreign Reference GB2398245.pdf 843128 (400.001.000.001.000.000.000.000.000.000.						
30 Foreign Reference GB2398245.pdf 843128 (4803.00000000000000000000000000000000000						
30 Foreign Reference GB2398245,pdf	Information:		i			
Image: Image:<	30	Foreign Reference	GB2398245.pdf	843128	no	24
Information: Information: 421428 no 44 31 Foreign Reference SU1271508.pdf 421428 no 4 Warnings: Information: 258 0 4 32 Foreign Reference SU1371700.pdf 251868 no 3 32 Foreign Reference SU1371700.pdf 251868 no 3 Warnings: Information: no 3 3 no 3 Warnings: Information: SU1371700.pdf 251868 no 3 Warnings: Information: No 3 3 No 3 33 Foreign Reference EP0103546B1.pdf 263304 no 6 Warnings: Information: No 3 10 14 34 Foreign Reference EP0144167B1.pdf 476368 no 14 34 Foreign Reference EP0144167B1.pdf 14 14 14						
$\begin{array}{cccccccccccccccccccccccccccccccccccc$						
31 Foreign Reference SU1271508.pdf	Information:		l	1		1
Warnings: 208 0 Information: Information: 251868 no 33 32 Foreign Reference SU1371700.pdf 251868 no 33 Warnings: 33 Foreign Reference SU1371700.pdf 263304 no 34 Warnings: Information: 263304 no 6 33 Foreign Reference EP0103546B1.pdf 263304 no 6 Warnings: Information: 7 264304493107664.3001487774e4778 no 6 33 Foreign Reference EP0103546B1.pdf 263304 no 6 33 Foreign Reference EP0103546B1.pdf 1 0 6 33 Foreign Reference EP0144167B1.pdf 0 0 6 34 Foreign Reference EP0144167B1.pdf 1 0 14	31	Foreign Reference	SU1271508.pdf	421428	no	4
Information:32Foreign ReferenceSU1371700.pdf $\frac{251868}{75d4/2ccdd952014870c424029764abb83}$ no332Warnings: Information:750442ccd4952014870c424029764abb83 54a12no333Foreign ReferenceEP0103546B1.pdf 263304 rc6542b2489310766Mc300148777de4778}no6Warnings:Information:7c6542b2489310766Mc300148777de4778 ccedecno633Foreign ReferenceEP0103546B1.pdf $1c6542b2489310766Mc300148777de4778$ ccedecno6Warnings:Information:141434Foreign ReferenceEP0144167B1.pdf 476368 bc1d91542cbf105d7dbabcb67c42acd25 						
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Warnings:					
32 Foreign Reference SU1371700.pdf Image:	Information:					
	32	Foreign Reference	SU1371700.pdf	251868	no	3
Information:33Foreign ReferenceEP0103546B1.pdf 263304 $7c542b248931076644c300148777de4778}cedocno6Warnings:Information:34Foreign ReferenceEP0144167B1.pdf476368bc1d915042cbf105d7dbebe0b7ef2a26d25cd07no14$						
$\begin{array}{c c} & & & & & & & \\ \hline 33 & Foreign Reference & & & & & \\ \hline 33 & Foreign Reference & & & & & \\ \hline & & & & & \\ \hline & & & & & \\ \hline & & & &$						
33Foreign ReferenceEP0103546B1.pdfno67c6542b2489310766f4c300148777de4778 ced6cno6Warnings:Information:34Foreign ReferenceEP0144167B1.pdf476368 bc1d915042cbf105d7dbebe0b7ef2a26d25 cd07no14	Information:					
Warnings: ced6c ced6c Information: 34 Foreign Reference EP0144167B1.pdf 476368 bc1d915042cbf105d7dbebe0b7ef2a26d25 cd07f no 14	33	Foreign Reference	EP0103546B1.pdf	263304	no	6
Information: 34 Foreign Reference EP0144167B1.pdf 476368 bc1d915042cbf105d7dbbeb0b7ef2a26d25 cd07f no 14						
34 Foreign Reference EP0144167B1.pdf 476368 no 14						
34 Foreign Reference EP0144167B1.pdf no 14	Information:					
cd07f	34	Foreign Reference	EP0144167B1.pdf	476368	no	14
Warnings:						
	Warnings:					
Information:	Information:					
35 Foreign Reference EP0597967B1.pdf 148911 no 13	35	Foreign Reference	EP0597967B1.pdf	148911	no	13
7019fe98d67bc1d9dbf787d2a65d9637496 0b0be						
Warnings:	Warnings:					
Information:	Information:					
36 Foreign Reference EP0850607A1.pdf no 33	36	Foreign Reference	EP0850607A1 pdf	435172	no	33
3bbead540a21698ef64965f205013f00d7c0 87a7						
Warnings:	Warnings:					
Information:	Information:					
37 Foreign Reference EP1088529A2.pdf no 8	37	Foreign Reference	EP1088529A2.pdf	78095	no	8
Edwards Lifesciences Corporation, et al. Exhibit B102, Page 270 of 442				al, Exhibit: 13102, Pag		

Warnings:					
Information:					
38	Foreign Reference	EP1435879.pdf	1401225	no	24
	5		2f78d29ad3f5f400c737996d9081fc24b680 1147		
Warnings:					
Information:					
39	Foreign Reference	EP1439800.pdf	3899814	no	55
			4210bee34dd3b5bb17e9b55a7b2d454884 35cd21		
Warnings:					
Information:		-			
40	Foreign Reference	EP1472996A1.pdf	274712	no	23
			1ea96c7683ad8e8ab2fd36972fddc3274d7 5da19		
Warnings:					
Information:					
41	Foreign Reference	EP1551274.pdf	5120150	no	70
			022e2375a629518c6ebad39908a03c2df3d 473c8		
Warnings:					
Information:					
42	Foreign Reference	EP1551336.pdf	2316389	no	35
			8e13663c900a322df42bfcc01d7f7a1fe5611 02b		
Warnings:		·	·····		
Information:					
43	Foreign Reference	EP1562515.pdf	2323220	no	27
	5		b84858e72a8c0730d02b1bbe10b7596627 42fbfd		
Warnings:					
Information:					
44	Foreign Reference	EP1570809A1.pdf	175707	no	13
			f1fc9b767988567cfd9445d27af9e273a7dc 3a53		
Warnings:					
Information:					
45	Foreign Reference	EP1589902.pdf	1339580	no	22
			dc203bdf0d2853d1b5c013f63f4d4583b0f1 eb61		
Warnings:					
Information:					
46	Foreign Reference	EP1605871B1.pdf	425270	no	44
		sciences Corporation, et			

Warnings:					
Information:					
47	Foreign Reference	WO1991017720A1.pdf	519864	no	21
	5		33ec53d85332070960c446b41d17babf428 ff8ec		
Warnings:					
Information:					
48	Foreign Reference	WO1992017118A1.pdf	1888973	no	76
	_	·	f39643e2edcedfe0f7d0a56ed7d351427716 c582		
Warnings:					
Information:		1			i
49	Foreign Reference	WO1993001768A1.pdf	931985	no	36
			6a089d06724e6de961d95e0d0860dc661fb 9c285		
Warnings:					
Information:					
50	Foreign Reference	WO1998029057A1.pdf	1471603	no	67
	· · · · · · · · · · · · · · · · · · ·		b832904a50ecb542d197695e9765e669ab bb5887		
Warnings:					
Information:		- 1	-,,		1
51	Foreign Reference	WO1999033414A1.pdf	736018	no	34
			23fb62b6f0770dc7abb9c6b53e165dae19ef 2d04		
Warnings:					
Information:					
52	Foreign Reference	WO1999040964A1.pdf	494640	no	26
			9d6df52b4aadcb7003abb105587dfce23cb 23ba5		
Warnings:					
Information:					
53	Foreign Reference	WO1999047075A1.pdf	371169	no	18
			cf650b71f86656da1414087bf020510e0533 cd40		
Warnings:					
Information:					
54	Foreign Reference	WO2000041652A1.pdf	674633	no	26
			4a45c103d78034a2368ad2c8d7b82471391 a6fef		
Warnings:					
Information:					
55	Foreign Reference	WO2000044311A2.pdf	3156891	no	100
		sciences Corporation, et a	fameffbegegezezegezebelentessdattessd HXhThToLetter	e 272 of 4	42

Information: 56 Foreign Reference WO2000045874.pdf 835957 75ad9372b4a3c30d2ebfbe1b30b 0850e3 Warnings:	I4b0ee2	25
56 Foreign Reference WO2000045874.pdf		25
Information:		
988001 57 Foreign Reference WO2000047139A1.pdf	no	46
01e39bf27db09602c1ef15f1c17bi 88b6	d05ca09	
Warnings:		
Information:		
58 Foreign Reference WO2001049213A2.pdf 1159722	no	42
1152ec804b010df9a3a6c9b440a 9bec6	5bbf78b	
Warnings:		
Information:		
59 Foreign Reference WO2001054625A1.pdf 739038	no	44
1fd1b7c7ad4a082f3702747a8aae 4030	e3bc0a9	
Warnings:		
Information:		
60 Foreign Reference WO2001062189A1.pdf	no	17
79b2e3651bd91df6ef8a5943c557 3099b	le7dbb9	
Warnings:		
Information:		
Total Files Size (in bytes):	65710711	
This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indic characterized by the applicant, and including page counts, where applicable. It serves as evid Post Card, as described in MPEP 503. <u>New Applications Under 35 U.S.C. 111</u> If a new application is being filed and the application includes the necessary components for a 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the d Acknowledgement Receipt will establish the filing date of the application. <u>National Stage of an International Application under 35 U.S.C. 371</u> If a timely submission to enter the national stage of an international application is compliant of U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance o national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, if <u>New International Application Filed with the USPTO as a Receiving Office</u> If a new international application is being filed and the international application includes the an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to national security, and the date shown on this Acknowledgement Receipt will establish the inter-	ence of receipt filing date (see ate shown on the the application n due course. necessary comp nal Application prescriptions c	similar to a a 37 CFR his ons of 35 n as a ponents for n Number concerning

Docket No.: S63.2Q-15141-US03

In re Application of:	Ulrich R. Haug, Hans F. Valencia, Robert A. Geshlider, Tom Saul, Amr Salahieh, Dwight P. Morejohn, Kenneth J. Michlitsch
Application No.:	12/492512
Filed:	June 26, 2009
For:	Everting Heart Valve
Group Art Unit:	3774

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

TRANSMITTAL LETTER

1. In regard to the above-identified application, in addition to this **1** page transmittal letter, we are submitting the attached:

14 page Information Disclosure Statement; 17 Non-Patent Literature Documents; 41 Foreign References.

2. With respect to fees, applicant believes the fees required herein, if any, are being paid electronically.

3. CONDITIONAL PETITION FOR EXTENSION OF TIME

This conditional petition is being filed along with the papers identified in Item 1 above and provides for the possibility that Applicant has inadvertently overlooked the need for a petition and fee for extension of time or for a petition and fee for any other matter petitionable to the Commissioner as required. If any extension of time for the accompanying response is required or if a petition for any other matter is required, by petitioner, Applicant requests that this be considered a petition therefor.

- 4. Notwithstanding paragraph 2 above, if any additional fees associated with this communication are required and have not otherwise been paid, including any fee associated with the Conditional Petition for Extension of Time, or any request in the accompanying papers for action which requires a fee as a petition to the Commissioner, please charge the additional fees to Deposit Account No. 22-0350. Please charge any additional fees associated with this communication to the Deposit Account No. 22-0350.
- 5. **Certification:** I hereby certify that this Transmittal Letter and the paper(s) as described herein are being transmitted electronically to the USPTO on March 23, 2012.

Respectfully submitted,

VIDAS, ARRETT & STEINKRAUS

Date: March 23, 2012

By: /James M. Urzedowski/

James M. Urzedowski Registration No.: 48596

6640 Shady Oak Rd., Suite 400 Eden Prairie, MN 55344-7834 Telephone: (952) 563-3000 Facsimile: (952) 563-3001 f:\wpwork\jmu\15141us03_tra_20120323.doc

In re Application of:	Ulrich R. Haug, Hans F. Valencia, Robert A. Geshlider, Tom Saul, Amr
	Salahieh, Dwight P. Morejohn, Kenneth J. Michlitsch
Application No.:	12/492512
Filed:	June 26, 2009
For:	Everting Heart Valve
Group Art Unit:	3774

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Docket No.: S63.2Q-15141-US03

TRANSMITTAL LETTER

1. In regard to the above-identified application, in addition to this 1 page transmittal letter, we are submitting the attached:

33 Foreign References.

2. With respect to fees, applicant believes the fees required herein, if any, are being paid electronically.

3. CONDITIONAL PETITION FOR EXTENSION OF TIME

- This conditional petition is being filed along with the papers identified in Item 1 above and provides for the possibility that Applicant has inadvertently overlooked the need for a petition and fee for extension of time or for a petition and fee for any other matter petitionable to the Commissioner as required. If any extension of time for the accompanying response is required or if a petition for any other matter is required, by petitioner, Applicant requests that this be considered a petition therefor.
- 4. Notwithstanding paragraph 2 above, if any additional fees associated with this communication are required and have not otherwise been paid, including any fee associated with the Conditional Petition for Extension of Time, or any request in the accompanying papers for action which requires a fee as a petition to the Commissioner, please charge the additional fees to Deposit Account No. 22-0350. Please charge any additional fees associated with this communication to the Deposit Account No. 22-0350.
- 5. **Certification:** I hereby certify that this Transmittal Letter and the paper(s) as described herein are being transmitted electronically to the USPTO on March 23, 2012.

Respectfully submitted,

VIDAS, ARRETT & STEINKRAUS

Date: March 23, 2012

By: /James M. Urzedowski/

James M. Urzedowski Registration No.: 48596

6640 Shady Oak Rd., Suite 400 Eden Prairie, MN 55344-7834 Telephone: (952) 563-3000 Facsimile: (952) 563-3001 f:\wpwork\jmu\15141us03_tra2_20120323.doc

Electronic Acknowledgement Receipt						
EFS ID:	12381442					
Application Number:	12492512					
International Application Number:						
Confirmation Number:	7439					
Title of Invention:	Everting Heart Valve					
First Named Inventor/Applicant Name:	Amr Salahieh					
Customer Number:	490					
Filer:	James M. Urzedowski/Samantha Painschab					
Filer Authorized By:	James M. Urzedowski					
Attorney Docket Number:	S63.2Q-15141-US03					
Receipt Date:	23-MAR-2012					
Filing Date:	26-JUN-2009					
Time Stamp:	15:28:48					
Application Type:	Utility under 35 USC 111(a)					

Payment information:

Submitted with F	Payment	no					
File Listing:							
Document Number	Document Description		File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)	
1	Transmittal Letter		141US03 tra2 20120323.pdf	80112	no	1	
			1410303_002_20120323.pdf	ceeeb4c384bc4a9c91f9d94c2c736fd2ab55 098d	110	1	
Warnings:		-		· · ·			
Information:	Edwards Life	scienc	es Corporation, et al	. Exhibit 1102. Pag	e 276 of 4	42	

2	Foreign Reference	WO2001097715A1.pdf	548231	no	32
	-		2287001fa5e7d67e83ffd3827ae5036902ee fc2f		
Warnings:					
Information:			1		1
3	Foreign Reference	WO2002043620A1.pdf	599090	no	28
	5		0454fc1f58f15765d669b6f6d8fd9ebd02a7 2ddc		
Warnings:					
Information:			1		
4	Foreign Reference	WO2002047575A2.pdf	739166	no	29
	roreignneterenee	W0200204757572.pdf	11201663288fcb754a49ad5ca5aeb566b85 3b0d2	110	
Warnings:					•
Information:					
5	Foreign Reference	WO2003094793A1.pdf	879936	20	35
5	i oleigii Kelerence	W02003094793A1.pdf	508c782daa5412287b14a55a3135bfc7f88f adee	no	
Warnings:			·		•
Information:					
6	Foreign Reference		1330789		57
0	Foleigh Referice	WO2004058106A2.pdf	7e0c7934817c2261510da61e298eb2453dd b2b23	no	
Warnings:					•
Information:					
7			1567625		52
7	Foreign Reference	WO2004089250A1.pdf	b70ab56e237b03e8faef41c3673f8ed3e5cf eb09	no	52
Warnings:			I		1
Information:					
2		W0200400025244	1107395		50
8	Foreign Reference	WO2004089253A1.pdf	8c807328a22dc81dbd6576ebc6f21ebef2f6 2765	no	50
Warnings:			1		1
Information:					
0		MO200400272042	890468		25
9	Foreign Reference	WO2004093728A2.pdf	b137ae0c00b70cc9a8e50d218c30f631806 28ca3	no	25
Warnings:			1		1
Information:					
10	Foreign Reference	WO2004105651A1.pdf	976253		35
	i oreign Nelerence	w02004105051A1.pdf	fb7517137f01abecc6f3ed2745a35808e05b 217d	no	
Warnings:			1		<u>.</u>
Information:	Edwards Lifesc	iences Corporation, et a	l. Exhibit 1102, Pag	ge 277 of 4	42

<u> </u>					1
11	Foreign Reference	WO2005002466A2.pdf	1036709 970ce55c02d347ee5ac672837c89c023e07	no	36
Warnings:			79447		
Information:					
			1569937		
12	Foreign Reference	WO2005004753A1.pdf	9a99f094ab7ce0dd9f338ef8ac6f888a5271 b319	no	54
 Warnings:			0319		
Information:					
			546512		
13	Foreign Reference	WO2005009285A2.pdf	b8f7eb3b6941ab41fc70338cd0046ef373e4	no	29
Warnings:			e511		
Information:					
			818200		
14	Foreign Reference	WO2005011534A1.pdf	51e2814f7d51c0c10a26e4e5ed5cb6aeb12 6494f	no	39
Warnings:		1	1		I
Information:					
			1164022		
15	Foreign Reference	WO2005011535A2.pdf	64966e60b6fcd262fad4c3175e463453f223 fb5d	no	34
Warnings:		1	1		1
Information:					
			857526		43
16	Foreign Reference	WO2005023155A1.pdf	bc9ea3d08d817360ebe726444e5fa76c971 343d6	no	
Warnings:		1			1
Information:					
17			263874		11
17	Foreign Reference	WO2005027790A1.pdf	a5239382b5e9efc2920f32ce3f19e2e5b0f2a af6	no	
Warnings:			1		
Information:					
18	Eoroign Poferon co	W0200504652841 pdf	2984004		126
18	Foreign Reference	WO2005046528A1.pdf	7b53510ec4610beebad81e559c6133e859e 3c091	no	136
Warnings:					
Information:					
19	Foreign Reference	WO2005046529A1.pdf	1436654	no	75
	i oreign Nererence	W02003040329A1.pdf	73ae17954b6c499b012c61736d1789949a7 4d808	no	
Warnings:			·		
Information:	Edwards Lifes	sciences Corporation, et a	ll. Exhibit 1102. Pag	e 278 of 4	42

<u> </u>		1			
20	Foreign Reference	WO2005048883A1.pdf	1833156 92c8fe3b052be89de7f0d46e790c8326279 53a1a	no	85
Warnings:					<u> </u>
Information:					
21		W(0200505200042 - 15	6547837		264
21	Foreign Reference	WO2005062980A2.pdf	a70f844f6b55b1e9ea1bcab4f2a05d57ebf1 6cd4	no	264
Warnings:					•
Information		1			
22	Foreign Reference	MO200506559541 pdf	1020731		46
22	Foreign Reference	WO2005065585A1.pdf	1a459a9e642439c4667f552550f77a51eb23 fcca	no	40
Warnings:					
Information:					
22			954268		12
23	Foreign Reference	WO2005096993A1.pdf	43decad59d86496e64fb9d267e5b35ebfdf bbf06	no	42
Warnings:		·			
Information:					
24	Foreign Poference		2287507		01
24	Foreign Reference	WO2006009690A1.pdf	92ca8967febafb983233fe9d8fb755cbe9b7 b929	no	91
Warnings:			1		
Information:					
	_		922423		
25	Foreign Reference	WO2006027499.pdf	b04a216aea164ae8ee02316e8658a16e0b3 ce29e	no	22
Warnings:					I
Information:					
			795307		
26	Foreign Reference	WO2006138391A2.pdf	a0ae366455847b84b3400bfa6b739b16d8f d622a	no	40
Warnings:		I	1		I
Information:					
			750007		
27	Foreign Reference	WO2007033093A2.pdf	a80f5b47c00fe64bae88b291872d57880cea 69c1	no	27
Warnings:					<u> </u>
Information:					
			1007281		
28	Foreign Reference	WO2007035471A2.pdf	15ec34abf44b7390e16ec5432e8b8771a03 764c8	no	36
Warnings:		1	I		1
Information:	Edwards Lifes	sciences Corporation, et a	l. Exhibit 1102. Pao	e 279 of 4	42

		Total Files Size (in bytes	465	37716	
Information:					
Warnings:			·		
34	Foreign Reference	WO2010042950A2.pdf	d03db01531af3dff5d78e8bc59ddbac6785 0b0d3	no	79
24	Fourier Defenses	MO201004205042 - 15	1766587		70
Information:					
Warnings:		1	· ·		
33	Foreign Reference	WO2007097983.pdf	64b9625791c569d7dd187102ec598e430d 9e1943	no	121
		W/02007007002 //	4203698		405
Information:					
Warnings:		1	1		
32	Foreign Reference	WO2007092354A2.pdf	90c6c128dcdb3087f1b3a29d6f997a58563 b5ebf	no	34
			1417930		
Information:					
Warnings:		1	1		
31	Foreign Reference	WO2007058847A2.pdf	9595ce748c70de1dae4bf2a0b39f832341d 45364	no	36
			1200216		
Information:					
Warnings:			b3303		
30	Foreign Reference	WO2007053243A2.pdf	7de8125ddc9391642b03a32129803b7dff6	no	59
			1587642		
Information:					
Warnings:					
29	Foreign Reference	WO2007044285A2.pdf	6915a680a8125967a69d3c9dfcf57cd3856b 1e31	no	27
	/		846623		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		12492512
	Filing Date		2009-06-26
	First Named Inventor	Ulrich	R. Haug
	Art Unit		3774
	Examiner NameAnn MAttorney Docket Number		1. Schillinger
			S63.2-15141-US03

					U.S.I	PATENTS			Remove				
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	do1 Issue Date				of cited Document		of cited Document		Relev	s,Columns,Lines where vant Passages or Relevant es Appear
	1	6364895		2002-04	1-02	Greenhalgh							
	2	6346116		2002-02	2-12	Brooks, et al.							
lf you wisl	n to ad	d additional U.S. Pater	t citatio	n inform	ation pl	ease click the	Add button.		Add				
			U.S.P	ATENT	APPLIC	CATION PUBL	LICATIONS		Remove				
Examiner Initial*	Cite N	lo Publication Number	Kind Code ¹	Publica Date	ation	on Name of Patentee or Applicant of cited Document		t Pages,Columns,Lines where Relevant Passages or Releva Figures Appear					
	1	20020161390		2002-10)-31	Mouw							
	2	20030100919		2003-05-29 2003-03-27		Hopkins, et al. Peterson, et al.							
	3	20030057156											
lf you wisl	n to ad	d additional U.S. Publis	i shed Ap	plication	n citatio	ı n information p	lease click the Ade	ı d butto	n. Add				
				FOREIC	GN PAT		ENTS		Remove				
Examiner Initial*		Foreign Document Number ³	Country Code ²	intry Kind		Publication Date	Name of Patente Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear				

	Application Number		12492512	
	Filing Date		2009-06-26	
INFORMATION DISCLOSURE	First Named Inventor Ulrich		n R. Haug	
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		3774	
	Examiner Name	Ann M	1. Schillinger	
	Attorney Docket Numb	er	S63.2-15141-US03	

	1									
If you wisl	n to ac	dd add	litional Foreign F	Patent Document	citation	information pl	ease click the Add butto	n Add		
				NON-PATE	NT LITE	RATURE DO	CUMENTS	Remove		
Examiner Initials*	Examiner No Cite No Cite No Cite author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.							T⁵		
	1	Exam	Examiner's First Report on AU Patent Application No. 2011202667, issued on May 17, 2012.							
If you wisl	h to ac	dd add	litional non-pate	nt literature docu	ment cit	ation informati	on please click the Add I	outton Add		
				EX	AMINE	R SIGNATUR	E			
Examiner	Signa	iture					Date Considered			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.										
¹ See Kind Codes of USPTO Patent Documents at <u>www.USPTO.GOV</u> or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.										

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		12492512	
	Filing Date		2009-06-26	
	First Named Inventor Ulrich R. Haug		R. Haug	
	Art Unit		3774	
	Examiner Name	Ann M	1. Schillinger	
	Attorney Docket Number		S63.2-15141-US03	

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

See attached certification statement.

The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

X A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/James M. Urzedowski/	Date (YYYY-MM-DD)	2012-06-29
Name/Print	James M. Urzedowski	Registration Number	48596

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- 2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- 3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- 5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- 6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
- 9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Electronic Acknowledgement Receipt			
EFS ID:	13141912		
Application Number:	12492512		
International Application Number:			
Confirmation Number:	7439		
Title of Invention:	Everting Heart Valve		
First Named Inventor/Applicant Name:	Amr Salahieh		
Customer Number:	490		
Filer:	James M. Urzedowski/Samantha Painschab		
Filer Authorized By:	James M. Urzedowski		
Attorney Docket Number:	S63.2Q-15141-US03		
Receipt Date:	29-JUN-2012		
Filing Date:	26-JUN-2009		
Time Stamp:	12:47:07		
Application Type:	Utility under 35 USC 111(a)		

Payment information:

Submitted with Payment		no				
File Listing:						
Document Number	Document Description		File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Transmittal Letter	15	141US03 tra 20120627.pdf	80686	no	1
	Hansmittar Letter		131410303_ttd_20120027.pdf	cdeccac18ae9f3c60e4038461880754ca5b1 cd63		I
Warnings:		-		· · · ·		
Information:	Edwards Lifesc	ienc	es Corporation, et al	. Exhibit 1102. Pag	ve 286 of 4	42

<u>Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 286 of 442</u>

		Total Files Size (in bytes)	. 9	65500	
Information	:				
Warnings:					
		U_App_No_2011202667.pdf	23dccfd1453abcfe4b8e6dea5a9718058fc4 2758		
3	Non Patent Literature	Examiners_First_Report_on_A	272422	no	3
Information	:	1			
Warnings:					
2	Information Disclosure Statement (IDS) Form (SB08)		f8aff49a7260ddd15015f01a40f57756feb77 933	no	4
2		15141US03 IDS 20120627.pdf	612392		

New Applications Under 35 U.S.C. 111

Post Card, as described in MPEP 503.

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

In re Application of:	Ulrich R. Haug, Hans F. Valencia, Robert A. Geshlider, Tom Saul,
	Amr Salahieh, Dwight P. Morejohn, Kenneth J. Michlitsch
Application No.:	12/492512
Filed:	June 26, 2009
For:	Everting Heart Valve

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Group Art Unit:

Docket No.: S63.2Q-15141-US03

TRANSMITTAL LETTER

1. In regard to the above-identified application, in addition to this **1** page transmittal letter, we are submitting the attached:

4 page Supplemental IDS; 1 Non-Patent Literature Document.

2. With respect to fees, applicant believes the fees required herein, if any, are being paid electronically.

3. CONDITIONAL PETITION FOR EXTENSION OF TIME

3774

- This conditional petition is being filed along with the papers identified in Item 1 above and provides for the possibility that Applicant has inadvertently overlooked the need for a petition and fee for extension of time or for a petition and fee for any other matter petitionable to the Commissioner as required. If any extension of time for the accompanying response is required or if a petition for any other matter is required, by petitioner, Applicant requests that this be considered a petition therefor.
- 4. Notwithstanding paragraph 2 above, if any additional fees associated with this communication are required and have not otherwise been paid, including any fee associated with the Conditional Petition for Extension of Time, or any request in the accompanying papers for action which requires a fee as a petition to the Commissioner, please charge the additional fees to Deposit Account No. 22-0350. Please charge any additional fees associated with this communication to the Deposit Account No. 22-0350.
- 5. **Certification:** I hereby certify that this Transmittal Letter and the paper(s) as described herein are being transmitted electronically to the USPTO on June 29, 2012.

Respectfully submitted,

VIDAS, ARRETT & STEINKRAUS

Date: June 29, 2012

By: /James M. Urzedowski/

James M. Urzedowski Registration No.: 48596

6640 Shady Oak Rd., Suite 400 Eden Prairie, MN 55344-7834 Telephone: (952) 563-3000 Facsimile: (952) 563-3001 v:\wpwork\jmu\15141us03_tra_20120627.doc Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		12492512			
	Filing Date		2009-06-26			
	First Named Inventor Amr S		Salahieh			
	Art Unit Examiner Name Ann M		3774			
			1. Schillinger			
	Attorney Docket Number		S63.2-15141-US03			

					U.S.	PATENTS			Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue D)ate	Name of Pate of cited Docu	entee or Applicant ment	Releva	s,Columns,Lines where ant Passages or Relevant s Appear
	1	8226710		2012-07	'-24	Nguyen et al.			
lf you wisl	h to ac	d additional U.S. Pate	nt citatio	n inform	ation pl	ease click the	Add button.		Add
			U.S.P	ATENT	APPLI	CATION PUBI			Remove
Examiner Initial*	Cite I	No Publication Number				t Pages,Columns,Lines when Relevant Passages or Rele Figures Appear			
	1	20040019374		2004-01	-29	Hojeibane et al.			
	2	20060149360		2006-07	'- 06	Schwammenth	al et al.		
lf you wisl	h to ac	ld additional U.S. Publ	ished Ap	plication	n citatio	n information p	lease click the Ade	d buttor	n. Add
				FOREI	GN PAT	ENT DOCUM	ENTS		Remove
Examiner Initial*	Cite No			Kind Code⁴	Publication Date	Name of Patented Applicant of cited Document	e or	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1								
lf you wisl	h to ac	ld additional Foreign F	atent Do	cument	citation	information pl	ease click the Add	button	Add
			NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove

INFORMATION DISCLOSURE Application Number 12492512 Filing Date 2009-06-26 First Named Inventor Amr Salahieh Art Unit 3774 Examiner Name Ann M. Schillinger Attorney Docket Number \$63.2-15141-U\$03

Examiner Initials*	Examiner nitials* Cite No linclude name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.								
	1								
If you wis	If you wish to add additional non-patent literature document citation information please click the Add button Add								
			EXAMINER SIGNATURE						
Examiner	Signa	iture	Date Considered						
	*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								
Standard ST ⁴ Kind of doo	Г.З). ^З F cument	[:] or Japa by the a	O Patent Documents at <u>www.USPTO.GOV</u> or MPEP 901.04. ² Enter office that issued the document anese patent documents, the indication of the year of the reign of the Emperor must precede the ser appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applic in is attached.	ial number of the patent doc	ument.				

	Application Number		12492512	
	Filing Date		2009-06-26	
INFORMATION DISCLOSURE	First Named Inventor Amr S		Salahieh	
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		3774	
	Examiner Name	Ann M	1. Schillinger	
	Attorney Docket Numb	er	S63.2-15141-US03	

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

See attached certification statement.

The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

X A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/James A. Zak, Esq./	Date (YYYY-MM-DD)	2012-09-11
Name/Print	James A. Zak	Registration Number	60190

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- 2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- 3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- 5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- 6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
- 9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Electronic Ac	knowledgement Receipt
EFS ID:	13715112
Application Number:	12492512
International Application Number:	
Confirmation Number:	7439
Title of Invention:	Everting Heart Valve
First Named Inventor/Applicant Name:	Amr Salahieh
Customer Number:	490
Filer:	James Anthony Zak
Filer Authorized By:	
Attorney Docket Number:	S63.2Q-15141-US03
Receipt Date:	11-SEP-2012
Filing Date:	26-JUN-2009
Time Stamp:	17:41:49
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with F	Payment	no	no					
File Listing:								
Document Number	Document Description		File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)			
1	Transmittal Letter	15141US03 tra 20120911.p	80858	no	1			
'		131410305_114_20120311.p	694872ddffcf88e77c7cd0b9d73a9aecc414 c811	110				
Warnings:			· · ·					
Information:	Edwards Lifesc	iences Corporation, et	al. Exhibit 1102, Pag	e 293 of 4	42			

2	Information Disclosure Statement (IDS)		612150	no	4
	Form (SB08)	.pdf	bcd867f18bd38b48c5826272d837edda53 d3a1ab		

Warnings:

Information:

Total Files Size (in bytes	: 693008
----------------------------	----------

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

In re Application of:	Ulrich R. Haug, Hans F. Valencia, Robert A. Geshlider, Tom Saul, Amr Salahieh, Dwight P. Morejohn, Kenneth J. Michlitsch
Application No.: Filed:	12/492512 June 26, 2009
For:	Everting Heart Valve
Group Art Unit:	3774

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Mail Stop _____ Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Docket No.: S63.2Q-15141-US03

TRANSMITTAL LETTER

- 1. In regard to the above-identified application, in addition to this **1** page transmittal letter, we are submitting the attached: **4 page Supplemental Information Disclosure Statement.**
- 2. With respect to fees, applicant believes the fees required herein, if any, are being paid electronically.

3. CONDITIONAL PETITION FOR EXTENSION OF TIME

- This conditional petition is being filed along with the papers identified in Item 1 above and provides for the possibility that Applicant has inadvertently overlooked the need for a petition and fee for extension of time or for a petition and fee for any other matter petitionable to the Commissioner as required. If any extension of time for the accompanying response is required or if a petition for any other matter is required, by petitioner, Applicant requests that this be considered a petition therefor.
- 4. Notwithstanding paragraph 2 above, if any additional fees associated with this communication are required and have not otherwise been paid, including any fee associated with the Conditional Petition for Extension of Time, or any request in the accompanying papers for action which requires a fee as a petition to the Commissioner, please charge the additional fees to Deposit Account No. 22-0350. Please charge any additional fees associated with this communication to the Deposit Account No. 22-0350.
- 5. **Certification:** I hereby certify that this Transmittal Letter and the paper(s) as described herein are being transmitted electronically to the USPTO on September 11, 2012.

Respectfully submitted, VIDAS, ARRETT & STEINKRAUS

Date: September 11, 2012

By: /James A. Zak, Esq./

James A. Zak Registration No.: 60190

6640 Shady Oak Rd., Suite 400 Eden Prairie, MN 55344-7834 Telephone: (952) 563-3000 Facsimile: (952) 563-3001 v:\wpwork\jaz\15141us03_tra_20120911.doc Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		12492512		
	Filing Date		2009-06-26		
	Art Unit		Salahieh		
			3774		
			1. Schillinger		
	Attorney Docket Number		S63.2-15141-US03		

					U.S.F	PATENTS			Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Da	ate	Name of Pate of cited Docu	entee or Applicant ment	Releva	s,Columns,Lines wher ant Passages or Rele es Appear	
	1	6352554	B2	2002-03-1	05	Sulzer Vascute	ek Limited			
If you wis	h to ac	dd additional U.S. Pate	nt citatio	n informa	tion pl	ease click the	Add button.		Add	
			U.S.P	ATENT A	PPLIC	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cito No 1. manual cita in a cita de la cita		Publicati Date	ion	Name of Pate of cited Docu	entee or Applicant ment	Releva	s,Columns,Lines wher ant Passages or Rele es Appear		
	1									
lf you wis	h to ac	d additional U.S. Pub	lished Ap	plication	citatior	n information p	please click the Ade	d buttor	n. Add	
				FOREIG	Ν ΡΑΤ	ENT DOCUM	ENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Countr Code ²	·	Kind Code⁴	Publication Date	Name of Patented Applicant of cited Document	e or	Pages,Columns,Line where Relevant Passages or Relevan Figures Appear	T5
	1									
lf you wis	h to ac	l d additional Foreign F	atent Do	cument c	itation	information pl	lease click the Add	button	Add	1
			NON	I-PATEN		RATURE DO	CUMENTS		Remove	
Examiner Initials*	Cite No	Include name of the a (book, magazine, jou publisher, city and/or	rnal, seria	al, sympo	sium,	catalog, etc), c				T⁵

	Application Number		12492512	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Filing Date		2009-06-26	
	First Named Inventor Amr S		Salahieh	
	Art Unit		3774	
	Examiner Name	Ann N	1. Schillinger	
	Attorney Docket Number		S63.2-15141-US03	

	1		litional non-natorit literatura decument citation information places aligh the Ad	hutton Add		
	n to at	a auc	litional non-patent literature document citation information please click the Add			
			EXAMINER SIGNATURE			
Examiner	Examiner Signature Date Considered					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						
Standard ST ⁴ Kind of doo	⁻ .3). ³ F cument	[:] or Japa by the a	O Patent Documents at <u>www.USPTO.GOV</u> or MPEP 901.04. ² Enter office that issued the docur anese patent documents, the indication of the year of the reign of the Emperor must precede the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Ap n is attached.	serial number of the patent doo	ument.	

INFORMATION DISCLOSURE	Application Number		12492512	
	Filing Date		2009-06-26	
	First Named Inventor	irst Named Inventor Amr Salahieh		
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		3774	
	Examiner Name	Ann M	1. Schillinger	
	Attorney Docket Number		S63.2-15141-US03	

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

See attached certification statement.

The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

X A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/James M. Urzedowski/	Date (YYYY-MM-DD)	2013-02-13
Name/Print	James M. Urzedowski	Registration Number	48596

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- 2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- 3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- 5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- 6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
- 9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Electronic Ac	knowledgement Receipt
EFS ID:	14949353
Application Number:	12492512
International Application Number:	
Confirmation Number:	7439
Title of Invention:	Everting Heart Valve
First Named Inventor/Applicant Name:	Amr Salahieh
Customer Number:	490
Filer:	James M. Urzedowski/Rebecca Leaf
Filer Authorized By:	James M. Urzedowski
Attorney Docket Number:	S63.2Q-15141-US03
Receipt Date:	13-FEB-2013
Filing Date:	26-JUN-2009
Time Stamp:	14:43:42
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment			no				
File Listing:							
Document Number	Document Description		File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)	
1	Transmittal Letter	15	151411502 + 20120212 - 45	103581	no	1	
	Hansmittar Letter	······	fa4632afb6d129ef547053eb19a3bde58738 901a	no	I		
Warnings:				· · · · · ·			
Information:	Edwards Lifesc	ienc	es Corporation, et al	. Exhibit 1102. Pag	e 300 of 4	42	

<u>Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 300 of 442</u>

2 Information Disclosure Statement (IDS) Form (SB08) 15141US03_IDS_20130213.pdf	4	
--	---	--

Warnings:

Information:

Total Files Size (in by	tes): 715756	
-------------------------	--------------	--

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

In re Application of:	Ulrich R. Haug, Hans F. Valencia, Robert A. Geshlider, Tom Saul, Amr
	Salahieh, Dwight P. Morejohn, Kenneth J. Michlitsch
Application No.:	12/492512
Filed:	June 26, 2009
For:	Everting Heart Valve
Examiner:	Ann M. Schillinger
Group Art Unit:	3774

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Docket No.: S63.2Q-15141-US03

TRANSMITTAL LETTER

1. In regard to the above-identified application, in addition to this 1 page transmittal letter, we are submitting the attached:

4 page Information Disclosure Statement.

2. With respect to fees, applicant believes the fees required herein, if any, are being paid electronically.

3. CONDITIONAL PETITION FOR EXTENSION OF TIME

- This conditional petition is being filed along with the papers identified in Item 1 above and provides for the possibility that Applicant has inadvertently overlooked the need for a petition and fee for extension of time or for a petition and fee for any other matter petitionable to the Commissioner as required. If any extension of time for the accompanying response is required or if a petition for any other matter is required, by petitioner, Applicant requests that this be considered a petition therefor.
- 4. Notwithstanding paragraph 2 above, if any additional fees associated with this communication are required and have not otherwise been paid, including any fee associated with the Conditional Petition for Extension of Time, or any request in the accompanying papers for action which requires a fee as a petition to the Commissioner, please charge the additional fees to Deposit Account No. 22-0350. Please charge any additional fees associated with this communication to the Deposit Account No. 22-0350.
- 5. **Certification:** I hereby certify that this Transmittal Letter and the paper(s) as described herein are being transmitted electronically to the USPTO on February 13, 2013.

Respectfully submitted,

VIDAS, ARRETT & STEINKRAUS

Date: February 13, 2013

By: /James M. Urzedowski/

James M. Urzedowski Registration No.: 48596

6640 Shady Oak Rd., Suite 400 Eden Prairie, MN 55344-7834 Telephone: (952) 563-3000 Facsimile: (952) 563-3001 v:\wpwork\jmu\15141us03_tra_20130213.doc Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		12492512	
Filing Date		2009-06-26	
First Named Inventor	Haug	et al.	
Art Unit		3774	
Examiner Name	Not ye	et assigned	
Attorney Docket Number		S63.2-15141-US03	

		-		U.S.	PATENTS	Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1	5443477		1995-08-22	Marin et al.			
	2	6572643		2003-06-03	Gharibadeh			
	3	6755854		2004-06-29	Gillick et al.			
	4	6866669		2005-03-15	Buzzard et al.			
	5	6939352		2005-09-06	Buzzard et al.			
	6	7326236		2008-02-05	Andreas et al.			
	7	7491232		2009-02-17	Bolduc et al.			
	8	7674282		2010-03-09	Wu et al.			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT))

(Not for submission	under 37	CFR	1.99)
---------------------	----------	-----	-------

Application Number		12492512		
Filing Date		2009-06-26		
First Named Inventor	Haug	et al.		
Art Unit		3774		
Examiner Name	Not ye	et assigned		
Attorney Docket Numb	er	S63.2-15141-US03		

		_	-		
9	7722638		2010-05-25	Deyette, Jr. et al.	
10	7736388		2010-06-15	Goldfarb et al.	
11	7758625		2010-07-20	Wu et al.	
12	7799065		2010-09-21	Pappas	
13	7892292		2011-02-22	Stack et al.	
14	7918880		2011-04-05	Austin	
15	7938851		2011-05-10	Olson et al.	
16	8192351		2012-06-05	Fishler et al.	
17	8236049		2012-08-07	Rowe et al.	
18	8252051		2012-08-28	Chau et al.	
19	8308798		2012-11-13	Pintor et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT))

(Not for se	ubmission	under 3	7 CFR	1.99)
-------------	-----------	---------	-------	-------

Application Number		12492512		
Filing Date		2009-06-26		
First Named Inventor	Haug	et al.		
Art Unit		3774		
Examiner Name	Not ye	et assigned		
Attorney Docket Numb	er	S63.2-15141-US03		

	20	8323335		2012-12-04	Rowe et al.	
	21	8376865		2013-02-19	Forster et al.	
	22	8377117		2013-02-19	Keidar et al.	
	23	8398708		2013-03-19	Meiri et al.	
If you wis	h to add	additional U.S. Paten	t citatio	n information pl	ease click the Add button.	Add
			U.S.P		CATION PUBLICATIONS	Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20050060016		2005-03-17	Wu et al.	
	2	20050090890		2005-04-28	Wu et al.	
	3	20050149159		2005-07-07	Andreas et al.	
	4	20080255661		2008-10-16	Straubinger et al.	
	5	20090093877		2009-04-09	Keidar et al.	

INFORMATION DISCLOSURE Application Number 12492512 Filing Date 2009-06-26 First Named Inventor Haug et al. Art Unit 3774 Examiner Name Not yet assigned Attorney Docket Number \$63.2-15141-U\$03

	6	:	20100094399		2010-04	-15	Dorn et al.				
	7	:	20100191326		2010-07	'-29	Alkhatib				
	8	:	20130030520		2013-01	-31	Lee et al.				
If you wis	h to ao	dd ad	ditional U.S. Publi	shed Ap	plicatior	n citation	n information p	lease click the Add	d butto	on. Add	
FOREIGN PATENT DOCUMENTS Remove											
Examiner Initial*	Cite No	1	eign Document nber ³	Country Code ²		Kind Code⁴	Publication Date	Name of Patentee Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T5
	1										
If you wis	h to ao	dd ad	ditional Foreign Pa	atent Do	cument	citation	information pl	ease click the Add	buttor	n Add	
				NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove	
Examiner Initials*	Cite No	(bod		nal, seria	al, symp	osium,	catalog, etc), c	the article (when a date, pages(s), volเ		riate), title of the item ssue number(s),	T⁵
	1										
If you wis	h to ac	dd ad	ditional non-paten	t literatu	re docui	ment cit	ation informati	ion please click the	Add	outton Add	1
					EX	AMINE	R SIGNATUR	E			
Examiner	Signa	ature						Date Conside	ered		
								ormance with MPE with next communic		. Draw line through a to applicant.	

INFORMATION DISCLOSURE	Application Number		12492512	
	Filing Date		2009-06-26	
	First Named Inventor Hauge		g et al.	
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		3774	
	Examiner Name	Not ye	et assigned	
	Attorney Docket Numb	er	S63.2-15141-US03	

¹ See Kind Codes of USPTO Patent Documents at <u>www.USPTO.GOV</u> or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE	Application Number		12492512	
	Filing Date		2009-06-26	
	First Named Inventor Haug		g et al.	
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		3774	
	Examiner Name Not y		t yet assigned	
	Attorney Docket Numb	er	S63.2-15141-US03	

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

See attached certification statement.

The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

X A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/James M. Urzedowski/	Date (YYYY-MM-DD)	2013-05-06
Name/Print	James M. Urzedowski	Registration Number	48596

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- 2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- 3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- 5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- 6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
- 9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Electronic Ac	Electronic Acknowledgement Receipt					
EFS ID:	15701994					
Application Number:	12492512					
International Application Number:						
Confirmation Number:	7439					
Title of Invention:	Everting Heart Valve					
First Named Inventor/Applicant Name:	Amr Salahieh					
Customer Number:	490					
Filer:	James M. Urzedowski/Rebecca Leaf					
Filer Authorized By:	James M. Urzedowski					
Attorney Docket Number:	S63.2Q-15141-US03					
Receipt Date:	06-MAY-2013					
Filing Date:	26-JUN-2009					
Time Stamp:	16:32:05					
Application Type:	Utility under 35 USC 111(a)					

Payment information:

Submitted with F	Payment	no						
File Listing:								
Document Number	Document Description		File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)		
1	Transmittal Letter 15141US03_tra_20130506.		14111503 tra 20130506 pdf	103562	no	1		
			1410505_114_20150500.pdf	a47123e685eb2463621fe7a79389de86bd0 94ca1	110			
Warnings:				· · · · · ·				
Information:	Edwards Lifes	cienc	es Corporation, et al	Exhibit 1102, Pag	e 310 of 4	42		

2	Information Disclosure Statement (IDS)	15141US03_IDS_20130506.pdf	613122	no	7	
	Form (SB08)	·····	492615daa3c0fc3c4d6e737229194a78478 97f38			

Warnings:

Information:

Total Files Size (in bytes): 716684
--

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

In re Application of:	Ulrich R. Haug, Hans F. Valencia, Robert A. Geshlider, Tom Saul, Amr
in to appreciation on	Salahieh, Dwight P. Morejohn, Kenneth J. Michlitsch
Application No.:	12/492512
Filed:	June 26, 2009
For:	Everting Heart Valve
Examiner:	Ann M. Schillinger
Group Art Unit:	3774

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Docket No.: S63.2Q-15141-US03

TRANSMITTAL LETTER

1. In regard to the above-identified application, in addition to this 1 page transmittal letter, we are submitting the attached:

7 page Information Disclosure Statement.

2. With respect to fees, applicant believes the fees required herein, if any, are being paid electronically.

3. CONDITIONAL PETITION FOR EXTENSION OF TIME

- This conditional petition is being filed along with the papers identified in Item 1 above and provides for the possibility that Applicant has inadvertently overlooked the need for a petition and fee for extension of time or for a petition and fee for any other matter petitionable to the Commissioner as required. If any extension of time for the accompanying response is required or if a petition for any other matter is required, by petitioner, Applicant requests that this be considered a petition therefor.
- 4. Notwithstanding paragraph 2 above, if any additional fees associated with this communication are required and have not otherwise been paid, including any fee associated with the Conditional Petition for Extension of Time, or any request in the accompanying papers for action which requires a fee as a petition to the Commissioner, please charge the additional fees to Deposit Account No. 22-0350. Please charge any additional fees associated with this communication to the Deposit Account No. 22-0350.
- 5. **Certification:** I hereby certify that this Transmittal Letter and the paper(s) as described herein are being transmitted electronically to the USPTO on May 6, 2013.

Respectfully submitted,

VIDAS, ARRETT & STEINKRAUS

Date: May 6, 2013

By: /James M. Urzedowski/

James M. Urzedowski Registration No.: 48596

6640 Shady Oak Rd., Suite 400 Eden Prairie, MN 55344-7834 Telephone: (952) 563-3000 Facsimile: (952) 563-3001 v:\wpwork\jmu\15141us03_tra_20130506.doc Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		12492512
Filing Date		2009-06-26
First Named Inventor Ulrich		R. Haug
Art Unit		3774
Examiner Name Ann M		1. Schillinger
Attorney Docket Number		S63.2-15141-US03

					U.S.I	PATENTS			Remove
Examiner Cite Initial* No Patent N		Patent Number	ber Kind Code ¹		Issue Date Name of Patent of cited Docume		mont Rele		,Columns,Lines where ant Passages or Relevant s Appear
	1								
lf you wisl	n to ac	d additional U.S. Pate	nt citatio	n informa	ation pl	ease click the	Add button.		Add
			U.S.P	ATENT /	APPLI	CATION PUB			Remove
Examiner Initial*	Cite I	No Publication Number	Kind Code ¹	Publicat Date	tion	Name of Pate of cited Docu	entee or Applicant iment	Releva	,Columns,Lines where ant Passages or Relevant s Appear
	1	20060287717	A1	2006-12-	-21	Rowe et al.			
	2	20080033541	A1	2008-02-	-07	Gelbart et al.			
lf you wisl	n to ac	d additional U.S. Pub	lished Ap	plication	citatio	l n information p	please click the Ad	l d buttor	Add
				FOREIG	N PAT		IENTS		Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code⁴	Publication Date	Name of Patente Applicant of cited Document	e or ,	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	96/40012	wo			1996-12-19	St. Jude Medical, Ir	10.	
lf you wisl	h to ac	ld additional Foreign F	atent Do	cument o	citation	information p	lease click the Add	button	Add
			NON	I-PATEN		RATURE DO	CUMENTS		Remove

INFORMATION DISCLOSURE Application Number 12492512 Filing Date 2009-06-26 First Named Inventor Ulrich R. Haug Art Unit 3774 Examiner Name Ann M. Schillinger Attorney Docket Number \$63.2-15141-U\$03

Examiner Initials*	Cite No	(bool	de name of the author (in CAPITAL LETTERS), title of the article (when approp k, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-is sher, city and/or country where published.		T⁵	
	1					
lf you wis	h to ac	dd add	litional non-patent literature document citation information please click the Add b	outton Add	L	
	EXAMINER SIGNATURE					
Examiner	Signa	ture	Date Considered			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						
Standard S ⁻ ⁴ Kind of do	Г.З). ^З F cument	^F or Japa by the a	O Patent Documents at <u>www.USPTO.GOV</u> or MPEP 901.04. ² Enter office that issued the docume anese patent documents, the indication of the year of the reign of the Emperor must precede the ser appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applic in is attached.	rial number of the patent doo	ument.	

	Application Number		12492512	
	Filing Date		2009-06-26	
INFORMATION DISCLOSURE	First Named Inventor Ulrich		h R. Haug	
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		3774	
	Examiner Name Ann M		M. Schillinger	
	Attorney Docket Numb	er	S63.2-15141-US03	

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

See attached certification statement.

The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

X A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/James M. Urzedowski/	Date (YYYY-MM-DD)	2013-07-12
Name/Print	James M. Urzedowski	Registration Number	48596

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- 2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- 3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- 5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- 6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
- 9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Electronic Acknowledgement Receipt				
EFS ID:	16302074			
Application Number:	12492512			
International Application Number:				
Confirmation Number:	7439			
Title of Invention:	Everting Heart Valve			
First Named Inventor/Applicant Name:	Amr Salahieh			
Customer Number:	490			
Filer:	James M. Urzedowski/Rebecca Leaf			
Filer Authorized By:	James M. Urzedowski			
Attorney Docket Number:	S63.2Q-15141-US03			
Receipt Date:	12-JUL-2013			
Filing Date:	26-JUN-2009			
Time Stamp:	14:42:43			
Application Type:	Utility under 35 USC 111(a)			

Payment information:

Submitted with Payment			no				
File Listing:							
Document Number	Document Description		File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)	
1	Transmittal Letter	151/11/503 tra 20	103579 15141US03 tra 20130712.pdf	no	1		
·			1410303_da_20130712.pdf	50fa69dd7dc9ac713e283fc3155925beadac db2b	110	I	
Warnings:							
Information:	Edwards Lifes	cienc	es Corporation, et al	Exhibit 1102. Pag	e 317 of 4	42	

Informatio					
	n:				
Warnings:					
-		pdf	8356b9e363a19ea35e04d290698ad1d852 759121		
3	Foreign Reference	15141US03_WO1996040012.	4663156	no	31
Informatio	n:		1		1
Warnings:					
2	Form (SB08)		cf94e1d433d81dc9ce4ba7edf6d7b287ac7 7551a		
	Information Disclosure Statement (IDS)	15141US03_IDS_20130712.pdf	612274	no	4

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

In re Application of:	Ulrich R. Haug, Hans F. Valencia, Robert A. Geshlider, Tom Saul, Amr
	Salahieh, Dwight P. Morejohn, Kenneth J. Michlitsch
Application No.:	12/492512
Filed:	June 26, 2009
For:	Everting Heart Valve
Examiner:	Ann M. Schillinger
Group Art Unit:	3774

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Docket No.: S63.2Q-15141-US03

TRANSMITTAL LETTER

1. In regard to the above-identified application, in addition to this 1 page transmittal letter, we are submitting the attached:

4 page Information Disclosure Statement and copy of 1 reference.

2. With respect to fees, applicant believes the fees required herein, if any, are being paid electronically.

3. CONDITIONAL PETITION FOR EXTENSION OF TIME

- This conditional petition is being filed along with the papers identified in Item 1 above and provides for the possibility that Applicant has inadvertently overlooked the need for a petition and fee for extension of time or for a petition and fee for any other matter petitionable to the Commissioner as required. If any extension of time for the accompanying response is required or if a petition for any other matter is required, by petitioner, Applicant requests that this be considered a petition therefor.
- 4. Notwithstanding paragraph 2 above, if any additional fees associated with this communication are required and have not otherwise been paid, including any fee associated with the Conditional Petition for Extension of Time, or any request in the accompanying papers for action which requires a fee as a petition to the Commissioner, please charge the additional fees to Deposit Account No. 22-0350. Please charge any additional fees associated with this communication to the Deposit Account No. 22-0350.
- 5. **Certification:** I hereby certify that this Transmittal Letter and the paper(s) as described herein are being transmitted electronically to the USPTO on July 12, 2013.

Respectfully submitted,

VIDAS, ARRETT & STEINKRAUS

Date: July 12, 2013

By: /James M. Urzedowski/ James M. Urzedowski Registration No.: 48596

6640 Shady Oak Rd., Suite 400 Eden Prairie, MN 55344-7834 Telephone: (952) 563-3000 Facsimile: (952) 563-3001 v:\wpwork\jmu\15141us03_tra_20130712.doc Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		12492512
Filing Date		2009-06-26
First Named Inventor	Ulrich	R. Haug
Art Unit		3774
Examiner Name Ann M		1. Schillinger
Attorney Docket Number		S63.2-15141-US03

						U.S.I	PATENTS			Remove
Examiner Initial*	Cite No	P	Patent Number	Kind Code ¹ Issue		Issue Date Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Releva Figures Appear		
	1	6	363938		2002-04-6		Saadat, et al.			
lf you wisl	n to ac	ld a	dditional U.S. Pater	I nt citatio	n inform	ation pl	ease click the	Add button.		Add
				U.S.P	ATENT	APPLIC	CATION PUBI	LICATIONS		Remove
Examiner Initial*	Cite N	٩o	Publication Number	n Kind Publicatio Code ¹ Date		tion	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1		20040148018		2004-07	-29	Carpentier, et al.			
	2		20040199245		2004-10	-07	Lauterjung			
If you wisl	n to ac	ld a	dditional U.S. Publi	shed Ap	plication	citatio	n information p	blease click the Ade	d butto	n. Add
					FOREIC	GN PAT		ENTS		Remove
Examiner Initial*			-		Kind Code⁴	Publication Date	Name of Patente Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1									
lf you wisl	n to ac	ld a	dditional Foreign Pa	atent Do	cument	citation	information pl	ease click the Add	button	Add
				NON	I-PATEN	NT LITE	RATURE DO	CUMENTS		Remove

INFORMATION DISCLOSURE Application Number 12492512 Filing Date 2009-06-26 First Named Inventor Ulrich R. Haug Art Unit 3774 Examiner Name Ann M. Schillinger Attorney Docket Number \$63.2-15141-U\$03

Examiner Initials*	Aminer Cite No linclude name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.			T⁵		
	1					
If you wish to add additional non-patent literature document citation information please click the Add button Add						
EXAMINER SIGNATURE						
Examiner Signature Date Considered						
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						
Standard ST ⁴ Kind of doo	F.3). ³ F cument	For Japa by the a	⁻ O Patent Documents at <u>www.USPTO.GOV</u> or MPEP 901.04. ² Enter office that issued the documer anese patent documents, the indication of the year of the reign of the Emperor must precede the ser appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applic on is attached.	ial number of the patent doc	ument.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		12492512	
	Filing Date		2009-06-26	
	First Named Inventor Ulrich		n R. Haug	
	Art Unit		3774	
	Examiner Name	Ann M	M. Schillinger	
	Attorney Docket Number		S63.2-15141-US03	

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

See attached certification statement.

The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

X A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Michael J. McKeen/	Date (YYYY-MM-DD)	2013-09-17
Name/Print	Michael J. McKeen	Registration Number	66069

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- 2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- 3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- 5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- 6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
- 9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Electronic Acknowledgement Receipt					
EFS ID:	16879013				
Application Number:	12492512				
International Application Number:					
Confirmation Number:	7439				
Title of Invention:	Everting Heart Valve				
First Named Inventor/Applicant Name:	Amr Salahieh				
Customer Number:	490				
Filer:	Michael James McKeen/Wendy Skelly				
Filer Authorized By:	Michael James McKeen				
Attorney Docket Number:	S63.2Q-15141-US03				
Receipt Date:	17-SEP-2013				
Filing Date:	26-JUN-2009				
Time Stamp:	17:13:05				
Application Type:	Utility under 35 USC 111(a)				

Payment information:

Submitted with Payment			no					
File Listing:								
Document Number	Document Description		File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)		
1	Transmittal Letter	15	5141US03_tra_20130917.pdf	80504	no	1		
				c6a993b68190875fd97887ab5f147390d2b 7b1b8	.10			
Warnings:								
Information:	Edwards Lifes	scienc	es Corporation, et al	Exhibit 1102, Pag	e 324 of 4	42		

		Total Files Size (in bytes)	78	31687	
Information	:				
Warnings:					
5	Form (SB08)	·	4104ece5c326bfc8a5cb6be0df8baad0c8a7 9910	10	
3	Information Disclosure Statement (IDS)	15141US03_IDS_20130917.pdf	612169	no	4
Information	:				
Warnings:					
2	Miscellaneous incoming Letter	17.pdf	b5343874d7efb1eec6c9edb61374f52c429 efb9b		
2	Miscellaneous Incoming Letter	15141US03_Letter_ids_201309	89014	no	2

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	Ulrich R. Haug, Hans F. Valencia, Robert A. Geshlider, Tom Saul, Amr Salahich, Dwight P. Morejohn, Kenneth J. Michlitsch
Application No.:	12/492512
Filed:	June 26, 2009
For:	Everting Heart Valve
Examiner:	Ann M. Schillinger
Group Art Unit:	3774

Mail Stop _____ Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Docket No.: S63.2Q-15141-US03

TRANSMITTAL LETTER

- 1. In regard to the above-identified application, in addition to this 1 page transmittal letter, we are submitting the attached: 4 page Information Disclosure Statement and 2 page Information Disclosure Statement
- 2. With respect to fees, applicant believes the fees required herein, if any, are being paid electronically.

3. CONDITIONAL PETITION FOR EXTENSION OF TIME

- This conditional petition is being filed along with the papers identified in Item 1 above and provides for the possibility that Applicant has inadvertently overlooked the need for a petition and fee for extension of time or for a petition and fee for any other matter petitionable to the Commissioner as required. If any extension of time for the accompanying response is required or if a petition for any other matter is required, by petitioner, Applicant requests that this be considered a petition therefor.
- 4. Notwithstanding paragraph 2 above, if any additional fees associated with this communication are required and have not otherwise been paid, including any fee associated with the Conditional Petition for Extension of Time, or any request in the accompanying papers for action which requires a fee as a petition to the Commissioner, please charge the additional fees to Deposit Account No. 22-0350. Please charge any additional fees associated with this communication to the Deposit Account No. 22-0350.
- 5. **Certification:** I hereby certify that this Transmittal Letter and the paper(s) as described herein are being transmitted electronically to the USPTO on September 17, 2013.

Respectfully submitted,

VIDAS, ARRETT & STEINKRAUS

Date: September 17, 2013

By: /Michael J. McKeen/

Michael J. McKeen Registration No.: 66069

6640 Shady Oak Rd., Suite 400 Eden Prairie, MN 55344-7834 Telephone: (952) 563-3000 Facsimile: (952) 563-3001

v:\wpwork\mjm\15141us03_tra_20130917.doc

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	Ulrich R. Haug, Hans F. Valencia, Robert A.
	Geshlider, Tom Saul, Amr Salahieh, Dwight P.
	Morejohn, Kenneth J. Michlitsch
Application No.:	12/492512
Filed:	June 26, 2009
For:	Everting Heart Valve
Examiner:	Ann M. Schillinger
Group Art Unit:	3774

Mail Stop _____ Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Docket No.: S63.2Q-15141-US03

Letter Regarding IDS

Applicant has listed, on the accompanying form, information for consideration in the above-mentioned application. Applicant respectfully requests that the listed information be considered by the Examiner and be made of record in the above-identified application. Applicant requests that the Examiner return an initialed copy of the accompanying form(s) indicating that the listed information has been considered, in accordance with MPEP § 609. This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability.

For information submitted herewith in a foreign language, Applicant includes herewith a concise explanation of relevance as it is presently understood by the undersigned Attorney and/or an English language abstract, in accordance with 37 C.F.R. § 1.98(a)(3) and M.P.E.P. § 609.

Applicant respectfully requests that any copies of unpublished US applications submitted herewith be excluded from the file wrapper pursuant to 37 C.F.R. § 1.14.

The present application is a division of and claims priority under 35 U.S.C. § 120 to U.S. Pat. Appl. Ser. No. 12/269,213, filed on November 12, 2008; which is a continuation of 10/870,340 filed on June 16, 2004. Pursuant to 37 C.F.R. § 1.98(d), copies of documents cited by

Application No. 12/492512 Page 2

or submitted to the United States Patent and Trademark Office in a previous application to which priority was claimed under 35 U.S.C. § 120 need not be submitted and are not submitted herewith.

If a \$180 fee is due for consideration of this Information Disclosure Statement and full payment has not been submitted herewith, the Commissioner is hereby authorized to charge any additional fees associated with this communication to Deposit Account No. 22-0350. The Commissioner is hereby authorized to credit any overpayment associated with this communication to Deposit Account No. 22-0350.

Applicant requests that this Information Disclosure Statement be considered if it is timely submitted under any of the provisions of 37 C.F.R. § 1.97.

Respectfully submitted,

VIDAS, ARRETT & STEINKRAUS


Date: September 17, 2013

By: /Michael J. McKeen/

Michael J. McKeen Registration No.: 66069

6640 Shady Oak Rd., Suite 400 Eden Prairie, MN 55344-7834 Telephone: (952) 563-3000 Facsimile: (952) 563-3001

v:\wpwork\mjm\15141us03_ids_20130917.doc



Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

mail@vaslaw.com rleaf@vaslaw.com rarrett@vaslaw.com

	Application No. 12/492,512	Applicant(s SALAHIEH E	
Office Action Summary	Examiner ANN SCHILLINGER	Art Unit 3774	AIA (First Inventor to File) Status No
The MAILING DATE of this communication app Period for Reply	bears on the cover sheet with the	corresponden	ce address
A SHORTENED STATUTORY PERIOD FOR REPL' THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.1: after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	G(a). In no event, however, may a reply be ti vill apply and will expire SIX (6) MONTHS from , cause the application to become ABANDONE	mely filed h the mailing date o ED (35 U.S.C. § 13:	f this communication.
Status			
1) Responsive to communication(s) filed on <u>6/10/</u> A declaration(s)/affidavit(s) under 37 CFR 1.1			
	action is non-final.		
3) An election was made by the applicant in resp		set forth duri	ng the interview on
; the restriction requirement and election	have been incorporated into this	s action.	
4) Since this application is in condition for allowar			to the merits is
closed in accordance with the practice under E	<i>Ex parte Quayle</i> , 1935 C.D. 11, 4	53 O.G. 213.	
Disposition of Claims* 5) Claim(s) <u>1-15</u> is/are pending in the application. 5a) Of the above claim(s) is/are withdray 6) Claim(s) is/are allowed. 7) Claim(s) is/are rejected. 8) Claim(s) is/are objected to. 9) Claim(s) <u>1-15</u> are subject to restriction and/or estimation and/or estimation of the above been determined allowable, you may be estimated and the second s	wn from consideration. election requirement. igible to benefit from the Patent Pro oplication. For more information, ple an inquiry to <u>PPHfeedback@uspto.</u> r. epted or b) objected to by the drawing(s) be held in abeyance. Se	ase see gov. Examiner. e 37 CFR 1.85	(a).
Priority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign Certified copies: a) All b) Some** c) None of the: 1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority document ** See the attached detailed Office action for a list of the certified	ts have been received. ts have been received in Applica prity documents have been receiv u (PCT Rule 17.2(a)).	tion No	
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Information Disclosure Statement(s) (PTO/SB/08a and/or PTO/S	3)		
Paper No(s)/Mail Date			

The present application is being examined under the pre-AIA first to invent provisions.

DETAILED ACTION

Election/Restrictions

The claim(s) is/are directed to the following disclosed patentably distinct species: Species A: a system for replacing a heart valve comprising a seal made from an expandable foam; Species B: a system for replacing a heart valve comprising a fabric seal with flaps to extend into the spaces of the native valve leaflets; and Species C: a system for replacing a heart valve having seals made of sacs disposed around the valve anchor. The species are independent or distinct because as disclosed the different species have mutually exclusive characteristics for each identified species. In addition, these species are not obvious variants of each other based on the current record.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species, or a single grouping of patentably indistinct species, for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable.

There is a search and/or examination burden for the patentably distinct species as set forth above because at least the following reason(s) apply:

The disparate nature of the currently claimed species may hinder a quality and thorough examination of the claims on the merits.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or a grouping of patentably indistinct species to be examined even though the requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected species or grouping of patentably indistinct species, including

any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

The election may be made with or without traverse. To preserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the election of species requirement, the election shall be treated as an election without traverse. Traversal must be presented at the time of election in order to be considered timely. Failure to timely traverse the requirement will result in the loss of right to petition under 37 CFR 1.144. If claims are added after the election, applicant must indicate which of these claims are readable on the elected species or grouping of patentably indistinct species.

Should applicant traverse on the ground that the species, or groupings of patentably indistinct species from which election is required, are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the species unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103 or pre-AIA 35 U.S.C. 103(a) of the other species.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR 1.141.

A telephone call was made to Michael McKeen on 12/19/2013 to request an oral election to the above restriction requirement, but did not result in an election being made.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be corrected in compliance with 37 CFR 1.48(a) if one or more of the

currently named inventors is no longer an inventor of at least one claim remaining in the application. A request to correct inventorship under 37 CFR 1.48(a) must be accompanied by an application data sheet in accordance with 37 CFR 1.76 that identifies each inventor by his or her legal name and by the processing fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ann Schillinger whose telephone number is (571)272-6652. The examiner can normally be reached on Monday-Friday (9am-5:30pm).

If attempts to reach the examiner by telephone are unsuccessful, please contact the examiner's supervisor, David Isabella, at 571-272-4749. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/A. S./ Examiner, Art Unit 3774

/DAVID ISABELLA/ Supervisory Patent Examiner, Art Unit 3774

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	Amr Salahieh, Ulrich R. Haug, Hans F. Valencia, Robert A. Geshlider, Tom Saul, Dwight P.
	Morejohn, Kenneth J. Michlitsch
Application No.	
Application No.:	12/492512
Filed:	June 26, 2009
For:	Everting Heart Valve
Examiner:	Ann M. Schillinger
Group Art Unit:	3774

Mail Stop <u>Amendment</u> Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Docket No.: S63.2Q-15141-US03

RESPONSE TO RESTRICTION REQUIREMENT

This communication is in response to the Requirement for Species Election dated

December 30, 2013.

If an extension of time is required to make this response timely and no separate petition is enclosed, Applicants hereby petition for an extension of time sufficient to make the response timely. In the event that this response requires the payment of government fees and payment is not enclosed, please charge Deposit Account No. 22-0350.

Status of the Claims

Claims 1-8 (Canceled)

Claim 9 (Previously Presented): A system for replacing a heart valve, comprising:

an expandable anchor having a collapsed delivery configuration and an expanded configuration;

a replacement valve commissure support element attached to the expandable anchor;

a commissure portion of a replacement valve leaflet attached to the commissure support element; and

a fabric seal at least partially disposed around an exterior portion of the expandable anchor when the anchor is in the expanded configuration, wherein the seal is adapted to prevent blood from flowing between the seal and heart tissue, wherein the fabric seal has an undeployed state and a deployed state, wherein in the deployed state the fabric seal comprises flaps that extend into spaces formed by native valve leaflets, and

wherein a distal end of the replacement valve leaflet is attached to the seal.

Claims 10-15 (Canceled)

Claim 16 (New): The system of claim 9, wherein the expandable anchor comprises a distal end, and wherein, when the expandable anchor is in the collapsed delivery configuration, the fabric seal extends over the distal end of the expandable anchor.

Claim 17 (New): The system of claim 9, wherein, in the deployed state, the fabric seal defines a plurality of pockets.

Claim 18 (New): The system of claim 17, wherein the pockets are adapted to fill with blood in response to backflow blood pressure.

Claim 19 (New): The system of claim 9, wherein the expandable anchor is formed from stainless steel or nickel-titanium alloy.

Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 335 of 442

Claim 20 (New): The system of claim 9, wherein the commissure support element is configured to interface with an anchor actuator.

Claim 21 (New): The system of claim 20, wherein the anchor actuator is adapted to apply a proximally directed force on the commissure support element to foreshorten the expandable anchor.

Claim 22 (New): The system of claim 1 further comprising a lock having a first lock element and a second lock element, the first and second lock elements being attached to the expandable anchor and configured to interlockingly engage one another to lock the expandable anchor in the expanded configuration.

Claim 23 (New): The system of claim 22, wherein the commissure support element includes the first lock element.

Claim 24 (New): The system of claim 23, wherein the second lock element is attached to the expandable anchor and is disposed proximal to the first lock element when the expandable anchor is in the collapsed delivery configuration.

Application No. 12/492512 Page 4

REMARKS

This communication is in response to the Requirement for Species Election of December 30, 2013.

The Requirement identified three species and required the election of a single species, as follows:

The claim(s) is/are directed to the following disclosed patentably distinct species: Species A: a system for replacing a heart valve comprising a seal made from an expandable foam; Species B: a system for replacing a heart valve comprising a fabric seal with flaps to extend into the spaces of the native valve leaflets; and Species C: a system for replacing a heart valve having seals made of sacs disposed around the valve anchor.

Applicants are not herein making any admission that the identification of species is accurate as there could be other features that are identified as being patentably distinct. Moreover, Applicants note that in addition to those species identified in the Requirement as corresponding to specific figures depicted in the Application, additional species may exist which are described in the specification and claims and which are not subject to the restriction requirement identified by the Requirement.

Also, Applicants understand that the Examiner has made a determination that the subject matter any of the claims specific to any of the various species does not render obvious the subject matter of any claim specific to any of the other species. *See* MPEP 802.01 (II).

With that understanding, the Applicants provisionally elect species B. Claims 9 and 16-24 are readable upon the elected species.

If the Examiner does not agree with this characterization of the determination, the election is made with traverse on the grounds that the requirement has not complied with 35 U.S.C. 121 and MPEP 802.01. Patentable distinction between species means exactly that prior art showing only the subject matter of one species does not render obvious another species.

Additionally, Applicants have canceled claims 1-8 and 10-15 without prejudice or disclaimer and reserve the right to prosecute these claims in one or more divisional applications.

Claims 16-24 are added and depend, either directly or indirectly, from independent claim 9. Support for these claims can be found in the Specification at least in paragraphs [0068], [0069], [00112], and [00113], and at least in FIGs. 1A, 1B, and 32-34.

Conclusion

In view of the foregoing it is believed that the present application, with claims 9 and 16-24 is in condition for allowance. Early action to that effect is earnestly solicited.

Respectfully submitted,

VIDAS, ARRETT & STEINKRAUS

Date: February 28, 2014

By: /Michael J. McKeen/

Michael J. McKeen Registration No.: 66069

6640 Shady Oak Rd., Suite 400 Eden Prairie, MN 55344-7834 Telephone: (952) 563-3000 Facsimile: (952) 563-3001

v:\wpwork\mjm\15141us03_rsp_20140128.doc

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	Amr Salahieh, Ulrich R. Haug, Hans F. Valencia,
	Robert A. Geshlider, Tom Saul, Dwight P.
	Morejohn, Kenneth J. Michlitsch
Application No.:	12/492512
Filed:	June 26, 2009
For:	Everting Heart Valve
Examiner:	Ann M. Schillinger
Group Art Unit:	3774

Mail Stop _____ Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Docket No.: S63.2Q-15141-US03

Letter Regarding IDS

Applicant has listed, on the accompanying form, information for consideration in the above-mentioned application. Applicant respectfully requests that the listed information be considered by the Examiner and be made of record in the above-identified application. Applicant requests that the Examiner return an initialed copy of the accompanying form(s) indicating that the listed information has been considered, in accordance with MPEP § 609. This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability.

Applicant respectfully requests that any copies of unpublished US applications submitted herewith be excluded from the file wrapper pursuant to 37 C.F.R. § 1.14.

The present application is a division of and claims priority under 35 U.S.C. § 120 to U.S. Pat. Appl. Ser. No. 12/269,213, filed on November 12, 2008; which is a continuation of 10/870,340 filed on June 16, 2004. Pursuant to 37 C.F.R. § 1.98(d), copies of documents cited by or submitted to the United States Patent and Trademark Office in a previous application to which priority was claimed under 35 U.S.C. § 120 need not be submitted and are not submitted herewith.

If a \$180 fee is due for consideration of this Information Disclosure Statement and

Application No. 12/492512 Page 2

Letter Regarding IDS Attorney Docket No. S63.2Q-15141-US03

full payment has not been submitted herewith, the Commissioner is hereby authorized to charge any additional fees associated with this communication to Deposit Account No. 22-0350. The Commissioner is hereby authorized to credit any overpayment associated with this communication to Deposit Account No. 22-0350.

Applicant requests that this Information Disclosure Statement be considered if it is timely submitted under any of the provisions of 37 C.F.R. § 1.97.

Respectfully submitted,

VIDAS, ARRETT & STEINKRAUS

Date: February 28, 2014

By: /Michael J. McKeen/ Michael J. McKeen Registration No.: 66069

6640 Shady Oak Rd., Suite 400 Eden Prairie, MN 55344-7834 Telephone: (952) 563-3000 Facsimile: (952) 563-3001

v:\wpwork\mjm\15141us03_ids_20140228.doc

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		12492512
Filing Date		2009-06-26
First Named Inventor	Amr S	Salahieh
Art Unit		3774
Examiner Name Ann M		1. Schillinger
Attorney Docket Number		S63.2-15141-US03

						U.S.I	PATENTS			Remove		
Examiner Initial*	Cite No	P	Patent Number	Kind Code ¹	Issue D)ate	Name of Patentee or Applicant of cited Document			t Relevant Passages or Relevant Figures Appear		
	1											
lf you wis	h to ac	dd a	dditional U.S. Pater	nt citatio	n inform	ation pl	ease click the	Add button.		Add		
				U.S.P.	ATENT	APPLIC	CATION PUBL			Remove		
Examiner Initial*	Cite	No	Publication Number	Kind Code ¹	Publica Date	ition	Name of Patentee or Applicant of cited Document					
	1		20040167620		2004-08	3-26	Ortiz, et al.					
lf you wis	h to ao	dd a	dditional U.S. Publi	shed Ap	plication	n citation	n information p	lease click the Ad	d butto	n. Add		
					FOREI	GN PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	1	reign Document ımber³	Country Code ²		Kind Code⁴	Publication Date	Name of Patented Applicant of cited Document	eor	Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear	T 5	
	1											
lf you wis	h to ac	dd a	dditional Foreign Pa	atent Do	cument	citation	information pl	ease click the Add	button	Add		
				NON	I-PATE		RATURE DO	CUMENTS		Remove		
Examiner Initials*	Cite No	(bc	clude name of the an bok, magazine, journ blisher, city and/or o	nal, seria	al, symp	osium,	catalog, etc), c			iate), title of the item sue number(s),	T⁵	

	Application Number		12492512
	Filing Date		2009-06-26
INFORMATION DISCLOSURE	First Named Inventor	Amr S	Salahieh
(Not for submission under 37 CFR 1.99)	Art Unit		3774
	Examiner Name	Ann N	1. Schillinger
	Attorney Docket Numb	er	S63.2-15141-US03

	1		litional non-natorit literatura decument citation information places aligh the Ad	hutton Add		
	n to at	a auc	litional non-patent literature document citation information please click the Add			
			EXAMINER SIGNATURE			
Examiner	Signa	iture	Date Considered			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						
Standard ST ⁴ Kind of doo	⁻ .3). ³ F cument	[:] or Japa by the a	O Patent Documents at <u>www.USPTO.GOV</u> or MPEP 901.04. ² Enter office that issued the docur anese patent documents, the indication of the year of the reign of the Emperor must precede the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Ap n is attached.	serial number of the patent doo	ument.	

	Application Number		12492512	
	Filing Date		2009-06-26	
INFORMATION DISCLOSURE	First Named Inventor Amr S		Salahieh	
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		3774	
	Examiner Name Ann M		M. Schillinger	
	Attorney Docket Numb	er	S63.2-15141-US03	

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

See attached certification statement.

The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

X A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Michael J. McKeen/	Date (YYYY-MM-DD)	2014-02-28
Name/Print	Michael J. McKeen	Registration Number	66069

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- 2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- 3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- 5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- 6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
- 9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Electronic Acknowledgement Receipt				
EFS ID:	18336529			
Application Number:	12492512			
International Application Number:				
Confirmation Number:	7439			
Title of Invention:	Everting Heart Valve			
First Named Inventor/Applicant Name:	Amr Salahieh			
Customer Number:	490			
Filer:	Michael James McKeen/Wendy Skelly			
Filer Authorized By:	Michael James McKeen			
Attorney Docket Number:	S63.2Q-15141-US03			
Receipt Date:	28-FEB-2014			
Filing Date:	26-JUN-2009			
Time Stamp:	14:56:17			
Application Type:	Utility under 35 USC 111(a)			

Payment information:

Submitted with Payment			no				
File Listing:							
Document Number	Document Description		File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)	
1	Transmittal Letter	15	15141US03_tra_20140228.pdf	80606	no	1	
, , , , , , , , , , , , , , , , , , ,				ef152c242af1a259b81b0ab016b7783c055 604d0	110	·	
Warnings:							
Information:	Edwards Lifes	cienc	es Corporation, et al	Exhibit 1102, Pag	e 345 of 4	42	

2	Response to Election / Restriction Filed	15141US03 rsp 20140128.pdf	105227	no	5		
2	Response to Election / Restriction / neg	191410303_15p_20140120.pdf	58e4bfd5fd3a7628ce47a40ee1cfdffa71264 322	10	5		
Warnings:					-		
Information:					_		
з	Miscellaneous Incoming Letter	15141US03_ids_20140228.pdf	89172	no	2		
	······································	p	951a2456fbc6ccecafa32c54f5c0c0070abb2 4b1				
Warnings:							
Information:							
4	Information Disclosure Statement (IDS)	15141US03_IDSFORM_201402	611931	no	4		
4	Form (SB08)	25.pdf	460ebcea4fd2285db144c592fcf4c78413d2 5f6d	110	4		
Warnings:							
ind in 1950							
Information:							
Information:		Total Files Size (in bytes)		86936			
Information: This Acknow characterized Post Card, as <u>New Applica</u> If a new appl 1.53(b)-(d) an Acknowledg <u>National Stat</u> If a timely su U.S.C. 371 an	ledgement Receipt evidences receip d by the applicant, and including pag described in MPEP 503. <u>tions Under 35 U.S.C. 111</u> lication is being filed and the applica nd MPEP 506), a Filing Receipt (37 CF ement Receipt will establish the filing <u>ge of an International Application un</u> bmission to enter the national stage of other applicable requirements a Fo ge submission under 35 U.S.C. 371 wi	t on the noted date by the U ge counts, where applicable. tion includes the necessary o R 1.54) will be issued in due g date of the application. <u>ider 35 U.S.C. 371</u> of an international applicati orm PCT/DO/EO/903 indicati	SPTO of the indicated It serves as evidence components for a filir course and the date s on is compliant with ng acceptance of the	l document of receipt s ng date (see shown on th the condition application	imilar to a 37 CFR iis ons of 35		

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	Amr Salahieh, Ulrich R. Haug, Hans F. Valencia, Robert A. Geshlider, Tom Saul, Dwight P. Morejohn, Kenneth J. Michlitsch
Application No.:	12/492512
Filed:	June 26, 2009
For:	Everting Heart Valve
Examiner:	Ann M. Schillinger
Group Art Unit:	3774

Mail Stop <u>Amendment</u> Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Docket No.: S63.2Q-15141-US03

TRANSMITTAL LETTER

- 1. In regard to the above-identified application, in addition to this 1 page transmittal letter, we are submitting the attached: 5 page Response to Restriction Requirement, 2 page Letter Regarding IDS, and 4 page Information Disclosure Statement
- 2. With respect to fees, applicant believes the fees required herein, if any, are being paid electronically.

3. CONDITIONAL PETITION FOR EXTENSION OF TIME

- This conditional petition is being filed along with the papers identified in Item 1 above and provides for the possibility that Applicant has inadvertently overlooked the need for a petition and fee for extension of time or for a petition and fee for any other matter petitionable to the Commissioner as required. If any extension of time for the accompanying response is required or if a petition for any other matter is required, by petitioner, Applicant requests that this be considered a petition therefor.
- 4. Notwithstanding paragraph 2 above, if any additional fees associated with this communication are required and have not otherwise been paid, including any fee associated with the Conditional Petition for Extension of Time, or any request in the accompanying papers for action which requires a fee as a petition to the Commissioner, please charge the additional fees to Deposit Account No. 22-0350. Please charge any additional fees associated with this communication to the Deposit Account No. 22-0350.
- 5. **Certification:** I hereby certify that this Transmittal Letter and the paper(s) as described herein are being transmitted electronically to the USPTO on February 28, 2014.

Respectfully submitted,

VIDAS, ARRETT & STEINKRAUS

Date: February 28, 2014

By: /Michael J. McKeen/

Michael J. McKeen Registration No.: 66069


6640 Shady Oak Rd., Suite 400 Eden Prairie, MN 55344-7834 Telephone: (952) 563-3000 Facsimile: (952) 563-3001

v:\wpwork\mjm\15141us03 tra 20140228.doc

								to a collection of informati	on unless it displays a	valid OMB control number.
P/	ATENT APPL			Form P		N RECORD		n or Docket Number 2/492,512	Filing Date 06/26/2009	To be Mailed
								ENTITY: 🛛 I	ARGE 🗌 SMA	
					APPLIC.	ATION AS FIL	FD – PAR	т I		
			((Column 1		(Column 2)				
	FOR		NL	JMBER FIL	.ED	NUMBER EXTRA		RATE (\$)		FEE (\$)
	BASIC FEE (37 CFR 1.16(a), (b),	or (c))		N/A		N/A		N/A		
	SEARCH FEE (37 CFR 1.16(k), (i), (N/A		N/A		N/A		
	EXAMINATION FE (37 CFR 1.16(o), (p),	E		N/A		N/A		N/A		
	CFR 1.16(i))	(4//		min	us 20 = *			X \$ =		
IND	EPENDENT CLAIM CFR 1.16(h))	S		mi	nus 3 = *			X \$ =		
	APPLICATION SIZE 37 CFR 1.16(s))	FEE	of pap for sn fractio	per, the a nall entity	application size f	gs exceed 100 s ee due is \$310 (ional 50 sheets c . 41(a)(1)(G) and	\$155 vr			
	MULTIPLE DEPEN	IDENT CLA	AIM PRE	ESENT (3	7 CFR 1.16(j))					
* If t	he difference in colu	umn 1 is les	ss than z	zero, ente	r "0" in column 2.			TOTAL		
		(Colum	ın 1)		APPLICAT (Column 2)	ION AS AMEN (Column 3		ART II		
AMENDMENT	02/28/2014	CLAIMS REMAIN AFTER AMENDI	ING		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EX	TRA	RATE (\$)	ADDITI	ONAL FEE (\$)
ME	Total (37 CFR 1.16(i))	* 10		Minus	** 20	= 0		x \$80 =		0
N N	Independent (37 CFR 1.16(h))	* 1		Minus	***3	= 0		x \$420 =		0
AME	Application Si	ize Fee (37	CFR 1.	16(s))						
		NTATION OF	MULTIP	LE DEPENI	DENT CLAIM (37 CFI	R 1.16(j))				
								TOTAL ADD'L FE	E	0
		(Colum	in 1)		(Column 2)	(Column 3)			
		CLAII REMAII AFTE AMENDI	NING ER		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EX	TRA	RATE (\$)	ADDITI	ONAL FEE (\$)
	Total (37 CFR 1.16(i))	*		Minus	**	=		X \$ =		
ENDMENT	Independent (37 CFR 1.16(h))	*		Minus	***	=		X \$ =		
EN	Application Si	ize Fee (37	' CFR 1.	16(s))						
AMI		NTATION OF	MULTIP	LE DEPENI	DENT CLAIM (37 CFI	R 1.16(j))				
								TOTAL ADD'L FE	E	
** If *** I The	 * If the entry in column 1 is less than the entry in column 2, write "0" in column 3. ** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20". *** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3". The "Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1. his collection of information is required by 37 CFR 1.16. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to 									
										e including gathering

process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 GFH 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

mail@vaslaw.com rleaf@vaslaw.com rarrett@vaslaw.com

	Application No. 12/492,512		Applicant(s SALAHIEH	;) ET AL.
Office Action Summary	Examiner ANN SCHILLING		Art Unit 3774	AIA (First Inventor to File) Status No
The MAILING DATE of this communication app Period for Poply	pears on the cover	sheet with the co	orresponder	
Period for Reply A SHORTENED STATUTORY PERIOD FOR REPL THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period of - Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, howe will apply and will expire S e, cause the application to	ver, may a reply be time IX (6) MONTHS from the become ABANDONED	ely filed ne mailing date o (35 U.S.C. § 13	of this communication. (3).
Status				
1) Responsive to communication(s) filed on <u>2/28</u> A declaration(s)/affidavit(s) under 37 CFR 1 .		led on		
	action is non-fina			
3) An election was made by the applicant in resp	onse to a restrictio	on requirement s	et forth duri	ng the interview on
; the restriction requirement and election 4) Since this application is in condition for allowa closed in accordance with the practice under <i>B</i>	nce except for forr	nal matters, pros	secution as	
 Disposition of Claims* 5) ☐ Claim(s) <u>9 and 16-24</u> is/are pending in the app 5a) Of the above claim(s) is/are withdrate 6) ☐ Claim(s) is/are allowed. 7) ☐ Claim(s) <u>9 and 16-24</u> is/are rejected. 8) ☐ Claim(s) is/are objected to. 9) ☐ Claim(s) are subject to restriction and/ot * If any claims have been determined <u>allowable</u>, you may be e participating intellectual property office for the corresponding a <u>http://www.uspto.gov/patents/init_events/pph/index.jsp</u> or send Application Papers 10) ☐ The specification is objected to by the Examined 	wn from considera or election requirer ligible to benefit fron pplication. For more an inquiry to <u>PPHfe</u> er.	nent. h the Patent Pros e information, pleas eedback@uspto.go	se see	h way program at a
11) The drawing(s) filed on is/are: a) acc Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct	drawing(s) be held i	n abeyance. See	37 CFR 1.85	
Priority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign Certified copies: a) All b) Some** c) None of the: 1. Certified copies of the priority documen 2. Certified copies of the priority documen 3. Copies of the certified copies of the priority documen 3. Copies of the certified copies of the priority documen see the attached detailed Office action for a list of the certified	priority under 35 ts have been rece ts have been rece prity documents ha u (PCT Rule 17.2(U.S.C. § 119(a)- ived. ived in Applicatio ave been receive a)).	(d) or (f). on No	
Attachment(s) 1) X Notice of References Cited (PTO-892) 2) Information Disclosure Statement(s) (PTO/SB/08a and/or PTO/Paper No(s)/Mail Date <u>See Continuation Sheet</u> . U.S. Patent and Trademark Office	SB/08b)	nterview Summary (^p aper No(s)/Mail Dat Dther:		

Continuation of Attachment(s) 2). Information Disclosure Statement(s) (PTO/SB/08), Paper No(s)/Mail Date :3/23/12,6/29/12,9/11/12,2/13/13,5/6/13,7/12/13,9/17/13,2/28/14.

The present application is being examined under the pre-AIA first to invent provisions.

DETAILED ACTION

Election/Restrictions

Applicant's election without traverse of Species B in the reply filed on 2/28/2014 is

acknowledged. Claims 1-8 and 10-15 are canceled from further consideration pursuant to 37

CFR 1.142(b) as being drawn to a nonelected Species A, there being no allowable generic or

linking claim. Election was made without traverse in the reply filed on 2/28/2014.

Claim Rejections - 35 USC § 103

The following is a quotation of pre-AIA 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 9 and 16-21 are rejected under pre-AIA 35 U.S.C. 103(a) as being unpatentable over Leonhardt et al. (US Pat. No. 5,957,949) in view of De Paulis (US Pat. No. 6,352,554). Leonhardt et al. teaches the following regarding claim 9: a system for replacing a heart valve, comprising: an expandable anchor (26) having a collapsed delivery configuration and an expanded configuration; a replacement valve commissure support element (22) attached to the expandable anchor (Fig. 4); a commissure portion (68) of a replacement valve leaflet attached to the commissure support element; and a fabric seal (24) at least partially disposed around an exterior portion of the expandable anchor when the anchor is in the expanded configuration, wherein the seal is adapted to prevent blood from flowing between the seal and heart tissue and

wherein a distal end of the replacement valve leaflet is attached to the seal. (Fig. 4; col. 5, line 53 through col. 6, line 8).

Leonhardt et al. does not teach the fabric seal comprising flaps and pockets. An implantable fabric having pleats and pockets is well known in the art, as taught by De Paulis in Figure 2, and it would have been obvious to one of ordinary skill in the art to modify seal of Leonhardt et al. to include pleats as an obvious alternate design choice. At least a portion of Leonhardt et al.'s seal is adapted to be filled with blood, and captured between the leaflets (14) and a wall of the patient's heart (18) when the anchor and replacement valve are fully deployed.

Leonhardt et al. teaches the following regarding claim 16: the system of claim 9, wherein the expandable anchor comprises a distal end (Figs. 3A-3B), and wherein, when the expandable anchor is in the collapsed delivery configuration, the fabric seal extends over the distal end of the expandable anchor (Fig. 4).

Leonhardt et al. teaches the following regarding claim 19: the system of claim 9, wherein the expandable anchor is formed from stainless steel or nickel-titanium alloy (col. 5, lines 11-22).

Leonhardt et al. teaches the following regarding claim 20: the system of claim 9, wherein the commissure support element is configured to interface with an anchor actuator (cols. 10-11).

Leonhardt et al. teaches the following regarding claim 21: the system of claim 20, wherein the anchor actuator is adapted to apply a proximally directed force on the commissure support element to foreshorten the expandable anchor (cols. 10-11).

Claims 22-24 are rejected under pre-AIA 35 U.S.C. 103(a) as being unpatentable over Leonhardt et al. in view of De Paulis further in view of Artof et al. (US Pub. No. 2005/0075731).

Leonhardt et al., as modified by De Paulis, does not teach the device comprising a lock having a first and a second interlocking elements. Artof et al. teaches a first lock element (35) on its commissure support interlocking with a second lock element (54) that may be attached to an anchor (53) as shown in Figures 11-13. It would have been obvious to one having ordinary skill in the art at the time the invention was made to modify the device of Leonhardt et al. and De Paulis to include a lock in order to better stabilize the device.

Response to Arguments

Applicant's arguments with respect to claims 9 and 16-24 have been considered but are moot because the arguments do not apply to any of the references being used in the current rejection.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ann Schillinger whose telephone number is (571)272-6652. The examiner can normally be reached on Monday-Friday (9am-5:30pm).

If attempts to reach the examiner by telephone are unsuccessful, please contact the examiner's supervisor, David Isabella, at 571-272-4749. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the

Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from

a USPTO Customer Service Representative or access to the automated information system, call

800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/A. S./ Examiner, Art Unit 3774

/DAVID ISABELLA/ Supervisory Patent Examiner, Art Unit 3774

	Application/Control No.	Applicant(s)/Patent Under Reexamination
Search Notes	12492512	SALAHIEH ET AL.
	Examiner	Art Unit
	ANN SCHILLINGER	3774

CPC- SEARCHED		
Symbol	Date	Examiner

CPC COMBINATION SETS - SEARCHED							
Symbol Date Examiner							

US CLASSIFICATION SEARCHED							
Class	Subclass	Date	Examiner				

SEARCH NOTES		
Search Notes	Date	Examiner
Updated prior search	3/29/2011	AS
Updated prior search	4/2/2014	AS

INTERFERENCE SEARCH								
US Class/ CPC Symbol	US Subclass / CPC Group	Date	Examiner					

/A. S./ Examiner.Art Unit 3774	
-----------------------------------	--

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	Amr Salahieh, Ulrich R. Haug, Hans F. Valencia,
	Robert A. Geshlider, Tom Saul, Dwight P.
	Morejohn, Kenneth J. Michlitsch
Application No.:	12/492512
Filed:	June 26, 2009
For:	Everting Heart Valve
Examiner:	Ann M. Schillinger
Group Art Unit:	3774

Mail Stop _____ Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Docket No.: S63.2Q-15141-US03

AMENDMENT

This Amendment is in response to the Office Action dated April 10, 2014.

If an extension of time is required to make this response timely and no separate petition is enclosed, Applicants hereby petition for an extension of time sufficient to make the response timely. In the event that this response requires the payment of government fees and payment is not enclosed, please charge Deposit Account No. 22-0350.

Please amend the application as follows:

Amendments To The Claims:

Claims 1-8 (Canceled)

Claim 9 (Currently Amended): A system for replacing a heart valve, comprising: an expandable anchor having a collapsed delivery configuration and an expanded configuration, the expandable anchor comprising a distal end;

a replacement valve commissure support element attached to the expandable anchor;

a commissure portion of a replacement valve leaflet attached to the commissure support element; and

a fabric seal at least partially disposed around an exterior portion of the expandable anchor when the anchor is in the expanded configuration, the fabric seal having an undeployed <u>state and a deployed state</u>, wherein the seal is adapted to prevent blood from flowing between the seal and heart tissue, wherein the fabric seal has an undeployed state and a deployed state, wherein in the deployed state the fabric seal comprises flaps that extend into spaces formed by native valve leaflets<u>;</u>, and

wherein a distal end of the replacement valve leaflet is attached to the <u>fabric seal and</u> when the expandable anchor is in the collapsed delivery configuration, the fabric seal extends from the distal end of the replacement valve and back proximally over the expandable anchor, the fabric seal being adapted to prevent blood from flowing between the fabric seal and heart <u>tissue</u>.

Claims 10-16 (Canceled)

Claim 17 (Previously Presented): The system of claim 9, wherein, in the deployed state, the fabric seal defines a plurality of pockets.

Claim 18 (Previously Presented): The system of claim 17, wherein the pockets are adapted to fill with blood in response to backflow blood pressure.

Claim 19 (Previously Presented): The system of claim 9, wherein the expandable anchor is

Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 358 of 442

formed from stainless steel or nickel-titanium alloy.

Claim 20 (Previously Presented): The system of claim 9, wherein the commissure support element is configured to interface with an anchor actuator.

Claim 21 (Previously Presented): The system of claim 20, wherein the anchor actuator is adapted to apply a proximally directed force on the commissure support element to foreshorten the expandable anchor.

Claim 22 (Currently Amended): The system of claim [[1]]9 further comprising a lock having a first lock element and a second lock element, the first and second lock elements being attached to the expandable anchor and configured to interlockingly engage one another to lock the expandable anchor in the expanded configuration.

Claim 23 (Previously Presented): The system of claim 22, wherein the commissure support element includes the first lock element.

Claim 24 (Previously Presented): The system of claim 23, wherein the second lock element is attached to the expandable anchor and is disposed proximal to the first lock element when the expandable anchor is in the collapsed delivery configuration.

Remarks

This Amendment is in response to the Office Action dated **April 10, 2014.** In the Office Action, the Examiner rejected claims 9 and 16-21 under 35 USC § 103(a) over Leonhardt (US 5,957,949) in view of De Paulis (US 6,352,554) and rejected claims 22-24 under 35 USC § 103(a) over Leonhardt in view of De Paulis in further view of Artof (US Pub. No. 2005/0075731).

Without acquiescing to the validity of the rejections, independent claim 9 is herein amended to incorporate the subject matter of previous claim 16 and to provide additional clarity. Support for the amendment can be found in the Specification at least in paragraph [00112] and at least in FIG. 32 of the Application as-filed.

Claim 16 is accordingly canceled without prejudice or disclaimer.


Dependent claim 22 is amended to depend from claim 9.

In light of the foregoing amendments and following comments, Applicants request reconsideration.

Claim Rejections – 35 USC § 103(a)

Without acquiescing to the validity of the rejection of claims 9 and 16-21 over Leonhardt in view of De Paulis, independent claim 9 is herein amended to recite, in-part, "when the expandable anchor is in the collapsed delivery configuration, the fabric seal extends from the distal end of the replacement valve and back proximally over the expandable anchor, the fabric seal being adapted to prevent blood from flowing between the fabric seal and heart tissue."

As shown for example in FIG. 32 of the immediate Application, reproduced below, the fabric seal doubles over the distal end of the expandable anchor. Further, paragraph [00112] states, in-part, "a fabric seal 380 extends from the distal end of valve 20 and back proximally over anchor 30 during delivery."





In contrast, neither Leonhardt nor De Paulis, whether considered independently or in combination, teaches, suggests, or otherwise renders obvious a "when the expandable anchor is in the collapsed delivery configuration, the fabric seal extends from the distal end of the replacement valve and back proximally over the expandable anchor, the fabric seal being adapted to prevent blood from flowing between the fabric seal and heart tissue," as is claimed. Consequently, Applicants request withdrawal of the rejection and reconsideration of independent claim 9 and dependent claims 17-21, which depend either directly or indirectly therefrom.

The Examiner rejected claims 22-24 over Leonhardt in view of De Paulis and Artof. Each of dependent claims 22-24 depends either directly or indirectly from independent claim 9 and the addition of Artof does not remedy the deficiencies of Leonhardt and De Paulis as discussed above with respect to independent claim 9. As such, Applicants request withdrawal of the rejection of dependent claims 22-24 over Leonhardt in view of De Paulis and Artof.

Conclusion

Based on at least the foregoing remarks and amendments, Applicants request withdrawal of the rejections and allowance of claims 9 and 17-23. Favorable consideration and prompt allowance of these claims is earnestly solicited.

Should the Examiner believe that anything further would be desirable in order to place this application in better condition for allowance the Examiner is invited to contact Applicants' undersigned representative at the telephone number listed below.

Respectfully submitted,

VIDAS, ARRETT & STEINKRAUS

Date: July 9, 2014

By: /Michael J. McKeen/

Michael J. McKeen Registration No.: 66069

6640 Shady Oak Rd., Suite 400 Eden Prairie, MN 55344-7834 Telephone: (952) 563-3000 Facsimile: (952) 563-3001

/home/mmckeen/Desktop/15141US03_Amendment_20140527.doc

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	Amr Salahieh, Ulrich R. Haug, Hans F. Valencia,
	Robert A. Geshlider, Tom Saul, Dwight P.
	Morejohn, Kenneth J. Michlitsch
Application No.:	12/492512
Filed:	June 26, 2009
For:	Everting Heart Valve
Examiner:	Ann M. Schillinger
Group Art Unit:	3774

Mail Stop _____ Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Docket No.: S63.2Q-15141-US03

Letter Regarding IDS

Applicant has listed, on the accompanying form, information for consideration in the above-mentioned application. Applicant respectfully requests that the listed information be considered by the Examiner and be made of record in the above-identified application. Applicant requests that the Examiner return an initialed copy of the accompanying form(s) indicating that the listed information has been considered, in accordance with MPEP § 609. This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability.

Applicant respectfully requests that any copies of unpublished US applications submitted herewith be excluded from the file wrapper pursuant to 37 C.F.R. § 1.14.

The present application is a division of and claims priority under 35 U.S.C. § 120 to U.S. Pat. Appl. Ser. No. 12/269,213, filed on November 12, 2008; which is a continuation of 10/870,340 filed on June 16, 2004. Pursuant to 37 C.F.R. § 1.98(d), copies of documents cited by or submitted to the United States Patent and Trademark Office in a previous application to which priority was claimed under 35 U.S.C. § 120 need not be submitted and are not submitted herewith.

If a \$180 fee is due for consideration of this Information Disclosure Statement and

Application No. 12/492512 Page 2

Letter Regarding IDS Attorney Docket No. S63.2Q-15141-US03

full payment has not been submitted herewith, the Commissioner is hereby authorized to charge any additional fees associated with this communication to Deposit Account No. 22-0350. The Commissioner is hereby authorized to credit any overpayment associated with this communication to Deposit Account No. 22-0350.

Applicant requests that this Information Disclosure Statement be considered if it is timely submitted under any of the provisions of 37 C.F.R. § 1.97.

Respectfully submitted,

VIDAS, ARRETT & STEINKRAUS

Date: July 9, 2014

By: /Michael J. McKeen/ Michael J. McKeen Registration No.: 66069

6640 Shady Oak Rd., Suite 400 Eden Prairie, MN 55344-7834 Telephone: (952) 563-3000 Facsimile: (952) 563-3001

v:\wpwork\mjm\15141us03_ids_20140709.doc

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	12/492,512
	Filing Date	6/26/2009
	First Named Inventor	Ulrich R. Haug
	Art Unit	3774
	Client Number	
Page 1 of 2	Matter Number	S63.2-15141-US03

	U.S. PATENT DOCUMENTS						
Initials Cite No. Document Number Issue/Publication Date		Issue/Publication Date	First Named Inventor	Т			
	1	20130018457	01/17/2013	Gregg et al.			
	2	20130158656	06/20/2013	Sutton et al.			
	3	20130304199	11/14/2013	Sutton et al.			
	4	20140018911	01/16/2014	Zhou et al.			
	5	5725549	03/10/1998	Lam			
	6	5876419	03/02/1999	Carpenter et al.			
	7	6623521	09/23/2003	Steinke et al.			
	8	7004176	02/28/2006	Lau			
	9	7141063	11/28/2006	White et al.			
	10	7722662	05/25/2010	Steinke et al.			

Examiner Signature		Date Considered	
609. Please draw a line	if citation considered, wheth through the citation if it is no the next communication to the	ot in conformance and it is n	mance with MPEP Section ot considered. Please include

SynclDS.com

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	12/492,512
	Filing Date	6/26/2009
	First Named Inventor	Ulrich R. Haug
	Art Unit	3774
	Client Number	
Page 2 of 2	Matter Number	S63.2-15141-US03

Pursuant to 37 C.F.R. 1.97 and 1.98 and to the duty of disclosure set forth in 37 C.F.R. 1.56, the Examiner in charge of the above-identified application is requested to consider and make of record the references listed herewith. A copy of each listed reference, other than U.S. patents/applications and references cited in a parent application, is enclosed.

Although the information submitted herewith may be "material" to the Examiner's consideration of the subject application, this submission is not intended to constitute an admission that such information is "prior art" as to the claimed invention.

In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

SIGNATURE			
Signature	Signature /Michael J. McKeen/ Date 7/9/2014		
Name	Michael J. McKeen	Registration Number	66069

SyncIDS.com

Electronic Patent Application Fee Transmittal					
Application Number:	lication Number: 12492512				
Filing Date:	26	26-Jun-2009			
Title of Invention:	Ev	erting Heart Valve			
First Named Inventor/Applicant Name:	Amr Salahieh				
Filer:	Mi	chael James McKee	n/Wendy Skelly		
Attorney Docket Number:	S6.	3.2Q-15141-US03			
Filed as Large Entity					
Utility under 35 USC 111(a) Filing Fees					
Description		Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Basic Filing:					
Pages:					
Claims:					
Miscellaneous-Filing:					
Petition:					
Patent-Appeals-and-Interference:					
Post-Allowance-and-Post-Issuance:					
Extension-of-Time:					

Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)	
Miscellaneous:					
Submission- Information Disclosure Stmt	1806	1	180	180	
	Tot	al in USD	(\$)	180	

Electronic A	Electronic Acknowledgement Receipt		
EFS ID:	19533043		
Application Number:	12492512		
International Application Number:			
Confirmation Number:	7439		
Title of Invention:	Everting Heart Valve		
First Named Inventor/Applicant Name:	Amr Salahieh		
Customer Number:	490		
Filer:	Michael James McKeen/Wendy Skelly		
Filer Authorized By:	Michael James McKeen		
Attorney Docket Number:	S63.2Q-15141-US03		
Receipt Date:	09-JUL-2014		
Filing Date:	26-JUN-2009		
Time Stamp:	16:00:53		
Application Type:	Utility under 35 USC 111(a)		

Payment information:

Submitted with Payment		yes			
Payment Type		Credit Card			
Payment was successfully received in RAM		\$180			
RAM confirmation Number		2415			
Deposit Account					
Authorized User					
File Listing	g:				
Document Number	Document Description Edwards Lifesciel	File Size(Bytes)/ Multi Page: nces Corporation, et al. Exhibit del DigeRage Eary/Dip42if app			

1	Transmittal Letter	15141US03_VASTransmittal_20	80571	no	1
		140709.pdf	5f73c3eebf344590bc56394d150fd145b871 3af6		
Warnings:					
Information	:				
2	Amendment/Req. Reconsideration-After Non-Final Reject	15141US03_Amendment_2014 0527.pdf	95097	no	6
		0527.pd1	1cfce51bb0dfd7f2657b7c89346284fed221 b823		
Warnings:					
Information	:		1	i	
3	Miscellaneous Incoming Letter	15141US03_ids_20140709.pdf	89159	no	2
			3b2db4da8d2c7c7fd91e6d825168cf3c755 ad572		
Warnings:					
Information	:				
4	Information Disclosure Statement (IDS)	15141US03_IDSFORM_201407	345418	no	2
·	Form (SB08)	09.pdf	b4fe1b27254104cf40a104defb29f9b641b2 e067	2	
Warnings:					
Information	:				
This is not an l	JSPTO supplied IDS fillable form				
5	Fee Worksheet (SB06)	fee-info.pdf	30161	no	2
	5 Fee Worksheet (SB06)		ffa644e0122ef132e2e2e08004209d4dd6ab 956c		
Warnings:					
Information	:				
		Total Files Size (in bytes)	: 6	40406	
characterize Post Card, as <u>New Applica</u> If a new app 1.53(b)-(d) a	vledgement Receipt evidences receip ed by the applicant, and including pag s described in MPEP 503. <u>ations Under 35 U.S.C. 111</u> lication is being filed and the applica and MPEP 506), a Filing Receipt (37 CF gement Receipt will establish the filin	ge counts, where applicable. tion includes the necessary o R 1.54) will be issued in due	It serves as evidence components for a filir	of receipt s	imilar to a 37 CFR
National Stage of an International Application under 35 U.S.C. 371 If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course. New International Application Filed with the USPTO as a Receiving Office					
an internatio and of the In national sec	<u>New International Application Filed with the USPTO as a Receiving Office</u> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.				

Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 370 of 442

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	Amr Salahieh, Ulrich R. Haug, Hans F. Valencia, Robert A.
	Geshlider, Tom Saul, Dwight P. Morejohn, Kenneth J. Michlitsch
Application No.:	12/492512
Filed:	June 26, 2009
For:	Everting Heart Valve
Examiner:	Ann M. Schillinger
Group Art Unit:	3774

Mail Stop <u>Amendment</u> Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Docket No.: S63.2Q-15141-US03

TRANSMITTAL LETTER

- In regard to the above-identified application, in addition to this 1 page transmittal letter, we are submitting the attached:
 6 page Amendment, 2 page Information Disclosure Statement and 2 page Letter Regarding IDS
- 2. With respect to fees, applicant believes the fees required herein, if any, are being paid electronically.

3. CONDITIONAL PETITION FOR EXTENSION OF TIME

- This conditional petition is being filed along with the papers identified in Item 1 above and provides for the possibility that Applicant has inadvertently overlooked the need for a petition and fee for extension of time or for a petition and fee for any other matter petitionable to the Commissioner as required. If any extension of time for the accompanying response is required or if a petition for any other matter is required, by petitioner, Applicant requests that this be considered a petition therefor.
- 4. Notwithstanding paragraph 2 above, if any additional fees associated with this communication are required and have not otherwise been paid, including any fee associated with the Conditional Petition for Extension of Time, or any request in the accompanying papers for action which requires a fee as a petition to the Commissioner, please charge the additional fees to Deposit Account No. 22-0350. Please charge any additional fees associated with this communication to the Deposit Account No. 22-0350.
- 5. **Certification:** I hereby certify that this Transmittal Letter and the paper(s) as described herein are being transmitted electronically to the USPTO on July 9, 2014.

Respectfully submitted,

VIDAS, ARRETT & STEINKRAUS

Date: July 9, 2014

By: /Michael J. McKeen/

Michael J. McKeen Registration No.: 66069

6640 Shady Oak Rd., Suite 400 Eden Prairie, MN 55344-7834 Telephone: (952) 563-3000 Facsimile: (952) 563-3001

v:\wpwork\mjm\15141us03_vastransmittal_20140709.doc

	Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.								
P	PATENT APPLICATION FEE DETERMINATION RECORD Substitute for Form PTO-875						or Docket Number /492,512	Filing Date 06/26/2009	To be Mailed
							ENTITY: 🛛 L	ARGE 🗌 SMA	
				APPLIC	ATION AS FIL	ED – PAR	ТІ		
			(Column 1)	(Column 2)				
	FOR		NUMBER FIL	.ED	NUMBER EXTRA		RATE (\$)	F	EE (\$)
	BASIC FEE (37 CFR 1.16(a), (b), (or (c))	N/A		N/A		N/A		
	SEARCH FEE (37 CFR 1.16(k), (i), c	or (m))	N/A		N/A		N/A		
	EXAMINATION FE (37 CFR 1.16(o), (p), (N/A		N/A		N/A		
	TAL CLAIMS CFR 1.16(i))		min	us 20 = *			X \$ =		
IND	EPENDENT CLAIM CFR 1.16(h))	S	mi	nus 3 = *			X \$ =		
APPLICATION SIZE FEE If the specification and drawings exceed 100 sheets of paper, the application size fee due is \$310 (\$155 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).									
	MULTIPLE DEPEN	IDENT CLAIM	PRESENT (3	7 CFR 1.16(j))					
* If f	* If the difference in column 1 is less than zero, enter "0" in column 2.					TOTAL			
APPLICATION AS AMENDED – PART II (Column 1) (Column 2) (Column 3)									
AMENDMENT	07/09/2014	CLAIMS REMAINING AFTER AMENDMEN		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EX	TRA	RATE (\$)	ADDITIC	ONAL FEE (\$)
ME	Total (37 CFR 1.16(i))	* 9	Minus	** 20	=		X \$ =		
ND	Independent (37 CFR 1.16(h))	* 1	Minus	***3	=		X \$ =		
١ME	Application Size Fee (37 CFR 1.16(s))								
ł	FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))								
							TOTAL ADD'L FE	E	
		(Column 1)	(Column 2)	(Column 3)			
		CLAIMS REMAININ AFTER AMENDMEN		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EX	TRA	RATE (\$)	ADDITIC	ONAL FEE (\$)
ENT	Total (37 CFR 1.16(i))	×	Minus	**	=		X \$ =		
ND	Independent (37 CFR 1.16(h))	*	Minus	***	=		X \$ =		
ENDM	Application Si	ze Fee (37 CF	R 1.16(s))						
AM	FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))								
** If *** The	FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j)) TOTAL ADD'L FEE * If the entry in column 1 is less than the entry in column 2, write "0" in column 3. LIE *** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20". /SONYA HILLIARD/ *** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3". IE The "Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1. Image: Collection of information is required by 37 CFR 1.16. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to								

preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS

ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

NOTICE OF ALLOWANCE AND FEE(S) DUE

490 7590 10/06/2014 VIDAS, ARRETT & STEINKRAUS, P.A. Richard A. Arrett 9531 West 78th Street Suite 400 Eden Prairie, MN 55344 EXAMINER SCHILLINGER, ANN M

ART UNIT PAPER NUMBER
3774

DATE MAILED: 10/06/2014

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
12/492,512	06/26/2009	Amr Salahieh	\$63.2Q-15141-U\$03	7439
			·····	

TITLE OF INVENTION: Everting Heart Valve

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	UNDISCOUNTED	\$960	\$0	\$0	\$960	01/06/2015

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. <u>PROSECUTION ON THE MERITS IS CLOSED</u>. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN <u>THREE MONTHS</u> FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. <u>THIS STATUTORY PERIOD CANNOT BE EXTENDED</u>. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION. IF AN ISSUE FEE HAS PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW DUE.

HOW TO REPLY TO THIS NOTICE:

I. Review the ENTITY STATUS shown above. If the ENTITY STATUS is shown as SMALL or MICRO, verify whether entitlement to that entity status still applies.

If the ENTITY STATUS is the same as shown above, pay the TOTAL FEE(S) DUE shown above.

If the ENTITY STATUS is changed from that shown above, on PART B - FEE(S) TRANSMITTAL, complete section number 5 titled "Change in Entity Status (from status indicated above)".

For purposes of this notice, small entity fees are 1/2 the amount of undiscounted fees, and micro entity fees are 1/2 the amount of small entity fees.

II. PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted. If an equivalent of Part B is filed, a request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing the paper as an equivalent of Part B.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: <u>Mail</u> Mail Stop ISSUE FEE Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

or <u>Fax</u> (571)-273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

490 7590 10/06/2014 VIDAS, ARRETT & STEINKRAUS, P.A. Richard A. Arrett 9531 West 78th Street Suite 400 Eden Prairie, MN 55344

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

Certificate of Mailing or Transmission I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below.

(Depositor's nam	ie)
(Signatu	re)
(Da	te)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.		
12/492,512	06/26/2009	Amr Salahieh	\$63.2Q-15141-U\$03	7439		
ITLE OF INVENTION, Eventing Heart Value						

ITLE OF INVENTION: Everting Heart Valve

recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment. (A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY)	EXAI SCHILLIN						
SCHILLINGER, ANN M 3774 623-021000 1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363). 2. For printing on the patent front page, list 1 Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. 2. For printing on the patent attorneys or agents OR, alternatively, 1 (2) The name of a single firm (having as a member a PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required. 2 2 3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type) 9 9 PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. (A) NAME OF ASSIGNEE 16 an assignee is identified below, the document ha recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment. (A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY)	SCHILLIN						
 1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363). Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required. 2. For printing on the patent front page, list (1) The names of up to 3 registered patent attorneys or agents OR, alternatively, (2) The name of a single firm (having as a member a registered patent attorneys or agents. If no name is listed, no name will be printed. 3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type) PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document ha recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment. (A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY) 	. Change of correspond						
CFR 1.363). ¹ Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. ¹ The names of up to 3 registered patent attorneys or agents OR, alternatively, ¹ (2) The name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed. ²	. Change of correspon						
 PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document ha recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment. (A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY) 	 CFR 1.363). Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer 						
Please check the appropriate assignee category or categories (will not be printed on the patent): 🛄 Individual 🛄 Corporation or other private group entity	PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment. (A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY)						
4a. The following fee(s) are submitted: 4b. Payment of Fee(s): (Please first reapply any previously paid issue fee shown abore the fee shown	 Issue Fee Publication Fee (No small entity discount permitted) Advance Order - # of Copies 						
 5. Change in Entity Status (from status indicated above) Applicant certifying micro entity status. See 37 CFR 1.29 Applicant asserting small entity status. See 37 CFR 1.27 MOTE: Absent a valid certification of Micro Entity Status (see forms PTO/SB/15A a fee payment in the micro entity amount will not be accepted at the risk of application MOTE: If the application was previously under micro entity status, checking this box to be a notification of loss of entitlement to micro entity status. Applicant asserting small entity status. See 37 CFR 1.27 	Applicant certifying micro entity status. See 37 CFR 1.29						

NOTE: This form must be signed in accordance with 37 CFR 1.31 and 1.33. See 37 CFR 1.4 for signature requirements and certifications. Authorized Signature _ Date _ Typed or printed name _ Registration No.

Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 374 of 442

Applicant changing to regular undiscounted fee status.

OMB 0651-0033 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

<u>NOTE:</u> Checking this box will be taken to be a notification of loss of entitlement to small or micro entity status, as applicable.

	ted States Pate	UNITED STATES DEPAR United States Patent and Address: COMMISSIONER F P.O. Box 1450 Alexandria, Virginia 223 www.uspto.gov	Trademark Office OR PATENTS		
APPLICATION NO.	FILING DATE	ATTORNEY DOCKET NO.	CONFIRMATION NO.		
12/492,512	06/26/2009	\$63.2Q-15141-U\$03	7439		
490 75	90 10/06/2014		EXAMINER		
,	Γ & STEINKRAUS,	SCHILLING	ER, ANN M		
Richard A. Arrett 9531 West 78th Street			ART UNIT	PAPER NUMBER	
Suite 400			3774		
Eden Prairie, MN 5	55344	DATE MAILED: 10/06/201	4		

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)

(Applications filed on or after May 29, 2000)

The Office has discontinued providing a Patent Term Adjustment (PTA) calculation with the Notice of Allowance.

Section 1(h)(2) of the AIA Technical Corrections Act amended 35 U.S.C. 154(b)(3)(B)(i) to eliminate the requirement that the Office provide a patent term adjustment determination with the notice of allowance. See Revisions to Patent Term Adjustment, 78 Fed. Reg. 19416, 19417 (Apr. 1, 2013). Therefore, the Office is no longer providing an initial patent term adjustment determination with the notice of allowance. The Office will continue to provide a patent term adjustment determination with the Issue Notification Letter that is mailed to applicant approximately three weeks prior to the issue date of the patent, and will include the patent term adjustment on the patent. Any request for reconsideration of the patent term adjustment determination (or reinstatement of patent term adjustment) should follow the process outlined in 37 CFR 1.705.

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at 1-(888)-786-0101 or (571)-272-4200.

OMB Clearance and PRA Burden Statement for PTOL-85 Part B

The Paperwork Reduction Act (PRA) of 1995 requires Federal agencies to obtain Office of Management and Budget approval before requesting most types of information from the public. When OMB approves an agency request to collect information from the public, OMB (i) provides a valid OMB Control Number and expiration date for the agency to display on the instrument that will be used to collect the information and (ii) requires the agency to inform the public about the OMB Control Number's legal significance in accordance with 5 CFR 1320.5(b).

The information collected by PTOL-85 Part B is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- 1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
- 2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- 3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- 5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- 6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
- 9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation. Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 376 of 442

	Application No. 12/492,512	Applicant(SALAHIEH	
Notice of Allowability	Examiner	Art Unit	AIA (First Inventor to File) Status
	ANN SCHILLINGER	3774	No
The MAILING DATE of this communication appe All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT R of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in the or other appropriate communication is sub-	nis application. If no cation will be mailed	ot included d in due course. THIS
1. ☑ This communication is responsive to <u>the amendment made</u> ☐ A declaration(s)/affidavit(s) under 37 CFR 1.130(b) was		<u>on 4/10/2014</u> .	
 2. An election was made by the applicant in response to a resirequirement and election have been incorporated into this a 	-	uring the interview o	n; the restriction
 3. ☑ The allowed claim(s) is/are <u>9 and 17-24</u>. As a result of the a Prosecution Highway program at a participating intellectual please see <u>http://www.uspto.gov/patents/init_events/pph/inc</u> 	al property office for the corres	oonding application.	For more information,
4. Acknowledgment is made of a claim for foreign priority under	er 35 U.S.C. § 119(a)-(d) or (f).		
Certified copies: a) □ All b) □ Some *c) □ None of the: 1. □ Certified copies of the priority documents have 2. □ Certified copies of the priority documents have 3. □ Copies of the certified copies of the priority do	e been received in Application		application from the
International Bureau (PCT Rule 17.2(a)).	cuments have been received i	n inis national stage	
* Certified copies not received:			
Applicant has THREE MONTHS FROM THE "MAILING DATE" noted below. Failure to timely comply will result in ABANDONN THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		reply complying wit	h the requirements
5. CORRECTED DRAWINGS (as "replacement sheets") mus	t be submitted.		
including changes required by the attached Examiner' Paper No./Mail Date			
Identifying indicia such as the application number (see 37 CFR 1 each sheet. Replacement sheet(s) should be labeled as such in t	.84(c)) should be written on the header according to 37 CFR	drawings in the fron 1.121(d).	t (not the back) of
6. DEPOSIT OF and/or INFORMATION about the deposit of E attached Examiner's comment regarding REQUIREMENT FO			the
Attachment(s)			
1. Notice of References Cited (PTO-892)		mendment/Comme	
 Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date <u>7/9/2014</u> 	6. 🛄 Examiner's S	tatement of Reasor	is for Allowance
 3. Examiner's Comment Regarding Requirement for Deposit of Biological Material 4. Interview Summary (PTO-413), 	7. 🛄 Other		
Paper No./Mail Date /A. S./	/DAVID ISABEL	Δ/	
Examiner, Art Unit 3774		ent Examiner, Art I	Jnit 3774

	Application/Control No.	Applicant(s)/Patent Under Reexamination
Search Notes	12492512	SALAHIEH ET AL.
	Examiner	Art Unit
	ANN SCHILLINGER	3774

CPC- SEARCHED		
Symbol	Date	Examiner
A61F2/2412; A61F2/2427; A61F2220/0016; A61F2/24; A61F2/2454; A61F2/07	9/25/2014	AS

CPC COMBINATION SETS - SEAR	CHED	
Symbol	Date	Examiner

	US CLASSIFICATION SEA	RCHED	
Class	Subclass	Date	Examiner

SEARCH NOTES										
Search Notes	Date	Examiner								
Updated prior search	3/29/2011	AS								
Updated prior search	4/2/2014	AS								
Updated prior search	9/25/2014	AS								
Interference search EAST, see printout	9/25/2014	AS								

US Class/ CPC Symbol	US Subclass / CPC Group	Date	Examiner							
A61F	A61F2/2412; A61F2/2427; A61F2220/0016; A61F2/24; A61F2/2454; A61F2/07	9/25/2014	AS							

/A. S./ Examiner.Art Unit 3774	

	Application/Control No.	Applicant(s)/Patent Under Reexamination
Issue Classification	12492512	SALAHIEH ET AL.
	Examiner	Art Unit
	ANN SCHILLINGER	3774

Cumhal				Turr -	Varcian
Symbol				Туре	Version
A61F	2		2418	F	2013-01-01
461F	2		2439	1	2013-01-01
A61F	2		2433	A	2013-01-01
A61F	2		2436	A	2013-01-01
		1			

CPC Combination Sets										
Symbol	Туре	Set	Ranking	Version						

Examiner.Art Unit 3774	09/25/2014	Total Claims Allowed:				
(Assistant Examiner)	(Date)	×				
/DAVID ISABELLA/ Supervisory Patent Examiner.Art Unit 3774	09/28/2014	O.G. Print Claim(s)	O.G. Print Figure			
(Primary Examiner)	(Date)	1	32			

U.S. Patent and Trademark Office

Part of Paper No. 20140925

Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 379 of 442

	Application/Control No.	Applicant(s)/Patent Under Reexamination
Issue Classification	12492512	SALAHIEH ET AL.
	Examiner	Art Unit
	ANN SCHILLINGER	3774

	US ORIGINAL CLASSIFICATION					INTERNATIONAL CLASSIFICATION									ON
	CLASS SUBCLASS							С	LAIMED		NON-CLAIMED				
623			2.38			А	6	1	F	2 / 24 (2006.01.01)					
CROSS REFERENCE(S)															
CLASS	SUB	CLASS (ONE	SUBCLAS	S PER BLO	CK)										
											-				
						-									

/A.S./ Examiner.Art Unit 3774	09/25/2014	Total Claims Allowed:				
(Assistant Examiner)	(Date)	9				
/DAVID ISABELLA/ Supervisory Patent Examiner.Art Unit 3774	09/28/2014	O.G. Print Claim(s)	O.G. Print Figure			
(Primary Examiner)	(Date)	1	32			

U.S. Patent and Trademark Office

Part of Paper No. 20140925

Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 380 of 442

	Application/Control No.	Applicant(s)/Patent Under Reexamination
Issue Classification	12492512	SALAHIEH ET AL.
	Examiner	Art Unit
	ANN SCHILLINGER	3774

	Claims renumbered in the same order as presented by applicant								СР] т.р.	[] R.1.	47	
Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original
	1	2	17												
	2	3	18												
	3	4	19												
	4	5	20												
	5	6	21												
	6	7	22												
	7	8	23												
	8	9	24												
1	9														
	10														
	11														
	12														
	13														
	14														
	15														
	16														

/A.S./ Examiner.Art Unit 3774	09/25/2014	Total Claims Allowed: 9		
(Assistant Examiner)	(Date)			
/DAVID ISABELLA/ Supervisory Patent Examiner.Art Unit 3774	09/28/2014	O.G. Print Claim(s)	O.G. Print Figure	
(Primary Examiner)	(Date)	1	32	

U.S. Patent and Trademark Office

Part of Paper No. 20140925

Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 381 of 442



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

BIB DATA SHEET

CONFIRMATION NO. 7439

SERIAL NUM	BER	FILING	_ 371(c)		CLASS	GR	OUP ART	UNIT	ATTORNEY DOCKET	
12/492,51	2	DAT 06/26/2			623		3774		S63.	NO. 2Q-15141-US03
		RUL	E							
APPLICANT	s									
INVENTORS Amr Salahieh, Saratoga, CA; Ulrich R. Haug, Campbell, CA; Hans F. Valencia, Berkeley, CA; Robert A. Geshlider, San Francisco, CA; Tom Saul, El Granada, CA; Dwight P. Morejohn, Davis, CA; Kenneth J. Michlitsch, Livermore, CA;										
						20				
					008 PAT 866873 4 PAT 7780725					
** FOREIGN A	PPLICA	TIONS *****	*******	******						
** IF REQUIRED, FOREIGN FILING LICENSE GRANTED ** 07/07/2009										
Foreign Priority claime		Yes No	D Met af	tor	STATE OR	I	HEETS	тот		INDEPENDENT
		LLINGER/	Met af Allowa	ance	COUNTRY CA		WINGS 63	CLAII 7	1012	CLAIMS 1
ADDRESS										
VIDAS, ARRETT & STEINKRAUS, P.A. Richard A. Arrett SUITE 400, 6640 SHADY OAK ROAD 6640 Shady Oak Rd. EDEN PRAIRIE, MN 55344 UNITED STATES										
TITLE										
Everting	Heart V	alve								
							🗅 All Fe	es		
	FEES	Authority has	been aive	en in Pa	ner		🖵 1.16 F	Fees (Fil	ing)	
FILING FEE FEES: Authority has been given in Paper RECEIVED Noto charge/credit DEPOSIT ACCOUNT					ng Ext. of time)					
462	No	foi	following	:			🖵 1.18 F	ees (lss	sue)	
							Other			
	Credit									

EAST Search History

EAST Search History (Interference)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L4	2	(heart and valve and commissure and seal and fabric).clm.	US-PGPUB; USPAT; UPAD	OR	ON	2014/09/25 17:37
L6	5	(replacement and heart and valve and delivery and blood and seal and vessel).clm.	US-PGPUB; USPAT; UPAD	OR	ON	2014/09/25 17:50
L7	3	(support and element and heart and valve and commissure and blood and seal).clm.		OR	ON	2014/09/25 17:52
L8	1	(expand\$4 and replacement and valve and commissure and fabric and seal and leaflet).clm.	US-PGPUB; USPAT; UPAD	OR	ON	2014/09/25 17:58
L9		(deployed and state and heart and valve and fabric and seal and flaps).clm.	US-PGPUB; USPAT; UPAD	OR	ON	2014/09/25 18:00

9/25/2014 6:01:09 PM

C:\ Users\ aschillinger\ Documents\ EAST\ Workspaces\ 12492512.wsp

Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 383 of 442

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	REQ	UEST FO		D EXAMINATIO I Only via EFS	N(RCE)TRANSMITTA -Web)	۱L	
Application Number	12492512	Filing Date	2009-06-26	Docket Number (if applicable)	S63.2-15141-US03	Art Unit	3774
First Named Inventor	Amr Salahieh			Examiner Name	Ann M. Schillinger	ł	
Request for C	ontinued Examina	ation (RCE)		R 1.114 does not ap	above-identified application oply to any utility or plant appli WWW.USPTO.GOV		prior to June 8,
		S	UBMISSION REQ	UIRED UNDER 37	CFR 1.114		
in which they	were filed unless	applicant ins		pplicant does not wi	nents enclosed with the RCE v sh to have any previously filed		
	y submitted. If a fi n even if this box			any amendments file	d after the final Office action n	nay be con	sidered as a
□ Co	nsider the argum	ents in the A	ppeal Brief or Reply	Brief previously filed	on		
🗌 Ott	ner						
X Enclosed							
🗌 An	nendment/Reply						
🗙 Info	ormation Disclosu	ire Statemer	nt (IDS)				
Aff	davit(s)/ Declarat	tion(s)					
	her						
			MIS	CELLANEOUS			
			ntified application is d 3 months; Fee und		CFR 1.103(c) for a period of n quired)	n onths	
Other							
FEES							
The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed. Image: State of the Director is hereby authorized to charge any underpayment of fees, or credit any overpayments, to Deposit Account No 220350							
		SIGNATUF	RE OF APPLICANT	T, ATTORNEY, OF	R AGENT REQUIRED		
🗙 Patent	Practitioner Sign	ature					
Applica	ant Signature						

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Signature of Registered U.S. Patent Practitioner					
Signature	/Michael J. McKeen/	Date (YYYY-MM-DD)	2014-11-26		
Name	Michael J. McKeen	Registration Number	66069		

This collection of information is required by 37 CFR 1.114. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
- 2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- 3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- 5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- 6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
- 9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number12/492,512Filing Date6/26/2009First Named InventorUlrich R. HaugArt Unit3774

Page 1 of 3

Matter Number S63.2-15141-US03

U.S. PATENT DOCUMENTS							
Initials	Cite No.	Document Number	Issue/Publication Date	First Named Inventor	Т		
	1	20110257735	10/20/2011	Salahieh et al.			
	2	20120022642	01/26/2012	Haug et al.			
	3	20120029627	02/02/2012	Salahieh et al.			
	4	20120041550	02/16/2012	Salahieh et al.			
	5	20120053683	03/01/2012	Salahieh et al.			
	6	20120089224	04/12/2012	Haug et al.			
	7	20120330409	12/27/2012	Haug et al.			
	8	20130190865	07/25/2013	Anderson			
	9	20140094904	04/03/2014	Salahieh et al.			
	10	20140114405	04/24/2014	Paul et al.			
	11	20140114406	04/24/2014	Salahieh et al.			
	12	20140121766	05/01/2014	Salahieh et al.			
	13	20140135912	05/15/2014	Salahieh et al.			
	14	20140243967	08/28/2014	Salahieh et al.			
	15	5258023	11/02/1993	Reger			
	16	7824442	11/02/2010	Salahieh et al.			
	17	7824443	11/02/2010	Salahieh et al.			
	18	7959666	06/14/2011	Salahieh et al.			
	19	7959672	06/14/2011	Salahieh et al.			
	20	7988724	08/02/2011	Salahieh et al.			
	21	8048153	11/01/2011	Salahieh et al.			
	22	8052749	11/08/2011	Salahieh et al.			
	23	8182528	05/22/2012	Salahieh et al.			
	24	8231670	07/31/2012	Salahieh et al.			
	25	8246678	08/21/2012	Salahieh et al.			
	26	8252052	08/28/2012	Salahieh et al.			
	27	8328868	12/11/2012	Paul et al.			
	28	8343213	01/01/2013	Salahieh et al.			
	29	8579962	11/12/2013	Salahieh et al.			
	30	8603160	12/10/2013	Salahieh et al.			

Examiner SignatureDate ConsideredExaminer: Please initial if citation considered, whether or not citation is in conformance with MPEP Section609. Please draw a line through the citation if it is not in conformance and it is not considered. Please include
a copy of this form with the next communication to the applicant.

	Application Number	12/492,512
	Filing Date	6/26/2009
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	Ulrich R. Haug
	Art Unit	3774
Page 2 of 3	Matter Number	S63.2-15141-US03
Page 2 of 3	Matter Number	S63.2-15141-US03

	U.S. PATENT DOCUMENTS									
Initials	Cite No.	Document Number	Issue/Publication Date	First Named Inventor	Т					
	31	8617236	12/31/2013	Paul et al.						
	32	8623076	01/07/2014	Salahieh et al.						
	33	8623078	01/07/2014	Salahieh et al.						
	34	8668733	03/11/2014	Haug et al.						
	35	8828078	09/09/2014	Salahieh et al.						
	36	8840662	09/23/2014	Salahieh et al.						
	37	8840663	09/23/2014	Salahieh et al.						
	38	8858620	10/14/2014	Salahieh et al.						

Examiner SignatureDate ConsideredExaminer: Please initial if citation considered, whether or not citation is in conformance with MPEP Section609. Please draw a line through the citation if it is not in conformance and it is not considered. Please include
a copy of this form with the next communication to the applicant.

	Application Number	12/492,512
	Filing Date	6/26/2009
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	Ulrich R. Haug
	Art Unit	3774
		_
Page 3 of 3	Matter Number	S63.2-15141-US03

SIGNATURE						
Signature /Michael J. McKeen/	Date	11/26/2014				
Name Michael J. McKeen	Registration Number	66069				

Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 389 of 442

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	Amr Salahieh, Ulrich R. Haug, Hans F. Valencia,
	Robert A. Geshlider, Tom Saul, Dwight P.
	Morejohn, Kenneth J. Michlitsch
Application No.:	12/492512
Filed:	June 26, 2009
For:	Everting Heart Valve
Examiner:	Ann M. Schillinger
Group Art Unit:	3774

Mail Stop _____ Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Docket No.: S63.2Q-15141-US03

Letter Regarding IDS

Applicant has listed, on the accompanying form, information for consideration in the above-mentioned application. Applicant respectfully requests that the listed information be considered by the Examiner and be made of record in the above-identified application. Applicant requests that the Examiner return an initialed copy of the accompanying form(s) indicating that the listed information has been considered, in accordance with MPEP §609. This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability. Moreover, no aspect of this submission constitutes a disclaimer of claim scope.

Applicant respectfully requests that any copies of unpublished US applications submitted herewith be excluded from the file wrapper pursuant to 37 C.F.R. §1.14.

The present application is a division of and claims priority under 35 U.S.C. § 120 to U.S. Pat. Appl. Ser. No. 12/269,213, filed on November 12, 2008; which is a continuation of 10/870,340 filed on June 16, 2004. Pursuant to 37 C.F.R. § 1.98(d), copies of documents cited by or submitted to the United States Patent and Trademark Office in a previous application to which priority was claimed under 35 U.S.C. § 120 need not be submitted and are not submitted herewith.

Application No. 12/492512 Page 2

Letter Regarding IDS Attorney Docket No. S63.2Q-15141-US03

If a \$180 fee is due for consideration of this Information Disclosure Statement and full payment has not been submitted herewith, the Commissioner is hereby authorized to charge any additional fees associated with this communication to Deposit Account No. 22-0350. The Commissioner is hereby authorized to credit any overpayment associated with this communication to Deposit Account No. 22-0350.

Respectfully submitted,

VIDAS, ARRETT & STEINKRAUS

Date: November 26, 2014

By: /Michael J. McKeen/

Michael J. McKeen Registration No.: 66069

9531 West 78th Street, Suite 400 Eden Prairie, MN 55344-8006 Telephone: (952) 563-3000 Facsimile: (952) 563-3001

v:\wpwork\mjm\15141us03_informationdisclosurestatement_20141126.doc

Electronic Patent Application Fee Transmittal							
Application Number:	12	492512					
Filing Date:	26	-Jun-2009					
Title of Invention:	Everting Heart Valve						
First Named Inventor/Applicant Name:	Amr Salahieh						
Filer:	Mi	chael James McKee	n/Wendy Skelly				
Attorney Docket Number:	S6.	3.2Q-15141-US03					
Filed as Large Entity							
Utility under 35 USC 111(a) Filing Fees							
Description		Fee Code	Quantity	Amount	Sub-Total in USD(\$)		
Basic Filing:							
Pages:							
Claims:							
Miscellaneous-Filing:							
Petition:							
Patent-Appeals-and-Interference:							
Post-Allowance-and-Post-Issuance:							
Extension-of-Time:							

Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Miscellaneous:				
RCE - 2nd and Subsequent Request	1820	1	1700	1700
	Total in USD (\$)		1700	

Electronic Acknowledgement Receipt			
EFS ID:	20807575		
Application Number:	12492512		
International Application Number:			
Confirmation Number:	7439		
Title of Invention:	Everting Heart Valve		
First Named Inventor/Applicant Name:	Amr Salahieh		
Customer Number:	490		
Filer:	Michael James McKeen/Wendy Skelly		
Filer Authorized By:	Michael James McKeen		
Attorney Docket Number:	S63.2Q-15141-US03		
Receipt Date:	26-NOV-2014		
Filing Date:	26-JUN-2009		
Time Stamp:	11:46:20		
Application Type:	Utility under 35 USC 111(a)		

Payment information:

Submitted wit	th Payment	yes		
Payment Type	2	Credit Card		
Payment was	successfully received in RAM	\$1700		
RAM confirma	ation Number	55		
Deposit Accou	unt			
Authorized Us	ser			
File Listing:				
Document Number	Document Description Edwards Lifescie	File Size(Bytes)/ Multi Pages nces Corporation, et al. ExhibitigeDigeBageBah4/Off#42ifappl.)		

1	Transmittal Letter	15141US03_VASTransmittal_20 141126.pdf	80777 ff6c8a3263ae7344e81aa3c5934cc9d5b435	no	1
Warnings:			0a77		
Information:					
2	Request for Continued Examination (RCE)	15141US03_RCE_20141125.pdf	697611	20	
			5e28742fc7d3d8b2ee20cc8a980cb09128c 511fb	no	3
Warnings:					
Information:					
3	Information Disclosure Statement (IDS) Form (SB08)	15141US03_IDS_20141125.pdf	612784	no	5
			8f7e418a9d16886a8c4f4b5d016be4b9d5d bce3c		
Warnings:					
Information:					
4 Informat	Information Disclosure Statement (IDS)	15141US03_IDS2_20141125.	39202	no	3
	Form (SB08)	pdf	8aeaa839ffb4c4415ccdb3535fc5a2bc5455 8aa0		
Warnings:					
Information:					
This is not an U	SPTO supplied IDS fillable form				
5	Miscellaneous Incoming Letter	15141US03_InformationDisclos ureStatement_20141126.pdf	89909	no no	2
			33402f733df01ba8a908903900dc1a4bc32 0a9ae		
Warnings:					
Information:					
6	Foreign Reference	15141US03_FR1_20141125.pdf	2378335	no	26
			37f6ebf39676f817bf729b791b1aff8a9abd2 93c		
Warnings:					
Information:					
7	Foreign Reference	15141US03_FR2_20141125.pdf	2177492	no	54
			db5e6459c092ecf89a3a840791c8a3d8c70 b137a		
Warnings:					
Information:					
8	Foreign Reference	15141US03_FR3_20141125.pdf	2626955	no f	64
			279e33b8540623dbd51f5451a8785c6f74ff 060b		
Warnings:					
Information:					
9	Foreign Reference	15141US03_FR4_20141125.pdf	2407205	no	29
	Edwards I :fass	on and Componentian at a	05098afc75261fa259aaf3c4da80e4438347 e646		

Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 395 of 442

	1514111503 EP5 20141125 pdf	744283		20
	131410305_rtt5_20141125.pdf	27fd6cac5b5298bf7ed3c7e56a781d96469a 97fe	110	
	1			i
Foreign Reference	15141US03_EB6_20141125.pdf	5991154	no	97
		87cc13a00ebeaf24b5f0b33e92b72f73cc0f0 647		
Foreign Reference	15141US03_EB7_20141125.pdf	745574	no	24
l'oreign neierenee	131110303_110_20111123.pdf	76b47ae6385abebdc1e5e642ef9f5795d2a 8a874	110	24
Fac Workshart (SDOG)	for info ndf	30128	20	2
	ree-into.put	dbaa42c41f905c70e7074977ef21741f7953 ddde	no	
	Total Files Size (in bytes):	186	18621409	
by the applicant, and including pa described in MPEP 503. <u>tions Under 35 U.S.C. 111</u> faction is being filed and the applicand MPEP 506), a Filing Receipt (37 Cl ement Receipt will establish the filing ge of an International Application un omission to enter the national stage d other applicable requirements a F e submission under 35 U.S.C. 371 w <u>ional Application Filed with the USF</u> national application is being filed a nal filing date (see PCT Article 11 artices)	ge counts, where applicable. ation includes the necessary of FR 1.54) will be issued in due of ng date of the application. <u>Inder 35 U.S.C. 371</u> of an international applicati Form PCT/DO/EO/903 indicati ill be issued in addition to the <u>PTO as a Receiving Office</u> nd the international application of MPEP 1810), a Notification O/105) will be issued in due co	It serves as evidence components for a filin course and the date s on is compliant with t ng acceptance of the Filing Receipt, in due ion includes the neces of the International A ourse, subject to pres	of receipt s g date (see hown on th the condition application course. ssary comp Application criptions c	imilar to a 37 CFR is ons of 35 n as a onents for Number oncerning
	by the applicant, and including pa described in MPEP 503. <u>tions Under 35 U.S.C. 111</u> faction is being filed and the applica ad MPEP 506), a Filing Receipt (37 Cl ement Receipt will establish the filir ge of an International Application u omission to enter the national stage d other applicable requirements a F e submission under 35 U.S.C. 371 w <u>ional Application Filed with the USI</u> national application is being filed a nal filing date (see PCT Article 11 artices)	Foreign Reference 15141US03_FR6_20141125.pdf Foreign Reference 15141US03_FR7_20141125.pdf Fee Worksheet (SB06) fee-info.pdf Fee Worksheet (SB06) fee-info.pdf Total Files Size (in bytes) edgement Receipt evidences receipt on the noted date by the US by the applicant, and including page counts, where applicable. described in MPEP 503. tions Under 35 U.S.C. 111 cation is being filed and the application includes the necessary comission to enter the national stage of an international application. ge of an International Application under 35 U.S.C. 371 omission under 35 U.S.C. 371 will be issued in addition to the issue of an international application. ge of an International Application under 35 U.S.C. 371 pational application Filed with the USPTO as a Receiving Office national application is being filed and the international application the issued in addition to the isonal application is being filed and the international application ternational application application filed with the USPTO as a Receiving Office	Foreign Reference 15141US03_FR5_20141125.pdf Foreign Reference 15141US03_FR6_20141125.pdf Foreign Reference 15141US03_FR6_20141125.pdf Foreign Reference 15141US03_FR7_20141125.pdf Foreign Reference 15141US03_FR7_20141125.pdf Foreign Reference 15141US03_FR7_20141125.pdf Fee Worksheet (SB06) fee-info.pdf Get Processore 30128 Get Processore 30128 Get Processore 15141US03_FR7_20141125.pdf Fee Worksheet (SB06) fee-info.pdf Get Processore 30128 Get Processore 180 Get Processore 18	Foreign Reference 15141US03_FR5_20141125.pdf no Foreign Reference 15141US03_FR6_20141125.pdf 5991154 no Foreign Reference 15141US03_FR6_20141125.pdf \$991154 no Foreign Reference 15141US03_FR7_20141125.pdf \$745574 no Foreign Reference 15141US03_FR7_20141125.pdf 745574 no Foreign Reference 15141US03_FR7_20141125.pdf 745574 no Fee Worksheet (SB06) fee-info.pdf 30128 no Fee Worksheet (SB06) fee-info.pdf 30128 no Model 30128 no 18621409 Edgement Receipt evidences receipt on the noted date by the USPTO of the indicated document by the applicant, and including page counts, where applicable. It serves as evidence of receipt s described in MPEP 503. 18621409 Edgement Receipt evidences receipt on the noted date by the USPTO of the indicated document by the application includes the necessary components for a filing date (see of an international Application includes the necessary components for a filing date (see of an international Application is compliant with the condition or the ment Receipt will establish the filing date of the application. te of an International Application under 35 U.S.C. 371 omission to enter the national stage of an international application is compliant with the condit

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	Amr Salahieh, Ulrich R. Haug, Hans F. Valencia, Robert A.
	Geshlider, Tom Saul, Dwight P. Morejohn, Kenneth J. Michlitsch
Application No.:	12/492512
Filed:	June 26, 2009
For:	Everting Heart Valve
Examiner:	Ann M. Schillinger
Group Art Unit:	3774

Mail Stop _____ Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Docket No.: S63.2Q-15141-US03

TRANSMITTAL LETTER

- In regard to the above-identified application, in addition to this 1 page transmittal letter, we are submitting the attached:
 5 page Information Disclosure Statement, 3 page Information Disclosure Statement, 3 page Request for
 Continued Examination, 2 page Letter Regarding IDS, and 7 Foreign References
- 2. With respect to fees, applicant believes the fees required herein, if any, are being paid electronically.

3. CONDITIONAL PETITION FOR EXTENSION OF TIME

- This conditional petition is being filed along with the papers identified in Item 1 above and provides for the possibility that Applicant has inadvertently overlooked the need for a petition and fee for extension of time or for a petition and fee for any other matter petitionable to the Commissioner as required. If any extension of time for the accompanying response is required or if a petition for any other matter is required, by petitioner, Applicant requests that this be considered a petition therefor.
- 4. Notwithstanding paragraph 2 above, if any additional fees associated with this communication are required and have not otherwise been paid, including any fee associated with the Conditional Petition for Extension of Time, or any request in the accompanying papers for action which requires a fee as a petition to the Commissioner, please charge the additional fees to Deposit Account No. 22-0350. Please charge any additional fees associated with this communication to the Deposit Account No. 22-0350.
- 5. **Certification:** I hereby certify that this Transmittal Letter and the paper(s) as described herein are being transmitted electronically to the USPTO on November 26, 2014.

Respectfully submitted,

VIDAS, ARRETT & STEINKRAUS

By: /Michael J. McKeen/

Michael J. McKeen Registration No.: 66069

9531 West 78th Street, Suite 400 Eden Prairie, MN 55344-8006 Telephone: (952) 563-3000 Facsimile: (952) 563-3001

Date: November 26, 2014

v:\wpwork\mjm\15141us03_vastransmittal_20141126.doc

PTO/SB/08a (01-10) Approved for use through 07/31/2012. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		12492512		
Filing Date		2009-06-26		
First Named Inventor	Amr S	Salahieh		
Art Unit		3774		
Examiner Name	Ann M	1. Schillinger		
Attorney Docket Numb	er	S63.2-15141-US03		

				U.S.	PATENTS	Remove
Examiner Initial*	er Cite No Patent Number Kind Code ¹ Issue Date Name of Patentee or Applie		Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1	6402736		2002-06-11	Brown et al.	
	2 5755783			1998-05-26 Stobie et al.		
	3	6585766		2003-07-01	Huynh et al.	
	4	6258129		2001-07-10	Dybdal et al.	
If you wis	h to add	additional U.S. Paten	t citatio	n information p	lease click the Add button.	Add
			U.S.P		CATION PUBLICATIONS	Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20030195609		2003-10-16	Berenstein et al.	
	2	20030171803		2003-09-11	Shimon	

INFORMATION DISCLOSURE Application Number 12492512 Filing Date 2009-06-26 First Named Inventor Amr Salahieh Art Unit 3774 Examiner Name Ann M. Schillinger Attorney Docket Number \$63.2-15141-U\$03

	3	20030199759	200	3-10-23	Richard			
lf you wisł	n to ac	dd additional U.S. Pul			I n information FENT DOCUM		button. Add Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code4	Publication	Name of Patentee Applicant of cited Document	or Pages,Columns,Lines	T⁵
	1	2004021922	wo		2004-03-18	Morrill et al.		
	2	2004006804	wo		2004-01-22	EV3 Inc.		
	3	2004006803	wo		2004-01-22	EV3 Inc.		
	4	2003047648	wo		2003-06-12	Sagax Inc.		
	5	2002056955	wo		2002-07-25	Embol-X, Inc.		
	6	2004043293	wo		2004-05-27	Viacor, Inc.		
	7	2004019817	wo		2004-03-11	Belson et al.		
lf you wisł	n to ac	d additional Foreign			information p		Remove	

INFORMATION DISCLOSURE Application Number 12492512 Filing Date 2009-06-26 First Named Inventor Amr Salahieh Art Unit 3774 Examiner Name Ann M. Schillinger Attorney Docket Number \$63.2-15141-U\$03

Examiner Initials*	xaminer Cite No Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						
	1						
If you wis	h to ao	dd ado	ditional non-patent literature document citation information please click the Add b	outton Add	•		
			EXAMINER SIGNATURE				
Examiner	Signa	ature	Date Considered				
	*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						
Standard S ⁻¹ ⁴ Kind of do	T.3). ³ F cument	For Japa by the	O Patent Documents at <u>www.USPTO.GOV</u> or MPEP 901.04. ² Enter office that issued the docume anese patent documents, the indication of the year of the reign of the Emperor must precede the ser appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applic on is attached.	rial number of the patent doo	ument.		

	Application Number		12492512	
	Filing Date		2009-06-26	
INFORMATION DISCLOSURE	First Named Inventor Amr S		r Salahieh	
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		3774	
	Examiner Name	Ann M	Λ. Schillinger	
	Attorney Docket Numb	er	S63.2-15141-US03	

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

See attached certification statement.

The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

X A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Michael J. McKeen/	Date (YYYY-MM-DD)	2014-11-26
Name/Print	Michael J. McKeen	Registration Number	66069

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- 2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- 3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- 5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- 6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
- 9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		12492512		
Filing Date		2009-06-26		
First Named Inventor	Amr S	Salahieh		
Art Unit		3774		
Examiner Name	Ann M	1. Schillinger		
Attorney Docket Numb	er	S63.2-15141-US03		

					U.S.F	PATENTS			Remove	
Examiner Cite Initial* No		Patent Number	Kind Code ¹				e of Patentee or Applicant ed Document		Pages,Columns,Lines where Relevant Passages or Releva Figures Appear	
	1									
lf you wisł	n to ac	dd additional U.S. Pat	ent citatio	n informatio	on ple	ease click the	Add button.		Add	
			U.S.P	ATENT AF	PLIC	ATION PUB			Remove	
Examiner Initial*	Cite I	No Publication Number	Kind Code ¹			Name of Patentee or Applicant of cited Document		Relev	s,Columns,Lines where ant Passages or Relev es Appear	
	1									
If you wish	n to ac	d additional U.S. Pub	lished Ap	plication ci	tatior	information	please click the Ade	d butto	n. Add	
				FOREIGN	PAT		IENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	·	ind ode⁴	Publication Date	Name of Patented Applicant of cited Document	e or	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	т5
	1	2006/005015	WO	Až	2	2006-01-12	EDWARDS LIFESCIENCES PV INC	/Т		
	2 2001/76510		WO	Aź	2	2001-10-18	EDWARDS LIFESCIENCES CO	ORP		
lf you wisl	h to ac	dd additional Foreign I	Patent Do	cument cita	ation	information p	lease click the Add	button	Add	I
			NON	-PATENT	LITE	RATURE DO	CUMENTS		Remove	

INFORMATION DISCLOSURE Application Number 12492512 Filing Date 2009-06-26 First Named Inventor Amr Salahieh Art Unit 3774 Examiner Name Ann M. Schillinger Attorney Docket Number \$63.2-15141-U\$03

Examiner Initials* Cite No Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.							
	1						
If you wis	h to ac	dd add	ditional non-patent literature document citation information please click the Add b	outton Add	•		
			EXAMINER SIGNATURE				
Examiner	Signa	ture	Date Considered				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							
¹ See Kind Codes of USPTO Patent Documents at <u>www.USPTO.GOV</u> or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.							

	Application Number		12492512	
	Filing Date		2009-06-26	
INFORMATION DISCLOSURE	First Named Inventor Amr S		r Salahieh	
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		3774	
	Examiner Name	Ann M	Λ. Schillinger	
	Attorney Docket Numb	er	S63.2-15141-US03	

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

See attached certification statement.

The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

X A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Michael J. McKeen/	Date (YYYY-MM-DD)	2014-12-03
Name/Print	Michael J. McKeen	Registration Number	66069

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- 2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- 3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- 5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- 6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
- 9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Electronic Acknowledgement Receipt						
EFS ID:	20857411					
Application Number:	12492512					
International Application Number:						
Confirmation Number:	7439					
Title of Invention:	Everting Heart Valve					
First Named Inventor/Applicant Name:	Amr Salahieh					
Customer Number:	490					
Filer:	Michael James McKeen/Wendy Skelly					
Filer Authorized By:	Michael James McKeen					
Attorney Docket Number:	S63.2Q-15141-US03					
Receipt Date:	03-DEC-2014					
Filing Date:	26-JUN-2009					
Time Stamp:	16:57:33					
Application Type:	Utility under 35 USC 111(a)					

Payment information:

Submitted with	Payment		no				
File Listing:							
Document Number	Document Description		File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)	
1	Transmittal Letter	15	15141US03_VASTransmittal_20	80617	no	1	
			141203.pdf	3aa9a91b5c4ad330daa87b46921d0c6a26e a7412			
Warnings:							
Information:	Edwards Lifesc	ienc	es Corporation, et al	Exhibit 1102. Pag	e 407 of 4	42	

<u>Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 407 of 442</u>

2	Miscellaneous Incoming Letter	15141US03_InformationDisclos ureStatement_20141203.pdf	659c9d859c34b9348197d0d70313725923	no	2
Warnings:			9cd919		
Information:					
	Information Disclosure Statement (IDS)		612096		
3	Form (SB08)	15141US03_IDS_20141201.pdf	1bf4a7a3124fba003fd6097a59042c58b259 ff3f	no	4
Warnings:			•		•
Information:					
autoloading of you are citing U within the Imag	umber Citation or a U.S. Publication Numbe data into USPTO systems. You may remove J.S. References. If you chose not to include U ge File Wrapper (IFW) system. However, no Non Patent Literature will be manually revie	the form to add the required dat J.S. References, the image of the f data will be extracted from this fo	a in order to correct the I form will be processed ar rm. Any additional data s	nformational Id be made av	Message if /ailable
4	Foreign Reference	15141US03_FR1_20141201.pdf	2564344 	no	68
Warnings:					
Information:					
5	Foreign Reference	15141US03_FR2_20141201.pdf	1839898	no	39
			7588216c8433c3f5779a6b5b5ea84c43c8e b2600		
Warnings:					
Information:					
		Total Files Size (in bytes)	: 51	86854	
characterized Post Card, as <u>New Applica</u> If a new appl 1.53(b)-(d) an Acknowledg <u>National Stag</u> If a timely su U.S.C. 371 an national stag <u>New Internat</u> If a new inter	ledgement Receipt evidences receip d by the applicant, and including page described in MPEP 503. tions Under 35 U.S.C. 111 ication is being filed and the applica nd MPEP 506), a Filing Receipt (37 CF ement Receipt will establish the filin ge of an International Application un bmission to enter the national stage of other applicable requirements a F ge submission under 35 U.S.C. 371 wi tional Application Filed with the USP mational application is being filed ar	ge counts, where applicable. tion includes the necessary of R 1.54) will be issued in due g date of the application. <u>Inder 35 U.S.C. 371</u> of an international applicati orm PCT/DO/EO/903 indicati Il be issued in addition to the <u>TO as a Receiving Office</u> and the international applicat	It serves as evidence components for a filir course and the date s ion is compliant with ing acceptance of the e Filing Receipt, in du ion includes the nece	of receipt s ing date (see shown on th the condition application le course.	imilar to a 37 CFR nis ons of 35 n as a

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	Amr Salahieh, Ulrich R. Haug, Hans F. Valencia, Robert A.
	Geshlider, Tom Saul, Dwight P. Morejohn, Kenneth J. Michlitsch
Application No.:	12/492512
Filed:	June 26, 2009
For:	Everting Heart Valve
Examiner:	Ann M. Schillinger
Group Art Unit:	3774

Mail Stop _____ Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Docket No.: S63.2Q-15141-US03

TRANSMITTAL LETTER

- 1. In regard to the above-identified application, in addition to this 1 page transmittal letter, we are submitting the attached: 4 page Information Disclosure Statement, 2 page Letter Regarding IDS and 2 Foreign References
- 2. With respect to fees, applicant believes the fees required herein, if any, are being paid electronically.

3. CONDITIONAL PETITION FOR EXTENSION OF TIME

- This conditional petition is being filed along with the papers identified in Item 1 above and provides for the possibility that Applicant has inadvertently overlooked the need for a petition and fee for extension of time or for a petition and fee for any other matter petitionable to the Commissioner as required. If any extension of time for the accompanying response is required or if a petition for any other matter is required, by petitioner, Applicant requests that this be considered a petition therefor.
- 4. Notwithstanding paragraph 2 above, if any additional fees associated with this communication are required and have not otherwise been paid, including any fee associated with the Conditional Petition for Extension of Time, or any request in the accompanying papers for action which requires a fee as a petition to the Commissioner, please charge the additional fees to Deposit Account No. 22-0350. Please charge any additional fees associated with this communication to the Deposit Account No. 22-0350.
- 5. **Certification:** I hereby certify that this Transmittal Letter and the paper(s) as described herein are being transmitted electronically to the USPTO on December 3, 2014.

Respectfully submitted,

VIDAS, ARRETT & STEINKRAUS

Date: December 3, 2014

By: /Michael J. McKeen/

Michael J. McKeen Registration No.: 66069

9531 West 78th Street, Suite 400 Eden Prairie, MN 55344-8006 Telephone: (952) 563-3000 Facsimile: (952) 563-3001

v:\wpwork\mjm\15141us03_vastransmittal_20141203.doc

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	Amr Salahieh, Ulrich R. Haug, Hans F. Valencia,
	Robert A. Geshlider, Tom Saul, Dwight P.
	Morejohn, Kenneth J. Michlitsch
Application No.:	12/492512
Filed:	June 26, 2009
For:	Everting Heart Valve
Examiner:	Ann M. Schillinger
Group Art Unit:	3774

Mail Stop _____ Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Docket No.: S63.2Q-15141-US03

Letter Regarding IDS

Applicant has listed, on the accompanying form, information for consideration in the above-mentioned application. Applicant respectfully requests that the listed information be considered by the Examiner and be made of record in the above-identified application. Applicant requests that the Examiner return an initialed copy of the accompanying form(s) indicating that the listed information has been considered, in accordance with MPEP §609. This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability. Moreover, no aspect of this submission constitutes a disclaimer of claim scope.

Applicant respectfully requests that any copies of unpublished US applications submitted herewith be excluded from the file wrapper pursuant to 37 C.F.R. §1.14.

The present application is a division of and claims priority under 35 U.S.C. § 120 to U.S. Pat. Appl. Ser. No. 12/269,213, filed on November 12, 2008; which is a continuation of 10/870,340 filed on June 16, 2004. Pursuant to 37 C.F.R. § 1.98(d), copies of documents cited by or submitted to the United States Patent and Trademark Office in a previous application to which priority was claimed under 35 U.S.C. § 120 need not be submitted and are not submitted herewith.

Application No. 12/492512 Page 2

Letter Regarding IDS Attorney Docket No. S63.2Q-15141-US03

If a \$180 fee is due for consideration of this Information Disclosure Statement and full payment has not been submitted herewith, the Commissioner is hereby authorized to charge any additional fees associated with this communication to Deposit Account No. 22-0350. The Commissioner is hereby authorized to credit any overpayment associated with this communication to Deposit Account No. 22-0350.

Respectfully submitted,

VIDAS, ARRETT & STEINKRAUS

Date: December 3, 2014

By: /Michael J. McKeen/ Michael J. McKeen Registration No.: 66069

9531 West 78th Street, Suite 400 Eden Prairie, MN 55344-8006 Telephone: (952) 563-3000 Facsimile: (952) 563-3001

v:\wpwork\mjm\15141us03_informationdisclosurestatement_20141203.doc

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

NOTICE OF ALLOWANCE AND FEE(S) DUE

490 7590 02/12/2015
VIDAS, ARRETT & STEINKRAUS, P.A.
Richard A. Arrett
9531 West 78th Street
Suite 400
Eden Prairie, MN 55344

EXAMINER SCHILLINGER, ANN M

ART UNIT PAPER NUMBER
3774

DATE MAILED: 02/12/2015

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.					
12/492,512	06/26/2009	Amr Salahieh	\$63.2Q-15141-U\$03	7439					

TITLE OF INVENTION: Everting Heart Valve

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	UNDISCOUNTED	\$960	\$0	\$O	\$960	05/12/2015

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. <u>PROSECUTION ON THE MERITS IS CLOSED</u>. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN <u>THREE MONTHS</u> FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. <u>THIS STATUTORY PERIOD CANNOT BE EXTENDED</u>. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION. IF AN ISSUE FEE HAS PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW DUE.

HOW TO REPLY TO THIS NOTICE:

I. Review the ENTITY STATUS shown above. If the ENTITY STATUS is shown as SMALL or MICRO, verify whether entitlement to that entity status still applies.

If the ENTITY STATUS is the same as shown above, pay the TOTAL FEE(S) DUE shown above.

If the ENTITY STATUS is changed from that shown above, on PART B - FEE(S) TRANSMITTAL, complete section number 5 titled "Change in Entity Status (from status indicated above)".

For purposes of this notice, small entity fees are 1/2 the amount of undiscounted fees, and micro entity fees are 1/2 the amount of small entity fees.

II. PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted. If an equivalent of Part B is filed, a request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing the paper as an equivalent of Part B.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: <u>Mail</u> Mail Stop ISSUE FEE Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

or <u>Fax</u> (571)-273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

490 7590 02/12/2015 VIDAS, ARRETT & STEINKRAUS, P.A. Richard A. Arrett 9531 West 78th Street Suite 400 Eden Prairie, MN 55344

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

Certificate of Mailing or Transmission I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below.

(Depositor's name)
(Signature)
(Date)

APPLICATION NO.	FILING DATE		FIRST NAMED INVENTOR			ATTORNEY DOCKET NO. CONFIRMATION NO		
12/492,512	06/26/2009		Amr Salahieh		\$63.2	Q-15141-US03	7439	
TITLE OF INVENTION	: Everting Heart Valve							
				PREV. PAID ISSUI				
APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE		3 FEE	TOTAL FEE(S) DUE	DATE DUE	
nonprovisional	UNDISCOUNTED	\$960	\$0	\$0		\$960	05/12/2015	
EXAM	IINER	ART UNIT	CLASS-SUBCLASS]				
SCHILLING	ER, ANN M	3774	623-021000	•				
1. Change of correspond CFR 1.363).	ence address or indicatio	on of "Fee Address" (37	2. For printing on the p	10,				
,	ondence address (or Cha 3/122) attached.	ange of Correspondence	(1) The names of up to or agents OR, alternativ	o 3 registered paten vely,	t attorney	5		
			(2) The name of a sing registered attorney or a 2 registered patent atto	le firm (having as a	member	a 2		
PTO/SB/47; Rev 03-0 Number is required.	ication (or "Fee Address)2 or more recent) attach	ed. Use of a Customer	2 registered attorney of a 2 registered patent atto listed, no name will be	rneys or agents. If printed.	no name i	s 3		
3. ASSIGNEE NAME A	ND RESIDENCE DAT.	A TO BE PRINTED ON	FIE PATENT (print or type)	pe)				
PLEASE NOTE: Un	less an assignee is ident	tified below, no assignee	data will appear on the p	atent. If an assign	ee is iden	tified below, the d	ocument has been filed for	
(A) NAME OF ASSI		pletion of this form is NO	(B) RESIDENCE: (CITY					
(A) NAME OF ASST	ONEL		(b) RESIDENCE, (CIT I		OUNIK	1)		
Please check the appropr	iate assignee category or	r categories (will not be pr	cinted on the patent): \Box	Individual 🗖 Co	orporation	or other private gro	oup entity 📮 Government	
4a. The following fee(s)	are submitted:	41	o. Payment of Fee(s): (Plea	use first reapply ar	y previo	usly paid issue fee	shown above)	
Issue Fee			A check is enclosed.					
	o small entity discount		Payment by credit car					
Advance Order - #	t of Copies		The director is hereby overpayment, to Depo	authorized to charg sit Account Numbe	ge the requer	uired fee(s), any def (enclose a	iciency, or credits any nextra copy of this form).	
						· ·		
5. Change in Entity Sta		-			E 1. 0.			
Applicant certifying	ng micro entity status. Se	ee 37 CFR 1.29	<u>NOTE:</u> Absent a valid ce fee payment in the micro	entity amount will	not be ac	cepted at the risk of	D/SB/15A and 15B), issue application abandonment.	
Applicant assertin	g small entity status. See	e 37 CFR 1.27	<u>NOTE:</u> If the application to be a notification of los	was previously und s of entitlement to i	ler micro nicro enti	entity status, check ty status.	ing this box will be taken	
Applicant changin	g to regular undiscounte	d fee status.	<u>NOTE:</u> Checking this box entity status, as applicabl	x will be taken to b e.	e a notific	ation of loss of enti	tlement to small or micro	
NOTE: This form must t	be signed in accordance v	with 37 CFR 1.31 and 1.3.	3. See 37 CFR 1.4 for sign	ature requirements	and certif	ications.		
Authorized Signature				Date				
-								
Typed or printed nam	e			Registration N	lo			

Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 413 of 442

OMB 0651-0033 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

UNITED STATES PATENT AND TRADEMARK OFFICE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Address: COMMISSIONER FOR PATENTS P.O. Box							
APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.			
12/492,512	06/26/2009	Amr Salahieh	\$63.2Q-15141-U\$03	7439			
490 75	90 02/12/2015		EXAN	IINER			
,	Γ & STEINKRAUS,	P.A.	SCHILLING	ER, ANN M			
Richard A. Arrett 9531 West 78th Str	reet		ART UNIT	PAPER NUMBER			
Suite 400			3774				
Eden Prairie, MN 5	55344		DATE MAILED: 02/12/201	5			

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)

(Applications filed on or after May 29, 2000)

The Office has discontinued providing a Patent Term Adjustment (PTA) calculation with the Notice of Allowance.

Section 1(h)(2) of the AIA Technical Corrections Act amended 35 U.S.C. 154(b)(3)(B)(i) to eliminate the requirement that the Office provide a patent term adjustment determination with the notice of allowance. See Revisions to Patent Term Adjustment, 78 Fed. Reg. 19416, 19417 (Apr. 1, 2013). Therefore, the Office is no longer providing an initial patent term adjustment determination with the notice of allowance. The Office will continue to provide a patent term adjustment determination with the Issue Notification Letter that is mailed to applicant approximately three weeks prior to the issue date of the patent, and will include the patent term adjustment on the patent. Any request for reconsideration of the patent term adjustment determination (or reinstatement of patent term adjustment) should follow the process outlined in 37 CFR 1.705.

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at 1-(888)-786-0101 or (571)-272-4200.

OMB Clearance and PRA Burden Statement for PTOL-85 Part B

The Paperwork Reduction Act (PRA) of 1995 requires Federal agencies to obtain Office of Management and Budget approval before requesting most types of information from the public. When OMB approves an agency request to collect information from the public, OMB (i) provides a valid OMB Control Number and expiration date for the agency to display on the instrument that will be used to collect the information and (ii) requires the agency to inform the public about the OMB Control Number's legal significance in accordance with 5 CFR 1320.5(b).

The information collected by PTOL-85 Part B is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- 1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
- 2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- 3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- 5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- 6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
- 9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation. Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 415 of 442

	Application No.	Applicant(s SALAHIEH	
Notice of Allowability	12/492,512 Examiner ANN SCHILLINGER	Art Unit 3774	L I AL. AIA (First Inventor to File) Status No
The MAILING DATE of this communication a All claims being allowable, PROSECUTION ON THE MERITS herewith (or previously mailed), a Notice of Allowance (PTOL- NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT of the Office or upon petition by the applicant. See 37 CFR 1.	IS (OR REMAINS) CLOSED in the set of the set	nis application. If no ication will be mailed	t included I in due course. THIS
1. X This communication is responsive to the Request for Co	ntinued Examination filed on 11/2	<u>26/2014</u> .	
A declaration(s)/affidavit(s) under 37 CFR 1.130(b)	was/were filed on		
2. An election was made by the applicant in response to a requirement and election have been incorporated into this		uring the interview o	n; the restriction
 Image: Second State St	ctual property office for the corres	ponding application.	For more information,
4. Acknowledgment is made of a claim for foreign priority u	nder 35 U.S.C. § 119(a)-(d) or (f).		
Certified copies:			
a) 🔲 All b) 🗌 Some *c) 🗌 None of the:			
1. 🔲 Certified copies of the priority documents h			
2. 🔲 Certified copies of the priority documents h			
Copies of the certified copies of the priority	documents have been received in	n this national stage	application from the
International Bureau (PCT Rule 17.2(a)).			
* Certified copies not received:			
Applicant has THREE MONTHS FROM THE "MAILING DAT noted below. Failure to timely comply will result in ABANDC THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		reply complying with	n the requirements
5. CORRECTED DRAWINGS (as "replacement sheets") n	nust be submitted.		
including changes required by the attached Examir Paper No./Mail Date	ner's Amendment / Comment or ir	the Office action of	
Identifying indicia such as the application number (see 37 CF each sheet. Replacement sheet(s) should be labeled as such			(not the back) of
6. DEPOSIT OF and/or INFORMATION about the deposit attached Examiner's comment regarding REQUIREMENT			the
Attachment(s)			
1. 🔲 Notice of References Cited (PTO-892)	5. 🔲 Examiner's A	mendment/Commer	nt
2. X Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date <u>11/26/14,11/26/14,12/3/14</u>	6. 🗌 Examiner's S	tatement of Reason	s for Allowance
 3. ☐ Examiner's Comment Regarding Requirement for Depos of Biological Material 	sit 7. 🗌 Other		
4. Interview Summary (PTO-413), Paper No./Mail Date			
/A. S./	/DAVID ISABEL	LA/	
Examiner, Art Unit 3774	Supervisory Pate	ent Examiner, Art l	Jnit 3774



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

BIB DATA SHEET

CONFIRMATION NO. 7439

		FILING or	271(0)							RNEY DOCKET
SERIAL NUM		DATE			CLASS			UNIT		NO.
12/492,51;	2	06/26/2			623		3774		S63.	2Q-15141-US03
		RULE								
APPLICANTS	S									
Ulrich R. I Hans F. V Robert A. Tom Saul Dwight P.	Haug, C /alencia Geshlid , El Gra Morejo	aratoga, CA; Campbell, CA a, Berkeley, C der, San Fran anada, CA; ohn, Davis, CA itsch, Livermo	A; icisco, CA \;							
** CONTINUING DATA ******************										
This application is a DIV of 12/269,213 11/12/2008 PAT 8668733 which is a CON of 10/870,340 06/16/2004 PAT 7780725										
** FOREIGN AF	PPLICA	TIONS *****	*******	******						
** IF REQUIRED, FOREIGN FILING LICENSE GRANTED ** 07/07/2009										
Foreign Priority claime		Yes No			STATE OR	-	HEETS	тот		INDEPENDENT
35 USC 119(a-d) cond Verified and		U Yes M No	Met af Allowa	ince	COUNTRY		WINGS	CLAI		CLAIMS
	Examiner's		Initials		CA		63	7		1
ADDRESS										
VIDAS, ARRETT & STEINKRAUS, P.A. Richard A. Arrett 9531 West 78th Street Suite 400 Eden Prairie, MN 55344 UNITED STATES										
TITLE										
Everting H	Heart Va	alve								
							🗅 All Fe	es		
		A	h				🖵 1.16 F	Fees (Fil	ing)	
		Authority has			aper POSIT ACCOUI	NT	🖸 1.17 F	ees (Pr	ocessi	ing Ext. of time)
		for					🖵 1.18 F	ees (lss	sue)	
							C Other			
							Credit			
1							-			

	Application/Control No.	Applicant(s)/Patent Under Reexamination
Issue Classification	12492512	SALAHIEH ET AL.
	Examiner	Art Unit
	ANN SCHILLINGER	3774

Symbol			Туре	Version	
A61F	2	/ 2418	F	2013-01-01	
A61F	2	2433	А	2013-01-01	
A61F	2	2436	A	2013-01-01	
A61F	2	2439	1	2013-01-01	
A61F	2220	0016	A	2013-01-01	
A61F	2220	005	A	2013-01-01	
A61F	2220	0058	A	2013-01-01	
A61F	2220	0075	A	2013-01-01	
A61F	2230	005	A	2013-01-01	
A61F	2230	0054	A	2013-01-01	
A61F	2230	0065	A	2013-01-01	
A61F	2230	0078	A	2013-01-01	

CPC Combination Sets									
Symbol	Туре	Set	Ranking	Version					

/A.S./ Examiner.Art Unit 3774	02/04/2015		ns Allowed:
(Assistant Examiner)	(Date)	ç)
/DAVID ISABELLA/ Supervisory Patent Examiner.Art Unit 3774	02/08/2015	O.G. Print Claim(s)	O.G. Print Figure
(Primary Examiner)	(Date)	1	32
		_	

U.S. Patent and Trademark Office

Part of Paper No. 20150204

Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 418 of 442

	Application/Control No.	Applicant(s)/Patent Under Reexamination
Issue Classification	12492512	SALAHIEH ET AL.
	Examiner	Art Unit
	ANN SCHILLINGER	3774

	US ORIGINAL CLASSIFICATION									INTERNATIONAL	CLA	SSI	FIC	ΑΤΙ	ON
	CLASS			SUBCLASS					С	LAIMED		NON-CLAIMED			
623			2.38			А	6	1	F	2 / 24 (2006.01.01)					
	CR	OSS REF	ERENCE(S)											
CLASS	SUB	CLASS (ONE	SUBCLAS	S PER BLO	CK)										
											-				
						-									

/A.S./ Examiner.Art Unit 3774	02/04/2015	Total Claims Allowed:			
(Assistant Examiner)	(Date)	9			
/DAVID ISABELLA/ Supervisory Patent Examiner.Art Unit 3774	02/08/2015	O.G. Print Claim(s)	O.G. Print Figure		
(Primary Examiner)	(Date)	1	32		

U.S. Patent and Trademark Office

Part of Paper No. 20150204

Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 419 of 442

	Application/Control No.	Applicant(s)/Patent Under Reexamination
Issue Classification	12492512	SALAHIEH ET AL.
	Examiner	Art Unit
	ANN SCHILLINGER	3774

Claims renumbered in the same order as presented by applicant CPA T.D. R.1.									47						
Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original
	1	2	17												
	2	3	18												
	3	4	19												
	4	5	20												
	5	6	21												
	6	7	22												
	7	8	23												
	8	9	24												
1	9														
	10														
	11														
	12														
	13														
	14														
	15														
	16														

/A.S./ Examiner.Art Unit 3774	02/04/2015		ns Allowed:	
(Assistant Examiner)	(Date)	9		
/DAVID ISABELLA/ Supervisory Patent Examiner.Art Unit 3774	02/08/2015	O.G. Print Claim(s)	O.G. Print Figure	
(Primary Examiner)	(Date)	1	32	

U.S. Patent and Trademark Office

Part of Paper No. 20150204

Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 420 of 442

EAST Search History

EAST Search History (Interference)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	1 2	(heart and valve and commissure and seal and fabric).clm.	US-PGPUB; USPAT; UPAD	OR	ON	2015/02/04 14:37
L2		(replacement and heart and valve and delivery and blood and seal and vessel).clm.	US-PGPUB; USPAT; UPAD	OR	ON	2015/02/04 14:42
L3		(support and element and heart and valve and commissure and blood and seal).clm.		OR	ON	2015/02/04 14:44
L4	1	(expand\$4 and replacement and valve and commissure and fabric and seal and leaflet).clm.	US-PGPUB; USPAT; UPAD	OR	ON	2015/02/04 14:45
L5		(deployed and state and heart and valve and fabric and seal and flaps).clm.	US-PGPUB; USPAT; UPAD	OR	ON	2015/02/04 15:07

2/4/2015 3:08:03 PM

 $C:\ Users\ aschillinger\ Documents\ EAST\ Workspaces\ 12492512.wsp$

Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 421 of 442

	Application Number	12/492,512
	Filing Date	6/26/2009
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	Ulrich R. Haug
STATEMENT BI AFFLICANT	Art Unit	3774
Page 1 of 3	Matter Number	S63.2-15141-US03

	U.S. PATENT DOCUMENTS							
Initials	Cite No.	Document Number	Issue/Publication Date	First Named Inventor	Т			
	1	20110257735	10/20/2011	Salahieh et al.				
	2	20120022642	01/26/2012	Haug et al.				
	3	20120029627	02/02/2012	Salahieh et al.				
	4	20120041550	02/16/2012	Salahieh et al.				
	5	20120053683	03/01/2012	Salahieh et al.				
	6	20120089224	04/12/2012	Haug et al.				
	7	20120330409	12/27/2012	Haug et al.				
	8	20130190865	07/25/2013	Anderson				
	9	20140094904	04/03/2014	Salahieh et al.				
	10	20140114405	04/24/2014	Paul et al.				
	11	20140114406	04/24/2014	Salahieh et al.				
	12	20140121766	05/01/2014	Salahieh et al.				
	13	20140135912	05/15/2014	Salahieh et al.				
	14	20140243967	08/28/2014	Salahieh et al.				
	15	5258023	11/02/1993	Reger				
	16	7824442	11/02/2010	Salahieh et al.				
	17	7824443	11/02/2010	Salahieh et al.				
	18	7959666	06/14/2011	Salahieh et al.				
	19	7959672	06/14/2011	Salahieh et al.				
	20	7988724	08/02/2011	Salahieh et al.				
	21	8048153	11/01/2011	Salahieh et al.				
	22	8052749	11/08/2011	Salahieh et al.				
	23	8182528	05/22/2012	Salahieh et al.				
	24	8231670	07/31/2012	Salahieh et al.				
	25	8246678	08/21/2012	Salahieh et al.				
	26	8252052	08/28/2012	Salahieh et al.				
	27	8328868	12/11/2012	Paul et al.				
	28	8343213	01/01/2013	Salahieh et al.				
	29	8579962	11/12/2013	Salahieh et al.				
	30	8603160	12/10/2013	Salahieh et al.				

Examiner SignatureDate ConsideredExaminer: Please initial if citation considered, whether or not citation is in conformance with MPEP Section609. Please draw a line through the citation if it is not in conformance and it is not considered. Please include
a copy of this form with the next communication to the applicant.

Syncids.com/ALL REFERENCES GRONSIDE PERFORENCE PAT. WHILE REI 02, NED 232 BO42GH. /A.S./

	Application Number	12/492,512	
	Filing Date		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	Ulrich R. Haug	
STATEMENT BY AFFLICANT	Art Unit	3774	
Page 2 of 3	Matter Number	S63.2-15141-US03	

	U.S. PATENT DOCUMENTS							
Initials	Cite No.	Document Number	Issue/Publication Date	First Named Inventor	Т			
	31	8617236	12/31/2013	Paul et al.				
32 8623076		01/07/2014	Salahieh et al.					
	33	8623078	01/07/2014	Salahieh et al.				
	34 8668733		03/11/2014	Haug et al.				
	35	8828078	09/09/2014	Salahieh et al.				
	36	8840662	09/23/2014	Salahieh et al.				
	37	8840663	09/23/2014	Salahieh et al.				
	38	8858620	10/14/2014	Salahieh et al.				

Examiner Signature/Ann Schillinger/Date Considered02/04/2015Examiner: Please initial if citation considered, whether or not citation is in conformance with MPEP Section609. Please draw a line through the citation if it is not in conformance and it is not considered. Please includea copy of this form with the next communication to the applicant.

	Application Number	12/492,512
	Filing Date	6/26/2009
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	Ulrich R. Haug
STATEWEINT BEAFFLICANT	Art Unit	3774
Page 3 of 3	Matter Number	S63.2-15141-US03

SIGNATURE				
Signature /Michael J. McKeen/	Date	11/26/2014		
Name Michael J. McKeen	Registration Number	66069		

12492512 - GALL, 3774) Approved for use through 07/31/2012. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		12492512	
Filing Date		2009-06-26	
First Named Inventor Amr S		alahieh	
Art Unit		3774	
Examiner Name Ann N		1. Schillinger	
Attorney Docket Numb	er	S63.2-15141-US03	

				U.S.	PATENTS	Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	6402736		2002-06-11	Brown et al.	
	2	5755783		1998-05-26	Stobie et al.	
	3	6585766		2003-07-01	Huynh et al.	
	4	6258129		2001-07-10	Dybdal et al.	
If you wis	h to add	additional U.S. Paten	it citatio	n information pl	lease click the Add button.	Add
			U.S.P	ATENT APPLI	CATION PUBLICATIONS	Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20030195609		2003-10-16	Berenstein et al.	
	2	20030171803		2003-09-11	Shimon	

12492512 - GAU: 3774 Application Number 12492512 Filing Date 2009-06-26 **INFORMATION DISCLOSURE** First Named Inventor Amr Salahieh **STATEMENT BY APPLICANT** 3774 Art Unit (Not for submission under 37 CFR 1.99) **Examiner** Name Ann M. Schillinger Attorney Docket Number S63.2-15141-US03

	3	20030199759	200)3-10-23	Richard			
lf you wisl	h to ac	dd additional U.S. Pi			information	please click the Add	button. Add Remove	
Examiner Initial*	Cite No	Foreign Document Number ³		Kind Code4	Publication	Name of Patentee Applicant of cited Document	Pages Columns Lines	T5
	1	2004021922	wo		2004-03-18	Morrill et al.		
	2	2004006804	wo		2004-01-22	EV3 Inc.		
	3	2004006803	wo		2004-01-22	EV3 Inc.		
	4	2003047648	wo		2003-06-12	Sagax Inc.		
	5	2002056955	wo		2002-07-25	Embol-X, Inc.		
	6	2004043293	wo		2004-05-27	Viacor, Inc.		
	7	2004019817	wo		2004-03-11	Belson et al.		
lf you wisl	h to ac	dd additional Foreigi			information p	lease click the Add k	Add Remove	<u> </u>

12492512 - GAU: 3774 Application Number 12492512 Filing Date 2009-06-26 **INFORMATION DISCLOSURE** First Named Inventor Amr Salahieh **STATEMENT BY APPLICANT** 3774 Art Unit (Not for submission under 37 CFR 1.99) **Examiner** Name Ann M. Schillinger Attorney Docket Number S63.2-15141-US03

Examiner Initials* Cite No linclude name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.				T⁵		
	1					
If you wis	h to ac	dd additional non-patent literature document citation information	please click the Add I	outton Add		
		EXAMINER SIGNATURE				
Examiner	Signa	ature /Ann Schillinger/	Date Considered	02/04/2015		
	*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					
Standard ST ⁴ Kind of doo	¹ See Kind Codes of USPTO Patent Documents at <u>www.USPTO.GOV</u> or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.					

	Application Number		12492512	12492512 -	· GAU: 3774
	Filing Date		2009-06-26		
INFORMATION DISCLOSURE	First Named Inventor	· Amr Salahieh			
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit	-	3774		
	Examiner Name	Ann M. Schillinger			
	Attorney Docket Numbe		S63.2-15141-US03	3	

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

See attached certification statement.

The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

X A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Michael J. McKeen/	Date (YYYY-MM-DD)	2014-11-26
Name/Print	Michael J. McKeen	Registration Number	66069

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- 2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- 3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- 5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- 6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
- 9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

12492512 - GALL:03774 Approved for use through 07/31/2012. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		12492512	
Filing Date		2009-06-26	
First Named Inventor Amr S		Salahieh	
Art Unit		3774	
Examiner Name Ann M		1. Schillinger	
Attorney Docket Numb	er	S63.2-15141-US03	

				L	J.S.P	ATENTS			Remove	
Examiner Cite Initial* No Patent Number		Kind Code ¹	Issue Date		Name of Patentee or Applicant of cited Document			Pages,Columns,Lines where Relevant Passages or Relevar Figures Appear		
	1									
lf you wis	h to ac	dd additional U.S. Pat	ent citatio	n informatio	on ple	ase click the	Add button.		Add	
			U.S.P	ATENT AP	PLIC	ATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No Publication Number		Kind Code ¹	Publicatior Date		Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1									
lf you wis	h to ao	dd additional U.S. Pub	lished Ap	plication cit	ation	information	please click the Ad	d butto		
		1	- 1	FOREIGN	PATE				Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²			Publication Date	Name of Patente Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T 5
	1	2006/005015	wo	A2	2	2006-01-12	EDWARDS LIFESCIENCES PV INC	/т		
	2	2001/76510	wo	A2	2	2001-10-18	EDWARDS LIFESCIENCES CO	ORP		
lf you wis	n to ao	dd additional Foreign l	Patent Do	cument cita	ation i	nformation p	lease click the Add	buttor		I
			NON	I-PATENT I	LITEF	RATURE DO	CUMENTS		Remove	

12492512 - GAU: 3774 Application Number 12492512 Filing Date 2009-06-26 **INFORMATION DISCLOSURE** First Named Inventor Amr Salahieh **STATEMENT BY APPLICANT** 3774 Art Unit (Not for submission under 37 CFR 1.99) **Examiner** Name Ann M. Schillinger Attorney Docket Number S63.2-15141-US03

Examiner Initials* Cite No Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						T⁵
	1					
If you wis	h to ac	dd additio	nal non-patent literature document citation information	please click the Add I	outton Add	
			EXAMINER SIGNATURE			
Examiner	Signa	iture	/Ann Schillinger/	Date Considered	02/04/2015	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						
Standard ST	F.3). ³ F cum <mark>ent</mark>	⁻ or Japanes by the appr	Patent Documents at <u>www.USPTO.GOV</u> or MPEP 901.04. ² Enter off se patent documents, the indication of the year of the reign of the Em ropriate symbols as indicated on the document under WIPO Standard attached.	peror must precede the se	rial number of the patent doc	ument.

	Application Number		12492512	12492512 - GAU: 3774	
	Filing Date		2009-06-26		
INFORMATION DISCLOSURE	First Named Inventor	st Named Inventor Amr Salahieh			
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		3774		
	Examiner Name	Ann M. Schillinger			
	Attorney Docket Numb	er	\$63.2-15141-U\$03		

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

See attached certification statement.

The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

X A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Michael J. McKeen/	Date (YYYY-MM-DD)	2014-12-03
Name/Print	Michael J. McKeen	Registration Number	66069

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- 2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- 3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- 5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- 6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
- 9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

	Application/Control No.	Applicant(s)/Patent Under Reexamination
Search Notes	12492512	SALAHIEH ET AL.
	Examiner	Art Unit
	ANN SCHILLINGER	3774

CPC- SEARCHED		
Symbol	Date	Examiner
A61F2/2412; A61F2/2427; A61F2220/0016; A61F2/24; A61F2/2454; A61F2/07	9/25/2014	AS

CPC COMBINATION SETS - SEARCHED						
Symbol Date Examine						

US CLASSIFICATION SEARCHED							
Class	Subclass	Date	Examiner				

SEARCH NOTE	ES	
Search Notes	Date	Examiner
Updated prior search	3/29/2011	AS
Updated prior search	4/2/2014	AS
Updated prior search	9/25/2014	AS
Interference search EAST, see printout	9/25/2014	AS
Updated prior search	2/4/2015	AS
Interference search EAST, see printout	2/4/2015	AS

	INTERFERENCE SEARCH		
US Class/ CPC Symbol	US Subclass / CPC Group	Date	Examiner
A61F	A61F2/2412; A61F2/2427; A61F2220/0016; A61F2/24; A61F2/2454; A61F2/07	9/25/2014	AS
A61F	A61F2/2412; A61F2/2427; A61F2220/0016; A61F2/24; A61F2/2454; A61F2/07	2/4/2015	AS

/A. S./ Examiner.Art Unit 3774

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: Mail Mail Stop ISSUE FEE

Commissioner for Patents P.O. Box 1450

Alexandria, Virginia 22313-1450

or <u>Fax</u> (571)-273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

490 7590 02/12/2015 VIDAS, ARRETT & STEINKRAUS, P.A. Richard A. Arrett 9531 West 78th Street Suite 400 Eden Prairie, MN 55344

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

Certificate of Mailing or Transmission I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below.

(Depositor's name)
(Signature)
(Date)

APPLICATION NO.	FILING DATE		FIRST NAMED INVENTOR			RNEY DOCKET NO.	CONFIRMATION NO.
12/492,512	06/26/2009	•	Amr Salahieh		\$63	.2Q-15141-US03	7439
TITLE OF INVENTION	V: Everting Heart Valve						
APPLN, TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUI	EFEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	UNDISCOUNTED	\$960	\$0	\$0		\$960	05/12/2015
EXAM	IINER	ARTUNIT	CLASS-SUBCLASS	1			
SCHILLING	ER, ANN M	3774	623-021000	1			
CFR 1.363). Change of corresp Address form PTO/S	ence address or indication ondence address (or Cha B/122) attached. lication (or "Fee Address" 02 or more recent) attached.	nge of Correspondence	 For printing on the p The names of up to or agents OR, alternative The name of a singler registered attorney or a 2 registered patternation attorney in the listed, no name will be 	3 registered paten vely, e firm (having as a gent) and the name rneys or agents. If 1	t attorne membe es of up	stein Stein to	, Arrett & kraus, P.A.
(A) NAME OF ASSI Sadra Mec	-		(B) RESIDENCE: (CITY Los Gatos,	and STATE OR C Californ	ounti nia	RY)	up entity Government
4a. The following fee(s) Issue Fee Publication Fee (N	1071 T.	41 ermitted)	 b. Payment of Fee(s): (Plea A check is enclosed. Payment by credit care The director is hereby overpayment, to Depoind 	se first reapply an d. Form PTO-2038 authorized to charg	is attack	ously paid issue fee s ned. quired fee(s), any defi	hown above)
Applicant certifyin	tus (from status indicated ng micro entity status. See g small entity status. See ng to regular undiscounted	e 37 CFR 1.29 37 CFR 1.27	<u>NOTE</u> : Absent a valid cer fee payment in the micro <u>NOTE</u> : If the application to be a notification of loss <u>NOTE</u> : Checking this box entity status, as applicable	entity amount will a was previously und of entitlement to n will be taken to be	not be a ler micr nicro en	ccepted at the risk of a o entity status, checki tity status.	application abandonment. ng this box will be taken
NOTE: This form must b	e signed in accordance w	ith 37 CFR 1.31 and 1.33	3. See 37 CFR 1.4 for signa		and cert	ifications.	
Authorized Signature		Malloon	*********	_{Date} _Febr	uar	y 23, 2015 069	
Typed or printed nam	"Michael"J.	MCKeen		Registration N	o	069	

PTOL-85 Part B (10-13) Approved for use throughd wands. Lifesciences Goopporationgaettala Exhibit ft 102, Bager 435 vo 6442 MMERCE

Electronic Patent Application Fee Transmittal					
Application Number:	12492512				
Filing Date:	26-Jun-2009				
Title of Invention:	Everting Heart Valve				
First Named Inventor/Applicant Name:	Am	nr Salahieh			
Filer:	Mio	chael James McKeer	n/Wendy Skelly	y	
Attorney Docket Number:	S63	3.2Q-15141-US03			
Filed as Large Entity					
Filing Fees for Utility under 35 USC 111(a)					
Description		Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Basic Filing:					
Pages:					
Claims:					
Miscellaneous-Filing:					
Petition:					
Patent-Appeals-and-Interference:					
Post-Allowance-and-Post-Issuance:					
Utility Appl Issue Fee 1501 1 960 960					

Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 436 of 442

Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)	
Extension-of-Time:					
Miscellaneous:					
	Tot	al in USD	(\$)	960	

Electronic Acknowledgement Receipt				
EFS ID:	21572124			
Application Number:	12492512			
International Application Number:				
Confirmation Number:	7439			
Title of Invention:	Everting Heart Valve			
First Named Inventor/Applicant Name:	Amr Salahieh			
Customer Number:	490			
Filer:	Michael James McKeen/Wendy Skelly			
Filer Authorized By:	Michael James McKeen			
Attorney Docket Number:	S63.2Q-15141-US03			
Receipt Date:	23-FEB-2015			
Filing Date:	26-JUN-2009			
Time Stamp:	15:52:52			
Application Type:	Utility under 35 USC 111(a)			

Payment information:

Submitted with Payment	yes			
Payment Type	Credit Card			
Payment was successfully received in RAM	\$ 960			
RAM confirmation Number	2596			
Deposit Account				
Authorized User				
The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:				

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Transmittal Letter	15141US03_VASTransmittal_20 150223.pdf	81300	no	1
		150223.pdf	c44062f4c1973e00d99b75652eb3f91fc86e f94e		
Warnings:					
Information:		1			
2	Post Allowance Communication - Incoming	15141US03_FeeAddressIndicati onForm_20150223.pdf	71197	no	1
	incoming	om om_20150225.pdf	68d4cc2ae62c2a9089d450badabbc4d3424 069b3		
Warnings:					
Information:					
3	lssue Fee Payment (PTO-85B)	15141US03_lssueFee_2015022	55047	no	1
		3.pdf	43afa2b480d38316b04d870b8b3a605041c e6f4d		
Warnings:					
Information:					
4	Fee Worksheet (SB06)	fee-info.pdf	30143	no	2
-			a516d2932739f01f8efb905820ed47deac48 b353		
Warnings:		·			
Information:					
		Total Files Size (in bytes)	• 23	37687	
characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503. <u>New Applications Under 35 U.S.C. 111</u> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application. <u>National Stage of an International Application under 35 U.S.C. 371</u> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.					
New Internat If a new inter an internatio and of the Int	ional Application Filed with the US national application is being filed a nal filing date (see PCT Article 11 a ternational Filing Date (Form PCT/R urity, and the date shown on this Ac	<u>PTO as a Receiving Office</u> and the international applicat nd MPEP 1810), a Notification 20/105) will be issued in due c	ion includes the nece of the International <i>J</i> ourse, subject to pres	ssary comp Application scriptions co	Number oncerning

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	Amr Salahieh, Ulrich R. Haug, Hans F. Valencia, Robert A.
	Geshlider, Tom Saul, Dwight P. Morejohn, Kenneth J. Michlitsch
Application No.:	12/492512
Filed:	June 26, 2009
For:	Everting Heart Valve
Examiner:	Ann M. Schillinger
Group Art Unit:	3774

Mail Stop <u>Issue Fee</u> Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Docket No.: S63.2Q-15141-US03

TRANSMITTAL LETTER

- In regard to the above-identified application, in addition to this 1 page transmittal letter, we are submitting the attached:
 1 page Fee Address Indication Form and 1 page Part B Fee(s) Transmittal
- 2. With respect to fees, applicant believes the fees required herein, if any, are being paid electronically.

3. CONDITIONAL PETITION FOR EXTENSION OF TIME

- This conditional petition is being filed along with the papers identified in Item 1 above and provides for the possibility that Applicant has inadvertently overlooked the need for a petition and fee for extension of time or for a petition and fee for any other matter petitionable to the Commissioner as required. If any extension of time for the accompanying response is required or if a petition for any other matter is required, by petitioner, Applicant requests that this be considered a petition therefor.
- 4. Notwithstanding paragraph 2 above, if any additional fees associated with this communication are required and have not otherwise been paid, including any fee associated with the Conditional Petition for Extension of Time, or any request in the accompanying papers for action which requires a fee as a petition to the Commissioner, please charge the additional fees to Deposit Account No. 22-0350. Please charge any additional fees associated with this communication to the Deposit Account No. 22-0350.
- 5. **Certification:** I hereby certify that this Transmittal Letter and the paper(s) as described herein are being transmitted electronically to the USPTO on February 23, 2015.

Respectfully submitted,

VIDAS, ARRETT & STEINKRAUS

Date: February 23, 2015

By: /Michael J. McKeen/

Michael J. McKeen Registration No.: 66069

9531 West 78th Street, Suite 400 Eden Prairie, MN 55344-8006 Telephone: (952) 563-3000 Facsimile: (952) 563-3001

v:\wpwork\mjm\15141us03_vastransmittal_20150223.doc

PATENT

FEE ADDRESS INDICATION FORM

Mail Stop M Correspondence Director of the U.S. Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450

Please recognize as the "Fee Address" under the provisions of 37 CFR 1.363 the following customer number for the following patents:

81995

Patent Number (if known)	Application Number	Patent Date (if known)	U.S. Filing Date
Not Assigned	12/492512	Not Assigned	June 26, 2009

Respectfully submitted,

VIDAS, ARRETT & STEINKRAUS

Date: February 23, 2015

By: /Michael J. McKeen/ Michael J. McKeen Registration No.: 66069

9531 West 78th Street, Suite 400 Eden Prairie, MN 55344-8006 Telephone: (952) 563-3000 Facsimile: (952) 563-3001

v:\wpwork\mjm\15141us03_feeaddressindicationform_20150223.doc





٦

APPLICATION NO.	ISSUE DATE	PATENT NO.	ATTORNEY DOCKET NO.	CONFIRMATION NO.
12/492,512	03/31/2015	8992608	\$63.2Q-15141-U\$03	7439

490 7590 03/11/2015 VIDAS, ARRETT & STEINKRAUS, P.A. Richard A. Arrett 9531 West 78th Street Suite 400 Eden Prairie, MN 55344

ISSUE NOTIFICATION

The projected patent number and issue date are specified above.

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)

(application filed on or after May 29, 2000)

The Patent Term Adjustment is 88 day(s). Any patent to issue from the above-identified application will include an indication of the adjustment on the front page.

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) WEB site (http://pair.uspto.gov).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Application Assistance Unit (AAU) of the Office of Data Management (ODM) at (571)-272-4200.

APPLICANT(s) (Please see PAIR WEB site http://pair.uspto.gov for additional applicants):

Amr Salahieh, Saratoga, CA; Ulrich R. Haug, Campbell, CA; Hans F. Valencia, Berkeley, CA; Robert A. Geshlider, San Francisco, CA; Tom Saul, El Granada, CA; Dwight P. Morejohn, Davis, CA; Kenneth J. Michlitsch, Livermore, CA;

The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location for business investment, innovation, and commercialization of new technologies. The USA offers tremendous resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation works to encourage and facilitate business investment. To learn more about why the USA is the best country in the world to develop technology, manufacture products, and grow your business, visit <u>SelectUSA.gov</u>.

Edwards Lifesciences Corporation, et al. Exhibit 1102, Page 442 of 442